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Figure 1: Proposed summary pathway for donor screening for centres preparing frozen FMT from recurring 
donors.  
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 4 
1. Abstract: 82 
Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing 83 
globally in recent years, particularly as a result of randomised studies in which it has been used as an 84 
intervention.  The main focus of these studies has been the treatment of recurrent or refractory 85 
Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential 86 
applications in non-CDI settings.  The key clinical stakeholders for the provision and governance of 87 
FMT services in the United Kingdom (UK) have tended to be in two major specialty areas:  88 
gastroenterology and microbiology/infectious diseases. Whilst the National Institute for Health and 89 
Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become 90 
accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking.  This resulted in 91 
discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society 92 
(HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the 93 
culmination of that joint dialogue.   94 
 95 
2. Executive summary: 96 
2.1. Overview: 97 
The remit of the British Society of Gastroenterology (BSG)/ Healthcare Infection Society (HIS) 98 
working group was to provide recommendations as to best practice in the provision of a faecal 99 
microbiota transplant (FMT) service.  This guideline considers the use of FMT for the treatment of 100 
Clostridium difficile infection (CDI) – as well as for potential non-CDI indications – in adults.  The 101 
working group have primarily targeted their report at clinicians involved in the use and provision of 102 
FMT services, but have also aimed it to be of interest to patients and their relatives.   103 
 104 
2.2. Summary of recommendations: 105 
2.2.1. Which patients with Clostridium difficile infection should be considered for faecal 106 
microbiota transplant, and how should they be followed up after treatment? 107 
2.2.1.1. Prior to faecal microbiota transplant. Patient selection: 108 
2.2.1.1.1. Recurrent Clostridium difficile infection: 109 
We recommend that FMT should be offered to patients with recurrent CDI who have had at 110 
least two recurrences, or those who have had one recurrence and have risk factors for 111 
further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; 112 
strength of recommendation: strong). 113 
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 114 
2.2.1.1.2. Refractory Clostridium difficile infection: 115 
We recommend that FMT should be considered in cases of refractory CDI (GRADE of 116 
evidence: moderate; strength of recommendation: strong). 117 
 118 
2.2.1.1.3. FMT as initial therapy for Clostridium difficile infection: 119 
We recommend that FMT should not be administered as initial treatment for CDI (GRADE of 120 
evidence: low; strength of recommendation: strong).   121 
 122 
2.2.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with CDI: 123 
i. We recommend that FMT for recurrent CDI should only be considered after 124 
recurrence of symptoms following resolution of an episode of CDI that was treated 125 
with appropriate antimicrobials for at least 10 days (GRADE of evidence: low; 126 
strength of recommendation: strong). 127 
ii. We recommend consideration of treatment with extended/ pulsed vancomycin 128 
and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE 129 
of evidence: low; strength of recommendation: strong).  130 
iii. For those with severe or complicated CDI, which appears to be associated with 131 
reduced cure rates, we recommend that consideration should be given to offering 132 
patients treatment with medications which are associated with reduced risk of 133 
recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of 134 
evidence: low; strength of recommendation: strong). 135 
 136 
2.2.1.2. Post-FMT follow-up, outcomes and adverse events: 137 
2.2.1.2.1. Management of FMT failure: 138 
We recommend that FMT should be offered after initial FMT failure (GRADE of evidence: 139 
high; strength of recommendation: strong).     140 
 141 
2.2.1.2.2. General approach to follow-up post-FMT: 142 
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 6 
We recommend that all FMT recipients should routinely receive follow-up.  Clinicians should 143 
follow-up FMT recipients for long enough to fully establish efficacy/adverse events, and for 144 
at least eight weeks in total (GRADE of evidence: low; strength of recommendation: strong).   145 
 146 
2.2.1.2.3. Management of the FMT recipient: 147 
i. We recommend that immediate management after endoscopic administration of 148 
FMT should be as per endoscopy unit protocol (GRADE of evidence: very low: 149 
strength of recommendation: strong).   150 
ii. We recommend that patients should be warned about short term adverse events, in 151 
particular the possibility of self-limiting GI symptoms. They should be advised that 152 
serious adverse events are rare (GRADE of evidence: very low; strength of 153 
recommendation: strong).  154 
iii. After enteral tube administration, we recommend that patients may have the tube 155 
removed and oral water given from 30 minutes post-administration (GRADE of 156 
evidence: very low; strength of recommendation: strong). 157 
 158 
2.2.1.2.4. Definition of cure post-FMT for CDI: 159 
We recommend that a decision regarding cure/remission from CDI should be recorded 160 
during follow-up.  However, this has no uniformly-agreed definition, and should be decided 161 
on a case-by-case basis (GRADE of evidence: very low; strength of recommendation: strong).             162 
 163 
2.2.1.2.5. Definition of treatment failure post-FMT for CDI: 164 
We recommend that treatment failure/recurrence should be defined on a case-by-case 165 
basis.  Routine testing for C. difficile toxin after FMT is not recommended, but it is 166 
appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 167 
of evidence: low; strength of recommendation: strong).   168 
 169 
2.2.2. What recipient factors influence the outcome of faecal microbiota transplant when 170 
treating people with Clostridium difficile infection? 171 
2.2.2.1. General approach to co-morbidities and FMT: 172 
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 7 
i. We recommend that FMT should be avoided in those with anaphylactic food allergy 173 
(GRADE of evidence: very low; strength of recommendation: strong). 174 
ii.  We suggest that FMT should be offered with caution to patients with CDI and 175 
decompensated chronic liver disease (GRADE of evidence: very low; strength of 176 
recommendation: weak). 177 
 178 
2.2.2.2. Immunosuppression and FMT: 179 
i. We recommend that FMT should be offered with caution to immunosuppressed 180 
patients, in whom FMT appears efficacious without significant additional adverse 181 
effects (GRADE of evidence: moderate; strength of recommendation: strong). 182 
ii. We recommend that immunosuppressed FMT recipients at risk of severe infection if 183 
exposed to EBV or CMV should only receive FMT from donors negative for EBV and 184 
CMV (GRADE of evidence: very low; strength of recommendation: strong). 185 
 186 
2.2.2.3. Other comorbidities and FMT: 187 
i. We recommend that FMT should be offered to those with recurrent CDI and 188 
inflammatory bowel disease, but patients should be counselled about a small but 189 
recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of 190 
recommendation: strong).    191 
ii. We recommend that FMT should be considered for appropriate patients with 192 
recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate; 193 
strength of recommendation: strong). 194 
 195 
2.2.3. What donor factors influence the outcome of faecal microbiota transplant when 196 
treating people with Clostridium difficile infection? 197 
2.2.3.1. General approach to donor selection:  198 
We recommend that related or unrelated donors should both be considered acceptable.  199 
However, where possible, FMT is best sourced from a centralised stool bank, from a healthy 200 
unrelated donor (GRADE of evidence: low; strength of recommendation: strong). 201 
 202 
2.2.3.2. Age and BMI restrictions for potential donors: 203 
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 8 
We suggest that people should only be considered as potential FMT donors if they are ≥18 204 
and ≤60 years old, and have a BMI of ≥18 and ≤30 kg/m2 (GRADE of evidence: low; strength 205 
of recommendation: weak).   206 
 207 
2.2.3.3. General approach to the donor screening assessment: 208 
It is mandatory to screen potential donors by questionnaire and personal interview, to 209 
establish risk factors for transmissible diseases and factors influencing the gut microbiota 210 
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).  211 
 212 
2.2.3.4. Laboratory screening of potential donors: 213 
Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: low; 214 
strength of recommendation: strong).  215 
 216 
2.2.3.5. Repeat donor checks, and d nation pathway: 217 
i. In centres using frozen FMT, before FMT may be used clinically, we recommend that 218 
donors should have successfully completed a donor health questionnaire and laboratory 219 
screening assays both before and after the period of stool donation.  This is the 220 
preferred means of donor screening (GRADE of evidence: low; strength of 221 
recommendation: strong).  222 
ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should be 223 
assessed at the time of each stool donation.  To ensure ongoing suitability for inclusion 224 
as a donor, the donor health questionnaire and laboratory screening should be repeated 225 
regularly (GRADE of evidence: low; strength of recommendation: strong).   226 
 227 
2.2.4. What factors related to the preparation of the transplant influence the outcome of 228 
faecal microbiota transplant when treating people with Clostridium difficile 229 
infection? 230 
2.2.4.1. General principles of FMT preparation: 231 
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 9 
i. We recommend that stool collection should follow a standard protocol (GRADE of 232 
evidence: low; strength of recommendation: strong).  233 
ii. We recommend that donor stool should be processed within 6 hours of defaecation 234 
(GRADE of evidence: low; strength of recommendation: strong). 235 
iii. We recommend that both aerobically and anaerobically prepared FMT treatments 236 
should be considered suitable when preparing FMT for the treatment of recurrent 237 
CDI (GRADE of evidence: moderate; strength of recommendation: strong). 238 
iv. We recommend that sterile 0.9% saline should be considered as an appropriate 239 
diluent for FMT production, and cryoprotectant such as glycerol should be added for 240 
frozen FMT (GRADE of evidence: moderate: strength of recommendation: strong). 241 
v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence: 242 
moderate: strength of recommendation: strong). 243 
vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal 244 
emulsion (GRADE of evidence: low; strength of recommendation: weak). 245 
vii. We suggest that homogenisation and filtration of FMT should be undertaken in a 246 
closed disposable system (GRADE of evidence: low; strength of recommendation: 247 
weak).  248 
 249 
2.2.4.2. Fresh vs frozen FMT: 250 
We recommend that the use of banked frozen FMT material should be considered 251 
preferable to fresh preparations for CDI (GRADE of evidence: high; strength of 252 
recommendation: strong). 253 
 254 
2.2.4.3. Use of frozen FMT: 255 
i. We recommend that FMT material stored frozen at -80oC should be regarded as having a 256 
maximum shelf life of six months from preparation (GRADE of evidence: low; strength of 257 
recommendation: strong). 258 
ii. We suggest consideration of thawing frozen FMT at ambient temperature, and using 259 
within six hours of thawing (GRADE of evidence: low; strength of recommendation: 260 
weak). 261 
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iii. We suggest not thawing FMT in warm water baths, due to the risks of cross 262 
contamination with Pseudomonas (and other contaminants) and reduced bacterial 263 
viability (GRADE of evidence: very low; strength of recommendation: weak).   264 
 265 
2.2.5. What factors related to administration of the transplant influence the outcome of 266 
faecal microbiota transplant when treating people with Clostridium difficile 267 
infection? 268 
2.2.5.1. Use of specific medications in the period around FMT administration: 269 
2.2.5.1.1. General principles of FMT administration: 270 
i. We recommended that bowel lavage should be administered prior to FMT via the 271 
lower GI route, and that bowel lavage should be considered prior to FMT via the 272 
upper GI route; polyethylene glycol preparation is preferred (GRADE of evidence: 273 
low; strength of recommendation: strong). 274 
ii. For upper GI FMT administration, we suggest that a proton pump inhibitor should be 275 
considered, e.g. the evening before and morning of delivery (GRADE of evidence: 276 
low; strength of recommendation: weak).   277 
iii. We suggest that a single dose of loperamide (or other anti-motility drugs) should be 278 
considered following lower GI FMT delivery (GRADE of evidence: low; strength of 279 
recommendation: weak).   280 
iv. We suggest that prokinetics (such as metoclopramide) should be considered prior to 281 
FMT via the upper GI route (GRADE of evidence: low; strength of recommendation: 282 
weak).   283 
v. We recommend that best practice for prevention of further transmission of CDI 284 
should be applied throughout when administering FMT to patients with CDI (nursing 285 
with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE of 286 
evidence: high; strength of recommendation: strong).   287 
 288 
2.2.5.1.2. Additional antibiotics pre-FMT: 289 
We recommend the administration of further antimicrobial treatment for CDI for at least 72 290 
hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).     291 
 292 
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2.2.5.1.3. Washout period between antibiotic use and FMT: 293 
i. To minimise any deleterious effect of antimicrobials on the FMT material, we 294 
recommend that there should be a minimum washout period of 24 hours between the 295 
last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of 296 
recommendation: strong). 297 
ii. We suggest considering consultation with infectious disease specialists or medical 298 
microbiologists for advice whenever FMT recipients also have an indication for long-299 
term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of FMT 300 
(GRADE of evidence: very low; strength of recommendation: weak). 301 
 302 
2.2.5.2. Route of FMT delivery: 303 
2.2.5.2.1. Upper gastrointestinal tract administration of FMT: 304 
i. We recommend that upper GI administration of FMT as treatment for recurrent or 305 
refractory CDI should be used where clinically appropriate (GRADE of evidence: high; 306 
strength of recommendation: strong). 307 
ii. Where upper GI administration is considered most appropriate, we recommend that 308 
FMT administration should be via nasogastric, nasoduodenal, or nasojejunal tube, or 309 
alternatively via upper GI endoscopy.  Administration via a permanent feeding tube 310 
is also appropriate (GRADE of evidence: high; strength of recommendation: strong).   311 
iii. We recommend that no more than 100ml of FMT is administered to the upper GI 312 
tract (GRADE of evidence: low; strength of recommendation: strong). 313 
iv. We recommend that upper GI administration of FMT should be used with caution in 314 
those at risk of regurgitation and/ or those with swallowing disorders (GRADE of 315 
evidence: low; strength of recommendation: strong). 316 
 317 
2.2.5.2.2. Lower gastrointestinal tract administration of FMT: 318 
i. We recommend that colonoscopic administration of FMT as treatment for recurrent 319 
or refractory CDI should be used where appropriate (GRADE of evidence: high; 320 
strength of recommendation: strong). 321 
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ii. Where colonoscopic administration is used, we suggest considering preferential 322 
delivery to the caecum or terminal ileum, as this appears to give the highest efficacy 323 
rate (GRADE of evidence: low; strength of recommendation: weak).  324 
iii. We recommend that FMT via enema should be used as a lower GI option when 325 
delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of 326 
evidence: high; strength of recommendation: strong).   327 
 328 
2.2.5.2.3. Capsulised FMT: 329 
Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend 330 
that this should be offered to patients as a potential treatment modality where available.  331 
Capsule preparations should follow a standard protocol.  Further evidence regarding 332 
optimal dosing and formulation is required (GRADE of evidence: high; strength of 333 
recommendation: strong). 334 
 335 
2.2.6. What is the clinical effectiveness of FMT in treating conditions other than 336 
Clostridium difficile infection? 337 
We do not currently recommended FMT as treatment for inflammatory bowel disease.  338 
Apart from CDI, there is insufficient evidence to recommend FMT for any other 339 
gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength of 340 
recommendation: strong). 341 
 342 
2.2.7. Basic requirements for implementing a FMT service: 343 
2.2.7.1. General considerations: 344 
i. The development of FMT centres should be encouraged (GRADE of evidence: very 345 
low; strength of recommendation: strong). 346 
ii. We suggest that FMT centres should work to raise awareness about FMT as a 347 
treatment option amongst clinicians caring for patients with CDI, and provide 348 
training to relevant healthcare professionals on the practicalities of delivering an 349 
FMT service (GRADE of evidence: very low; strength of recommendation: weak).   350 
 351 
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2.2.7.2. Legal aspects and clinical governance: 352 
In the UK, FMT must be manufactured in accordance with MHRA guidance for human 353 
medicines regulation.  When FMT is supplied on a named patient basis, within a single 354 
organisation, a pharmacy exemption may be used, subject to ensuring proper governance 355 
and traceability.  All centres that are processing and distributing FMT should seek guidance 356 
from the MHRA and where necessary obtain appropriate licenses prior to establishing an 357 
FMT service.  This is a legal requirement.  In countries other than the UK, FMT should only 358 
be manufactured following appropriate approval from the national authority of that country 359 
(GRADE of evidence: very low; strength of recommendation: strong).  360 
 361 
2.2.7.3. Multidisciplinary teams: 362 
We recommend that a multidisciplinary team should be formed to deliver FMT services 363 
(GRADE of evidence: very low; strength of recommendation: strong). 364 
 365 
2.2.7.4. Infrastructure: 366 
We recommend utilisation of suitable laboratory facilities and infrastructure for FMT 367 
production (GRADE of evidence: very low; strength of recommendation: strong). 368 
 369 
2.2.7.5. FMT manufacturing: 370 
We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength 371 
of recommendation: strong). 372 
 373 
2.2.7.6. FMT production quality control: 374 
We recommend monitoring, notification and investigation of all adverse events and 375 
reactions related to FMT (GRADE of evidence: very low; strength of recommendation: 376 
strong). 377 
 378 
2.2.7.7. Donor screening governance: 379 
We recommend ensuring the clinical governance of donor screening (GRADE of evidence: 380 
very low; strength of recommendation: strong). 381 
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 382 
3. Introduction: 383 
The aim of the BSG/ HIS FMT working group was to establish a guideline that defined best practice in 384 
all aspects of a FMT service, by providing evidence-based recommendations wherever possible, and 385 
consensus multi-disciplinary expert opinion where specific published evidence is currently lacking.  386 
This included the evaluation of the use of FMT in the treatment of Clostridium difficile infection (CDI; 387 
also referred to as Clostridioides difficile1), and also in potential non-CDI indications.  Relevant 388 
guidance published to date includes the interventional procedure guidance from the National 389 
Institute for Health and Care Excellence (NICE)2, UK, European and US microbiological guidelines on 390 
the treatment of Clostridium difficile infection (CDI)3–5, and recent expert consensus documents on 391 
FMT in clinical practice6,7.  Furthermore, there have also been national recommendations regarding 392 
FMT produced by working groups in several different countries8–10. Principally as a result of 393 
randomised studies that have been published in recent years11–18, FMT has become an accepted 394 
treatment for recurrent/refractory CDI.   395 
 396 
The unique remit and objectives of this guideline when commissioned by the BSG and HIS was: 397 
i. To review the rapidly-growing body of randomised trial evidence for the efficacy of FMT in the 398 
treatment of adults (≥18 years), both in CDI and in other clinical conditions, much of which has been 399 
published after the publication of current CDI treatment algorithms3,4. 400 
ii. To provide specific guidance about best practice for an FMT service within the context of the 401 
regulatory framework for the intervention as it currently exists in the UK19,20.   402 
 403 
The elucidation of the mechanisms underlying the efficacy of FMT in treating CDI remains an active 404 
area of global research, with the aim of rationalising FMT from its current crude form to a more 405 
targeted, refined therapeutic modality21.  Previous research has demonstrated that commensal 406 
bacteria cultured from the stool of healthy donors22, sterile faecal filtrate23, and/ or spores of 407 
Firmicutes derived from ethanol-treated stool from healthy donors24, may have similar efficacy to 408 
conventional FMT in treating CDI, although results of the latter approach produced disappointing 409 
outcome data when extended to a Phase II clinical trial25.  For the purposes of this guideline, the 410 
BSG/HIS working group considered only studies that used the administration of manipulated whole 411 
stool (including encapsulated faeces).  They deemed studies using cultured microorganisms (or their 412 
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proteins, metabolites or other components), or microbiota suspensions, to be in the pre-clinical 413 
research stage, without firm evidence.  414 
 415 
FMT has been shown to be very acceptable to patients, both in the setting of CDI11,26 and in non-CDI 416 
settings, e.g. ulcerative colitis27.  However, the absence of appropriate protocols28–31 specifically 417 
taking into account UK clinical practice and regulation of FMT has been perceived as a barrier to the 418 
use of FMT in the UK and Ireland; these guidelines seek to rectify this problem. 419 
 420 
4. Guideline development: 421 
4.1. Guideline development team 422 
BSG and HIS commissioned the authors to undertake the Working Party Report.  The authors 423 
represent the membership of both societies.  The working group included gastroenterologists, 424 
infectious diseases/microbiology clinicians, a clinical scientist, a systematic reviewer, and patient 425 
representatives.  The views expressed in this publication are those of the authors, and have been 426 
endorsed by BSG and HIS following consultation. 427 
 428 
4.2. Scope of the guidelines 429 
The main scope of the guidelines is to provide guidance for the optimal provision of an effective and 430 
safe FMT service, principally for recurrent or refractory CDI, but non-CDI indications are also 431 
considered.  These guidelines only apply to adult patients (≥18 years); the working party did not 432 
consider the role of FMT in the treatment of either CDI or non-CDI indications in children or young 433 
people.  The guidelines were written with a focus upon UK practice, but also with consideration of 434 
more global practice as it applied.  The diagnosis and management of Clostridium difficile infection in 435 
general are outside the remit of these guidelines. 436 
 437 
4.3. Evidence appraisal 438 
Questions for review were derived from the Working Party Group, which included patient 439 
representatives in accordance with the PICO process32.  To prepare these recommendations, the 440 
working group collectively reviewed relevant peer-reviewed research.   441 
 442 
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4.4. Data sources and search strategy 443 
A systematic literature search was undertaken using MEDLINE, EMBASE databases and Cochrane 444 
Library for relevant articles published from 1st January 1980 to 1st January 2018.  The MEDLINE and 445 
EMBASE strategy are shown in Supplementary Material 1, Appendix 2ii.  Free text and MESH/ index 446 
terms for faecal microbial transplant and Clostridium difficile or other diseases of interest were 447 
combined.  In addition, conference proceedings from microbiology, infectious disease, and 448 
gastroenterology conferences were also searched to identify additional studies.   449 
 450 
4.5. Study eligibility and selection criteria 451 
The members of the guideline group determined criteria for study inclusion.  Two reviewers (BHM, 452 
MNQ) screened the titles and abstracts of each article for relevance independently; any 453 
disagreements were resolved by discussion with a third reviewer (JPS).  Copies of relevant articles 454 
were obtained and assessed for inclusion as evidence in the guideline by all three reviewers.  The 455 
reason for not selecting studies was recorded.  Only articles published in English and human clinical 456 
studies were included.  For evidence on FMT for CDI, both randomised studies (including randomised 457 
controlled trials (RCTs)) and case series with at least 10 patients were selected.  Only randomised 458 
trials were included as evidence for FMT for non-CDI indications.  Conference abstracts were only 459 
included for CDI and non-CDI indications if they reported a randomised trial; where abstracts were 460 
available reporting data from a randomised trial that was subsequently published, only the 461 
published paper was reviewed.   462 
 463 
4.6. Data extraction and quality assessment 464 
The initial search identified 2658 publications, and of these, 802 duplicates were excluded.  1856 465 
studies were subsequently screened, from which 78 studies were assessed by reviewing the full text 466 
for eligibility (see Supplementary Material 1, Appendix 2iii and Supplementary Material 2, 467 
Additional Appendix D).  Of these 78 studies, 58 studies were included as the basis of evidence for 468 
writing this guideline.  In total, 39 were case studies in CDI including at least 10 patients (see 469 
Supplementary Material 2, Additional Appendix C.1), and ten were randomised studies in CDI (see 470 
Supplementary Material 2, Additional Appendix C.2). Nine were randomised trials for non-CDI 471 
indications (see Supplementary Material 2, Additional Appendix C.3).  Data were extracted for 472 
patient demographics, disease characteristics, donor screening characteristics, stool preparation and 473 
administration, clinical outcomes and adverse events.  The quality of randomised studies was 474 
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assessed with the Cochrane Collaboration’s risk of bias tool.  Case series were assessed using the 475 
Centre for Reviews and Dissemination guidance.   476 
 477 
4.7. Rating of evidence and recommendations 478 
The BSG version of these guidelines was prepared in keeping with the BSG Clinical Services & 479 
Standards Committee (CSSC) advice document on the writing of clinical guidelines33.  Evidence tables 480 
were presented and discussed by the working group, and guidelines were prepared according to the 481 
nature and applicability of the evidence regarding efficacy and patient preference and acceptability.  482 
For the BSG version of this guideline, the GRADE system (Grades of Recommendation Assessment, 483 
Development and Evaluation)34 was used to assess the strength of evidence (high/ moderate/ low/ 484 
very low) and strength of recommendation (strong/ weak) (Table 4).  The section entitled ‘Basic 485 
requirements for implementing an FMT service’ (Supplementary Material 3) was based on expert 486 
opinion, since this was a key area of the working party’s remit but not one amenable to evaluation 487 
by the PICO process.  Face-to-face meetings and group teleconferences were held to agree on 488 
recommendations.  Any disagreements on recommendations or the strength of recommendation 489 
were resolved by discussion and, where necessary, voting by the members of the working group, 490 
with consensus achieved when >80% were in agreement.   491 
 492 
4.8. Consultation process 493 
Feedback on draft guidelines was received from the Scientific Development Committee (SDC) of HIS, 494 
and changes made.  These guidelines were then opened to consultation with relevant stakeholders 495 
(see Supplementary Material 1, Appendix 3 of this document).  The draft report was available on 496 
the HIS website for one month.  Views were invited on format, content, local applicability, patient 497 
acceptability, and recommendations.  The working group reviewed stakeholder comments, and 498 
collectively agreed revisions.  Final changes were made after repeat reviews from HIS (Chair of the 499 
SDC and HIS Council) and BSG (BSG CSSC and BSG Council), and after further external peer review.      500 
 501 
4.9. Guideline accreditation and scheduled review 502 
The guidelines will be reviewed at least every four years and updated if change(s) in the evidence are 503 
sufficient to require a change in practice.  504 
 505 
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4.0. Additional information: 506 
Additional information related to this guideline (including a lay summary, background on the 507 
working party report, and information on the implementation of these guidelines) is contained 508 
within Supplementary Material 1, Section 1.   509 
 510 
5. Rationale for recommendations: 511 
5.1. Which patients with Clostridium difficile infection should be considered for faecal 512 
microbiota transplant, and how should they be followed up after treatment? 513 
5.1.1. Prior to faecal microbiota transplant. Patient selection: 514 
5.1.1.1. Recurrent Clostridium difficile infection: 515 
As already described, there is widespread consensus that FMT is an efficacious treatment for 516 
recurrent CDI.  In defining recurrent CDI, some studies have relied on a minimum threshold of return 517 
of clinical symptoms (e.g. at least three unformed bowel movements within 24 hours, for at least 518 
two consecutive days)12,18 following previous successful CDI treatment; most studies have also 519 
included a requirement for a positive microbiological test12,14,18,35–45.  Other studies explicitly state 520 
that a positive test was not required46.  Recommendations for CDI testing are beyond the scope of 521 
this guideline, and there are already well-established evidence-based guidelines47.  These 522 
recommend testing with either a nucleic acid amplification test (NAAT) or GDH assay, followed by 523 
detection of free toxin (either by toxin A/B enzyme immunoassay (EIA) or cytotoxin neutralisation 524 
assay), which allows differentiation of patients with active disease as well as those who are likely 525 
colonised47.  However, the working group discussed the importance of the accurate diagnosis of true 526 
recurrent CDI prior to consideration of FMT; in particular, they noted a study which observed that of 527 
117 patients with presumed recurrent CDI referred for work-up for FMT, 25% (n=29/117) were 528 
determined to have a non-CDI diagnosis, with irritable bowel syndrome (n=18) and inflammatory 529 
bowel disease (n=3) being the most common alternative diagnoses, and younger patients more likely 530 
to be misdiagnosed48.   531 
 532 
All of the reviewed studies have included patients with recurrent CDI, however some studies offered 533 
FMT to patients at the first recurrence (second episode)12,15,16,18,35,37,42,43,46,49, whereas others offered 534 
FMT after the second recurrence (third episode)13,14,39,41,44,45,50,51.  Some protocols offered FMT after 535 
three or more recurrences52, whilst others did not define the point at which it was adminstered40,53.   536 
 537 
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The severity of infection has been used as a parameter to decide at which stage FMT is offered. 538 
Youngster et al. offered FMT to patients with at least three episodes of mild to moderate CDI, or at 539 
least two episodes of severe CDI resulting in hospitalisation and associated with significant 540 
morbidity17.  Another study selected patients for FMT using four categories of severity, which also 541 
accounted for prior anti-CDI therapy and requirement for hospitalisation54.   542 
 543 
None of the studies directly compared the efficacy of FMT according to the stage at which it was 544 
offered (i.e. first recurrence vs. ≥ two recurrences).  A small number of studies55–57 included patients 545 
with severe CDI (defined as hypoalbuminaemia with increased peripheral white cell count and/or 546 
abdominal tenderness) or complicated CDI (defined as admission to Intensive Care, altered mental 547 
status, hypotension, fever, ileus, white blood cell count > 30 x 109/l, lactate > 2.2mmol/l, or evidence 548 
of end organ damage).  A single study described an apparent lower rate of treatment success when 549 
FMT was used to treat patients with recurrent CDI with disease caused by ribotype 02743, but this is 550 
the case for all anti-CDI treatment modalities for this ribotype in comparison to others.  The working 551 
group agreed that there was insufficient evidence to suggest that C. difficile ribotype should 552 
influence whether or not FMT is offered.     553 
 554 
A lower primary cure rate was reported for complicated CDI (66%) compared with recurrent CDI 555 
(82%) and severe CDI (91%) in one study55; in a case series of 17 patients who all had severe and/or 556 
complicated CDI, a primary cure rate of 88% was described57.  A cohort of 328 patients was analysed 557 
to determine which factors were associated with failure of FMT58. Higher early (one month) failure 558 
rates were found in patients with severe (72%, n=19/25) or severe-complicated (52.9%, n=9/17) CDI 559 
than for recurrent CDI (11.9%, n=34/286).  This study also identified that patients who were treated 560 
with FMT as an inpatient were nearly four times more likely to fail as those who had FMT as an 561 
outpatient; however, the working group noted that the authors of this study themselves identified 562 
that inpatient status is likely a proxy of severity of CDI and/or co-morbidities.  A further similar study, 563 
including 64 patients treated with FMT as treatment for recurrent CDI, also identified severe CDI as 564 
the strongest independent risk factor for FMT failure on multivariate analysis59.     565 
 566 
The working group discussed their experience of treating patients with CDI whose disease fitted an 567 
intermediate pattern to the typical descriptions given of recurrent or refractory CDI, e.g. patients 568 
with CDI who have some (but incomplete) symptomatic improvement with anti-CDI antibiotics and 569 
worsening of disease when these are stopped.  The experience of the working group was that such 570 
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patients experienced excellent responses to FMT, and that these patients should be considered for 571 
FMT.     572 
 573 
As FMT is currently an unlicensed medicine with poorly-studied long term sequelae, the working 574 
group considered that it should generally be reserved for patients who have had three or more 575 
episodes of infection.  There are no studies directly comparing its effectiveness with some of the 576 
newer agents such as fidaxomicin or bezlotoxumab, hence this recommendation is made on the 577 
basis of safety.  However, the working group agreed that it may be reasonable in certain patient 578 
groups with ongoing risk factors for further recurrence to offer FMT after the second episode. 579 
 580 
Recommendation:   581 
We recommend that FMT should be offered to patients with recurrent CDI who have had 582 
at least two recurrences, or those who have had one recurrence and have risk factors for 583 
further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; 584 
strength of recommendation: strong). 585 
 586 
5.1.1.2. Refractory Clostridium difficile infection: 587 
Two randomised trials allowed the recruitment of patients with refractory CDI.  The first defined this 588 
as at least three weeks of ongoing severe symptoms despite standard antimicrobial therapy for 589 
CDI17.  The second required persistent or worsening diarrhoea and one of the following: ongoing 590 
abdominal pain, fever > 38oC, or white blood cell count > 15x 109/l despite oral vancomycin at a dose 591 
of 500mg four times daily for at least five days16.  Both studies included only small numbers of 592 
patients with refractory CDI (n=4/20 (20%) and n=15/219 (6.8%), respectively).  There did not appear 593 
to be any significant difference in primary outcome measure (clinical cure) in patients with recurrent 594 
or refractory CDI, although neither study was designed to assess this difference.  There are also a 595 
number of case series in which FMT was given to patients with refractory CDI; however, outcome 596 
measures were not reported for these groups individually in these studies37,38,54,60.   597 
 598 
Overall, the working group concluded that there is little consensus on the definition of refractory 599 
CDI, with some studies using the terms ‘refractory’ and ‘recurrent’ interchangeably (as well as other 600 
terms, e.g. ‘salvage therapy’).  Consequently, the quality of evidence for the utility of FMT in 601 
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refractory cases of CDI is lower than for recurrent CDI.  The standardisation of definitions will allow 602 
more robust comparison between patient cohorts. 603 
 604 
Recommendation:     605 
We recommend that FMT should be considered in cases of refractory CDI (GRADE of 606 
evidence: moderate; strength of recommendation: strong). 607 
 608 
5.1.1.3. FMT as initial therapy for Clostridium difficile infection: 609 
Experience of the use of FMT as initial therapy for CDI is very limited.  In a case series of patients 610 
with CDI with ribotype 027, use of anti-CDI antibiotics together with nasogastric FMT within a week 611 
of diagnosis during an initial episode of CDI was associated with reduced mortality when compared 612 
to using FMT only after the failure of three courses of antibiotics (mortality of 18.75% (n=3/16 613 
patients) vs 64.4% (n=29/45 patients))61.  However, 37.5% (n=6/16) of the patients treated with FMT 614 
within a week of CDI diagnosis required further antibiotics and a second FMT within one month of 615 
the first FMT because of relapse61.  In a small pilot randomised trial, patients were randomised to 616 
either vancomycin or multi-donor FMT (administered either via upper or lower GI routes) as initial 617 
therapy for CDI; CDI resolution occurred in 88.9% (n=8/9) patients with vancomycin, compared to 618 
57.1% of patients (n=4/7) patients with one FMT, and 71.4% of patients (n=5/7) after two FMTs62.  619 
Given the small size of these studies and equivocal results, the working group concluded that the 620 
reviewed studies did not support FMT as initial therapy for CDI.   621 
 622 
Recommendation: 623 
We recommend that FMT should not be administered as initial treatment for CDI (GRADE 624 
of evidence: low; strength of recommendation: strong).   625 
 626 
5.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with 627 
CDI: 628 
There are now at least two licensed agents (fidaxomicin and bezlotoxumab) which have been shown 629 
to significantly reduce the risk of recurrence compared with vancomycin63,64.  There is also some 630 
evidence that pulsed/tapered dosing of vancomycin and fidaxomicin (including pulsed fidaxomicin65) 631 
results in fewer recurrences than with standard dosing of these agents66,67 (although this finding has 632 
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not been replicated in all studies68).  Pre-planned subgroup analysis of patients with severe CDI in a 633 
randomised trial demonstrated a significantly lower recurrence rate when treated with fidaxomicin 634 
(13.0%, n=12/92) than when treated with vancomycin (26.6%, n=29/209)63; this finding was 635 
replicated in another randomised controlled trial, with 8.3% (n=4/48) and 32.6% (n=14/43) 636 
experiencing a recurrence respectively69.  In a further randomised trial, bezlotoxumab (together with 637 
standard of care antibiotics) was shown to reduce recurrence of severe CDI compared to standard of 638 
care antibiotics alone (10.9% (n=6/55) vs 20% (n=13/65) respectively)64.     639 
 640 
As discussed above, the working group noted that there are no studies comparing FMT to 641 
fidaxomicin or bezlotoxumab, and only one study comparing a vancomycin taper to FMT12.  The 642 
working group agreed that in the absence of this evidence, on the balance of safety and potential 643 
risks, consideration should be given to using antimicrobial/antitoxin therapy associated with reduced 644 
CDI recurrence prior to considering the use of FMT.   645 
 646 
Several studies specify that patients should be treated with anti-C. difficile antibiotics for a minimum 647 
period of 10 days before diagnosing recurrent CDI and offering FMT12,15,16,18. 648 
 649 
Recommendations:   650 
i. We recommend that FMT for recurrent CDI should only be considered after 651 
recurrence of symptoms following resolution of an episode of CDI that was treated 652 
with appropriate antimicrobials for at least 10 days (GRADE of evidence: low; 653 
strength of recommendation: strong). 654 
ii. We recommend consideration of treatment with extended/ pulsed vancomycin 655 
and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE 656 
of evidence: low; strength of recommendation: strong).  657 
iii. For those with severe or complicated CDI, which appears to be associated with 658 
reduced cure rates, we recommend that consideration should be given to offering 659 
patients treatment with medications which are associated with reduced risk of 660 
recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of 661 
evidence: low; strength of recommendation: strong). 662 
 663 
5.1.2. Post-FMT follow-up, outcomes and adverse events: 664 
5.1.2.1. Management of FMT failure: 665 
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Where patients were deemed not to have responded to an initial FMT, many studies have offered 666 
repeat FMT and success rates have been excellent even in patients with modest response to a first 667 
FMT14,15,17,18,35,43,46,51,54,70,71.  The success of a second FMT appears to be high whether treatment 668 
failure represents non-response to the first FMT, or a late failure (i.e. further relapse of CDI after an 669 
initial response); however, these terms have been defined variably between different studies (also 670 
see Section 5.1.2.5).  Second FMTs have been offered as soon as 24-72 hours after an initial FMT for 671 
presumed non-response37,72,73.  For FMT failure in patients with pseudomembranous colitis, repeat 672 
FMT every three days until resolution of pseudomembranes has been a successful approach18.  Good 673 
outcomes in pseudomembranous disease have also been achieved through a protocol that routinely 674 
restarted five days of vancomycin if FMT failed, before offering another FMT73.  Other studies have 675 
demonstrated potential success in treating initial FMT failure with further antibiotics, including 676 
repeat FMT with vancomycin between procedures42, or anti-CDI antibiotics alone35,42,43,45,51,70,71.  677 
Patients unresponsive to two FMTs have been offered further FMT or antibiotic therapy16, or even 678 
the administration of intravenous immunoglobulin35.  Whilst the working group collectively agreed 679 
that there was strong evidence to recommend repeat FMT after initial FMT failure, they were not 680 
able to recommend a specific protocol for administering repeat FMT and/ or maximum number of 681 
FMTs, given the wide heterogeneity of approach described within the reviewed literature.   682 
 683 
Recommendation:   684 
We recommend that FMT should be offered after initial FMT failure (GRADE of evidence: 685 
high; strength of recommendation: strong).     686 
 687 
5.1.2.2. General approach to follow-up post-FMT: 688 
Follow-up post-FMT (in terms of duration, modality and regimen for follow-up) varies considerably 689 
between studies, and is largely dependent upon study design.  Follow-up regimens vary not only 690 
between studies but within them too, reflecting the retrospective nature of many early FMT studies 691 
in CDI, where follow-up mostly reflected pragmatic routine clinical care. 692 
 693 
Modalities of follow-up have included outpatient review14,43,58,71,74–76, telephone 694 
interview17,39,43,46,58,71,74 and case note/ database review35,39,70,71,74,40,42,43,45,46,49,51,54.  Follow-up 695 
duration has varied from 60 days45 to 8 years36, with very different durations used in each study.  696 
Once again, however, this variability in follow-up largely reflects the retrospective analysis of case 697 
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series rather than being justified by any specific methodology.  The working group decided by 698 
consensus that at least eight weeks of follow-up was appropriate post-FMT to fully assess efficacy 699 
and potential adverse events; this figure was also influenced by discussions regarding the timepoint 700 
after FMT at which a decision could be made regarding cure/ remission of CDI (see Section 5.1.2.4).     701 
 702 
Recommendation:   703 
We recommend that all FMT recipients should routinely receive follow-up.  Clinicians 704 
should follow-up FMT recipients for long enough to fully establish efficacy/adverse events, 705 
and for at least eight weeks in total (GRADE of evidence: low; strength of 706 
recommendation: strong).   707 
 708 
5.1.2.3. Management of the FMT recipient: 709 
Procedural adverse events during administration of FMT have predominantly occurred with 710 
colonoscopic administration of FMT.  These have included mild nausea and vomiting attributed to 711 
sedation for the colonoscopy, minor mucosal tears during colonoscopy49,60, and microperforation 712 
following biopsy of an area of presumed ischaemic small bowel injury in a patient with chronically 713 
dilated small bowel (which resolved with conservative management46).  One death occurred due to 714 
witnessed aspiration at the time of colonoscopy60.  Faecal regurgitation and vomiting with temporal 715 
association to upper GI FMT administration has also been described (discussed further in Section 716 
5.5.2.2)77.   717 
 718 
The predominant short term adverse events post-FMT for CDI are mild: self-limiting GI symptoms 719 
have been the most frequently reported adverse events.  These may be related to the route of 720 
administration and include belching15, nausea15,16,49,60, abdominal cramps/ discomfort/ bloating/ 721 
pain15,18,49,60,72, and diarrhoea15,16,18,60.  One patient with a history of autonomic dysfunction 722 
experienced dizziness with diarrhoea after FMT15.  These symptoms are typically short-lived, 723 
resolving in hours to days15,16,18,49,72.  Minor subsequent adverse events have included a range of GI 724 
side effects including self-limiting abdominal discomfort14,17,57,76, nausea14,49,70, 725 
flatulence14,16,17,41,42,49,57, self-limiting irregular bowel movements41, C. difficile-toxin negative 726 
diarrhoea52,55, constipation14,15,42,55,70 and constitutional symptoms/ temperature disturbance14,17.  727 
 728 
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As such, immediately post-endoscopic administration of FMT, most FMT centres typically manage 729 
patients using standard protocols for an endoscopic procedure41,49, without any specific adaptations 730 
(apart from to reiterate advice about the possibility of self-limiting GI side effects, and the use of 731 
departmental infection control protocols).  There is often a relatively short period of post-procedural 732 
observation15,18.  Most studies allow patients to leave the administration site after the period of 733 
observation, although overnight observation was the protocol used for a cohort of very elderly 734 
patients with multiple comorbidities51.  Where enteral tube administration is used, post-procedure 735 
management has ranged between removal of the tube after 30 minutes (following nasoenteral 736 
administration of 500ml of FMT15) to prompt post-procedure removal and oral water administration 737 
(after nasogastric a ministration of 90ml of FMT72), with no direct adverse outcomes in either case.  738 
The working group felt that removal of the tube at 30 minutes, with administration of water at this 739 
point, was a pragmatic approach.   740 
 741 
The definition of post-FMT serious adverse events has varied between studies, but has included 742 
significant morbidity necessitating hospital admission and death in the follow up period.  Many of 743 
these events are described as not directly caused by the FMT, including the scenario of post-FMT 744 
severe CDI recurrences72 and probable or certain CDI-related deaths16,60,70 occurring in the context of 745 
FMT failure, or deaths related to patient comorbidities17,55.  One patient was admitted to hospital 746 
with self-limiting abdominal pain post-FMT60, and four patients with flares of inflammatory bowel 747 
disease60.  Three patients underwent colectomy during the post-FMT follow-up period, with all 748 
related to ulcerative colitis and not believed to be due to CDI60.  Other reported serious adverse 749 
events include recurrent urinary tract infection15, fever during haemodialysis15 and upper 750 
gastrointestinal haemorrhage after nasogastric FMT (in a patient taking NSAIDs51), none of which 751 
were thought to be strongly linked to FMT.  There have also been a number of new onset 752 
autoimmune, inflammatory and metabolic conditions described post-FMT, although these have 753 
been described from single centres only, with these findings not replicated elsewhere. Such 754 
conditions include microscopic colitis, Sjögren’s syndrome, follicular lymphoma, peripheral 755 
neuropathy, immune thrombocytopenia and rheumatoid arthritis53,55.     756 
 757 
Significant adverse events are therefore rare but well-described.  Furthermore, the procedure is 758 
relatively novel, and longer-term follow-up data regarding safety are required.  Therefore, the 759 
working group opined that formal follow-up post-FMT to assess outcome and possible adverse 760 
events is essential.   761 
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 762 
The use of questionnaires to compare symptoms pre- and post-FMT is common.  Specifically, data 763 
collected have included clinical response to symptom severity55, stool frequency15,17,46,55,57,72, stool 764 
consistency14,15,72, abdominal pain or tenderness55,57, rating of gastrointestinal symptoms72, general 765 
well-being55,72, days to improvement post-FMT57, weight change72, functional status55, and changes 766 
in medication/use of antibiotics57,72.  Additionally, certain patients have been given specific advice 767 
post-FMT to contact their clinical team if there is recurrence of diarrhoea or symptoms14,35,41,43.  768 
Where patients underwent outpatient clinical evaluation, this was generally undertaken relatively 769 
early post-FMT39,52,76.  In one study, patients were additionally given instructions for cleaning and 770 
disinfection at home, with the aim of reducing the possibility of C. difficile reinfection43, and 771 
counselling on the risk of recurrent CDI with future antibiotic courses76. 772 
 773 
Recommendations: 774 
i. We recommend that immediate management after endoscopic administration of 775 
FMT should be as per endoscopy unit protocol (GRADE of evidence: very low: 776 
strength of recommendation: strong).   777 
ii. We recommend that patients should be warned about short term adverse events, 778 
in particular the possibility of self-limiting GI symptoms. They should be advised 779 
that serious adverse events are rare (GRADE of evidence: very low; strength of 780 
recommendation: strong).  781 
iii. After enteral tube administration, we recommend that patients may have the tube 782 
removed and oral water given from 30 minutes post-administration (GRADE of 783 
evidence: very low; strength of recommendation: strong). 784 
 785 
5.1.2.4. Definition of cure post-FMT for CDI: 786 
It is recognised that symptoms of CDI resolve relatively promptly post-successful FMT, although this 787 
has been variably described (within hours in some studies52, at an average of 4-5 days in others57,71).  788 
Treatment success post-FMT for CDI has no uniformly-agreed definition, with the time point at 789 
which cure/ remission is defined on clinical grounds varying between 3-5 days36 up to six months42.  790 
A consensus document from the USA recommends ‘resolution of symptoms as a primary end point; 791 
absence within eight weeks of FMT as a secondary end point’78. The working group recommended 792 
that this definition should be made on a case-by-case basis; however, they agreed that an 793 
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assessment for cure/ remission of CDI within eight weeks post-FMT was reasonable in most cases, 794 
and therefore that this was also a reasonable minimum length of time to undertake follow-up post-795 
FMT (see Section 5.1.2.2). 796 
 797 
Recommendation:   798 
We recommend that a decision regarding cure/remission from CDI should be recorded 799 
during follow-up.  However, this has no uniformly-agreed definition, and should be 800 
decided on a case-by-case basis (GRADE of evidence: very low; strength of 801 
recommendation: strong).             802 
 803 
5.1.2.5. Definition of treatment failure post-FMT for CDI: 804 
There is no uniformly-agreed definition of treatment failure/recurrence post-FMT for CDI, with 805 
varied definitions used in studies.  The use of C. difficile toxin as a marker of treatment success or 806 
failure is variable, with some studies opting not to test for CDT unless symptoms consistent with CDI 807 
recurred49,52–54,60,72,74.  Some studies have routinely performed CDT testing without specifying any 808 
action taken after a positive result14,15,18,36,39,41, whilst others have tested for C. difficile PCR but relied 809 
on clinical criteria (even if PCR was positive) post-FMT for evaluating FMT efficacy14.  A recent 810 
prospective study from the USA identified that only 3% (3/129) of patients who were asymptomatic 811 
at four weeks post-FMT for recurrent CDI had positive C. difficile PCR, again emphasising that 812 
symptoms rather than laboratory assays are more useful contributors to establishing FMT success79.   813 
 814 
Recommendation: 815 
We recommend that treatment failure/recurrence should be defined on a case-by-case 816 
basis.  Routine testing for C. difficile toxin after FMT is not recommended, but it is 817 
appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 818 
of evidence: low; strength of recommendation: strong).   819 
 820 
5.2. What recipient factors influence the outcome of faecal microbiota transplant when 821 
treating people with Clostridium difficile infection? 822 
5.2.1. General approach to co-morbidities and FMT: 823 
Most published studies had a core set of general recipient exclusions which included: significant/ 824 
anaphylactic food allergy14,17, pregnancy12–15,17,18, breastfeeding14, admission to Intensive Care or the 825 
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requirement for vasopressors12,15,18, chronic diarrhoea or other infectious cause of diarrhoea12,14,18,50, 826 
inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)14,36, immunodeficiency due to 827 
recent chemotherapy and/ or neutropenia12,14–18,50, HIV/AIDS14,17,18, prolonged use of 828 
corticosteroids15,17,18, graft versus host disease12, and decompensated cirrhosis14,15,17,18.   829 
 830 
The working group discussed the reported practice of several centres of treating patients with 831 
recurrent CDI and food allergies through the use of FMT prepared from a patient-directed donor 832 
instructed to avoid trigger foods before stool donation.  They agreed that this seemed reasonable 833 
for patients with true adverse immunological reactions to defined food groups (e.g. gluten-free diet 834 
donor for a recipient with coeliac disease).  However, the working group noted that food allergies 835 
are often poorly-defined clinically, and also expressed concerns that there was no means to verify 836 
how closely a donor had followed an exclusion diet; as such, they felt unable to make any specific 837 
recommendation about FMT in patients with food allergies in general.  In contrast, whilst the 838 
working group were unaware of any reports in the literature of anaphylaxis attributable to FMT, 839 
they felt that the theoretical risk of a serious adverse outcome in patients with anaphylactic food 840 
allergy merited a specific recommendation that such individuals should not be offered 841 
FMT.  Similarly, the working group expressed concern about the theoretical risk of adverse outcomes 842 
when administering FMT to patients with advanced decompensated chronic liver disease (including 843 
translocation of microbial material from the intestinal tract into the portal and systemic circulations, 844 
and theoretical risk of sepsis), and felt that FMT should be used with caution in this patient group.    845 
 846 
Recommendations: 847 
i. We recommend that FMT should be avoided in those with anaphylactic food allergy 848 
(GRADE of evidence: very low; strength of recommendation: strong). 849 
ii.  We suggest that FMT should be offered with caution to patients with CDI and 850 
decompensated chronic liver disease (GRADE of evidence: very low; strength of 851 
recommendation: weak). 852 
 853 
5.2.2. Immunosuppression and FMT: 854 
One randomised study16 included patients with immunodeficiency (treatment with 855 
immunosuppressive therapy (azathioprine, ciclosporin, infliximab, methotrexate alone, or in 856 
combination with corticosteroids) (n=18), renal transplant (n=5), chronic haemodialysis (n=5), solid 857 
organ tumours (n=3) and haematological malignancy (n=4)) at the time of FMT.  Clinical resolution 858 
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rates after up to two FMTs were high: 27/29 (93%) for immunocompromised individuals, 5/6 (83%) 859 
for patients with IBD. 860 
 861 
There are also limited data from case series and single case reports describing the use of FMT in 862 
patients with immunocompromise.  Agrawal and colleagues55 included 46/146 (32%) patients with a 863 
history of cancer, and an additional 15/146 (10%) patients with non-cancer-related immunologic 864 
dysfunction, although primary outcome measures were not specifically reported for these groups.  865 
Overall cure at 12 weeks in a case series of 80 patients with immunocompromise was reported in 71 866 
(89%) of patients60.  Adverse events occurred in 12 (15%) immunocompromised patients; this 867 
included two deaths (one due to respiratory failure and another due to pneumonia resulting from 868 
aspiration at the time of FMT administration)60; however, such adverse events have also been 869 
reported in non-immunocompromised patient populations80.  Hefazi and coauthors described high 870 
efficacy rates in a case series of FMT for recurrent CDI and a range of haematological or solid organ 871 
malignancies (remission after one FMT in 11/12 with haematological patients, and 8/10 in solid 872 
organ malignancy patients). No significant FMT-related complications were reported81.  A further 873 
case series45 reported FMT treatment for 75 patients with recurrent CDI and found no significant 874 
difference in primary cure rates for patients with diabetes mellitus, malignancy, or steroid use in the 875 
preceding three months.    876 
 877 
The working group discussed the potential impact of donor EBV and CMV status for the 878 
immunocompromised FMT recipient at risk of severe infection if exposed to these viruses.  Their 879 
opinion was that such recipients should only receive FMT from donors with negative EBV and CMV 880 
status.  881 
 882 
Recommendations:   883 
i. We recommend that FMT should be offered with caution to immunosuppressed 884 
patients, in whom FMT appears efficacious without significant additional adverse 885 
effects (GRADE of evidence: moderate; strength of recommendation: strong). 886 
ii. We recommend that immunocompromised FMT recipients at risk of severe infection if 887 
exposed to EBV or CMV should only receive FMT from donors negative for EBV and 888 
CMV (GRADE of evidence: very low; strength of recommendation: strong). 889 
 890 
5.2.3. Other comorbidities and FMT: 891 
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Only a limited number of cited studies included specific detail about the presence of comorbidities in 892 
patients receiving FMT.  However, several studies reported median Charlson comorbidity 893 
scores12,14,15,18,50.  One randomised study reported the presence of IBD in 10/17 (59%) FMT 894 
recipients16, and there did not appear to be any significant difference in primary outcome measures 895 
in this group.  Another randomised trial included 14/72 (33%) patients with IBD and reported clinical 896 
cure of CDI in 12/14 (86%) of these patients13.  This study also included 64/72 (89%) patients with 897 
cardiac, respiratory, renal, central nervous system or multi-organ system comorbidities13; however 898 
outcomes were not stratified according to co-morbidity.  Kelly and coauthors60 reported an overall 899 
cure rate of 94% in a subset of CDI patients with IBD.  A meta-analysis of studies in which patients 900 
with IBD received FMT (either primarily as treatment for concurrent recurrent CDI, or with the aim 901 
of treating IBD) noted a small risk of exacerbation of IBD in association with the use of FMT82.  The 902 
working group noted the complexity of the relationship between IBD and CDI, given that IBD is itself 903 
a risk factor for CDI. 904 
 905 
Other exclusions have been more directly related to the mode of administration. For upper 906 
gastrointestinal delivery, exclusion criteria have included delayed gastric emptying, chronic 907 
aspiration, ‘swallow dysfunction’, and dysphagia17,50.  Exclusions for lower GI administration have 908 
included colostomy/ileostomy16,50, significant bleeding disorders12, untreated colorectal cancer14,36,54, 909 
and ileus/small bowel obstruction50. 910 
 911 
In summary, the working group noted that co-morbidities amongst patients with recurrent CDI are 912 
common.  Most studies did not analyse primary outcome measures according to co-morbidity; 913 
however, a small number of studies have analysed primary outcome measures (clinical cure) for 914 
patients with IBD receiving FMT for recurrent CDI and have found no significant difference compared 915 
to those without IBD, along with no overall significant worsening of IBD activity. 916 
 917 
Recommendations:   918 
i. We recommend that FMT should be offered to those with recurrent CDI and 919 
inflammatory bowel disease, but patients should be counselled about a small but 920 
recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of 921 
recommendation: strong).    922 
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ii. We recommend that FMT should be considered for appropriate patients with 923 
recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate; 924 
strength of recommendation: strong). 925 
 926 
5.3. What donor factors influence the outcome of faecal microbiota transplant when 927 
treating people with Clostridium difficile infection? 928 
5.3.1. General approach to donor selection:  929 
Excellent efficacy has been shown in treating recurrent CDI using FMT derived from both 930 
related14,36,54,57,59,61,83,38,40,41,43,45,46,49,53 and unrelated14,15,57,59,61,72,74,83–87,16,17,35,37,38,41,43,53 donors.  To 931 
date, there have been no randomised studies comparing differences in efficacy.  Case series have 932 
tended to rely more on donation of stool from healthy family members.  In randomised studies using 933 
FMT, all donors were healthy unrelated individuals12–18,88.  Three case series used donor stool from 934 
healthcare professionals39,61,85; no randomised studies have used stool from this cohort.  However, 935 
the working group noted that there were clear advantages to using FMT from a screened 936 
anonymous donor, in particular with regards to monitoring and traceability, as discussed further 937 
later. 938 
 939 
Recommendation:   940 
We recommend that related or unrelated donors should both be considered acceptable.  941 
However, where possible, FMT is best sourced from a centralised stool bank, from a 942 
healthy unrelated donor (GRADE of evidence: low; strength of recommendation: strong). 943 
 944 
5.3.2. Age and BMI restrictions for potential donors: 945 
There are no well-defined age restrictions on donors.  Randomised studies have used donors of 946 
≥1812,72 and ≤60 years old15,17,18 with satisfactory outcomes.  Two of the case series defined age 947 
limitations for donors as ≥18 and ≤ 50 years72,89.  A recent study demonstrated that Bacteroides: 948 
Firmicutes ratio and microbial diversity was similar for donors above and below 60 years, and their 949 
stool donations had similar clinical efficacy as FMT; however, there were loss of the phylum 950 
Actinobacteria and family Bifidobactericeae from donors older than 60 years90.  On balance, the 951 
working group agreed that an age range of 18 – 60 years was appropriate for donors.   952 
 953 
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A widely-reported case study noted apparent weight gain in a recipient of FMT for treatment of CDI 954 
when an overweight donor was used91, but any association between a donor with a raised BMI and 955 
weight gain post-FMT has not been replicated elsewhere in the literature92.  Whereas most 956 
randomised studies did not report donor-specific BMIs, some have excluded those without a 957 
‘normal’ BMI13,17.  The working group considered an acceptable BMI for donors as between ≥18 to 958 
≤30 kg/m2. 959 
 960 
Recommendation:   961 
We suggest that people should only be considered as potential FMT donors if they are ≥18 962 
and ≤60 years old, and have a BMI of ≥18 and ≤30 kg/m
2
 (GRADE of evidence: low; 963 
strength of recommendation: weak).   964 
 965 
5.3.3. General approach to the donor screening assessment: 966 
There is a clear theoretical risk of the transmission of infection by FMT; furthermore, given the large 967 
number of conditions in which perturbation of the gut microbiota has been described93, there is a 968 
concern regarding a risk of transmission of microbiota associated with vulnerability to disease.  969 
Whilst FMT is efficacious for recurrent CDI, adverse events may be associated with its use (discussed 970 
further later), and long-term safety follow-up is lacking.  The aim of a donor screening questionnaire 971 
and interview is to minimise post-FMT adverse events by excluding potential donors from whom 972 
FMT may be associated with risk to recipients.  Randomised studies performed to date used various 973 
pre-screening questionnaires, including self-screening questionnaires which focused on high risk 974 
behaviours for blood-borne infections12–16, questionnaires that focused on previous potential 975 
transferable medical conditions18, and adaptations from the American Association of Blood Banks 976 
Donor Questionnaire14,17.  One randomised study used the OpenBiome questionnaire as a screening 977 
questionnaire94.  Some studies have suggested excluding potential donors who have recently 978 
travelled to defined regions (typically tropical areas), varying between 3-6 months prior to 979 
donation38,39,49,52,55,59,74,87; this is also the protocol employed in randomised studies14,16,18.  Another 980 
important point for assessment is recent use of medications by potential donors.  In particular, given 981 
the profound effects of antimicrobials on the gut microbiota95–98 (along with the theoretical concern 982 
that recent antimicrobials might precipitate gut colonisation with antimicrobial-resistant bacteria 983 
that could be transferred during FMT), studies advocate either a three month14,46,53–55,57,61,74 or six 984 
month16–18,35,38,39,43,49,85,99,100 period without antimicrobial use prior to FMT donation.  985 
Page 34 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 33
 986 
The working group agreed that, given the growing evidence for the contribution of the gut 987 
microbiota to the aetiopathogenesis of colorectal carcinoma, patients with a significant personal or 988 
family history of (or risk factors for) this condition should be excluded as donors (Table 1).  However, 989 
the working group noted an added complexity, in that their recommendation was that potential 990 
donors may be up to 60 years of age, but bowel scope screening for colorectal carcinoma currently 991 
begins within the UK at 55 years of age, and formal NHS bowel cancer screening starts at the age of 992 
60 years101.  The working group agreed that potential donors living in countries with bowel cancer 993 
screening programmes that start before the age of 60 years should have therefore completed 994 
appropriate screening with negative/ normal tests before they are considered further as donors.   995 
 996 
The working group was of the opinion that a screening process is mandatory; any positive responses 997 
should usually result in exclusion from donation, although this will depend upon the particular 998 
circumstances/ answers given.  A donor screening questionnaire should be performed both prior to 999 
considering a person as a donor, and also at a further point in time (discussed further in Section 1000 
5.3.5).   1001 
 1002 
Recommendation:   1003 
It is mandatory to screen potential donors by questionnaire and personal interview, to 1004 
establish risk factors for transmissible diseases and factors influencing the gut microbiota 1005 
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).  1006 
 1007 
5.3.4. Laboratory screening of potential donors: 1008 
Currently, there are no known confirmed cases of blood-borne pathogens being transmitted by FMT, 1009 
but strict preventative measures are important, as the potential risk of transmission is unknown.  1010 
Many of the suggestions are extended from established blood screening guidelines102.  Case series 1011 
almost universally screen for HIV, hepatitis B and hepatitis C as a minimum35,36,52–1012 
55,59,61,72,74,84,86,37,87,103,39–43,46,49;  other studies (including the randomised trials) have a more thorough 1013 
blood screening process14–18.  Many studies have also included a ‘metabolic/general blood screen’, to 1014 
select out donors with hitherto undiagnosed chronic illness.  Table 2 shows the suggested blood 1015 
screening protocol of the BSG/HIS working group.   1016 
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 1017 
The working group specifically discussed the role of screening donors for their EBV and CMV status; 1018 
the importance of the rationale for this is discussed in Section 5.2.2.  They agreed that EBV and CMV 1019 
testing was only required where there is the potential that the FMT prepared from that donor would 1020 
be administered to immunosuppressed patients at risk of severe infection if exposed to CMV and 1021 
EBV.       1022 
 1023 
The primary aim of stool screening of potential donors is to minimise the risk of transmission of 1024 
pathogens; again, the relative novelty of FMT for CDI means that these risks are not currently well-1025 
defined.  Stool screening protocols are universal amongst published studies, though widely-variable 1026 
protocols have been used.  Table 3 displays the suggested stool screening protocol of the working 1027 
group.  The working group discussed stool screening for multi-drug resistant bacteria carriage, and 1028 
agreed that carbapenemase-producing Enterobacteriaceae (CPE) should be screened for.  Although 1029 
these bacteria are carried only by a minority of the UK population, transfer into debilitated patients 1030 
with CDI is clearly undesirable given that CPE are potentially so difficult to treat.   They also agreed 1031 
that extended-spectrum beta-lactamase (ESBL)-producing organisms could also potentially cause 1032 
severe disease (with limited antimicrobial options) if transplanted into patients with CDI, and so 1033 
should also be screened for.  Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively 1034 
common in the community (probably related to food consumption)104, community strains of VRE are 1035 
genetically distinct from (and generally of much lower pathogenicity than) those found 1036 
nosocomially105; as such, the working group thought that routine screening was not justified.  The 1037 
working group also noted that methicillin-resistant Staphylococcus aureus (MRSA) carriage is very 1038 
rare in healthy adults in non-healthcare settings (with significant intestinal carriage even rarer), so 1039 
did not justify routine screening.  However, the working group acknowledged that the potential 1040 
infection risk from VRE and MRSA would vary regionally dependent upon local prevalence and 1041 
pathogenicity, and as such recommended that a risk assessment is performed to assess whether 1042 
screening for these organisms should be considered.   1043 
 1044 
A donor laboratory screening should be performed both prior to considering a person as a donor, 1045 
and also at a further point in time (discussed further in Section 5.3.5).        1046 
 1047 
Recommendation:   1048 
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Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: 1049 
low; strength of recommendation: strong).  1050 
 1051 
5.3.5. Repeat donor checks, and donation pathway: 1052 
Almost all reviewed studies have repeated at least some elements of the initial donor screening 1053 
process either at the time of donation of each stool sample used to prepare FMT, or at the end of a 1054 
period of donation to assess ongoing suitability for inclusion.  However, protocols have differed 1055 
widely between studies.    1056 
 1057 
The opinion of the working group was that when a donor had met criteria for donation (both with an 1058 
acceptable health questionnaire and satisfactory laboratory tests), they were suitable to begin 1059 
donation of stool that may be prepared into FMT. Repeat donor screening was also deemed 1060 
necessary.  In centres where frozen FMT is being prepared, stool may be collected and processed 1061 
immediately after the first donor screen is successfully completed, but should be stored in 1062 
‘quarantine’ pending further donor screening, rather than used immediately for clinical use.  At the 1063 
end of the locally-defined period of donation, potential donors should undergo repeat testing, with a 1064 
further health questionnaire and laboratory screening.  If the donor’s health questionnaire remains 1065 
acceptable and repeat laboratory screening is negative at this point, then the frozen FMT may be 1066 
released from ‘quarantine’, and used.  The working group thought that donor screening both before 1067 
and after donation was the safest route possible, and that this represented the preferred scenario.  1068 
A proposed summary pathway for donor screening in this scenario is provided in Figure 1.   1069 
 1070 
In centres using fresh FMT, the working group agreed that a repeat health questionnaire should be 1071 
completed at the time of donation of each stool sample used to prepare FMT. Formal repetition of 1072 
both the personal interview/ health questionnaire and laboratory screening tests should occur at 1073 
regular intervals to ensure ongoing suitability for inclusion as a donor.  The working group’s opinion 1074 
was that this repetition of the screening process should occur at least once every four months.           1075 
 1076 
Recommendations:   1077 
i. In centres using frozen FMT, before FMT may be used clinically, we recommend that 1078 
donors should have successfully completed a donor health questionnaire and 1079 
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laboratory screening assays both before and after the period of stool donation.  This is 1080 
the preferred means of donor screening (GRADE of evidence: low; strength of 1081 
recommendation: strong).  1082 
ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should 1083 
be assessed at the time of each stool donation.  To ensure ongoing suitability for 1084 
inclusion as a donor, the donor health questionnaire and laboratory screening should 1085 
be repeated regularly (GRADE of evidence: low; strength of recommendation: strong).   1086 
 1087 
5.4. What factors related to the preparation of the transplant influence the outcome of 1088 
faecal microbiota transplant when treating people with Clostridium difficile 1089 
infection? 1090 
5.4.1. General principles of FMT preparation: 1091 
There is very little evidence or guidance on the collection of donor stool.  Critical steps during this 1092 
process centre on the reduction of environmental cross-contamination risk, so the use of clean 1093 
collection devices and clean collection procedures is advocated.  To promote standardised practice 1094 
and a safe and effective product, clear instructions should be provided to the donor for stool 1095 
collection (Table 5). 1096 
 1097 
Regardless of the methods used to prepare FMT, stool donations should be processed within six 1098 
hours of defaecation.  The period of six hours has been generally applied across many successful 1099 
studies of FMT treatment in CDI14,18,35,39,43,52, although no formal comparative study has been 1100 
undertaken.  This strategy aims to minimise sample degradation and alteration over time, which may 1101 
occur due to the complex metabolic and environmental requirements of the faecal microbiota.  1102 
 1103 
There are no comparative trials of anaerobically versus aerobically prepared FMT in the treatment of 1104 
recurrent CDI.  With the exception of small observational studies41,74, the vast majority of FMT 1105 
preparation has been undertaken aerobically for the treatment of CDI and has proved highly 1106 
efficacious.  There appears to be no clear need to process anaerobically, a method which introduces 1107 
complexity and cost for the treatment of CDI.    1108 
 1109 
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The reviewed randomised studies reported variable amounts of stool used in the preparation of 1110 
each FMT aliquot, and the lack of comparative data means that it is not possible to link stool mass to 1111 
outcome from these studies.  However, a previous systematic review of case series using FMT as 1112 
treatment for recurrent CDI reported similar rates of treatment efficacy, but an approximate 1113 
fourfold increase in recurrence rates, if <50g of stool was used compared to ≥50g106.  Similarly, the 1114 
initial volume of diluent used to create the faecal emulsion is variable between studies, although the 1115 
most common practice appears to be creation of a stool: diluent ratio of approximately 1:5.  The 1116 
overwhelmi g majority of the reviewed studies used stool from only a single donor per FMT (rather 1117 
than stool pooled from a mixture of donors), and there are no comparative studies of outcomes of 1118 
CDI from single donor vs pooled donor FMT; as such, the working group found no justification to 1119 
recommend donor stool pooling for FMT for CDI.   1120 
 1121 
The majority of studies have used preservative-free sterile 0.9% saline as the diluent for FMT 1122 
production, although there have been a handful of reports of other diluents including potable 1123 
water16,35,43.  There have been no comparative studies of FMT diluent.  In cases where frozen FMT is 1124 
prepared, an appropriate cryoprotective substance should be added prior to freezing.  Most studies 1125 
use glycerol at a final concentration of ~10%16,41.  It has been demonstrated that storing stool at -1126 
80°C for up to six months in saline without glycerol decreases viable aerobic and anaerobic bacterial 1127 
counts; the reduction was statistically significant in all bacterial groups with the exception of E. coli 1128 
and total anaerobes.  When stored with glycerol, no significant reduction in viable counts was 1129 
observed74.  1130 
 1131 
A variety of homogenisation and open filtration systems have been used, with no apparent major 1132 
variation in efficacy.  Open filtration systems such as gauze16,37,40,55, filter paper39 and strainers/ 1133 
sieves17,41 are unpleasant to use and pose a risk of external contamination.  In order to best comply 1134 
with GMP standards, a sterile, single-use closed homogenisation and filtration system is 1135 
recommended.  An example of such a system includes the use of sterile filter bags inside a 1136 
laboratory paddle homogeniser. 1137 
 1138 
Recommendations:  1139 
i. We recommend that donor stool collection should follow a standard protocol 1140 
(GRADE of evidence: low; strength of recommendation: strong).  1141 
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ii. We recommend that donor stool should be processed within 6 hours of defaecation 1142 
(GRADE of evidence: low; strength of recommendation: strong). 1143 
iii. We recommend that both aerobically and anaerobically prepared FMT treatments 1144 
should be considered suitable when preparing FMT for the treatment of recurrent 1145 
CDI (GRADE of evidence: moderate; strength of recommendation: strong). 1146 
iv. We recommend that sterile 0.9% saline should be considered as an appropriate 1147 
diluent for FMT production, and cryoprotectant such as glycerol should be added 1148 
for frozen FMT (GRADE of evidence: moderate: strength of recommendation: 1149 
strong). 1150 
v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence: 1151 
moderate: strength of recommendation: strong). 1152 
vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal 1153 
emulsion (GRADE of evidence: low; strength of recommendation: weak). 1154 
vii. We suggest that homogenisation and filtration of FMT should be undertaken in a 1155 
closed disposable system (GRADE of evidence: low; strength of recommendation: 1156 
weak).  1157 
 1158 
5.4.2. Fresh vs frozen FMT: 1159 
Two randomised studies have examined this area.  One double-blind randomised study concluded 1160 
that enema frozen FMT (n=91) was non-inferior for clinical resolution of diarrhoea to fresh FMT 1161 
(n=87) for the treatment of recurrent or refractory CDI16 (with frozen FMT in this study stored at -1162 
20oC for up to 30 days).  A further randomised study demonstrated statistically comparable 1163 
remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n=25/25 vs 1164 
20/24 respectively, p=0.233) (using frozen FMT stored at -80oC for up to six months)13.  These data 1165 
support the findings of earlier small observational studies35,41.  Frozen FMT is preferable to fresh FMT 1166 
on logistical and cost grounds16.  Banked frozen FMT also enables the window period for donor 1167 
screening to be minimised, allowing centres to more closely to meet regulatory requirements (also 1168 
see Section 5.3.5).   1169 
 1170 
Recommendation:   1171 
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We recommend that the use of banked frozen FMT material should be considered 1172 
preferable to fresh preparations for CDI (GRADE of evidence: high; strength of 1173 
recommendation: strong). 1174 
 1175 
5.4.3. Use of frozen FMT: 1176 
Frozen FMT has been used up to six months after storage at -80oC17,41,74, with high efficacy rates 1177 
(>70%) observed in the cases treated.  However, there have been no comparative trials investigating 1178 
storage durations.  A trend towards decrease in the viability of certain gut microbiota taxa was noted 1179 
when faecal aliquots were frozen in 10% glycerol for six months74, and as such, the working group 1180 
agreed that six months was the acceptable limit for freezing of an FMT in glycerol.  Storage at -80oC 1181 
is recommended rather than -20oC to minimise sample degradation.    1182 
 1183 
Warm water baths have been recommended to speed thawing6; however, the working group 1184 
thought that this should be strongly discouraged, as this may introduce risks of cross contamination 1185 
by Pseudomonas species (and other contaminants) from the water bath107,108, and may reduce 1186 
bacterial viability in the FMT.  Repetitive freeze thawing of FMT samples should be avoided as 1187 
bacterial numbers will be reduced during this process109.  1188 
 1189 
Recommendations:   1190 
i. We recommend that FMT material stored frozen at -80
o
C should be regarded as 1191 
having a maximum shelf life of six months from preparation (GRADE of evidence: 1192 
low; strength of recommendation: strong). 1193 
ii. We suggest consideration of thawing frozen FMT at ambient temperature, and 1194 
using within six hours of thawing (GRADE of evidence: low; strength of 1195 
recommendation: weak). 1196 
iii. We suggest not thawing FMT in warm water baths, due to the risks of cross 1197 
contamination with Pseudomonas (and other contaminants) and reduced bacterial 1198 
viability (GRADE of evidence: very low; strength of recommendation: weak).   1199 
 1200 
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5.5. What factors related to administration of the transplant influence the outcome of 1201 
faecal microbiota transplant when treating people with Clostridium difficile 1202 
infection? 1203 
5.5.1. Use of specific medications in the period around FMT administration: 1204 
5.5.1.1. General principles of FMT administration: 1205 
Bowel purgatives have been proposed pre-FMT as a means of removing residual antibiotics that may 1206 
affect engraftment of transplanted microorganisms, and as a means of removing any residual C. 1207 
difficile toxin, spores and vegetative cells110–114. Furthermore, bowel purgatives pre-colonoscopic 1208 
FMT delivery facilitate safe endoscopy.  Various bowel purgatives have been used in colonoscopic 1209 
FMT studies, including polyethylene glycol (PEG) (often 4 litres)14,17,115–117,35,41,43,46,54–56,100, 1210 
MoviPrep®35,41, and  macrogol13,15,18,59.  In those studies that used an upper GI route for FMT, 1211 
PEG54,55,84 and Klean-Prep®15,61 were used. FMT without bowel preparation has also been used as 1212 
treatment for recurrent CDI without any apparent reduction in efficacy, including in randomised 1213 
studies16.  1214 
 1215 
The rationale for the use of proton pump inhibitors (PPI) prior to upper GI FMT is to minimise acidity 1216 
which may impair engraftment of transplanted microorganisms; however, PPIs have been shown to 1217 
alter the gut microbiota118,119, and have also been associated with primary and recurrent CDI120,121.  1218 
Some studies advocate the use of PPI prior to receiving FMT via the upper GI route37,39,45,84,85,122,123, 1219 
but there appears to be comparable efficacy data in studies where it has not been used.  Certain 1220 
studies have also given recipients PPI prior to receiving colonoscopic FMT17,87.   1221 
 1222 
The use of prokinetics (such as metoclopramide) has been described prior to FMT delivery via the 1223 
upper GI tract route, but only in a very small number of studies85.  Given the potential risk of 1224 
regurgitation/aspiration associated with upper GI administration of FMT, the working group felt that 1225 
its use should be considered where appropriate.  1226 
 1227 
A single dose/ short course of loperamide has been used following FMT (predominantly for lower GI 1228 
administration) in an attempt to prolong the exposure of the FMT to the mucosa, and to aid 1229 
retention of the FMT within the GI tract13,46,49,55,84,123.  One study utilised diphenoxylate with 1230 
atropine54 instead.   However, no studies have compared FMT with and without anti-motility drugs. 1231 
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 1232 
The working group also discussed infection control aspects as they apply to FMT administration.  1233 
Specifically, they agreed that recipients should ideally be cared for in a single room with en-suite 1234 
bathroom facilities and, where appropriate, be placed at the end of an endoscopy list, to facilitate 1235 
enhanced environmental decontamination and prevention of transmission of C. difficile spores.  1236 
Protocols for decontamination of endoscopes should follow national guidance124,125, using a 1237 
sporicidal agent.  Best practice for prevention of transmission of healthcare-associated infections, as 1238 
described in national guidelines126, should also be applied throughout.  1239 
 1240 
Recommendations:   1241 
i. We recommend that bowel lavage should be administered prior to FMT via the 1242 
lower GI route, and bowel lavage should be considered prior to FMT via the upper 1243 
GI route; polyethylene glycol preparation is preferred (GRADE of evidence: low; 1244 
strength of recommendation: strong). 1245 
ii. For upper GI FMT administration, we suggest that a proton pump inhibitor should 1246 
be considered, e.g. the evening before and morning of delivery (GRADE of 1247 
evidence: low; strength of recommendation: weak).   1248 
iii. We suggest that a single dose of loperamide (or other anti-motility drugs) should 1249 
be considered following lower GI FMT delivery (GRADE of evidence: low; strength 1250 
of recommendation: weak).   1251 
iv. We suggest that prokinetics (such as metoclopramide) should be considered prior 1252 
to FMT via the upper GI route (GRADE of evidence: low; strength of 1253 
recommendation: weak).   1254 
v. We recommend that best practice for prevention of further transmission of CDI 1255 
should be applied throughout when administering FMT to patients with CDI 1256 
(nursing with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE 1257 
of evidence: high; strength of recommendation: strong).   1258 
 1259 
5.5.1.2. Additional antibiotics pre-FMT: 1260 
Many studies have given further courses of conventional antimicrobial C. difficile treatment prior to 1261 
FMT.  Regimens have included vancomycin alone12,14,18,35,39,55,59,86,117, metronidazole or 1262 
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vancomycin40,41,43,122, or alternatively vancomycin, fidaxomicin or metronidazole56, with one study 1263 
using a range of regimens which included rifaximin123.  The length of treatment was also variable, 1264 
ranging from 24 hours54 up to four days prior to receiving FMT39,45; however, comparative studies 1265 
have not been undertaken. 1266 
 1267 
Recommendation:   1268 
We recommend the administration of further antimicrobial treatment for CDI for at least 1269 
72 hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).     1270 
 1271 
5.5.1.3. Washout period between antibiotic use and FMT: 1272 
Nearly all studies specified a washout period after completing anti-CDI antibiotics and before 1273 
administration of FMT.  However, this time period appeared to be arbitrarily selected and varied 1274 
from as little as four46 or 12 hours51, up to 72 hours36.  The majority of studies specified either 24 1275 
hours15,37,39,40,45,54,127 or 48 hours41,42,49,60, however some allowed a range from 1-3 days16,44,52,53,55.  1276 
One study appeared to allow co-administration of vancomycin with bowel preparation, without a 1277 
washout period18. 1278 
 1279 
The working group discussed the challenging scenario of providing FMT to patients with recurrent 1280 
CDI, but who also had a strong indication for long-term non-anti-CDI antibiotics (e.g. splenectomy, 1281 
osteomyelitis, or infective endocarditis), or patients who develop an indication for antibiotics for a 1282 
reason other than CDI shortly after receiving FMT.  The concern in this instance is that the use of 1283 
antibiotics may limit engraftment of microbial communities derived from the FMT, and therefore 1284 
reduce its effectiveness.  The working group discussed a recent retrospective study demonstrating 1285 
that exposure to non-anti-CDI antimicrobials within eight weeks of FMT is associated with an 1286 
approximate threefold risk of FMT failure (n=8/29 failures with antibiotic exposure vs 36/320 failures 1287 
without antibiotic exposure)128.  Similarly, the experience of the large pan-Netherlands stool bank129 1288 
was that ∼50% of their failures of FMT in the treatment of recurrent CDI occurred in patients who 1289 
had received antibiotics within one month of their FMT.  For patients requiring long-term antibiotics, 1290 
the working group’s expert opinion was that such patients should still be eligible for FMT, but that 1291 
the regimen for the use of non-anti-CDI antibiotics should be decided on a case-by-case basis, based 1292 
on factors including response to FMT and/or strength of indication of antibiotics.  Both in this 1293 
scenario, and the scenario in which antibiotics are required shortly after receiving FMT, the working 1294 
Page 44 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 43
party agreed that infectious diseases specialists/medical microbiologists should be involved in 1295 
making decisions regarding the choice of agents used.   1296 
 1297 
Recommendations:  1298 
iii. To minimise any deleterious effect of antimicrobials on the FMT material, we 1299 
recommend that there should be a minimum washout period of 24 hours between the 1300 
last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of 1301 
recommendation: strong). 1302 
iv. We suggest considering consultation with infectious disease specialists or medical 1303 
microbiologists for advice whenever FMT recipients also have an indication for long-1304 
term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of 1305 
FMT (GRADE of evidence: very low; strength of recommendation: weak). 1306 
 1307 
5.5.2. Route of FMT delivery: 1308 
5.5.2.1. Introduction: 1309 
FMT can be delivered via the lower GI route (retention enema, colonoscopy), upper GI route 1310 
(endoscopically, or via nasogastric tube, nasoduodenal or nasojejenal tube), or via capsules 1311 
(containing either frozen FMT or lyophilised faecal material).  Systematic reviews with meta-analysis 1312 
suggest that FMT for recurrent CDI via colonoscopy may have slightly higher efficacy compared to 1313 
upper GI administration127,130–132 with similar safety profiles, but also note the trend towards using 1314 
larger amounts of stool or ‘higher concentration’ FMT in lower GI administration.  One systematic 1315 
review (reviewing principally case series, and including only one randomised study) compared 1316 
remission rates for CDI using FMT delivered to different areas of the GI tract, and reported that for 1317 
FMT infused into the stomach, duodenum/jejunum, caecum/ascending colon, and rectum the rates 1318 
of cure rate were 81%, 86%, 93%, and 84%, respectively131.   1319 
 1320 
In the only randomised study that directly compared upper and lower GI administration, there was 1321 
no significant difference in overall cure rate (p = 0.53)17.   1322 
 1323 
5.5.2.2. Upper gastrointestinal tract administration of FMT: 1324 
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FMT has been shown to be safe and efficacious in the treatment of C. difficile when administered via 1325 
nasogastric tube37,39,45,61,83,123, nasoduodenal tube15,84,85, enteroscopy122,123, or via the infusion 1326 
channel on a gastroscope40,45.  In a randomised trial, nasoduodenal donor FMT has been shown to be 1327 
more efficacious than vancomycin in treating recurrent CDI15.  Furthermore, it has been shown that 1328 
FMT can also be safely and effectively delivered via a percutaneous endoscopic gastrectomy 1329 
tube45,83.  The working group noted that upper GI administration of FMT may be particularly suitable 1330 
for certain patient groups, such as those in whom there are contraindications or who would find it 1331 
difficult to tolerate lower GI endoscopy, and/ or patients unlikely to be unable to retain enemas.     1332 
 1333 
Typically, smaller volumes of faecal suspension are administered to the upper GI tract compared to 1334 
lower GI administration, with quoted volumes ranging from 25ml39 up to 150ml84- 250ml37,85. Up to 1335 
500ml of suspension has been given safely and effectively via the upper GI route15,77.  However, the 1336 
working group expressed concerns regarding the risk of regurgitation and aspiration if large volumes 1337 
of FMT are administered to the upper GI tract, and also discussed cases in which this has been 1338 
described with adverse outcomes80.  This included a reported death from aspiration, after 100-150ml 1339 
of FMT was delivered by enteroscope into the distal duodenum under general anaesthetic as 1340 
attempted treatment for recurrent CDI133.  A further reported case described a case of fatal 1341 
aspiration pneumonitis likely related to a 500ml FMT via nasoduodenal tube; this patient had a 1342 
swallowing disorder following oropharyngeal radiation after surgical removal of a maxillary 1343 
carcinoma two years previously77.  Based on their expert opinion, the working group recommended 1344 
that upper GI FMT should be used with caution in those at risk of regurgitation (e.g. known large 1345 
hiatus hernia, severe gastro-oesophageal reflux disease, etc) and/ or with swallowing disorders 1346 
(although administration via a gastrostomy tube would be acceptable).  They also recommended 1347 
that no more than 100ml of FMT should be administered to the upper GI tract to minimise these 1348 
risks.   1349 
  1350 
Recommendations:   1351 
i. We recommend that upper GI administration of FMT as treatment for recurrent or 1352 
refractory CDI should be used where clinically appropriate (GRADE of evidence: 1353 
high; strength of recommendation: strong). 1354 
ii. Where upper GI administration is considered most appropriate, we recommend 1355 
that FMT administration should be via nasogastric, nasoduodenal, or nasojejunal 1356 
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tube, or alternatively via upper GI endoscopy.  Administration via a permanent 1357 
feeding tube is also appropriate (GRADE of evidence: high; strength of 1358 
recommendation: strong).   1359 
v. We recommend that no more than 100ml of FMT is administered to the upper GI 1360 
tract (GRADE of evidence: low; strength of recommendation: strong). 1361 
vi. We recommend that upper GI administration of FMT should be used with caution 1362 
in those at risk of regurgitation and/ or those with swallowing disorders (GRADE of 1363 
evidence: low; strength of recommendation: strong). 1364 
 1365 
5.5.2.3. Lower gastrointestinal tract administration of FMT: 1366 
FMT via enema:  Successful treatment of C. difficile with FMT enema has been 1367 
demonstrated16,38,42,53,55,83,86 bu  enema appears to have a lower efficacy than other routes of FMT 1368 
administration.  Specifically, in a randomised study primarily comparing the efficacy of fresh and 1369 
frozen FMT in the treatment of recurrent CDI, only 52.8% of patients in the ‘frozen’ arm and 50.5% 1370 
of patients in the ‘fresh’ arm of the study (n=57/108 and 56/111 respectively) experienced 1371 
resolution of symptoms after a single enema, by modified intention to treat analysis16. However, 1372 
resolution rates in both arms only reached >80% after at least three enemas16.  A recent randomised 1373 
study demonstrated similar rates of recurrence of CDI in patients with recurrent CDI treated with 1374 
either a single FMT enema or a six week vancomycin taper (n=9/16 patients with recurrence vs 5/12 1375 
respectively)12. Notwithstanding this, enemas do have specific advantages, such as being a 1376 
treatment option where full colonoscopy is contraindicated. It is also possible to give multiple 1377 
infusions relatively easily and outside a hospital setting.   1378 
 1379 
FMT via colonoscopy:  Randomised study evidence has demonstrated that colonoscopic FMT has 1380 
higher efficacy in treating recurrent CDI than vancomycin18.  Efficacy is similar whether FMT is fresh 1381 
or frozen, but modestly reduced when using a lyophilised FMT product13.  Colonoscopic delivery of 1382 
donor FMT into the ileum or caecum was associated with a 91% cure rate for recurrent CDI14.  1383 
Observational studies highlighted similar success, describing cure rates of 88% (n=14/16)74 and 91%46 1384 
(n=21/23) in response to infusion of donor FMT into the caecum or terminal ileum.  A further 1385 
advantage of using colonoscopy to administer FMT has been to allow assessment for the presence of 1386 
pseudomembranes; in certain reviewed studies, the presence or absence of pseudomembranes has 1387 
influenced the FMT regimen used18,73.  However, the working group noted that that many patients 1388 
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with CDI are frail and elderly, and as such it will not always be safe or feasible to undertake 1389 
colonoscopy in this particular group of patients.  Flexible sigmoidoscopy appears to be an feasible 1390 
option where full colonoscopy cannot be performed e.g. unable to tolerate colonoscopy,  severity of 1391 
colitis56,60.   1392 
 1393 
The amount of faecal suspension via enema has varied between 150-500mls16,38,42,55,86.  The amount 1394 
of faecal suspension delivered via colonoscopy has been similarly variable, with some studies 1395 
suggesting as little as 100ml can be used with success rates of 94%43. 250ml-400ml had a success 1396 
rate of 100%36, whereas infusions of up to 500-700ml were associated with cure rates of 92%46.  1397 
However, the working group noted that it is difficult to compare ‘concentration’ of FMT in different 1398 
studies as different protocols used varied starting amounts of faecal material.  Currently, there are 1399 
no randomised studies that compare concentration/ volume of colonoscopic or enema FMT.  As 1400 
such, no recommendation was made to this regard.   1401 
 1402 
Recommendations:   1403 
i. We recommend that colonoscopic administration of FMT as treatment for 1404 
recurrent or refractory CDI should be used where appropriate (GRADE of evidence: 1405 
high; strength of recommendation: strong). 1406 
ii. Where colonoscopic administration is used, we suggest considering preferential 1407 
delivery to the caecum or terminal ileum, as this appears to give the highest 1408 
efficacy rate (GRADE of evidence: low; strength of recommendation: weak).  1409 
iii. We recommend that FMT via enema should be used as a lower GI option when 1410 
delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of 1411 
evidence: high; strength of recommendation: strong).   1412 
 1413 
5.5.2.4. Capsulised FMT: 1414 
Capsulised FMT aims to remove some of the concerns regarding conventional FMT, such as the 1415 
invasive means of administration and palatability.  The largest case series describing the use of 1416 
capsules as treatment for recurrent CDI72,89 noted clinical resolution at eight weeks off antibiotics for 1417 
CDI in 82% of cases (n=147/180) after one course of capsules, and 91% (n=164/180) after two 1418 
courses.  The capsules contained frozen FMT prepared in a diluent of saline with 10% glycerol; 15 1419 
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capsules were administered each day for two consecutive days (equating to a mean 48g of original 1420 
crude stool).  Other smaller case series have demonstrated comparable results87,123,134, including 1421 
when lyophilised stool is used instead of frozen whole FMT134.    1422 
 1423 
The working group reviewed two randomised studies which have examined the efficacy of 1424 
capsulised FMT in treating recurrent CDI.  In one study, published in abstract form94, a ‘high dose’ 1425 
regimen of frozen FMT capsules (30 capsules each day for two days) was compared to ‘low dose’  (30 1426 
capsules in one day).  CDI resolution was comparably high in both arms with one treatment course 1427 
(77% (n=7/9) in the ‘high dose’ arm vs 70% (n=7/10) in the ‘low dose arm’). 4/5 initial non-1428 
responders entered remission after a second capsule course with the ‘high dose’ regimen94.   In a 1429 
recent large randomised trial, patients with recurrent CDI were randomised to receive either thawed 1430 
frozen FMT either via colonoscopy or via capsules (one treatment of 40 capsules)11.  On per protocol 1431 
analysis, remission at 12 weeks after a single treatment occurred in 96% in both arms (n=51/53 by 1432 
capsule, n=50/52 by colonoscopy).     1433 
 1434 
The working group discussed certain unresolved issues regarding capsules.  Specifically, capsules are 1435 
often large, and swallowing 30 capsules in a single day may be a significant undertaking for patients 1436 
with CDI, such as the frail elderly with an existing high pill burden.  They also noted that follow-up 1437 
data post-capsule administration is relatively short compared to other modalities of FMT.   1438 
 1439 
Recommendation:   1440 
Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend 1441 
that this should be offered to patients as a potential treatment modality where available.  1442 
Capsule preparations should follow a standard protocol.  Further evidence regarding 1443 
optimal dosing and formulation is required (GRADE of evidence: high; strength of 1444 
recommendation: strong). 1445 
 1446 
5.6. What is the clinical effectiveness of FMT in treating conditions other than 1447 
Clostridium difficile infection? 1448 
5.6.1. Introduction: 1449 
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In current clinical practice, FMT is used predominantly in the treatment of recurrent CDI. Its success 1450 
has led to exploration of its efficacy in other GI diseases, primarily ulcerative colitis (UC), where 1451 
perturbation of the gut microbiota has been observed and implicated in disease pathogenesis135.  1452 
Due to variability of the quality, methodology and cohorts of patients recruited in trials of FMT for 1453 
non-CDI indications, and in order to control for significant confounding factors, the working group 1454 
only included randomised trials involving patients with well-defined conditions and in which there 1455 
was a primary clinical outcome.  To date, there have been a total of 71 such studies investigating the 1456 
role of FMT in IBD; of these, only four are prospective randomised controlled trials, limited to 1457 
patients with ulcerative colitis136–139.  Five other reviewed randomised studies investigated the use of 1458 
FMT in irritable bowel syndrome140, slow transit constipation141, hepatic encephalopathy142 and 1459 
metabolic syndrome143,144.   1460 
 1461 
5.6.2. Use of FMT for ulcerative colitis:  1462 
5.6.2.1. Efficacy: 1463 
All four RCTs, with a total of 277 subjects, included patients with mild to moderate UC (Mayo score 1464 
3-11 and endoscopic sub-score of at least 1).  Participants were aged between 27 and 56 years and 1465 
largely included patients on stable immunosuppressive therapy (only one study excluded patients 1466 
using biologic treatments and methotrexate within the preceding two months)136.  Three studies 1467 
included patients on oral corticosteroids at the time of FMT, however only two required a 1468 
mandatory wean of these to meet eligibility.  Studies generally included patients with all disease 1469 
distributions found in UC.  Time to evaluation of response to FMT in these studies varied between 1470 
seven and twelve weeks.  Two studies used autologous FMT as placebo136,139.  Three of the four 1471 
studies demonstrated that patients receiving donor FMT were significantly more likely to achieve 1472 
clinical and endoscopic remission compared to placebo137–139.  The pooled rate of combined clinical 1473 
and endoscopic remission was 27.9% for donor FMT and 9.5% for placebo.  A pooled risk ratio for 1474 
failure of FMT to achieve these combined outcomes was 0.8 (95% CI: 0.7-0.9).  Deep remission 1475 
(histological) was only reported in one RCT: 18.4% of patients receiving FMT achieved this outcome 1476 
compared to 2.7% of those receiving placebo137. 1477 
 1478 
5.6.2.2. Characteristics of FMT preparation and delivery: 1479 
The four RCTs varied in their FMT preparation and delivery methodology.  Two RCTs delivered frozen 1480 
FMT, one fresh FMT, and one used a combination.  Three RCTs with a positive outcome delivered the 1481 
FMT via the lower GI route; these studies used a high intensity protocol ranging from a total of three 1482 
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infusions in one week to 40 FMTs over an eight week period137–139.  The other RCT (that failed to 1483 
show efficacy of FMT for UC) had adopted a low intensity protocol of two nasoduodenal infusions 1484 
given three weeks apart136.  Interestingly, the only RCT that prepared stool in anaerobic conditions 1485 
demonstrated the highest rate of steroid-free clinical remission and steroid-free clinical response 1486 
with donor FMT139.  A further interesting observation in one study was a trend towards higher rates 1487 
of remission with one particular donor137. 1488 
 1489 
5.6.2.3. Adverse events: 1490 
Short-lived GI symptoms such as abdominal bloating, cramps, diarrhoea and fever were reported in 1491 
patients receiving FMT for UC.  There were no significant differences in serious adverse events 1492 
between patients receiving FMT compared to placebo (10 vs 7 respectively).  Most of the serious 1493 
adverse events were a consequence of worsening colitis: one patient who received FMT required a 1494 
colectomy136.  In addition, one patient developed concurrent CDI137.  No deaths were reported in any 1495 
of the studies. 1496 
 1497 
5.6.3. Use of FMT in functional bowel disorders:   1498 
Two RCTs have investigated the role of FMT in functional bowel disorders.  In a double-blind placebo 1499 
controlled RCT that recruited 90 patients with IBS with diarrhoea or with diarrhoea and 1500 
constipation140, the primary endpoint only just reached statistical significance in inducing symptom 1501 
relief (as assessed by 75 point reduction in IBS-severity scoring system at three months following a 1502 
single infusion FMT by colonoscopy) (p=0·049).  The second RCT randomised 60 patients with slow 1503 
transit constipation to either six consecutive days of nasogastric-delivered FMT or conventional 1504 
treatment141.  This demonstrated that a significant proportion of patients achieved the primary 1505 
endpoint of a mean of at least three complete spontaneous bowel movements per week (53.3% vs. 1506 
20.0%, p= 0.009) along with improvement in stool consistency score and colonic transit time.  1507 
However, the intervention group had more treatment-related adverse events than did the control 1508 
group (total of 50 vs 4 cases).  1509 
 1510 
5.6.4. Use of FMT in hepatic encephalopathy: 1511 
One small study has investigated the role of FMT in the management of hepatic encephalopathy 1512 
(HE)142.  This RCT randomised 20 male patients with cirrhosis with refractory HE to receive either five 1513 
days of broad-spectrum antibiotic pre-treatment followed by a single FMT enema or standard of 1514 
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care. Patients in the FMT arm had a significantly lower incidence of serious adverse events and 1515 
improved cognition.  The Model for End-Stage Liver Disease (MELD) score, however, transiently 1516 
worsened post-antibiotics in the FMT arm.  The study was potentially confounded as patients in the 1517 
FMT arm continued to receive lactulose and/or rifaximin for treatment of their HE.  1518 
 1519 
5.6.5. Use of FMT for metabolic syndrome: 1520 
Two randomised studies143,144, with a combined total of 56 patients, demonstrated an improvement 1521 
in peripheral (but not hepatic) insulin sensitivity in Caucasian male obese patients with metabolic 1522 
syndrome following one or two infusions via nasoduodenal tube of FMT obtained from lean donors.  1523 
This improvement was observed at six weeks post-FMT, but was no longer present by 18 weeks.  No 1524 
improvement in insulin sensitivity was identified in patients transplanted with autologous FMT (i.e. 1525 
patients transplanted with their own collected faeces).  The improvement in peripheral insulin 1526 
sensitivity in the lean donor FMT group was accompanied by a small but significant improvement in 1527 
HbA1c at six weeks144, but no improvements in other metabolic parameters, such as weight.  Whilst 1528 
these data are of interest, the working group felt that the limited, transient nature of the benefits 1529 
seen and small size of the studies meant that FMT could not be recommended as treatment for 1530 
metabolic syndrome.  1531 
 1532 
5.6.6. Future directions for randomised trials of FMT for non-CDI indications: 1533 
Currently there are a large number of randomised trials (including RCTs) being undertaken globally, 1534 
to evaluate the potential role of FMT as treatment for a wide range of conditions.  The working 1535 
group concluded that until there are more reliable data to inform decision-making, the best practice 1536 
principles described in this document for the governance of an FMT service for recurrent CDI should 1537 
also be applied to FMT clinical trials for other conditions.  However, specific adaptations may be 1538 
considered depending on the condition being studied, e.g. consideration of using anaerobic 1539 
conditions for the preparation of FMT in trials for the treatment of UC, as described above. 1540 
   1541 
In conclusion, FMT has the potential to be an effective treatment option for mild to moderate 1542 
ulcerative colitis, and appears to be safe despite the use of immunosuppressive therapy.  FMT may 1543 
also have a potential role in the treatment of functional bowel disorders.  However, 1544 
recommendations for clinical use for both these indications cannot be made until there is clearer 1545 
evidence of the most appropriate patient characteristics, preparation methodology, route of delivery 1546 
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and intensity of administration of FMT.  The evidence for the use of FMT in hepatic encephalopathy 1547 
and metabolic syndrome is currently limited, and further well-designed RCTs are needed to evaluate 1548 
its potential role here.     1549 
 1550 
Recommendation:   1551 
We do not currently recommended FMT as treatment for inflammatory bowel disease.  1552 
Apart from CDI, there is insufficient evidence to recommend FMT for any other 1553 
gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength 1554 
of recommendation: strong). 1555 
 1556 
6. Basic requirements for implementing a FMT service: 1557 
As discussed above, there is an absence of published studies to support the recommendations in this 1558 
section (although the experience of setting up a nationwide stool bank has recently been reported 1559 
from the Netherlands129).  This section is therefore based on the working group’s expert opinion and 1560 
experience of developing FMT services.  The working group considered best practice in this area as it 1561 
applied to legal and clinical governance aspects, the relevant professionals required to establish an 1562 
FMT service, the infrastructure of a service, and appropriate practices for FMT manufacturing and 1563 
quality control monitoring where relevant.  The full text of this section is in Supplementary Material 1564 
3.   1565 
 1566 
7. Key performance indicators: 1567 
• All donors to have completed initial screening questionnaires and blood and stool screening 1568 
results, as well as final health check prior to each stool donation processed to FMT.  Results from 1569 
each subsequent serial round of screening also to be documented.   1570 
• All FMT recipients to have clear documentation of details of their disease course and 1571 
preparation prior to FMT, including whether recurrent or refractory disease, previous 1572 
antimicrobial courses, and use of bowel purgatives/other preparatory medications pre-FMT. 1573 
• All FMT recipients to have sufficient documentation to allow clear traceability of the exact FMT 1574 
aliquot transfused.  Records should include identification of the donor, as well as a frozen FMT 1575 
aliquot (and original faecal sample) - as well as serum - from that donor (see Supplementary 1576 
Material 3).   1577 
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• All FMT recipients for recurrent or refractory CDI to have documentation during follow-up of 1578 
treatment success or failure (and subsequent treatment plan if failure), together with clear 1579 
documentation of any adverse events that may be attributable to FMT.    1580 
 1581 
8. Further research: 1582 
• As described within this guideline, many aspects of the terminology of CDI are used variably 1583 
betwee  studies, and end-points in FMT trials are inconsistent.  The working group noted the 1584 
need to standardise this terminology to allow more robust comparisons between studies.   1585 
• Given the relative novelty of FMT as a procedure, any potential long-term adverse events 1586 
associated with its use are poorly-defined.  The establishment of formal FMT registries should be 1587 
considered.  Whilst this would primarily act as an important tool for defining the safety and 1588 
efficacy of FMT, it would also be a valuable database for researchers within the field.  1589 
Standardisation of other key documentation related to FMT administration (e.g. establishment 1590 
of a proforma for assessing eligibility for FMT and/or follow-up after FMT) would also be 1591 
advantageous for the same reasons.   1592 
• The working group noted the lack of consistency in definitions related to the severity of CDI 1593 
disease and to response or failure to FMT.  This limited interpretation of the published studies.  1594 
As such, the working group thought that standardisation of these definitions would allow more 1595 
accurate delineation of the factors influencing the efficacy of FMT for CDI.  The working group 1596 
also noted that only one reviewed study had reported the relationship between C difficile 1597 
ribotype and FMT outcome, and that recording of this information should be encouraged better 1598 
to evaluate its influence.   1599 
• Further well-designed clinical trials (in particular, RCTs) are required to identify the optimal 1600 
means of administration of FMT as treatment for recurrent and/or refractory CDI.   1601 
• The working group noted that even capsulised FMT may be associated with potential drawbacks.  1602 
They also noted that there are many patients with recurrent CDI for whom FMT (or any form of 1603 
‘bacteriotherapy’) may be inappropriate, including those with very marked immunosuppression, 1604 
and/or multi-organ disease.  Despite high levels of efficacy, there is a small but appreciable FMT 1605 
failure rate and it is not currently understood whether this is due to underlying donor or 1606 
recipient factors.  Therefore, a research priority should be in basic and translational studies 1607 
better to define the mechanisms underlying the efficacy of FMT in CDI.  This includes comparing 1608 
the structure and function of the microbiota of donors to patients pre-FMT and post-FMT, via 1609 
techniques including next-generation microbial sequencing, metabolic profiling, and 1610 
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immunological assays.  This would allow the refinement of FMT from its current state to a more 1611 
targeted therapy, removing the concerns associated with FMT.   1612 
• The working group identified a need for further well-designed RCTs to investigate the potential 1613 
role of FMT for non-CDI indications.  1614 
 1615 
9. Conclusions: 1616 
FMT has become an accepted, efficacious treatment for recurrent and/or refractory CDI.  In 1617 
developing this guideline, the evidence for the technique has been reviewed in the context of other 1618 
available treatments.  Specific guidance for best practice for an FMT service is provided. 1619 
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 2098 
 2099 
 2100 
 2101 
 2102 
 2103 
 2104 
 2105 
 2106 
 2107 
 2108 
 2109 
 2110 
 2111 
 2112 
 2113 
 2114 
 2115 
 2116 
 2117 
15. Figure legends and tables: 2118 
Figure 1:  Proposed summary pathway for donor screening for centres preparing frozen FMT from 2119 
recurring donors.   2120 
 2121 
Table 1:  Recommended donor history/ questionnaire:  A positive response to any of these 2122 
questions would usually result in exclusion from further consideration as a donor, although this 2123 
would depend upon the particular circumstances/ answers given.   2124 
Page 71 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 70
1. Receipt of antimicrobials within the past three months. 2125 
2. Known prior exposure to HIV and/ or viral hepatitis, and known previous or latent 2126 
tuberculosis. 2127 
3. Risk factors for blood-borne viruses - including high risk sexual behaviours, use of illicit 2128 
drugs, any tattoo/ body piercing/ needlestick injury/ blood transfusion/ acupuncture, all 2129 
within the previous six months. 2130 
4. Receipt of a live attenuated virus within the past six months.   2131 
5. Underlying gastrointestinal conditions/ symptoms (e.g. history of IBD, IBS, chronic diarrhoea, 2132 
chronic constipation, coeliac disease, bowel resection or bariatric surgery) - also including 2133 
acute diarrhoea/ gastrointestinal symptoms within the past two weeks. 2134 
6. Family history of any significant gastrointestinal conditions (e.g. family history of IBD, or 2135 
colorectal cancer).  2136 
7.  History of atopy (e.g. asthma, eosinophilic disorders). 2137 
8. Any systemic autoimmune conditions. 2138 
9. Any metabolic conditions, including diabetes and obesity. 2139 
10. Any neurological or psychiatric conditions, or known risk of prion disease.  2140 
11. History of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia.  2141 
12. History of any malignancy.   2142 
13. Taking particular regular medications, or such medications within the past three months, i.e. 2143 
antimicrobials, proton pump inhibitors, immunosuppression, chemotherapy  2144 
14. History of receiving growth hormone, insulin from cows, or clotting factor concentrates. 2145 
15. History of receiving an experimental medicine or vaccine within the past six months.    2146 
16. History of travel to tropical countries within the past six months. 2147 
 2148 
 2149 
Table 2:  Recommended blood screening for stool donors:  *EBV and CMV testing is only 2150 
recommended where there is the potential that the FMT prepared from that donor will be 2151 
administered to immunosuppressed patients at risk of severe infection if exposed to CMV and EBV.       2152 
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 2153 
 2154 
 2155 
 2156 
 2157 
 2158 
 2159 
Table 3:  Recommended stool screening for stool donors:  *Whilst CPE and ESBL are the only multi-2160 
drug resistant bacteria that are recommended to be screened for universally, consider testing for 2161 
other resistant organisms (including vancomycin-resistant Enterococci (VRE) and/ or methicillin-2162 
resistant Staphylococcus aureus (MRSA)) based upon risk assessment and local prevalence.   2163 
Pathogen screening: 
• Hepatitis A IgM 
• Hepatitis B (HBsAg and HBcAb) 
• Hepatitis C antibody 
• Hepatitis E IgM 
• HIV -1 and -2 antibodies 
• HTLV-1 and -2 antibodies 
• Treponema pallidum antibodies (TPHA, VDRL) 
• Epstein-Barr virus IgM and IgG* 
• Cytomegalovirus IgM and IgG* 
• Strongyloides stercoralis IgG 
• Entamoeba histolytica serology 
 
General/ metabolic screening: 
• Full blood count with differential. 
• Creatinine and electrolytes 
• Liver enzymes (including albumin, bilirubin, aminotransferases, gamma-glutamyltransferase 
and alkaline phosphatase). 
• C-reactive protein 
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 2164 
 2165 
 2166 
 2167 
 2168 
 2169 
 2170 
 2171 
 2172 
 2173 
 2174 
 2175 
 2176 
 2177 
 2178 
Table 4:  A summary of the GRADE system: 2179 
GRADE - strength of evidence: GRADE - strength of recommendation: 
• Clostridium difficile PCR 
• Campylobacter, Salmonella, and Shigella by standard stool culture and/ or PCR 
• Shiga toxin-producing Escherichia coli by PCR.   
• Multi-drug resistant bacteria, at least carbapenemase-producing Enterobacteriaceae 
(CPE) and extended-spectrum beta-lactamases (ESBL)*.  
• Stool ova, cysts and parasite analysis, including for Microsporidia.  
• Faecal antigen for Cryptosporidium and Giardia.  
• Acid fast stain for Cyclospora and Isospora.  
• Helicobacter pylori faecal antigen. 
• Norovirus, Rotavirus PCR.  
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High quality: Further research is very unlikely to change our 
confidence in the estimate of effect. 
The trade-offs:  Taking into account the 
estimate size of the effect for main outcomes, 
the confidence limits around those estimates 
and the relative value placed on each outcome. 
Moderate quality: Further research is likely to have an 
important impact on our confidence in the estimate of effect 
and may change the estimate. 
The quality of the evidence.  
Low quality: Further research is very likely to have an 
important impact on our confidence in the estimate of effect 
and is likely to change the estimate. 
Translation of the evidence into practice in a 
particular setting:  Taking into consideration 
important factors that could be expected to 
modify the size of expected effects. 
Very low quality:  Any estimate of effect is very uncertain.   Uncertainty about the baseline risk for the 
population of interest.   
 2180 
 2181 
 2182 
 2183 
 2184 
 2185 
 2186 
 2187 
 2188 
  2189 
 2190 
 2191 
Table 5:  Criteria for stool collection: 
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 2192 
  2193 
 2194 
 2195 
 2196 
 2197 
 2198 
 2199 
Clear instructions should be given to donors regarding hand hygiene. 
Collect stool donations in a sealable clean container.  A number of specifically designed devices 
are available commercially.   
Stool should ideally be passed directly into the clean container for collection; alternatively, it may 
be collected in clean tissue and transferred to the clean container.  
Stool should be transported to the FMT production site as soon as possible post defaecation (and 
within six hours); however, if a short period of storage is necessary, this should be at 4°C.  
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 4 
1. Abstract: 82 
Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing 83 
globally in recent years, particularly as a result of randomised studies in which it has been used as an 84 
intervention.  The main focus of these studies has been the treatment of recurrent or refractory 85 
Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential 86 
applications in non-CDI settings.  The key clinical stakeholders for the provision and governance of 87 
FMT services in the United Kingdom (UK) have tended to be in two major specialty areas:  88 
gastroenterology and microbiology/infectious diseases. Whilst the National Institute for Health and 89 
Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become 90 
accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking.  This resulted in 91 
discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society 92 
(HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the 93 
culmination of that joint dialogue.   94 
 95 
2. Executive summary: 96 
2.1. Overview: 97 
The remit of the British Society of Gastroenterology (BSG)/ Healthcare Infection Society (HIS) 98 
working group was to provide recommendations as to best practice in the provision of a faecal 99 
microbiota transplant (FMT) service.  This guideline considers the use of FMT for the treatment of 100 
Clostridium difficile infection (CDI) – as well as for potential non-CDI indications – in adults.  The 101 
working group have primarily targeted their report at clinicians involved in the use and provision of 102 
FMT services, but have also aimed it to be of interest to patients and their relatives.   103 
 104 
2.2. Summary of recommendations: 105 
2.2.1. Which patients with Clostridium difficile infection should be considered for faecal 106 
microbiota transplant, and how should they be followed up after treatment? 107 
2.2.1.1. Prior to faecal microbiota transplant. Patient selection: 108 
2.2.1.1.1. Recurrent Clostridium difficile infection: 109 
We recommend that FMT should be offered to patients with recurrent CDI who have had at 110 
least two recurrences, or those who have had one recurrence and have risk factors for 111 
further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; 112 
strength of recommendation: strong). 113 
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 114 
2.2.1.1.2. Refractory Clostridium difficile infection: 115 
We recommend that FMT should be considered in cases of refractory CDI (GRADE of 116 
evidence: moderate; strength of recommendation: strong). 117 
 118 
2.2.1.1.3. FMT as initial therapy for Clostridium difficile infection: 119 
We recommend that FMT should not be administered as initial treatment for CDI (GRADE of 120 
evidence: low; strength of recommendation: strong).   121 
 122 
2.2.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with CDI: 123 
i. We recommend that FMT for recurrent CDI should only be considered after 124 
recurrence of symptoms following resolution of an episode of CDI that was treated 125 
with appropriate antimicrobials for at least 10 days (GRADE of evidence: low; 126 
strength of recommendation: strong). 127 
ii. We recommend consideration of treatment with extended/ pulsed vancomycin 128 
and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE 129 
of evidence: low; strength of recommendation: strong).  130 
iii. For those with severe or complicated CDI, which appears to be associated with 131 
reduced cure rates, we recommend that consideration should be given to offering 132 
patients treatment with medications which are associated with reduced risk of 133 
recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of 134 
evidence: low; strength of recommendation: strong). 135 
 136 
2.2.1.2. Post-FMT follow-up, outcomes and adverse events: 137 
2.2.1.2.1. Management of FMT failure: 138 
We recommend that FMT should be offered after initial FMT failure (GRADE of evidence: 139 
high; strength of recommendation: strong).     140 
 141 
2.2.1.2.2. General approach to follow-up post-FMT: 142 
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 6 
We recommend that all FMT recipients should routinely receive follow-up.  Clinicians should 143 
follow-up FMT recipients for long enough to fully establish efficacy/adverse events, and for 144 
at least eight weeks in total (GRADE of evidence: low; strength of recommendation: strong).   145 
 146 
2.2.1.2.3. Management of the FMT recipient: 147 
i. We recommend that immediate management after endoscopic administration of 148 
FMT should be as per endoscopy unit protocol (GRADE of evidence: very low: 149 
strength of recommendation: strong).   150 
ii. We recommend that patients should be warned about short term adverse events, in 151 
particular the possibility of self-limiting GI symptoms. They should be advised that 152 
serious adverse events are rare (GRADE of evidence: very low; strength of 153 
recommendation: strong).  154 
iii. After enteral tube administration, we recommend that patients may have the tube 155 
removed and oral water given from 30 minutes post-administration (GRADE of 156 
evidence: very low; strength of recommendation: strong). 157 
 158 
2.2.1.2.4. Definition of cure post-FMT for CDI: 159 
We recommend that a decision regarding cure/remission from CDI should be recorded 160 
during follow-up.  However, this has no uniformly-agreed definition, and should be decided 161 
on a case-by-case basis (GRADE of evidence: very low; strength of recommendation: strong).             162 
 163 
2.2.1.2.5. Definition of treatment failure post-FMT for CDI: 164 
We recommend that treatment failure/recurrence should be defined on a case-by-case 165 
basis.  Routine testing for C. difficile toxin after FMT is not recommended, but it is 166 
appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 167 
of evidence: low; strength of recommendation: strong).   168 
 169 
2.2.2. What recipient factors influence the outcome of faecal microbiota transplant when 170 
treating people with Clostridium difficile infection? 171 
2.2.2.1. General approach to co-morbidities and FMT: 172 
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 7 
i. We recommend that FMT should be avoided in those with anaphylactic food allergy 173 
(GRADE of evidence: very low; strength of recommendation: strong). 174 
ii.  We suggest that FMT should be offered with caution to patients with CDI and 175 
decompensated chronic liver disease (GRADE of evidence: very low; strength of 176 
recommendation: weak). 177 
 178 
2.2.2.2. Immunosuppression and FMT: 179 
i. We recommend that FMT should be offered with caution to immunosuppressed 180 
patients, in whom FMT appears efficacious without significant additional adverse 181 
effects (GRADE of evidence: moderate; strength of recommendation: strong). 182 
ii. We recommend that immunosuppressed FMT recipients at risk of severe infection if 183 
exposed to EBV or CMV should only receive FMT from donors negative for EBV and 184 
CMV (GRADE of evidence: very low; strength of recommendation: strong). 185 
 186 
2.2.2.3. Other comorbidities and FMT: 187 
i. We recommend that FMT should be offered to those with recurrent CDI and 188 
inflammatory bowel disease, but patients should be counselled about a small but 189 
recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of 190 
recommendation: strong).    191 
ii. We recommend that FMT should be considered for appropriate patients with 192 
recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate; 193 
strength of recommendation: strong). 194 
 195 
2.2.3. What donor factors influence the outcome of faecal microbiota transplant when 196 
treating people with Clostridium difficile infection? 197 
2.2.3.1. General approach to donor selection:  198 
We recommend that related or unrelated donors should both be considered acceptable.  199 
However, where possible, FMT is best sourced from a centralised stool bank, from a healthy 200 
unrelated donor (GRADE of evidence: low; strength of recommendation: strong). 201 
 202 
2.2.3.2. Age and BMI restrictions for potential donors: 203 
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 8 
We suggest that people should only be considered as potential FMT donors if they are ≥18 204 
and ≤60 years old, and have a BMI of ≥18 and ≤30 kg/m2 (GRADE of evidence: low; strength 205 
of recommendation: weak).   206 
 207 
2.2.3.3. General approach to the donor screening assessment: 208 
It is mandatory to screen potential donors by questionnaire and personal interview, to 209 
establish risk factors for transmissible diseases and factors influencing the gut microbiota 210 
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).  211 
 212 
2.2.3.4. Laboratory screening of potential donors: 213 
Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: low; 214 
strength of recommendation: strong).  215 
 216 
2.2.3.5. Repeat donor checks, and d nation pathway: 217 
i. In centres using frozen FMT, before FMT may be used clinically, we recommend that 218 
donors should have successfully completed a donor health questionnaire and laboratory 219 
screening assays both before and after the period of stool donation.  This is the 220 
preferred means of donor screening (GRADE of evidence: low; strength of 221 
recommendation: strong).  222 
ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should be 223 
assessed at the time of each stool donation.  To ensure ongoing suitability for inclusion 224 
as a donor, the donor health questionnaire and laboratory screening should be repeated 225 
regularly (GRADE of evidence: low; strength of recommendation: strong).   226 
 227 
2.2.4. What factors related to the preparation of the transplant influence the outcome of 228 
faecal microbiota transplant when treating people with Clostridium difficile 229 
infection? 230 
2.2.4.1. General principles of FMT preparation: 231 
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 9 
i. We recommend that stool collection should follow a standard protocol (GRADE of 232 
evidence: low; strength of recommendation: strong).  233 
ii. We recommend that donor stool should be processed within 6 hours of defaecation 234 
(GRADE of evidence: low; strength of recommendation: strong). 235 
iii. We recommend that both aerobically and anaerobically prepared FMT treatments 236 
should be considered suitable when preparing FMT for the treatment of recurrent 237 
CDI (GRADE of evidence: moderate; strength of recommendation: strong). 238 
iv. We recommend that sterile 0.9% saline should be considered as an appropriate 239 
diluent for FMT production, and cryoprotectant such as glycerol should be added for 240 
frozen FMT (GRADE of evidence: moderate: strength of recommendation: strong). 241 
v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence: 242 
moderate: strength of recommendation: strong). 243 
vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal 244 
emulsion (GRADE of evidence: low; strength of recommendation: weak). 245 
vii. We suggest that homogenisation and filtration of FMT should be undertaken in a 246 
closed disposable system (GRADE of evidence: low; strength of recommendation: 247 
weak).  248 
 249 
2.2.4.2. Fresh vs frozen FMT: 250 
We recommend that the use of banked frozen FMT material should be considered 251 
preferable to fresh preparations for CDI (GRADE of evidence: high; strength of 252 
recommendation: strong). 253 
 254 
2.2.4.3. Use of frozen FMT: 255 
i. We recommend that FMT material stored frozen at -80oC should be regarded as having a 256 
maximum shelf life of six months from preparation (GRADE of evidence: low; strength of 257 
recommendation: strong). 258 
ii. We suggest consideration of thawing frozen FMT at ambient temperature, and using 259 
within six hours of thawing (GRADE of evidence: low; strength of recommendation: 260 
weak). 261 
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iii. We suggest not thawing FMT in warm water baths, due to the risks of cross 262 
contamination with Pseudomonas (and other contaminants) and reduced bacterial 263 
viability (GRADE of evidence: very low; strength of recommendation: weak).   264 
 265 
2.2.5. What factors related to administration of the transplant influence the outcome of 266 
faecal microbiota transplant when treating people with Clostridium difficile 267 
infection? 268 
2.2.5.1. Use of specific medications in the period around FMT administration: 269 
2.2.5.1.1. General principles of FMT administration: 270 
i. We recommended that bowel lavage should be administered prior to FMT via the 271 
lower GI route, and that bowel lavage should be considered prior to FMT via the 272 
upper GI route; polyethylene glycol preparation is preferred (GRADE of evidence: 273 
low; strength of recommendation: strong). 274 
ii. For upper GI FMT administration, we suggest that a proton pump inhibitor should be 275 
considered, e.g. the evening before and morning of delivery (GRADE of evidence: 276 
low; strength of recommendation: weak).   277 
iii. We suggest that a single dose of loperamide (or other anti-motility drugs) should be 278 
considered following lower GI FMT delivery (GRADE of evidence: low; strength of 279 
recommendation: weak).   280 
iv. We suggest that prokinetics (such as metoclopramide) should be considered prior to 281 
FMT via the upper GI route (GRADE of evidence: low; strength of recommendation: 282 
weak).   283 
v. We recommend that best practice for prevention of further transmission of CDI 284 
should be applied throughout when administering FMT to patients with CDI (nursing 285 
with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE of 286 
evidence: high; strength of recommendation: strong).   287 
 288 
2.2.5.1.2. Additional antibiotics pre-FMT: 289 
We recommend the administration of further antimicrobial treatment for CDI for at least 72 290 
hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).     291 
 292 
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2.2.5.1.3. Washout period between antibiotic use and FMT: 293 
i. To minimise any deleterious effect of antimicrobials on the FMT material, we 294 
recommend that there should be a minimum washout period of 24 hours between the 295 
last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of 296 
recommendation: strong). 297 
ii. We suggest considering consultation with infectious disease specialists or medical 298 
microbiologists for advice whenever FMT recipients also have an indication for long-299 
term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of FMT 300 
(GRADE of evidence: very low; strength of recommendation: weak). 301 
 302 
2.2.5.2. Route of FMT delivery: 303 
2.2.5.2.1. Upper gastrointestinal tract administration of FMT: 304 
i. We recommend that upper GI administration of FMT as treatment for recurrent or 305 
refractory CDI should be used where clinically appropriate (GRADE of evidence: high; 306 
strength of recommendation: strong). 307 
ii. Where upper GI administration is considered most appropriate, we recommend that 308 
FMT administration should be via nasogastric, nasoduodenal, or nasojejunal tube, or 309 
alternatively via upper GI endoscopy.  Administration via a permanent feeding tube 310 
is also appropriate (GRADE of evidence: high; strength of recommendation: strong).   311 
iii. We recommend that no more than 100ml of FMT is administered to the upper GI 312 
tract (GRADE of evidence: low; strength of recommendation: strong). 313 
iv. We recommend that upper GI administration of FMT should be used with caution in 314 
those at risk of regurgitation and/ or those with swallowing disorders (GRADE of 315 
evidence: low; strength of recommendation: strong). 316 
 317 
2.2.5.2.2. Lower gastrointestinal tract administration of FMT: 318 
i. We recommend that colonoscopic administration of FMT as treatment for recurrent 319 
or refractory CDI should be used where appropriate (GRADE of evidence: high; 320 
strength of recommendation: strong). 321 
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ii. Where colonoscopic administration is used, we suggest considering preferential 322 
delivery to the caecum or terminal ileum, as this appears to give the highest efficacy 323 
rate (GRADE of evidence: low; strength of recommendation: weak).  324 
iii. We recommend that FMT via enema should be used as a lower GI option when 325 
delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of 326 
evidence: high; strength of recommendation: strong).   327 
 328 
2.2.5.2.3. Capsulised FMT: 329 
Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend 330 
that this should be offered to patients as a potential treatment modality where available.  331 
Capsule preparations should follow a standard protocol.  Further evidence regarding 332 
optimal dosing and formulation is required (GRADE of evidence: high; strength of 333 
recommendation: strong). 334 
 335 
2.2.6. What is the clinical effectiveness of FMT in treating conditions other than 336 
Clostridium difficile infection? 337 
We do not currently recommended FMT as treatment for inflammatory bowel disease.  338 
Apart from CDI, there is insufficient evidence to recommend FMT for any other 339 
gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength of 340 
recommendation: strong). 341 
 342 
2.2.7. Basic requirements for implementing a FMT service: 343 
2.2.7.1. General considerations: 344 
i. The development of FMT centres should be encouraged (GRADE of evidence: very 345 
low; strength of recommendation: strong). 346 
ii. We suggest that FMT centres should work to raise awareness about FMT as a 347 
treatment option amongst clinicians caring for patients with CDI, and provide 348 
training to relevant healthcare professionals on the practicalities of delivering an 349 
FMT service (GRADE of evidence: very low; strength of recommendation: weak).   350 
 351 
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2.2.7.2. Legal aspects and clinical governance: 352 
In the UK, FMT must be manufactured in accordance with MHRA guidance for human 353 
medicines regulation.  When FMT is supplied on a named patient basis, within a single 354 
organisation, a pharmacy exemption may be used, subject to ensuring proper governance 355 
and traceability.  All centres that are processing and distributing FMT should seek guidance 356 
from the MHRA and where necessary obtain appropriate licenses prior to establishing an 357 
FMT service.  This is a legal requirement.  In countries other than the UK, FMT should only 358 
be manufactured following appropriate approval from the national authority of that country 359 
(GRADE of evidence: very low; strength of recommendation: strong).  360 
 361 
2.2.7.3. Multidisciplinary teams: 362 
We recommend that a multidisciplinary team should be formed to deliver FMT services 363 
(GRADE of evidence: very low; strength of recommendation: strong). 364 
 365 
2.2.7.4. Infrastructure: 366 
We recommend utilisation of suitable laboratory facilities and infrastructure for FMT 367 
production (GRADE of evidence: very low; strength of recommendation: strong). 368 
 369 
2.2.7.5. FMT manufacturing: 370 
We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength 371 
of recommendation: strong). 372 
 373 
2.2.7.6. FMT production quality control: 374 
We recommend monitoring, notification and investigation of all adverse events and 375 
reactions related to FMT (GRADE of evidence: very low; strength of recommendation: 376 
strong). 377 
 378 
2.2.7.7. Donor screening governance: 379 
We recommend ensuring the clinical governance of donor screening (GRADE of evidence: 380 
very low; strength of recommendation: strong). 381 
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 382 
3. Introduction: 383 
The aim of the BSG/ HIS FMT working group was to establish a guideline that defined best practice in 384 
all aspects of a FMT service, by providing evidence-based recommendations wherever possible, and 385 
consensus multi-disciplinary expert opinion where specific published evidence is currently lacking.  386 
This included the evaluation of the use of FMT in the treatment of Clostridium difficile infection (CDI; 387 
also referred to as Clostridioides difficile1), and also in potential non-CDI indications.  Relevant 388 
guidance published to date includes the interventional procedure guidance from the National 389 
Institute for Health and Care Excellence (NICE)2, UK, European and US microbiological guidelines on 390 
the treatment of Clostridium difficile infection (CDI)3–5, and recent expert consensus documents on 391 
FMT in clinical practice6,7.  Furthermore, there have also been national recommendations regarding 392 
FMT produced by working groups in several different countries8–10. Principally as a result of 393 
randomised studies that have been published in recent years11–18, FMT has become an accepted 394 
treatment for recurrent/refractory CDI.   395 
 396 
The unique remit and objectives of this guideline when commissioned by the BSG and HIS was: 397 
i. To review the rapidly-growing body of randomised trial evidence for the efficacy of FMT in the 398 
treatment of adults (≥18 years), both in CDI and in other clinical conditions, much of which has been 399 
published after the publication of current CDI treatment algorithms3,4. 400 
ii. To provide specific guidance about best practice for an FMT service within the context of the 401 
regulatory framework for the intervention as it currently exists in the UK19,20.   402 
 403 
The elucidation of the mechanisms underlying the efficacy of FMT in treating CDI remains an active 404 
area of global research, with the aim of rationalising FMT from its current crude form to a more 405 
targeted, refined therapeutic modality21.  Previous research has demonstrated that commensal 406 
bacteria cultured from the stool of healthy donors22, sterile faecal filtrate23, and/ or spores of 407 
Firmicutes derived from ethanol-treated stool from healthy donors24, may have similar efficacy to 408 
conventional FMT in treating CDI, although results of the latter approach produced disappointing 409 
outcome data when extended to a Phase II clinical trial25.  For the purposes of this guideline, the 410 
BSG/HIS working group considered only studies that used the administration of manipulated whole 411 
stool (including encapsulated faeces).  They deemed studies using cultured microorganisms (or their 412 
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proteins, metabolites or other components), or microbiota suspensions, to be in the pre-clinical 413 
research stage, without firm evidence.  414 
 415 
FMT has been shown to be very acceptable to patients, both in the setting of CDI11,26 and in non-CDI 416 
settings, e.g. ulcerative colitis27.  However, the absence of appropriate protocols28–31 specifically 417 
taking into account UK clinical practice and regulation of FMT has been perceived as a barrier to the 418 
use of FMT in the UK and Ireland; these guidelines seek to rectify this problem. 419 
 420 
4. Guideline development: 421 
4.1. Guideline development team 422 
BSG and HIS commissioned the authors to undertake the Working Party Report.  The authors 423 
represent the membership of both societies.  The working group included gastroenterologists, 424 
infectious diseases/microbiology clinicians, a clinical scientist, a systematic reviewer, and patient 425 
representatives.  The views expressed in this publication are those of the authors, and have been 426 
endorsed by BSG and HIS following consultation. 427 
 428 
4.2. Scope of the guidelines 429 
The main scope of the guidelines is to provide guidance for the optimal provision of an effective and 430 
safe FMT service, principally for recurrent or refractory CDI, but non-CDI indications are also 431 
considered.  These guidelines only apply to adult patients (≥18 years); the working party did not 432 
consider the role of FMT in the treatment of either CDI or non-CDI indications in children or young 433 
people.  The guidelines were written with a focus upon UK practice, but also with consideration of 434 
more global practice as it applied.  The diagnosis and management of Clostridium difficile infection in 435 
general are outside the remit of these guidelines. 436 
 437 
4.3. Evidence appraisal 438 
Questions for review were derived from the Working Party Group, which included patient 439 
representatives in accordance with the PICO process32.  To prepare these recommendations, the 440 
working group collectively reviewed relevant peer-reviewed research.   441 
 442 
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4.4. Data sources and search strategy 443 
A systematic literature search was undertaken using MEDLINE, EMBASE databases and Cochrane 444 
Library for relevant articles published from 1st January 1980 to 1st January 2018.  The MEDLINE and 445 
EMBASE strategy are shown in Supplementary Material 1, Appendix 2ii.  Free text and MESH/ index 446 
terms for faecal microbial transplant and Clostridium difficile or other diseases of interest were 447 
combined.  In addition, conference proceedings from microbiology, infectious disease, and 448 
gastroenterology conferences were also searched to identify additional studies.   449 
 450 
4.5. Study eligibility and selection criteria 451 
The members of the guideline group determined criteria for study inclusion.  Two reviewers (BHM, 452 
MNQ) screened the titles and abstracts of each article for relevance independently; any 453 
disagreements were resolved by discussion with a third reviewer (JPS).  Copies of relevant articles 454 
were obtained and assessed for inclusion as evidence in the guideline by all three reviewers.  The 455 
reason for not selecting studies was recorded.  Only articles published in English and human clinical 456 
studies were included.  For evidence on FMT for CDI, both randomised studies (including randomised 457 
controlled trials (RCTs)) and case series with at least 10 patients were selected.  Only randomised 458 
trials were included as evidence for FMT for non-CDI indications.  Conference abstracts were only 459 
included for CDI and non-CDI indications if they reported a randomised trial; where abstracts were 460 
available reporting data from a randomised trial that was subsequently published, only the 461 
published paper was reviewed.   462 
 463 
4.6. Data extraction and quality assessment 464 
The initial search identified 2658 publications, and of these, 802 duplicates were excluded.  1856 465 
studies were subsequently screened, from which 78 studies were assessed by reviewing the full text 466 
for eligibility (see Supplementary Material 1, Appendix 2iii and Supplementary Material 2, 467 
Additional Appendix D).  Of these 78 studies, 58 studies were included as the basis of evidence for 468 
writing this guideline.  In total, 39 were case studies in CDI including at least 10 patients (see 469 
Supplementary Material 2, Additional Appendix C.1), and ten were randomised studies in CDI (see 470 
Supplementary Material 2, Additional Appendix C.2). Nine were randomised trials for non-CDI 471 
indications (see Supplementary Material 2, Additional Appendix C.3).  Data were extracted for 472 
patient demographics, disease characteristics, donor screening characteristics, stool preparation and 473 
administration, clinical outcomes and adverse events.  The quality of randomised studies was 474 
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assessed with the Cochrane Collaboration’s risk of bias tool.  Case series were assessed using the 475 
Centre for Reviews and Dissemination guidance.   476 
 477 
4.7. Rating of evidence and recommendations 478 
The BSG version of these guidelines was prepared in keeping with the BSG Clinical Services & 479 
Standards Committee (CSSC) advice document on the writing of clinical guidelines33.  Evidence tables 480 
were presented and discussed by the working group, and guidelines were prepared according to the 481 
nature and applicability of the evidence regarding efficacy and patient preference and acceptability.  482 
For the BSG version of this guideline, the GRADE system (Grades of Recommendation Assessment, 483 
Development and Evaluation)34 was used to assess the strength of evidence (high/ moderate/ low/ 484 
very low) and strength of recommendation (strong/ weak) (Table 4).  The section entitled ‘Basic 485 
requirements for implementing an FMT service’ (Supplementary Material 3) was based on expert 486 
opinion, since this was a key area of the working party’s remit but not one amenable to evaluation 487 
by the PICO process.  Face-to-face meetings and group teleconferences were held to agree on 488 
recommendations.  Any disagreements on recommendations or the strength of recommendation 489 
were resolved by discussion and, where necessary, voting by the members of the working group, 490 
with consensus achieved when >80% were in agreement.   491 
 492 
4.8. Consultation process 493 
Feedback on draft guidelines was received from the Scientific Development Committee (SDC) of HIS, 494 
and changes made.  These guidelines were then opened to consultation with relevant stakeholders 495 
(see Supplementary Material 1, Appendix 3 of this document).  The draft report was available on 496 
the HIS website for one month.  Views were invited on format, content, local applicability, patient 497 
acceptability, and recommendations.  The working group reviewed stakeholder comments, and 498 
collectively agreed revisions.  Final changes were made after repeat reviews from HIS (Chair of the 499 
SDC and HIS Council) and BSG (BSG CSSC and BSG Council), and after further external peer review.      500 
 501 
4.9. Guideline accreditation and scheduled review 502 
The guidelines will be reviewed at least every four years and updated if change(s) in the evidence are 503 
sufficient to require a change in practice.  504 
 505 
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4.0. Additional information: 506 
Additional information related to this guideline (including a lay summary, background on the 507 
working party report, and information on the implementation of these guidelines) is contained 508 
within Supplementary Material 1, Section 1.   509 
 510 
5. Rationale for recommendations: 511 
5.1. Which patients with Clostridium difficile infection should be considered for faecal 512 
microbiota transplant, and how should they be followed up after treatment? 513 
5.1.1. Prior to faecal microbiota transplant. Patient selection: 514 
5.1.1.1. Recurrent Clostridium difficile infection: 515 
As already described, there is widespread consensus that FMT is an efficacious treatment for 516 
recurrent CDI.  In defining recurrent CDI, some studies have relied on a minimum threshold of return 517 
of clinical symptoms (e.g. at least three unformed bowel movements within 24 hours, for at least 518 
two consecutive days)12,18 following previous successful CDI treatment; most studies have also 519 
included a requirement for a positive microbiological test12,14,18,35–45.  Other studies explicitly state 520 
that a positive test was not required46.  Recommendations for CDI testing are beyond the scope of 521 
this guideline, and there are already well-established evidence-based guidelines47.  These 522 
recommend testing with either a nucleic acid amplification test (NAAT) or GDH assay, followed by 523 
detection of free toxin (either by toxin A/B enzyme immunoassay (EIA) or cytotoxin neutralisation 524 
assay), which allows differentiation of patients with active disease as well as those who are likely 525 
colonised47.  However, the working group discussed the importance of the accurate diagnosis of true 526 
recurrent CDI prior to consideration of FMT; in particular, they noted a study which observed that of 527 
117 patients with presumed recurrent CDI referred for work-up for FMT, 25% (n=29/117) were 528 
determined to have a non-CDI diagnosis, with irritable bowel syndrome (n=18) and inflammatory 529 
bowel disease (n=3) being the most common alternative diagnoses, and younger patients more likely 530 
to be misdiagnosed48.   531 
 532 
All of the reviewed studies have included patients with recurrent CDI, however some studies offered 533 
FMT to patients at the first recurrence (second episode)12,15,16,18,35,37,42,43,46,49, whereas others offered 534 
FMT after the second recurrence (third episode)13,14,39,41,44,45,50,51.  Some protocols offered FMT after 535 
three or more recurrences52, whilst others did not define the point at which it was adminstered40,53.   536 
 537 
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The severity of infection has been used as a parameter to decide at which stage FMT is offered. 538 
Youngster et al. offered FMT to patients with at least three episodes of mild to moderate CDI, or at 539 
least two episodes of severe CDI resulting in hospitalisation and associated with significant 540 
morbidity17.  Another study selected patients for FMT using four categories of severity, which also 541 
accounted for prior anti-CDI therapy and requirement for hospitalisation54.   542 
 543 
None of the studies directly compared the efficacy of FMT according to the stage at which it was 544 
offered (i.e. first recurrence vs. ≥ two recurrences).  A small number of studies55–57 included patients 545 
with severe CDI (defined as hypoalbuminaemia with increased peripheral white cell count and/or 546 
abdominal tenderness) or complicated CDI (defined as admission to Intensive Care, altered mental 547 
status, hypotension, fever, ileus, white blood cell count > 30 x 109/l, lactate > 2.2mmol/l, or evidence 548 
of end organ damage).  A single study described an apparent lower rate of treatment success when 549 
FMT was used to treat patients with recurrent CDI with disease caused by ribotype 02743, but this is 550 
the case for all anti-CDI treatment modalities for this ribotype in comparison to others.  The working 551 
group agreed that there was insufficient evidence to suggest that C. difficile ribotype should 552 
influence whether or not FMT is offered.     553 
 554 
A lower primary cure rate was reported for complicated CDI (66%) compared with recurrent CDI 555 
(82%) and severe CDI (91%) in one study55; in a case series of 17 patients who all had severe and/or 556 
complicated CDI, a primary cure rate of 88% was described57.  A cohort of 328 patients was analysed 557 
to determine which factors were associated with failure of FMT58. Higher early (one month) failure 558 
rates were found in patients with severe (72%, n=19/25) or severe-complicated (52.9%, n=9/17) CDI 559 
than for recurrent CDI (11.9%, n=34/286).  This study also identified that patients who were treated 560 
with FMT as an inpatient were nearly four times more likely to fail as those who had FMT as an 561 
outpatient; however, the working group noted that the authors of this study themselves identified 562 
that inpatient status is likely a proxy of severity of CDI and/or co-morbidities.  A further similar study, 563 
including 64 patients treated with FMT as treatment for recurrent CDI, also identified severe CDI as 564 
the strongest independent risk factor for FMT failure on multivariate analysis59.     565 
 566 
The working group discussed their experience of treating patients with CDI whose disease fitted an 567 
intermediate pattern to the typical descriptions given of recurrent or refractory CDI, e.g. patients 568 
with CDI who have some (but incomplete) symptomatic improvement with anti-CDI antibiotics and 569 
worsening of disease when these are stopped.  The experience of the working group was that such 570 
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patients experienced excellent responses to FMT, and that these patients should be considered for 571 
FMT.     572 
 573 
As FMT is currently an unlicensed medicine with poorly-studied long term sequelae, the working 574 
group considered that it should generally be reserved for patients who have had three or more 575 
episodes of infection.  There are no studies directly comparing its effectiveness with some of the 576 
newer agents such as fidaxomicin or bezlotoxumab, hence this recommendation is made on the 577 
basis of safety.  However, the working group agreed that it may be reasonable in certain patient 578 
groups with ongoing risk factors for further recurrence to offer FMT after the second episode. 579 
 580 
Recommendation:   581 
We recommend that FMT should be offered to patients with recurrent CDI who have had 582 
at least two recurrences, or those who have had one recurrence and have risk factors for 583 
further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; 584 
strength of recommendation: strong). 585 
 586 
5.1.1.2. Refractory Clostridium difficile infection: 587 
Two randomised trials allowed the recruitment of patients with refractory CDI.  The first defined this 588 
as at least three weeks of ongoing severe symptoms despite standard antimicrobial therapy for 589 
CDI17.  The second required persistent or worsening diarrhoea and one of the following: ongoing 590 
abdominal pain, fever > 38oC, or white blood cell count > 15x 109/l despite oral vancomycin at a dose 591 
of 500mg four times daily for at least five days16.  Both studies included only small numbers of 592 
patients with refractory CDI (n=4/20 (20%) and n=15/219 (6.8%), respectively).  There did not appear 593 
to be any significant difference in primary outcome measure (clinical cure) in patients with recurrent 594 
or refractory CDI, although neither study was designed to assess this difference.  There are also a 595 
number of case series in which FMT was given to patients with refractory CDI; however, outcome 596 
measures were not reported for these groups individually in these studies37,38,54,60.   597 
 598 
Overall, the working group concluded that there is little consensus on the definition of refractory 599 
CDI, with some studies using the terms ‘refractory’ and ‘recurrent’ interchangeably (as well as other 600 
terms, e.g. ‘salvage therapy’).  Consequently, the quality of evidence for the utility of FMT in 601 
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refractory cases of CDI is lower than for recurrent CDI.  The standardisation of definitions will allow 602 
more robust comparison between patient cohorts. 603 
 604 
Recommendation:     605 
We recommend that FMT should be considered in cases of refractory CDI (GRADE of 606 
evidence: moderate; strength of recommendation: strong). 607 
 608 
5.1.1.3. FMT as initial therapy for Clostridium difficile infection: 609 
Experience of the use of FMT as initial therapy for CDI is very limited.  In a case series of patients 610 
with CDI with ribotype 027, use of anti-CDI antibiotics together with nasogastric FMT within a week 611 
of diagnosis during an initial episode of CDI was associated with reduced mortality when compared 612 
to using FMT only after the failure of three courses of antibiotics (mortality of 18.75% (n=3/16 613 
patients) vs 64.4% (n=29/45 patients))61.  However, 37.5% (n=6/16) of the patients treated with FMT 614 
within a week of CDI diagnosis required further antibiotics and a second FMT within one month of 615 
the first FMT because of relapse61.  In a small pilot randomised trial, patients were randomised to 616 
either vancomycin or multi-donor FMT (administered either via upper or lower GI routes) as initial 617 
therapy for CDI; CDI resolution occurred in 88.9% (n=8/9) patients with vancomycin, compared to 618 
57.1% of patients (n=4/7) patients with one FMT, and 71.4% of patients (n=5/7) after two FMTs62.  619 
Given the small size of these studies and equivocal results, the working group concluded that the 620 
reviewed studies did not support FMT as initial therapy for CDI.   621 
 622 
Recommendation: 623 
We recommend that FMT should not be administered as initial treatment for CDI (GRADE 624 
of evidence: low; strength of recommendation: strong).   625 
 626 
5.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with 627 
CDI: 628 
There are now at least two licensed agents (fidaxomicin and bezlotoxumab) which have been shown 629 
to significantly reduce the risk of recurrence compared with vancomycin63,64.  There is also some 630 
evidence that pulsed/tapered dosing of vancomycin and fidaxomicin (including pulsed fidaxomicin65) 631 
results in fewer recurrences than with standard dosing of these agents66,67 (although this finding has 632 
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not been replicated in all studies68).  Pre-planned subgroup analysis of patients with severe CDI in a 633 
randomised trial demonstrated a significantly lower recurrence rate when treated with fidaxomicin 634 
(13.0%, n=12/92) than when treated with vancomycin (26.6%, n=29/209)63; this finding was 635 
replicated in another randomised controlled trial, with 8.3% (n=4/48) and 32.6% (n=14/43) 636 
experiencing a recurrence respectively69.  In a further randomised trial, bezlotoxumab (together with 637 
standard of care antibiotics) was shown to reduce recurrence of severe CDI compared to standard of 638 
care antibiotics alone (10.9% (n=6/55) vs 20% (n=13/65) respectively)64.     639 
 640 
As discussed above, the working group noted that there are no studies comparing FMT to 641 
fidaxomicin or bezlotoxumab, and only one study comparing a vancomycin taper to FMT12.  The 642 
working group agreed that in the absence of this evidence, on the balance of safety and potential 643 
risks, consideration should be given to using antimicrobial/antitoxin therapy associated with reduced 644 
CDI recurrence prior to considering the use of FMT.   645 
 646 
Several studies specify that patients should be treated with anti-C. difficile antibiotics for a minimum 647 
period of 10 days before diagnosing recurrent CDI and offering FMT12,15,16,18. 648 
 649 
Recommendations:   650 
i. We recommend that FMT for recurrent CDI should only be considered after 651 
recurrence of symptoms following resolution of an episode of CDI that was treated 652 
with appropriate antimicrobials for at least 10 days (GRADE of evidence: low; 653 
strength of recommendation: strong). 654 
ii. We recommend consideration of treatment with extended/ pulsed vancomycin 655 
and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE 656 
of evidence: low; strength of recommendation: strong).  657 
iii. For those with severe or complicated CDI, which appears to be associated with 658 
reduced cure rates, we recommend that consideration should be given to offering 659 
patients treatment with medications which are associated with reduced risk of 660 
recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of 661 
evidence: low; strength of recommendation: strong). 662 
 663 
5.1.2. Post-FMT follow-up, outcomes and adverse events: 664 
5.1.2.1. Management of FMT failure: 665 
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Where patients were deemed not to have responded to an initial FMT, many studies have offered 666 
repeat FMT and success rates have been excellent even in patients with modest response to a first 667 
FMT14,15,17,18,35,43,46,51,54,70,71.  The success of a second FMT appears to be high whether treatment 668 
failure represents non-response to the first FMT, or a late failure (i.e. further relapse of CDI after an 669 
initial response); however, these terms have been defined variably between different studies (also 670 
see Section 5.1.2.5).  Second FMTs have been offered as soon as 24-72 hours after an initial FMT for 671 
presumed non-response37,72,73.  For FMT failure in patients with pseudomembranous colitis, repeat 672 
FMT every three days until resolution of pseudomembranes has been a successful approach18.  Good 673 
outcomes in pseudomembranous disease have also been achieved through a protocol that routinely 674 
restarted five days of vancomycin if FMT failed, before offering another FMT73.  Other studies have 675 
demonstrated potential success in treating initial FMT failure with further antibiotics, including 676 
repeat FMT with vancomycin between procedures42, or anti-CDI antibiotics alone35,42,43,45,51,70,71.  677 
Patients unresponsive to two FMTs have been offered further FMT or antibiotic therapy16, or even 678 
the administration of intravenous immunoglobulin35.  Whilst the working group collectively agreed 679 
that there was strong evidence to recommend repeat FMT after initial FMT failure, they were not 680 
able to recommend a specific protocol for administering repeat FMT and/ or maximum number of 681 
FMTs, given the wide heterogeneity of approach described within the reviewed literature.   682 
 683 
Recommendation:   684 
We recommend that FMT should be offered after initial FMT failure (GRADE of evidence: 685 
high; strength of recommendation: strong).     686 
 687 
5.1.2.2. General approach to follow-up post-FMT: 688 
Follow-up post-FMT (in terms of duration, modality and regimen for follow-up) varies considerably 689 
between studies, and is largely dependent upon study design.  Follow-up regimens vary not only 690 
between studies but within them too, reflecting the retrospective nature of many early FMT studies 691 
in CDI, where follow-up mostly reflected pragmatic routine clinical care. 692 
 693 
Modalities of follow-up have included outpatient review14,43,58,71,74–76, telephone 694 
interview17,39,43,46,58,71,74 and case note/ database review35,39,70,71,74,40,42,43,45,46,49,51,54.  Follow-up 695 
duration has varied from 60 days45 to 8 years36, with very different durations used in each study.  696 
Once again, however, this variability in follow-up largely reflects the retrospective analysis of case 697 
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series rather than being justified by any specific methodology.  The working group decided by 698 
consensus that at least eight weeks of follow-up was appropriate post-FMT to fully assess efficacy 699 
and potential adverse events; this figure was also influenced by discussions regarding the timepoint 700 
after FMT at which a decision could be made regarding cure/ remission of CDI (see Section 5.1.2.4).     701 
 702 
Recommendation:   703 
We recommend that all FMT recipients should routinely receive follow-up.  Clinicians 704 
should follow-up FMT recipients for long enough to fully establish efficacy/adverse events, 705 
and for at least eight weeks in total (GRADE of evidence: low; strength of 706 
recommendation: strong).   707 
 708 
5.1.2.3. Management of the FMT recipient: 709 
Procedural adverse events during administration of FMT have predominantly occurred with 710 
colonoscopic administration of FMT.  These have included mild nausea and vomiting attributed to 711 
sedation for the colonoscopy, minor mucosal tears during colonoscopy49,60, and microperforation 712 
following biopsy of an area of presumed ischaemic small bowel injury in a patient with chronically 713 
dilated small bowel (which resolved with conservative management46).  One death occurred due to 714 
witnessed aspiration at the time of colonoscopy60.  Faecal regurgitation and vomiting with temporal 715 
association to upper GI FMT administration has also been described (discussed further in Section 716 
5.5.2.2)77.   717 
 718 
The predominant short term adverse events post-FMT for CDI are mild: self-limiting GI symptoms 719 
have been the most frequently reported adverse events.  These may be related to the route of 720 
administration and include belching15, nausea15,16,49,60, abdominal cramps/ discomfort/ bloating/ 721 
pain15,18,49,60,72, and diarrhoea15,16,18,60.  One patient with a history of autonomic dysfunction 722 
experienced dizziness with diarrhoea after FMT15.  These symptoms are typically short-lived, 723 
resolving in hours to days15,16,18,49,72.  Minor subsequent adverse events have included a range of GI 724 
side effects including self-limiting abdominal discomfort14,17,57,76, nausea14,49,70, 725 
flatulence14,16,17,41,42,49,57, self-limiting irregular bowel movements41, C. difficile-toxin negative 726 
diarrhoea52,55, constipation14,15,42,55,70 and constitutional symptoms/ temperature disturbance14,17.  727 
 728 
Page 100 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 25
As such, immediately post-endoscopic administration of FMT, most FMT centres typically manage 729 
patients using standard protocols for an endoscopic procedure41,49, without any specific adaptations 730 
(apart from to reiterate advice about the possibility of self-limiting GI side effects, and the use of 731 
departmental infection control protocols).  There is often a relatively short period of post-procedural 732 
observation15,18.  Most studies allow patients to leave the administration site after the period of 733 
observation, although overnight observation was the protocol used for a cohort of very elderly 734 
patients with multiple comorbidities51.  Where enteral tube administration is used, post-procedure 735 
management has ranged between removal of the tube after 30 minutes (following nasoenteral 736 
administration of 500ml of FMT15) to prompt post-procedure removal and oral water administration 737 
(after nasogastric a ministration of 90ml of FMT72), with no direct adverse outcomes in either case.  738 
The working group felt that removal of the tube at 30 minutes, with administration of water at this 739 
point, was a pragmatic approach.   740 
 741 
The definition of post-FMT serious adverse events has varied between studies, but has included 742 
significant morbidity necessitating hospital admission and death in the follow up period.  Many of 743 
these events are described as not directly caused by the FMT, including the scenario of post-FMT 744 
severe CDI recurrences72 and probable or certain CDI-related deaths16,60,70 occurring in the context of 745 
FMT failure, or deaths related to patient comorbidities17,55.  One patient was admitted to hospital 746 
with self-limiting abdominal pain post-FMT60, and four patients with flares of inflammatory bowel 747 
disease60.  Three patients underwent colectomy during the post-FMT follow-up period, with all 748 
related to ulcerative colitis and not believed to be due to CDI60.  Other reported serious adverse 749 
events include recurrent urinary tract infection15, fever during haemodialysis15 and upper 750 
gastrointestinal haemorrhage after nasogastric FMT (in a patient taking NSAIDs51), none of which 751 
were thought to be strongly linked to FMT.  There have also been a number of new onset 752 
autoimmune, inflammatory and metabolic conditions described post-FMT, although these have 753 
been described from single centres only, with these findings not replicated elsewhere. Such 754 
conditions include microscopic colitis, Sjögren’s syndrome, follicular lymphoma, peripheral 755 
neuropathy, immune thrombocytopenia and rheumatoid arthritis53,55.     756 
 757 
Significant adverse events are therefore rare but well-described.  Furthermore, the procedure is 758 
relatively novel, and longer-term follow-up data regarding safety are required.  Therefore, the 759 
working group opined that formal follow-up post-FMT to assess outcome and possible adverse 760 
events is essential.   761 
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 762 
The use of questionnaires to compare symptoms pre- and post-FMT is common.  Specifically, data 763 
collected have included clinical response to symptom severity55, stool frequency15,17,46,55,57,72, stool 764 
consistency14,15,72, abdominal pain or tenderness55,57, rating of gastrointestinal symptoms72, general 765 
well-being55,72, days to improvement post-FMT57, weight change72, functional status55, and changes 766 
in medication/use of antibiotics57,72.  Additionally, certain patients have been given specific advice 767 
post-FMT to contact their clinical team if there is recurrence of diarrhoea or symptoms14,35,41,43.  768 
Where patients underwent outpatient clinical evaluation, this was generally undertaken relatively 769 
early post-FMT39,52,76.  In one study, patients were additionally given instructions for cleaning and 770 
disinfection at home, with the aim of reducing the possibility of C. difficile reinfection43, and 771 
counselling on the risk of recurrent CDI with future antibiotic courses76. 772 
 773 
Recommendations: 774 
i. We recommend that immediate management after endoscopic administration of 775 
FMT should be as per endoscopy unit protocol (GRADE of evidence: very low: 776 
strength of recommendation: strong).   777 
ii. We recommend that patients should be warned about short term adverse events, 778 
in particular the possibility of self-limiting GI symptoms. They should be advised 779 
that serious adverse events are rare (GRADE of evidence: very low; strength of 780 
recommendation: strong).  781 
iii. After enteral tube administration, we recommend that patients may have the tube 782 
removed and oral water given from 30 minutes post-administration (GRADE of 783 
evidence: very low; strength of recommendation: strong). 784 
 785 
5.1.2.4. Definition of cure post-FMT for CDI: 786 
It is recognised that symptoms of CDI resolve relatively promptly post-successful FMT, although this 787 
has been variably described (within hours in some studies52, at an average of 4-5 days in others57,71).  788 
Treatment success post-FMT for CDI has no uniformly-agreed definition, with the time point at 789 
which cure/ remission is defined on clinical grounds varying between 3-5 days36 up to six months42.  790 
A consensus document from the USA recommends ‘resolution of symptoms as a primary end point; 791 
absence within eight weeks of FMT as a secondary end point’78. The working group recommended 792 
that this definition should be made on a case-by-case basis; however, they agreed that an 793 
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assessment for cure/ remission of CDI within eight weeks post-FMT was reasonable in most cases, 794 
and therefore that this was also a reasonable minimum length of time to undertake follow-up post-795 
FMT (see Section 5.1.2.2). 796 
 797 
Recommendation:   798 
We recommend that a decision regarding cure/remission from CDI should be recorded 799 
during follow-up.  However, this has no uniformly-agreed definition, and should be 800 
decided on a case-by-case basis (GRADE of evidence: very low; strength of 801 
recommendation: strong).             802 
 803 
5.1.2.5. Definition of treatment failure post-FMT for CDI: 804 
There is no uniformly-agreed definition of treatment failure/recurrence post-FMT for CDI, with 805 
varied definitions used in studies.  The use of C. difficile toxin as a marker of treatment success or 806 
failure is variable, with some studies opting not to test for CDT unless symptoms consistent with CDI 807 
recurred49,52–54,60,72,74.  Some studies have routinely performed CDT testing without specifying any 808 
action taken after a positive result14,15,18,36,39,41, whilst others have tested for C. difficile PCR but relied 809 
on clinical criteria (even if PCR was positive) post-FMT for evaluating FMT efficacy14.  A recent 810 
prospective study from the USA identified that only 3% (3/129) of patients who were asymptomatic 811 
at four weeks post-FMT for recurrent CDI had positive C. difficile PCR, again emphasising that 812 
symptoms rather than laboratory assays are more useful contributors to establishing FMT success79.   813 
 814 
Recommendation: 815 
We recommend that treatment failure/recurrence should be defined on a case-by-case 816 
basis.  Routine testing for C. difficile toxin after FMT is not recommended, but it is 817 
appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 818 
of evidence: low; strength of recommendation: strong).   819 
 820 
5.2. What recipient factors influence the outcome of faecal microbiota transplant when 821 
treating people with Clostridium difficile infection? 822 
5.2.1. General approach to co-morbidities and FMT: 823 
Most published studies had a core set of general recipient exclusions which included: significant/ 824 
anaphylactic food allergy14,17, pregnancy12–15,17,18, breastfeeding14, admission to Intensive Care or the 825 
Page 103 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 28
requirement for vasopressors12,15,18, chronic diarrhoea or other infectious cause of diarrhoea12,14,18,50, 826 
inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)14,36, immunodeficiency due to 827 
recent chemotherapy and/ or neutropenia12,14–18,50, HIV/AIDS14,17,18, prolonged use of 828 
corticosteroids15,17,18, graft versus host disease12, and decompensated cirrhosis14,15,17,18.   829 
 830 
The working group discussed the reported practice of several centres of treating patients with 831 
recurrent CDI and food allergies through the use of FMT prepared from a patient-directed donor 832 
instructed to avoid trigger foods before stool donation.  They agreed that this seemed reasonable 833 
for patients with true adverse immunological reactions to defined food groups (e.g. gluten-free diet 834 
donor for a recipient with coeliac disease).  However, the working group noted that food allergies 835 
are often poorly-defined clinically, and also expressed concerns that there was no means to verify 836 
how closely a donor had followed an exclusion diet; as such, they felt unable to make any specific 837 
recommendation about FMT in patients with food allergies in general.  In contrast, whilst the 838 
working group were unaware of any reports in the literature of anaphylaxis attributable to FMT, 839 
they felt that the theoretical risk of a serious adverse outcome in patients with anaphylactic food 840 
allergy merited a specific recommendation that such individuals should not be offered 841 
FMT.  Similarly, the working group expressed concern about the theoretical risk of adverse outcomes 842 
when administering FMT to patients with advanced decompensated chronic liver disease (including 843 
translocation of microbial material from the intestinal tract into the portal and systemic circulations, 844 
and theoretical risk of sepsis), and felt that FMT should be used with caution in this patient group.    845 
 846 
Recommendations: 847 
i. We recommend that FMT should be avoided in those with anaphylactic food allergy 848 
(GRADE of evidence: very low; strength of recommendation: strong). 849 
ii.  We suggest that FMT should be offered with caution to patients with CDI and 850 
decompensated chronic liver disease (GRADE of evidence: very low; strength of 851 
recommendation: weak). 852 
 853 
5.2.2. Immunosuppression and FMT: 854 
One randomised study16 included patients with immunodeficiency (treatment with 855 
immunosuppressive therapy (azathioprine, ciclosporin, infliximab, methotrexate alone, or in 856 
combination with corticosteroids) (n=18), renal transplant (n=5), chronic haemodialysis (n=5), solid 857 
organ tumours (n=3) and haematological malignancy (n=4)) at the time of FMT.  Clinical resolution 858 
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rates after up to two FMTs were high: 27/29 (93%) for immunocompromised individuals, 5/6 (83%) 859 
for patients with IBD. 860 
 861 
There are also limited data from case series and single case reports describing the use of FMT in 862 
patients with immunocompromise.  Agrawal and colleagues55 included 46/146 (32%) patients with a 863 
history of cancer, and an additional 15/146 (10%) patients with non-cancer-related immunologic 864 
dysfunction, although primary outcome measures were not specifically reported for these groups.  865 
Overall cure at 12 weeks in a case series of 80 patients with immunocompromise was reported in 71 866 
(89%) of patients60.  Adverse events occurred in 12 (15%) immunocompromised patients; this 867 
included two deaths (one due to respiratory failure and another due to pneumonia resulting from 868 
aspiration at the time of FMT administration)60; however, such adverse events have also been 869 
reported in non-immunocompromised patient populations80.  Hefazi and coauthors described high 870 
efficacy rates in a case series of FMT for recurrent CDI and a range of haematological or solid organ 871 
malignancies (remission after one FMT in 11/12 with haematological patients, and 8/10 in solid 872 
organ malignancy patients). No significant FMT-related complications were reported81.  A further 873 
case series45 reported FMT treatment for 75 patients with recurrent CDI and found no significant 874 
difference in primary cure rates for patients with diabetes mellitus, malignancy, or steroid use in the 875 
preceding three months.    876 
 877 
The working group discussed the potential impact of donor EBV and CMV status for the 878 
immunocompromised FMT recipient at risk of severe infection if exposed to these viruses.  Their 879 
opinion was that such recipients should only receive FMT from donors with negative EBV and CMV 880 
status.  881 
 882 
Recommendations:   883 
i. We recommend that FMT should be offered with caution to immunosuppressed 884 
patients, in whom FMT appears efficacious without significant additional adverse 885 
effects (GRADE of evidence: moderate; strength of recommendation: strong). 886 
ii. We recommend that immunocompromised FMT recipients at risk of severe infection if 887 
exposed to EBV or CMV should only receive FMT from donors negative for EBV and 888 
CMV (GRADE of evidence: very low; strength of recommendation: strong). 889 
 890 
5.2.3. Other comorbidities and FMT: 891 
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Only a limited number of cited studies included specific detail about the presence of comorbidities in 892 
patients receiving FMT.  However, several studies reported median Charlson comorbidity 893 
scores12,14,15,18,50.  One randomised study reported the presence of IBD in 10/17 (59%) FMT 894 
recipients16, and there did not appear to be any significant difference in primary outcome measures 895 
in this group.  Another randomised trial included 14/72 (33%) patients with IBD and reported clinical 896 
cure of CDI in 12/14 (86%) of these patients13.  This study also included 64/72 (89%) patients with 897 
cardiac, respiratory, renal, central nervous system or multi-organ system comorbidities13; however 898 
outcomes were not stratified according to co-morbidity.  Kelly and coauthors60 reported an overall 899 
cure rate of 94% in a subset of CDI patients with IBD.  A meta-analysis of studies in which patients 900 
with IBD received FMT (either primarily as treatment for concurrent recurrent CDI, or with the aim 901 
of treating IBD) noted a small risk of exacerbation of IBD in association with the use of FMT82.  The 902 
working group noted the complexity of the relationship between IBD and CDI, given that IBD is itself 903 
a risk factor for CDI. 904 
 905 
Other exclusions have been more directly related to the mode of administration. For upper 906 
gastrointestinal delivery, exclusion criteria have included delayed gastric emptying, chronic 907 
aspiration, ‘swallow dysfunction’, and dysphagia17,50.  Exclusions for lower GI administration have 908 
included colostomy/ileostomy16,50, significant bleeding disorders12, untreated colorectal cancer14,36,54, 909 
and ileus/small bowel obstruction50. 910 
 911 
In summary, the working group noted that co-morbidities amongst patients with recurrent CDI are 912 
common.  Most studies did not analyse primary outcome measures according to co-morbidity; 913 
however, a small number of studies have analysed primary outcome measures (clinical cure) for 914 
patients with IBD receiving FMT for recurrent CDI and have found no significant difference compared 915 
to those without IBD, along with no overall significant worsening of IBD activity. 916 
 917 
Recommendations:   918 
i. We recommend that FMT should be offered to those with recurrent CDI and 919 
inflammatory bowel disease, but patients should be counselled about a small but 920 
recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of 921 
recommendation: strong).    922 
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ii. We recommend that FMT should be considered for appropriate patients with 923 
recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate; 924 
strength of recommendation: strong). 925 
 926 
5.3. What donor factors influence the outcome of faecal microbiota transplant when 927 
treating people with Clostridium difficile infection? 928 
5.3.1. General approach to donor selection:  929 
Excellent efficacy has been shown in treating recurrent CDI using FMT derived from both 930 
related14,36,54,57,59,61,83,38,40,41,43,45,46,49,53 and unrelated14,15,57,59,61,72,74,83–87,16,17,35,37,38,41,43,53 donors.  To 931 
date, there have been no randomised studies comparing differences in efficacy.  Case series have 932 
tended to rely more on donation of stool from healthy family members.  In randomised studies using 933 
FMT, all donors were healthy unrelated individuals12–18,88.  Three case series used donor stool from 934 
healthcare professionals39,61,85; no randomised studies have used stool from this cohort.  However, 935 
the working group noted that there were clear advantages to using FMT from a screened 936 
anonymous donor, in particular with regards to monitoring and traceability, as discussed further 937 
later. 938 
 939 
Recommendation:   940 
We recommend that related or unrelated donors should both be considered acceptable.  941 
However, where possible, FMT is best sourced from a centralised stool bank, from a 942 
healthy unrelated donor (GRADE of evidence: low; strength of recommendation: strong). 943 
 944 
5.3.2. Age and BMI restrictions for potential donors: 945 
There are no well-defined age restrictions on donors.  Randomised studies have used donors of 946 
≥1812,72 and ≤60 years old15,17,18 with satisfactory outcomes.  Two of the case series defined age 947 
limitations for donors as ≥18 and ≤ 50 years72,89.  A recent study demonstrated that Bacteroides: 948 
Firmicutes ratio and microbial diversity was similar for donors above and below 60 years, and their 949 
stool donations had similar clinical efficacy as FMT; however, there were loss of the phylum 950 
Actinobacteria and family Bifidobactericeae from donors older than 60 years90.  On balance, the 951 
working group agreed that an age range of 18 – 60 years was appropriate for donors.   952 
 953 
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A widely-reported case study noted apparent weight gain in a recipient of FMT for treatment of CDI 954 
when an overweight donor was used91, but any association between a donor with a raised BMI and 955 
weight gain post-FMT has not been replicated elsewhere in the literature92.  Whereas most 956 
randomised studies did not report donor-specific BMIs, some have excluded those without a 957 
‘normal’ BMI13,17.  The working group considered an acceptable BMI for donors as between ≥18 to 958 
≤30 kg/m2. 959 
 960 
Recommendation:   961 
We suggest that people should only be considered as potential FMT donors if they are ≥18 962 
and ≤60 years old, and have a BMI of ≥18 and ≤30 kg/m
2
 (GRADE of evidence: low; 963 
strength of recommendation: weak).   964 
 965 
5.3.3. General approach to the donor screening assessment: 966 
There is a clear theoretical risk of the transmission of infection by FMT; furthermore, given the large 967 
number of conditions in which perturbation of the gut microbiota has been described93, there is a 968 
concern regarding a risk of transmission of microbiota associated with vulnerability to disease.  969 
Whilst FMT is efficacious for recurrent CDI, adverse events may be associated with its use (discussed 970 
further later), and long-term safety follow-up is lacking.  The aim of a donor screening questionnaire 971 
and interview is to minimise post-FMT adverse events by excluding potential donors from whom 972 
FMT may be associated with risk to recipients.  Randomised studies performed to date used various 973 
pre-screening questionnaires, including self-screening questionnaires which focused on high risk 974 
behaviours for blood-borne infections12–16, questionnaires that focused on previous potential 975 
transferable medical conditions18, and adaptations from the American Association of Blood Banks 976 
Donor Questionnaire14,17.  One randomised study used the OpenBiome questionnaire as a screening 977 
questionnaire94.  Some studies have suggested excluding potential donors who have recently 978 
travelled to defined regions (typically tropical areas), varying between 3-6 months prior to 979 
donation38,39,49,52,55,59,74,87; this is also the protocol employed in randomised studies14,16,18.  Another 980 
important point for assessment is recent use of medications by potential donors.  In particular, given 981 
the profound effects of antimicrobials on the gut microbiota95–98 (along with the theoretical concern 982 
that recent antimicrobials might precipitate gut colonisation with antimicrobial-resistant bacteria 983 
that could be transferred during FMT), studies advocate either a three month14,46,53–55,57,61,74 or six 984 
month16–18,35,38,39,43,49,85,99,100 period without antimicrobial use prior to FMT donation.  985 
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 986 
The working group agreed that, given the growing evidence for the contribution of the gut 987 
microbiota to the aetiopathogenesis of colorectal carcinoma, patients with a significant personal or 988 
family history of (or risk factors for) this condition should be excluded as donors (Table 1).  However, 989 
the working group noted an added complexity, in that their recommendation was that potential 990 
donors may be up to 60 years of age, but bowel scope screening for colorectal carcinoma currently 991 
begins within the UK at 55 years of age, and formal NHS bowel cancer screening starts at the age of 992 
60 years101.  The working group agreed that potential donors living in countries with bowel cancer 993 
screening programmes that start before the age of 60 years should have therefore completed 994 
appropriate screening with negative/ normal tests before they are considered further as donors.   995 
 996 
The working group was of the opinion that a screening process is mandatory; any positive responses 997 
should usually result in exclusion from donation, although this will depend upon the particular 998 
circumstances/ answers given.  A donor screening questionnaire should be performed both prior to 999 
considering a person as a donor, and also at a further point in time (discussed further in Section 1000 
5.3.5).   1001 
 1002 
Recommendation:   1003 
It is mandatory to screen potential donors by questionnaire and personal interview, to 1004 
establish risk factors for transmissible diseases and factors influencing the gut microbiota 1005 
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).  1006 
 1007 
5.3.4. Laboratory screening of potential donors: 1008 
Currently, there are no known confirmed cases of blood-borne pathogens being transmitted by FMT, 1009 
but strict preventative measures are important, as the potential risk of transmission is unknown.  1010 
Many of the suggestions are extended from established blood screening guidelines102.  Case series 1011 
almost universally screen for HIV, hepatitis B and hepatitis C as a minimum35,36,52–1012 
55,59,61,72,74,84,86,37,87,103,39–43,46,49;  other studies (including the randomised trials) have a more thorough 1013 
blood screening process14–18.  Many studies have also included a ‘metabolic/general blood screen’, to 1014 
select out donors with hitherto undiagnosed chronic illness.  Table 2 shows the suggested blood 1015 
screening protocol of the BSG/HIS working group.   1016 
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 1017 
The working group specifically discussed the role of screening donors for their EBV and CMV status; 1018 
the importance of the rationale for this is discussed in Section 5.2.2.  They agreed that EBV and CMV 1019 
testing was only required where there is the potential that the FMT prepared from that donor would 1020 
be administered to immunosuppressed patients at risk of severe infection if exposed to CMV and 1021 
EBV.       1022 
 1023 
The primary aim of stool screening of potential donors is to minimise the risk of transmission of 1024 
pathogens; again, the relative novelty of FMT for CDI means that these risks are not currently well-1025 
defined.  Stool screening protocols are universal amongst published studies, though widely-variable 1026 
protocols have been used.  Table 3 displays the suggested stool screening protocol of the working 1027 
group.  The working group discussed stool screening for multi-drug resistant bacteria carriage, and 1028 
agreed that carbapenemase-producing Enterobacteriaceae (CPE) should be screened for.  Although 1029 
these bacteria are carried only by a minority of the UK population, transfer into debilitated patients 1030 
with CDI is clearly undesirable given that CPE are potentially so difficult to treat.   They also agreed 1031 
that extended-spectrum beta-lactamase (ESBL)-producing organisms could also potentially cause 1032 
severe disease (with limited antimicrobial options) if transplanted into patients with CDI, and so 1033 
should also be screened for.  Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively 1034 
common in the community (probably related to food consumption)104, community strains of VRE are 1035 
genetically distinct from (and generally of much lower pathogenicity than) those found 1036 
nosocomially105; as such, the working group thought that routine screening was not justified.  The 1037 
working group also noted that methicillin-resistant Staphylococcus aureus (MRSA) carriage is very 1038 
rare in healthy adults in non-healthcare settings (with significant intestinal carriage even rarer), so 1039 
did not justify routine screening.  However, the working group acknowledged that the potential 1040 
infection risk from VRE and MRSA would vary regionally dependent upon local prevalence and 1041 
pathogenicity, and as such recommended that a risk assessment is performed to assess whether 1042 
screening for these organisms should be considered.   1043 
 1044 
A donor laboratory screening should be performed both prior to considering a person as a donor, 1045 
and also at a further point in time (discussed further in Section 5.3.5).        1046 
 1047 
Recommendation:   1048 
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Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: 1049 
low; strength of recommendation: strong).  1050 
 1051 
5.3.5. Repeat donor checks, and donation pathway: 1052 
Almost all reviewed studies have repeated at least some elements of the initial donor screening 1053 
process either at the time of donation of each stool sample used to prepare FMT, or at the end of a 1054 
period of donation to assess ongoing suitability for inclusion.  However, protocols have differed 1055 
widely between studies.    1056 
 1057 
The opinion of the working group was that when a donor had met criteria for donation (both with an 1058 
acceptable health questionnaire and satisfactory laboratory tests), they were suitable to begin 1059 
donation of stool that may be prepared into FMT. Repeat donor screening was also deemed 1060 
necessary.  In centres where frozen FMT is being prepared, stool may be collected and processed 1061 
immediately after the first donor screen is successfully completed, but should be stored in 1062 
‘quarantine’ pending further donor screening, rather than used immediately for clinical use.  At the 1063 
end of the locally-defined period of donation, potential donors should undergo repeat testing, with a 1064 
further health questionnaire and laboratory screening.  If the donor’s health questionnaire remains 1065 
acceptable and repeat laboratory screening is negative at this point, then the frozen FMT may be 1066 
released from ‘quarantine’, and used.  The working group thought that donor screening both before 1067 
and after donation was the safest route possible, and that this represented the preferred scenario.  1068 
A proposed summary pathway for donor screening in this scenario is provided in Figure 1.   1069 
 1070 
In centres using fresh FMT, the working group agreed that a repeat health questionnaire should be 1071 
completed at the time of donation of each stool sample used to prepare FMT. Formal repetition of 1072 
both the personal interview/ health questionnaire and laboratory screening tests should occur at 1073 
regular intervals to ensure ongoing suitability for inclusion as a donor.  The working group’s opinion 1074 
was that this repetition of the screening process should occur at least once every four months.           1075 
 1076 
Recommendations:   1077 
i. In centres using frozen FMT, before FMT may be used clinically, we recommend that 1078 
donors should have successfully completed a donor health questionnaire and 1079 
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laboratory screening assays both before and after the period of stool donation.  This is 1080 
the preferred means of donor screening (GRADE of evidence: low; strength of 1081 
recommendation: strong).  1082 
ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should 1083 
be assessed at the time of each stool donation.  To ensure ongoing suitability for 1084 
inclusion as a donor, the donor health questionnaire and laboratory screening should 1085 
be repeated regularly (GRADE of evidence: low; strength of recommendation: strong).   1086 
 1087 
5.4. What factors related to the preparation of the transplant influence the outcome of 1088 
faecal microbiota transplant when treating people with Clostridium difficile 1089 
infection? 1090 
5.4.1. General principles of FMT preparation: 1091 
There is very little evidence or guidance on the collection of donor stool.  Critical steps during this 1092 
process centre on the reduction of environmental cross-contamination risk, so the use of clean 1093 
collection devices and clean collection procedures is advocated.  To promote standardised practice 1094 
and a safe and effective product, clear instructions should be provided to the donor for stool 1095 
collection (Table 5). 1096 
 1097 
Regardless of the methods used to prepare FMT, stool donations should be processed within six 1098 
hours of defaecation.  The period of six hours has been generally applied across many successful 1099 
studies of FMT treatment in CDI14,18,35,39,43,52, although no formal comparative study has been 1100 
undertaken.  This strategy aims to minimise sample degradation and alteration over time, which may 1101 
occur due to the complex metabolic and environmental requirements of the faecal microbiota.  1102 
 1103 
There are no comparative trials of anaerobically versus aerobically prepared FMT in the treatment of 1104 
recurrent CDI.  With the exception of small observational studies41,74, the vast majority of FMT 1105 
preparation has been undertaken aerobically for the treatment of CDI and has proved highly 1106 
efficacious.  There appears to be no clear need to process anaerobically, a method which introduces 1107 
complexity and cost for the treatment of CDI.    1108 
 1109 
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The reviewed randomised studies reported variable amounts of stool used in the preparation of 1110 
each FMT aliquot, and the lack of comparative data means that it is not possible to link stool mass to 1111 
outcome from these studies.  However, a previous systematic review of case series using FMT as 1112 
treatment for recurrent CDI reported similar rates of treatment efficacy, but an approximate 1113 
fourfold increase in recurrence rates, if <50g of stool was used compared to ≥50g106.  Similarly, the 1114 
initial volume of diluent used to create the faecal emulsion is variable between studies, although the 1115 
most common practice appears to be creation of a stool: diluent ratio of approximately 1:5.  The 1116 
overwhelmi g majority of the reviewed studies used stool from only a single donor per FMT (rather 1117 
than stool pooled from a mixture of donors), and there are no comparative studies of outcomes of 1118 
CDI from single donor vs pooled donor FMT; as such, the working group found no justification to 1119 
recommend donor stool pooling for FMT for CDI.   1120 
 1121 
The majority of studies have used preservative-free sterile 0.9% saline as the diluent for FMT 1122 
production, although there have been a handful of reports of other diluents including potable 1123 
water16,35,43.  There have been no comparative studies of FMT diluent.  In cases where frozen FMT is 1124 
prepared, an appropriate cryoprotective substance should be added prior to freezing.  Most studies 1125 
use glycerol at a final concentration of ~10%16,41.  It has been demonstrated that storing stool at -1126 
80°C for up to six months in saline without glycerol decreases viable aerobic and anaerobic bacterial 1127 
counts; the reduction was statistically significant in all bacterial groups with the exception of E. coli 1128 
and total anaerobes.  When stored with glycerol, no significant reduction in viable counts was 1129 
observed74.  1130 
 1131 
A variety of homogenisation and open filtration systems have been used, with no apparent major 1132 
variation in efficacy.  Open filtration systems such as gauze16,37,40,55, filter paper39 and strainers/ 1133 
sieves17,41 are unpleasant to use and pose a risk of external contamination.  In order to best comply 1134 
with GMP standards, a sterile, single-use closed homogenisation and filtration system is 1135 
recommended.  An example of such a system includes the use of sterile filter bags inside a 1136 
laboratory paddle homogeniser. 1137 
 1138 
Recommendations:  1139 
i. We recommend that donor stool collection should follow a standard protocol 1140 
(GRADE of evidence: low; strength of recommendation: strong).  1141 
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ii. We recommend that donor stool should be processed within 6 hours of defaecation 1142 
(GRADE of evidence: low; strength of recommendation: strong). 1143 
iii. We recommend that both aerobically and anaerobically prepared FMT treatments 1144 
should be considered suitable when preparing FMT for the treatment of recurrent 1145 
CDI (GRADE of evidence: moderate; strength of recommendation: strong). 1146 
iv. We recommend that sterile 0.9% saline should be considered as an appropriate 1147 
diluent for FMT production, and cryoprotectant such as glycerol should be added 1148 
for frozen FMT (GRADE of evidence: moderate: strength of recommendation: 1149 
strong). 1150 
v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence: 1151 
moderate: strength of recommendation: strong). 1152 
vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal 1153 
emulsion (GRADE of evidence: low; strength of recommendation: weak). 1154 
vii. We suggest that homogenisation and filtration of FMT should be undertaken in a 1155 
closed disposable system (GRADE of evidence: low; strength of recommendation: 1156 
weak).  1157 
 1158 
5.4.2. Fresh vs frozen FMT: 1159 
Two randomised studies have examined this area.  One double-blind randomised study concluded 1160 
that enema frozen FMT (n=91) was non-inferior for clinical resolution of diarrhoea to fresh FMT 1161 
(n=87) for the treatment of recurrent or refractory CDI16 (with frozen FMT in this study stored at -1162 
20oC for up to 30 days).  A further randomised study demonstrated statistically comparable 1163 
remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n=25/25 vs 1164 
20/24 respectively, p=0.233) (using frozen FMT stored at -80oC for up to six months)13.  These data 1165 
support the findings of earlier small observational studies35,41.  Frozen FMT is preferable to fresh FMT 1166 
on logistical and cost grounds16.  Banked frozen FMT also enables the window period for donor 1167 
screening to be minimised, allowing centres to more closely to meet regulatory requirements (also 1168 
see Section 5.3.5).   1169 
 1170 
Recommendation:   1171 
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We recommend that the use of banked frozen FMT material should be considered 1172 
preferable to fresh preparations for CDI (GRADE of evidence: high; strength of 1173 
recommendation: strong). 1174 
 1175 
5.4.3. Use of frozen FMT: 1176 
Frozen FMT has been used up to six months after storage at -80oC17,41,74, with high efficacy rates 1177 
(>70%) observed in the cases treated.  However, there have been no comparative trials investigating 1178 
storage durations.  A trend towards decrease in the viability of certain gut microbiota taxa was noted 1179 
when faecal aliquots were frozen in 10% glycerol for six months74, and as such, the working group 1180 
agreed that six months was the acceptable limit for freezing of an FMT in glycerol.  Storage at -80oC 1181 
is recommended rather than -20oC to minimise sample degradation.    1182 
 1183 
Warm water baths have been recommended to speed thawing6; however, the working group 1184 
thought that this should be strongly discouraged, as this may introduce risks of cross contamination 1185 
by Pseudomonas species (and other contaminants) from the water bath107,108, and may reduce 1186 
bacterial viability in the FMT.  Repetitive freeze thawing of FMT samples should be avoided as 1187 
bacterial numbers will be reduced during this process109.  1188 
 1189 
Recommendations:   1190 
i. We recommend that FMT material stored frozen at -80
o
C should be regarded as 1191 
having a maximum shelf life of six months from preparation (GRADE of evidence: 1192 
low; strength of recommendation: strong). 1193 
ii. We suggest consideration of thawing frozen FMT at ambient temperature, and 1194 
using within six hours of thawing (GRADE of evidence: low; strength of 1195 
recommendation: weak). 1196 
iii. We suggest not thawing FMT in warm water baths, due to the risks of cross 1197 
contamination with Pseudomonas (and other contaminants) and reduced bacterial 1198 
viability (GRADE of evidence: very low; strength of recommendation: weak).   1199 
 1200 
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5.5. What factors related to administration of the transplant influence the outcome of 1201 
faecal microbiota transplant when treating people with Clostridium difficile 1202 
infection? 1203 
5.5.1. Use of specific medications in the period around FMT administration: 1204 
5.5.1.1. General principles of FMT administration: 1205 
Bowel purgatives have been proposed pre-FMT as a means of removing residual antibiotics that may 1206 
affect engraftment of transplanted microorganisms, and as a means of removing any residual C. 1207 
difficile toxin, spores and vegetative cells110–114. Furthermore, bowel purgatives pre-colonoscopic 1208 
FMT delivery facilitate safe endoscopy.  Various bowel purgatives have been used in colonoscopic 1209 
FMT studies, including polyethylene glycol (PEG) (often 4 litres)14,17,115–117,35,41,43,46,54–56,100, 1210 
MoviPrep®35,41, and  macrogol13,15,18,59.  In those studies that used an upper GI route for FMT, 1211 
PEG54,55,84 and Klean-Prep®15,61 were used. FMT without bowel preparation has also been used as 1212 
treatment for recurrent CDI without any apparent reduction in efficacy, including in randomised 1213 
studies16.  1214 
 1215 
The rationale for the use of proton pump inhibitors (PPI) prior to upper GI FMT is to minimise acidity 1216 
which may impair engraftment of transplanted microorganisms; however, PPIs have been shown to 1217 
alter the gut microbiota118,119, and have also been associated with primary and recurrent CDI120,121.  1218 
Some studies advocate the use of PPI prior to receiving FMT via the upper GI route37,39,45,84,85,122,123, 1219 
but there appears to be comparable efficacy data in studies where it has not been used.  Certain 1220 
studies have also given recipients PPI prior to receiving colonoscopic FMT17,87.   1221 
 1222 
The use of prokinetics (such as metoclopramide) has been described prior to FMT delivery via the 1223 
upper GI tract route, but only in a very small number of studies85.  Given the potential risk of 1224 
regurgitation/aspiration associated with upper GI administration of FMT, the working group felt that 1225 
its use should be considered where appropriate.  1226 
 1227 
A single dose/ short course of loperamide has been used following FMT (predominantly for lower GI 1228 
administration) in an attempt to prolong the exposure of the FMT to the mucosa, and to aid 1229 
retention of the FMT within the GI tract13,46,49,55,84,123.  One study utilised diphenoxylate with 1230 
atropine54 instead.   However, no studies have compared FMT with and without anti-motility drugs. 1231 
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 1232 
The working group also discussed infection control aspects as they apply to FMT administration.  1233 
Specifically, they agreed that recipients should ideally be cared for in a single room with en-suite 1234 
bathroom facilities and, where appropriate, be placed at the end of an endoscopy list, to facilitate 1235 
enhanced environmental decontamination and prevention of transmission of C. difficile spores.  1236 
Protocols for decontamination of endoscopes should follow national guidance124,125, using a 1237 
sporicidal agent.  Best practice for prevention of transmission of healthcare-associated infections, as 1238 
described in national guidelines126, should also be applied throughout.  1239 
 1240 
Recommendations:   1241 
i. We recommend that bowel lavage should be administered prior to FMT via the 1242 
lower GI route, and bowel lavage should be considered prior to FMT via the upper 1243 
GI route; polyethylene glycol preparation is preferred (GRADE of evidence: low; 1244 
strength of recommendation: strong). 1245 
ii. For upper GI FMT administration, we suggest that a proton pump inhibitor should 1246 
be considered, e.g. the evening before and morning of delivery (GRADE of 1247 
evidence: low; strength of recommendation: weak).   1248 
iii. We suggest that a single dose of loperamide (or other anti-motility drugs) should 1249 
be considered following lower GI FMT delivery (GRADE of evidence: low; strength 1250 
of recommendation: weak).   1251 
iv. We suggest that prokinetics (such as metoclopramide) should be considered prior 1252 
to FMT via the upper GI route (GRADE of evidence: low; strength of 1253 
recommendation: weak).   1254 
v. We recommend that best practice for prevention of further transmission of CDI 1255 
should be applied throughout when administering FMT to patients with CDI 1256 
(nursing with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE 1257 
of evidence: high; strength of recommendation: strong).   1258 
 1259 
5.5.1.2. Additional antibiotics pre-FMT: 1260 
Many studies have given further courses of conventional antimicrobial C. difficile treatment prior to 1261 
FMT.  Regimens have included vancomycin alone12,14,18,35,39,55,59,86,117, metronidazole or 1262 
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vancomycin40,41,43,122, or alternatively vancomycin, fidaxomicin or metronidazole56, with one study 1263 
using a range of regimens which included rifaximin123.  The length of treatment was also variable, 1264 
ranging from 24 hours54 up to four days prior to receiving FMT39,45; however, comparative studies 1265 
have not been undertaken. 1266 
 1267 
Recommendation:   1268 
We recommend the administration of further antimicrobial treatment for CDI for at least 1269 
72 hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).     1270 
 1271 
5.5.1.3. Washout period between antibiotic use and FMT: 1272 
Nearly all studies specified a washout period after completing anti-CDI antibiotics and before 1273 
administration of FMT.  However, this time period appeared to be arbitrarily selected and varied 1274 
from as little as four46 or 12 hours51, up to 72 hours36.  The majority of studies specified either 24 1275 
hours15,37,39,40,45,54,127 or 48 hours41,42,49,60, however some allowed a range from 1-3 days16,44,52,53,55.  1276 
One study appeared to allow co-administration of vancomycin with bowel preparation, without a 1277 
washout period18. 1278 
 1279 
The working group discussed the challenging scenario of providing FMT to patients with recurrent 1280 
CDI, but who also had a strong indication for long-term non-anti-CDI antibiotics (e.g. splenectomy, 1281 
osteomyelitis, or infective endocarditis), or patients who develop an indication for antibiotics for a 1282 
reason other than CDI shortly after receiving FMT.  The concern in this instance is that the use of 1283 
antibiotics may limit engraftment of microbial communities derived from the FMT, and therefore 1284 
reduce its effectiveness.  The working group discussed a recent retrospective study demonstrating 1285 
that exposure to non-anti-CDI antimicrobials within eight weeks of FMT is associated with an 1286 
approximate threefold risk of FMT failure (n=8/29 failures with antibiotic exposure vs 36/320 failures 1287 
without antibiotic exposure)128.  Similarly, the experience of the large pan-Netherlands stool bank129 1288 
was that ∼50% of their failures of FMT in the treatment of recurrent CDI occurred in patients who 1289 
had received antibiotics within one month of their FMT.  For patients requiring long-term antibiotics, 1290 
the working group’s expert opinion was that such patients should still be eligible for FMT, but that 1291 
the regimen for the use of non-anti-CDI antibiotics should be decided on a case-by-case basis, based 1292 
on factors including response to FMT and/or strength of indication of antibiotics.  Both in this 1293 
scenario, and the scenario in which antibiotics are required shortly after receiving FMT, the working 1294 
Page 118 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 43
party agreed that infectious diseases specialists/medical microbiologists should be involved in 1295 
making decisions regarding the choice of agents used.   1296 
 1297 
Recommendations:  1298 
iii. To minimise any deleterious effect of antimicrobials on the FMT material, we 1299 
recommend that there should be a minimum washout period of 24 hours between the 1300 
last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of 1301 
recommendation: strong). 1302 
iv. We suggest considering consultation with infectious disease specialists or medical 1303 
microbiologists for advice whenever FMT recipients also have an indication for long-1304 
term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of 1305 
FMT (GRADE of evidence: very low; strength of recommendation: weak). 1306 
 1307 
5.5.2. Route of FMT delivery: 1308 
5.5.2.1. Introduction: 1309 
FMT can be delivered via the lower GI route (retention enema, colonoscopy), upper GI route 1310 
(endoscopically, or via nasogastric tube, nasoduodenal or nasojejenal tube), or via capsules 1311 
(containing either frozen FMT or lyophilised faecal material).  Systematic reviews with meta-analysis 1312 
suggest that FMT for recurrent CDI via colonoscopy may have slightly higher efficacy compared to 1313 
upper GI administration127,130–132 with similar safety profiles, but also note the trend towards using 1314 
larger amounts of stool or ‘higher concentration’ FMT in lower GI administration.  One systematic 1315 
review (reviewing principally case series, and including only one randomised study) compared 1316 
remission rates for CDI using FMT delivered to different areas of the GI tract, and reported that for 1317 
FMT infused into the stomach, duodenum/jejunum, caecum/ascending colon, and rectum the rates 1318 
of cure rate were 81%, 86%, 93%, and 84%, respectively131.   1319 
 1320 
In the only randomised study that directly compared upper and lower GI administration, there was 1321 
no significant difference in overall cure rate (p = 0.53)17.   1322 
 1323 
5.5.2.2. Upper gastrointestinal tract administration of FMT: 1324 
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FMT has been shown to be safe and efficacious in the treatment of C. difficile when administered via 1325 
nasogastric tube37,39,45,61,83,123, nasoduodenal tube15,84,85, enteroscopy122,123, or via the infusion 1326 
channel on a gastroscope40,45.  In a randomised trial, nasoduodenal donor FMT has been shown to be 1327 
more efficacious than vancomycin in treating recurrent CDI15.  Furthermore, it has been shown that 1328 
FMT can also be safely and effectively delivered via a percutaneous endoscopic gastrectomy 1329 
tube45,83.  The working group noted that upper GI administration of FMT may be particularly suitable 1330 
for certain patient groups, such as those in whom there are contraindications or who would find it 1331 
difficult to tolerate lower GI endoscopy, and/ or patients unlikely to be unable to retain enemas.     1332 
 1333 
Typically, smaller volumes of faecal suspension are administered to the upper GI tract compared to 1334 
lower GI administration, with quoted volumes ranging from 25ml39 up to 150ml84- 250ml37,85. Up to 1335 
500ml of suspension has been given safely and effectively via the upper GI route15,77.  However, the 1336 
working group expressed concerns regarding the risk of regurgitation and aspiration if large volumes 1337 
of FMT are administered to the upper GI tract, and also discussed cases in which this has been 1338 
described with adverse outcomes80.  This included a reported death from aspiration, after 100-150ml 1339 
of FMT was delivered by enteroscope into the distal duodenum under general anaesthetic as 1340 
attempted treatment for recurrent CDI133.  A further reported case described a case of fatal 1341 
aspiration pneumonitis likely related to a 500ml FMT via nasoduodenal tube; this patient had a 1342 
swallowing disorder following oropharyngeal radiation after surgical removal of a maxillary 1343 
carcinoma two years previously77.  Based on their expert opinion, the working group recommended 1344 
that upper GI FMT should be used with caution in those at risk of regurgitation (e.g. known large 1345 
hiatus hernia, severe gastro-oesophageal reflux disease, etc) and/ or with swallowing disorders 1346 
(although administration via a gastrostomy tube would be acceptable).  They also recommended 1347 
that no more than 100ml of FMT should be administered to the upper GI tract to minimise these 1348 
risks.   1349 
  1350 
Recommendations:   1351 
i. We recommend that upper GI administration of FMT as treatment for recurrent or 1352 
refractory CDI should be used where clinically appropriate (GRADE of evidence: 1353 
high; strength of recommendation: strong). 1354 
ii. Where upper GI administration is considered most appropriate, we recommend 1355 
that FMT administration should be via nasogastric, nasoduodenal, or nasojejunal 1356 
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tube, or alternatively via upper GI endoscopy.  Administration via a permanent 1357 
feeding tube is also appropriate (GRADE of evidence: high; strength of 1358 
recommendation: strong).   1359 
v. We recommend that no more than 100ml of FMT is administered to the upper GI 1360 
tract (GRADE of evidence: low; strength of recommendation: strong). 1361 
vi. We recommend that upper GI administration of FMT should be used with caution 1362 
in those at risk of regurgitation and/ or those with swallowing disorders (GRADE of 1363 
evidence: low; strength of recommendation: strong). 1364 
 1365 
5.5.2.3. Lower gastrointestinal tract administration of FMT: 1366 
FMT via enema:  Successful treatment of C. difficile with FMT enema has been 1367 
demonstrated16,38,42,53,55,83,86 bu  enema appears to have a lower efficacy than other routes of FMT 1368 
administration.  Specifically, in a randomised study primarily comparing the efficacy of fresh and 1369 
frozen FMT in the treatment of recurrent CDI, only 52.8% of patients in the ‘frozen’ arm and 50.5% 1370 
of patients in the ‘fresh’ arm of the study (n=57/108 and 56/111 respectively) experienced 1371 
resolution of symptoms after a single enema, by modified intention to treat analysis16. However, 1372 
resolution rates in both arms only reached >80% after at least three enemas16.  A recent randomised 1373 
study demonstrated similar rates of recurrence of CDI in patients with recurrent CDI treated with 1374 
either a single FMT enema or a six week vancomycin taper (n=9/16 patients with recurrence vs 5/12 1375 
respectively)12. Notwithstanding this, enemas do have specific advantages, such as being a 1376 
treatment option where full colonoscopy is contraindicated. It is also possible to give multiple 1377 
infusions relatively easily and outside a hospital setting.   1378 
 1379 
FMT via colonoscopy:  Randomised study evidence has demonstrated that colonoscopic FMT has 1380 
higher efficacy in treating recurrent CDI than vancomycin18.  Efficacy is similar whether FMT is fresh 1381 
or frozen, but modestly reduced when using a lyophilised FMT product13.  Colonoscopic delivery of 1382 
donor FMT into the ileum or caecum was associated with a 91% cure rate for recurrent CDI14.  1383 
Observational studies highlighted similar success, describing cure rates of 88% (n=14/16)74 and 91%46 1384 
(n=21/23) in response to infusion of donor FMT into the caecum or terminal ileum.  A further 1385 
advantage of using colonoscopy to administer FMT has been to allow assessment for the presence of 1386 
pseudomembranes; in certain reviewed studies, the presence or absence of pseudomembranes has 1387 
influenced the FMT regimen used18,73.  However, the working group noted that that many patients 1388 
Page 121 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
HIS/ BSG FMT Guideline:  Main Document, Gut version. 
 
 46
with CDI are frail and elderly, and as such it will not always be safe or feasible to undertake 1389 
colonoscopy in this particular group of patients.  Flexible sigmoidoscopy appears to be an feasible 1390 
option where full colonoscopy cannot be performed e.g. unable to tolerate colonoscopy,  severity of 1391 
colitis56,60.   1392 
 1393 
The amount of faecal suspension via enema has varied between 150-500mls16,38,42,55,86.  The amount 1394 
of faecal suspension delivered via colonoscopy has been similarly variable, with some studies 1395 
suggesting as little as 100ml can be used with success rates of 94%43. 250ml-400ml had a success 1396 
rate of 100%36, whereas infusions of up to 500-700ml were associated with cure rates of 92%46.  1397 
However, the working group noted that it is difficult to compare ‘concentration’ of FMT in different 1398 
studies as different protocols used varied starting amounts of faecal material.  Currently, there are 1399 
no randomised studies that compare concentration/ volume of colonoscopic or enema FMT.  As 1400 
such, no recommendation was made to this regard.   1401 
 1402 
Recommendations:   1403 
i. We recommend that colonoscopic administration of FMT as treatment for 1404 
recurrent or refractory CDI should be used where appropriate (GRADE of evidence: 1405 
high; strength of recommendation: strong). 1406 
ii. Where colonoscopic administration is used, we suggest considering preferential 1407 
delivery to the caecum or terminal ileum, as this appears to give the highest 1408 
efficacy rate (GRADE of evidence: low; strength of recommendation: weak).  1409 
iii. We recommend that FMT via enema should be used as a lower GI option when 1410 
delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of 1411 
evidence: high; strength of recommendation: strong).   1412 
 1413 
5.5.2.4. Capsulised FMT: 1414 
Capsulised FMT aims to remove some of the concerns regarding conventional FMT, such as the 1415 
invasive means of administration and palatability.  The largest case series describing the use of 1416 
capsules as treatment for recurrent CDI72,89 noted clinical resolution at eight weeks off antibiotics for 1417 
CDI in 82% of cases (n=147/180) after one course of capsules, and 91% (n=164/180) after two 1418 
courses.  The capsules contained frozen FMT prepared in a diluent of saline with 10% glycerol; 15 1419 
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capsules were administered each day for two consecutive days (equating to a mean 48g of original 1420 
crude stool).  Other smaller case series have demonstrated comparable results87,123,134, including 1421 
when lyophilised stool is used instead of frozen whole FMT134.    1422 
 1423 
The working group reviewed two randomised studies which have examined the efficacy of 1424 
capsulised FMT in treating recurrent CDI.  In one study, published in abstract form94, a ‘high dose’ 1425 
regimen of frozen FMT capsules (30 capsules each day for two days) was compared to ‘low dose’  (30 1426 
capsules in one day).  CDI resolution was comparably high in both arms with one treatment course 1427 
(77% (n=7/9) in the ‘high dose’ arm vs 70% (n=7/10) in the ‘low dose arm’). 4/5 initial non-1428 
responders entered remission after a second capsule course with the ‘high dose’ regimen94.   In a 1429 
recent large randomised trial, patients with recurrent CDI were randomised to receive either thawed 1430 
frozen FMT either via colonoscopy or via capsules (one treatment of 40 capsules)11.  On per protocol 1431 
analysis, remission at 12 weeks after a single treatment occurred in 96% in both arms (n=51/53 by 1432 
capsule, n=50/52 by colonoscopy).     1433 
 1434 
The working group discussed certain unresolved issues regarding capsules.  Specifically, capsules are 1435 
often large, and swallowing 30 capsules in a single day may be a significant undertaking for patients 1436 
with CDI, such as the frail elderly with an existing high pill burden.  They also noted that follow-up 1437 
data post-capsule administration is relatively short compared to other modalities of FMT.   1438 
 1439 
Recommendation:   1440 
Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend 1441 
that this should be offered to patients as a potential treatment modality where available.  1442 
Capsule preparations should follow a standard protocol.  Further evidence regarding 1443 
optimal dosing and formulation is required (GRADE of evidence: high; strength of 1444 
recommendation: strong). 1445 
 1446 
5.6. What is the clinical effectiveness of FMT in treating conditions other than 1447 
Clostridium difficile infection? 1448 
5.6.1. Introduction: 1449 
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In current clinical practice, FMT is used predominantly in the treatment of recurrent CDI. Its success 1450 
has led to exploration of its efficacy in other GI diseases, primarily ulcerative colitis (UC), where 1451 
perturbation of the gut microbiota has been observed and implicated in disease pathogenesis135.  1452 
Due to variability of the quality, methodology and cohorts of patients recruited in trials of FMT for 1453 
non-CDI indications, and in order to control for significant confounding factors, the working group 1454 
only included randomised trials involving patients with well-defined conditions and in which there 1455 
was a primary clinical outcome.  To date, there have been a total of 71 such studies investigating the 1456 
role of FMT in IBD; of these, only four are prospective randomised controlled trials, limited to 1457 
patients with ulcerative colitis136–139.  Five other reviewed randomised studies investigated the use of 1458 
FMT in irritable bowel syndrome140, slow transit constipation141, hepatic encephalopathy142 and 1459 
metabolic syndrome143,144.   1460 
 1461 
5.6.2. Use of FMT for ulcerative colitis:  1462 
5.6.2.1. Efficacy: 1463 
All four RCTs, with a total of 277 subjects, included patients with mild to moderate UC (Mayo score 1464 
3-11 and endoscopic sub-score of at least 1).  Participants were aged between 27 and 56 years and 1465 
largely included patients on stable immunosuppressive therapy (only one study excluded patients 1466 
using biologic treatments and methotrexate within the preceding two months)136.  Three studies 1467 
included patients on oral corticosteroids at the time of FMT, however only two required a 1468 
mandatory wean of these to meet eligibility.  Studies generally included patients with all disease 1469 
distributions found in UC.  Time to evaluation of response to FMT in these studies varied between 1470 
seven and twelve weeks.  Two studies used autologous FMT as placebo136,139.  Three of the four 1471 
studies demonstrated that patients receiving donor FMT were significantly more likely to achieve 1472 
clinical and endoscopic remission compared to placebo137–139.  The pooled rate of combined clinical 1473 
and endoscopic remission was 27.9% for donor FMT and 9.5% for placebo.  A pooled risk ratio for 1474 
failure of FMT to achieve these combined outcomes was 0.8 (95% CI: 0.7-0.9).  Deep remission 1475 
(histological) was only reported in one RCT: 18.4% of patients receiving FMT achieved this outcome 1476 
compared to 2.7% of those receiving placebo137. 1477 
 1478 
5.6.2.2. Characteristics of FMT preparation and delivery: 1479 
The four RCTs varied in their FMT preparation and delivery methodology.  Two RCTs delivered frozen 1480 
FMT, one fresh FMT, and one used a combination.  Three RCTs with a positive outcome delivered the 1481 
FMT via the lower GI route; these studies used a high intensity protocol ranging from a total of three 1482 
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infusions in one week to 40 FMTs over an eight week period137–139.  The other RCT (that failed to 1483 
show efficacy of FMT for UC) had adopted a low intensity protocol of two nasoduodenal infusions 1484 
given three weeks apart136.  Interestingly, the only RCT that prepared stool in anaerobic conditions 1485 
demonstrated the highest rate of steroid-free clinical remission and steroid-free clinical response 1486 
with donor FMT139.  A further interesting observation in one study was a trend towards higher rates 1487 
of remission with one particular donor137. 1488 
 1489 
5.6.2.3. Adverse events: 1490 
Short-lived GI symptoms such as abdominal bloating, cramps, diarrhoea and fever were reported in 1491 
patients receiving FMT for UC.  There were no significant differences in serious adverse events 1492 
between patients receiving FMT compared to placebo (10 vs 7 respectively).  Most of the serious 1493 
adverse events were a consequence of worsening colitis: one patient who received FMT required a 1494 
colectomy136.  In addition, one patient developed concurrent CDI137.  No deaths were reported in any 1495 
of the studies. 1496 
 1497 
5.6.3. Use of FMT in functional bowel disorders:   1498 
Two RCTs have investigated the role of FMT in functional bowel disorders.  In a double-blind placebo 1499 
controlled RCT that recruited 90 patients with IBS with diarrhoea or with diarrhoea and 1500 
constipation140, the primary endpoint only just reached statistical significance in inducing symptom 1501 
relief (as assessed by 75 point reduction in IBS-severity scoring system at three months following a 1502 
single infusion FMT by colonoscopy) (p=0·049).  The second RCT randomised 60 patients with slow 1503 
transit constipation to either six consecutive days of nasogastric-delivered FMT or conventional 1504 
treatment141.  This demonstrated that a significant proportion of patients achieved the primary 1505 
endpoint of a mean of at least three complete spontaneous bowel movements per week (53.3% vs. 1506 
20.0%, p= 0.009) along with improvement in stool consistency score and colonic transit time.  1507 
However, the intervention group had more treatment-related adverse events than did the control 1508 
group (total of 50 vs 4 cases).  1509 
 1510 
5.6.4. Use of FMT in hepatic encephalopathy: 1511 
One small study has investigated the role of FMT in the management of hepatic encephalopathy 1512 
(HE)142.  This RCT randomised 20 male patients with cirrhosis with refractory HE to receive either five 1513 
days of broad-spectrum antibiotic pre-treatment followed by a single FMT enema or standard of 1514 
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care. Patients in the FMT arm had a significantly lower incidence of serious adverse events and 1515 
improved cognition.  The Model for End-Stage Liver Disease (MELD) score, however, transiently 1516 
worsened post-antibiotics in the FMT arm.  The study was potentially confounded as patients in the 1517 
FMT arm continued to receive lactulose and/or rifaximin for treatment of their HE.  1518 
 1519 
5.6.5. Use of FMT for metabolic syndrome: 1520 
Two randomised studies143,144, with a combined total of 56 patients, demonstrated an improvement 1521 
in peripheral (but not hepatic) insulin sensitivity in Caucasian male obese patients with metabolic 1522 
syndrome following one or two infusions via nasoduodenal tube of FMT obtained from lean donors.  1523 
This improvement was observed at six weeks post-FMT, but was no longer present by 18 weeks.  No 1524 
improvement in insulin sensitivity was identified in patients transplanted with autologous FMT (i.e. 1525 
patients transplanted with their own collected faeces).  The improvement in peripheral insulin 1526 
sensitivity in the lean donor FMT group was accompanied by a small but significant improvement in 1527 
HbA1c at six weeks144, but no improvements in other metabolic parameters, such as weight.  Whilst 1528 
these data are of interest, the working group felt that the limited, transient nature of the benefits 1529 
seen and small size of the studies meant that FMT could not be recommended as treatment for 1530 
metabolic syndrome.  1531 
 1532 
5.6.6. Future directions for randomised trials of FMT for non-CDI indications: 1533 
Currently there are a large number of randomised trials (including RCTs) being undertaken globally, 1534 
to evaluate the potential role of FMT as treatment for a wide range of conditions.  The working 1535 
group concluded that until there are more reliable data to inform decision-making, the best practice 1536 
principles described in this document for the governance of an FMT service for recurrent CDI should 1537 
also be applied to FMT clinical trials for other conditions.  However, specific adaptations may be 1538 
considered depending on the condition being studied, e.g. consideration of using anaerobic 1539 
conditions for the preparation of FMT in trials for the treatment of UC, as described above. 1540 
   1541 
In conclusion, FMT has the potential to be an effective treatment option for mild to moderate 1542 
ulcerative colitis, and appears to be safe despite the use of immunosuppressive therapy.  FMT may 1543 
also have a potential role in the treatment of functional bowel disorders.  However, 1544 
recommendations for clinical use for both these indications cannot be made until there is clearer 1545 
evidence of the most appropriate patient characteristics, preparation methodology, route of delivery 1546 
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and intensity of administration of FMT.  The evidence for the use of FMT in hepatic encephalopathy 1547 
and metabolic syndrome is currently limited, and further well-designed RCTs are needed to evaluate 1548 
its potential role here.     1549 
 1550 
Recommendation:   1551 
We do not currently recommended FMT as treatment for inflammatory bowel disease.  1552 
Apart from CDI, there is insufficient evidence to recommend FMT for any other 1553 
gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength 1554 
of recommendation: strong). 1555 
 1556 
6. Basic requirements for implementing a FMT service: 1557 
As discussed above, there is an absence of published studies to support the recommendations in this 1558 
section (although the experience of setting up a nationwide stool bank has recently been reported 1559 
from the Netherlands129).  This section is therefore based on the working group’s expert opinion and 1560 
experience of developing FMT services.  The working group considered best practice in this area as it 1561 
applied to legal and clinical governance aspects, the relevant professionals required to establish an 1562 
FMT service, the infrastructure of a service, and appropriate practices for FMT manufacturing and 1563 
quality control monitoring where relevant.  The full text of this section is in Supplementary Material 1564 
3.   1565 
 1566 
7. Key performance indicators: 1567 
• All donors to have completed initial screening questionnaires and blood and stool screening 1568 
results, as well as final health check prior to each stool donation processed to FMT.  Results from 1569 
each subsequent serial round of screening also to be documented.   1570 
• All FMT recipients to have clear documentation of details of their disease course and 1571 
preparation prior to FMT, including whether recurrent or refractory disease, previous 1572 
antimicrobial courses, and use of bowel purgatives/other preparatory medications pre-FMT. 1573 
• All FMT recipients to have sufficient documentation to allow clear traceability of the exact FMT 1574 
aliquot transfused.  Records should include identification of the donor, as well as a frozen FMT 1575 
aliquot (and original faecal sample) - as well as serum - from that donor (see Supplementary 1576 
Material 3).   1577 
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• All FMT recipients for recurrent or refractory CDI to have documentation during follow-up of 1578 
treatment success or failure (and subsequent treatment plan if failure), together with clear 1579 
documentation of any adverse events that may be attributable to FMT.    1580 
 1581 
8. Further research: 1582 
• As described within this guideline, many aspects of the terminology of CDI are used variably 1583 
betwee  studies, and end-points in FMT trials are inconsistent.  The working group noted the 1584 
need to standardise this terminology to allow more robust comparisons between studies.   1585 
• Given the relative novelty of FMT as a procedure, any potential long-term adverse events 1586 
associated with its use are poorly-defined.  The establishment of formal FMT registries should be 1587 
considered.  Whilst this would primarily act as an important tool for defining the safety and 1588 
efficacy of FMT, it would also be a valuable database for researchers within the field.  1589 
Standardisation of other key documentation related to FMT administration (e.g. establishment 1590 
of a proforma for assessing eligibility for FMT and/or follow-up after FMT) would also be 1591 
advantageous for the same reasons.   1592 
• The working group noted the lack of consistency in definitions related to the severity of CDI 1593 
disease and to response or failure to FMT.  This limited interpretation of the published studies.  1594 
As such, the working group thought that standardisation of these definitions would allow more 1595 
accurate delineation of the factors influencing the efficacy of FMT for CDI.  The working group 1596 
also noted that only one reviewed study had reported the relationship between C difficile 1597 
ribotype and FMT outcome, and that recording of this information should be encouraged better 1598 
to evaluate its influence.   1599 
• Further well-designed clinical trials (in particular, RCTs) are required to identify the optimal 1600 
means of administration of FMT as treatment for recurrent and/or refractory CDI.   1601 
• The working group noted that even capsulised FMT may be associated with potential drawbacks.  1602 
They also noted that there are many patients with recurrent CDI for whom FMT (or any form of 1603 
‘bacteriotherapy’) may be inappropriate, including those with very marked immunosuppression, 1604 
and/or multi-organ disease.  Despite high levels of efficacy, there is a small but appreciable FMT 1605 
failure rate and it is not currently understood whether this is due to underlying donor or 1606 
recipient factors.  Therefore, a research priority should be in basic and translational studies 1607 
better to define the mechanisms underlying the efficacy of FMT in CDI.  This includes comparing 1608 
the structure and function of the microbiota of donors to patients pre-FMT and post-FMT, via 1609 
techniques including next-generation microbial sequencing, metabolic profiling, and 1610 
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immunological assays.  This would allow the refinement of FMT from its current state to a more 1611 
targeted therapy, removing the concerns associated with FMT.   1612 
• The working group identified a need for further well-designed RCTs to investigate the potential 1613 
role of FMT for non-CDI indications.  1614 
 1615 
9. Conclusions: 1616 
FMT has become an accepted, efficacious treatment for recurrent and/or refractory CDI.  In 1617 
developing this guideline, the evidence for the technique has been reviewed in the context of other 1618 
available treatments.  Specific guidance for best practice for an FMT service is provided. 1619 
 1620 
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 2098 
 2099 
 2100 
 2101 
 2102 
 2103 
 2104 
 2105 
 2106 
 2107 
 2108 
 2109 
 2110 
 2111 
 2112 
 2113 
 2114 
 2115 
 2116 
 2117 
15. Figure legends and tables: 2118 
Figure 1:  Proposed summary pathway for donor screening for centres preparing frozen FMT from 2119 
recurring donors.   2120 
 2121 
Table 1:  Recommended donor history/ questionnaire:  A positive response to any of these 2122 
questions would usually result in exclusion from further consideration as a donor, although this 2123 
would depend upon the particular circumstances/ answers given.   2124 
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1. Receipt of antimicrobials within the past three months. 2125 
2. Known prior exposure to HIV and/ or viral hepatitis, and known previous or latent 2126 
tuberculosis. 2127 
3. Risk factors for blood-borne viruses - including high risk sexual behaviours, use of illicit 2128 
drugs, any tattoo/ body piercing/ needlestick injury/ blood transfusion/ acupuncture, all 2129 
within the previous six months. 2130 
4. Receipt of a live attenuated virus within the past six months.   2131 
5. Underlying gastrointestinal conditions/ symptoms (e.g. history of IBD, IBS, chronic diarrhoea, 2132 
chronic constipation, coeliac disease, bowel resection or bariatric surgery) - also including 2133 
acute diarrhoea/ gastrointestinal symptoms within the past two weeks. 2134 
6. Family history of any significant gastrointestinal conditions (e.g. family history of IBD, or 2135 
colorectal cancer).  2136 
7.  History of atopy (e.g. asthma, eosinophilic disorders). 2137 
8. Any systemic autoimmune conditions. 2138 
9. Any metabolic conditions, including diabetes and obesity. 2139 
10. Any neurological or psychiatric conditions, or known risk of prion disease.  2140 
11. History of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia.  2141 
12. History of any malignancy.   2142 
13. Taking particular regular medications, or such medications within the past three months, i.e. 2143 
antimicrobials, proton pump inhibitors, immunosuppression, chemotherapy  2144 
14. History of receiving growth hormone, insulin from cows, or clotting factor concentrates. 2145 
15. History of receiving an experimental medicine or vaccine within the past six months.    2146 
16. History of travel to tropical countries within the past six months. 2147 
 2148 
 2149 
Table 2:  Recommended blood screening for stool donors:  *EBV and CMV testing is only 2150 
recommended where there is the potential that the FMT prepared from that donor will be 2151 
administered to immunosuppressed patients at risk of severe infection if exposed to CMV and EBV.       2152 
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 2153 
 2154 
 2155 
 2156 
 2157 
 2158 
 2159 
Table 3:  Recommended stool screening for stool donors:  *Whilst CPE and ESBL are the only multi-2160 
drug resistant bacteria that are recommended to be screened for universally, consider testing for 2161 
other resistant organisms (including vancomycin-resistant Enterococci (VRE) and/ or methicillin-2162 
resistant Staphylococcus aureus (MRSA)) based upon risk assessment and local prevalence.   2163 
Pathogen screening: 
• Hepatitis A IgM 
• Hepatitis B (HBsAg and HBcAb) 
• Hepatitis C antibody 
• Hepatitis E IgM 
• HIV -1 and -2 antibodies 
• HTLV-1 and -2 antibodies 
• Treponema pallidum antibodies (TPHA, VDRL) 
• Epstein-Barr virus IgM and IgG* 
• Cytomegalovirus IgM and IgG* 
• Strongyloides stercoralis IgG 
• Entamoeba histolytica serology 
 
General/ metabolic screening: 
• Full blood count with differential. 
• Creatinine and electrolytes 
• Liver enzymes (including albumin, bilirubin, aminotransferases, gamma-glutamyltransferase 
and alkaline phosphatase). 
• C-reactive protein 
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 2164 
 2165 
 2166 
 2167 
 2168 
 2169 
 2170 
 2171 
 2172 
 2173 
 2174 
 2175 
 2176 
 2177 
 2178 
Table 4:  A summary of the GRADE system: 2179 
GRADE - strength of evidence: GRADE - strength of recommendation: 
• Clostridium difficile PCR 
• Campylobacter, Salmonella, and Shigella by standard stool culture and/ or PCR 
• Shiga toxin-producing Escherichia coli by PCR.   
• Multi-drug resistant bacteria, at least carbapenemase-producing Enterobacteriaceae 
(CPE) and extended-spectrum beta-lactamases (ESBL)*.  
• Stool ova, cysts and parasite analysis, including for Microsporidia.  
• Faecal antigen for Cryptosporidium and Giardia.  
• Acid fast stain for Cyclospora and Isospora.  
• Helicobacter pylori faecal antigen. 
• Norovirus, Rotavirus PCR.  
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High quality: Further research is very unlikely to change our 
confidence in the estimate of effect. 
The trade-offs:  Taking into account the 
estimate size of the effect for main outcomes, 
the confidence limits around those estimates 
and the relative value placed on each outcome. 
Moderate quality: Further research is likely to have an 
important impact on our confidence in the estimate of effect 
and may change the estimate. 
The quality of the evidence.  
Low quality: Further research is very likely to have an 
important impact on our confidence in the estimate of effect 
and is likely to change the estimate. 
Translation of the evidence into practice in a 
particular setting:  Taking into consideration 
important factors that could be expected to 
modify the size of expected effects. 
Very low quality:  Any estimate of effect is very uncertain.   Uncertainty about the baseline risk for the 
population of interest.   
 2180 
 2181 
 2182 
 2183 
 2184 
 2185 
 2186 
 2187 
 2188 
  2189 
 2190 
 2191 
Table 5:  Criteria for stool collection: 
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 2192 
  2193 
 2194 
 2195 
 2196 
 2197 
 2198 
 2199 
Clear instructions should be given to donors regarding hand hygiene. 
Collect stool donations in a sealable clean container.  A number of specifically designed devices 
are available commercially.   
Stool should ideally be passed directly into the clean container for collection; alternatively, it may 
be collected in clean tissue and transferred to the clean container.  
Stool should be transported to the FMT production site as soon as possible post defaecation (and 
within six hours); however, if a short period of storage is necessary, this should be at 4°C.  
Page 150 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 1 for Gut  
 
 1 
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium 
difficile infection and other potential indications: joint British Society of Gastroenterology 
(BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Supplementary Material 1:  General additional information: 
 
1. Additional information: 
1.1. Lay summary: 
Faecal microbiota transplant (FMT) involves the transfer of a sample of faeces from a healthy donor 
to a recipient.  There are several different ways to administer the transplant, including via endoscopy, 
rectally as an enema, via nasogastric/ nasoenteral tube (tube passed through the nose into the 
stomach/ upper part of the small intestine), or via oral ingestion of capsules that contain faecal 
material.  The transplant may either be administered fresh (i.e. immediately after preparation), or may 
be prepared in advance, stored in a freezer and thawed when required.  FMT is an accepted and 
effective treatment for recurrent infection by Clostridium difficile, a bacterium which can cause severe 
illness with diarrhoea, most commonly in frail elderly populations as a complication of antibiotic use.  
Despite adequate treatment, Clostridium difficile infection recurs in about 25% of patients, and some 
may suffer multiple recurrences.    
 
This guideline reviews the evidence for FMT as a treatment for Clostridium difficile infection (CDI) and 
other conditions.  Recommendations are made for: which patients are most likely to benefit, how 
donors should be selected and screened, how FMT should be prepared and administered, how 
patients should be followed up, and how FMT services should be configured. 
 
1.2. Working Party Report 
1.2.1. What is the Working Party Report?  
The report is a set of recommendations covering key aspects of safe and efficacious delivery of a FMT 
service for recurrent/ refractory Clostridium difficile infection (CDI).  The guidelines also review the 
evidence for the use of FMT for non-CDI indications.  
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 2 
 
The working group recommendations have been developed systematically through multi-disciplinary 
discussions based on published evidence.  They should be used in the development of local protocols 
for all relevant healthcare settings.   
   
1.2.2. Why do we need a Working Party Report for this topic?  
There is widespread and growing interest in the use of FMT as a treatment for recurrent CDI.  The 
previous absence of randomised trials and lack of evidence-based guidelines describing best practice 
related to its use has led to uncertainty as to how to establish an FMT service. Existing services may 
be providing suboptimal clinical care.  There is now a developing portfolio of randomised study 
evidence (including randomised controlled trial data) regarding the use of FMT in CDI and non-CDI 
indications, providing the opportunity to develop an evidence-based guideline for its use.  There have 
also been recent changes to the UK regulatory framework for FMT (see Supplementary Material 3), 
which are not well-understood by clinicians.   
 
1.2.3. What is the purpose of the Working Party Report’s recommendations? 
The main purpose is to inform clinicians about the use of FMT (and about the establishment of this 
service) for the treatment of recurrent and refractory CDI, and other possible future indications. The 
recommendations provide an evidence-based approach to a high quality clinical service, with 
appropriate governance structures.  This document also serves to illustrate areas in which there are 
current gaps in knowledge, which will help to direct future areas of research.   
 
1.2.4. Who are these guidelines for?  
Any healthcare practitioner may use these guidelines and adapt them for their use.  It is anticipated 
that users will include clinical staff, as well as healthcare infection prevention and control teams.  It is 
expected that these guidelines will raise awareness of FMT amongst clinicians who care for patients 
with recurrent or refractory CDI, but who may be unaware that it is a feasible and accessible treatment 
option.  The guidelines are also designed to be read by patients with CDI, helping them to understand 
whether FMT may be an appropriate treatment option for them.   
 
1.2.5. How are the guidelines structured?  
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 3 
Each section comprises an introduction, a summary of the evidence base with levels, and a 
recommendation graded according to the available evidence.   
 
1.2.6. Aim  
The primary aim of this report was to assess the current evidence for all aspects relating to provision 
of an FMT service as treatment for recurrent or refractory CDI.  A secondary aim was to review the 
current evidence for the efficacy of FMT in treating non-CDI conditions.   
 
1.3. Implementation of these guidelines: 
1.3.1. How can these guidelines be used to improve clinical effectiveness? 
Primarily, these guidelines will inform the development of local FMT services and appropriate local 
operational protocols, and will guide clinical decision-making.  They also provide a framework for 
clinical audit, a tool for improving clinical effectiveness.  In addition, the future research priorities 
identified by the working group will allow researchers to refine applications to funding bodies.   
  
1.3.2. How much will it cost to implement these guidelines? 
Where FMT is being provided under a MHRA license according to Good Manufacturing Practice (GMP) 
standards, there are significant costs associated with initial setup and maintenance of the service.  
These include the cost of obtaining the relevant license, laboratory design and equipment to enable 
quality assurance, storage facilities for samples, etc.  However, there is counterbalance to this, as the 
expectation of the working group is that the publication of this guideline may encourage provision of 
FMT as treatment for recurrent or refractory CDI.  This has consistently been shown to be cost 
effective in comparison with anti-C. difficile antimicrobial therapy1–4, so overall costs associated with 
treating the condition may actually decrease.  Furthermore, there may be changes to the practice of 
clinicians already offering the service.  For example, encouraging the use of healthy unrelated donors 
(who can provide multiple stool donations after one screening) reduces the cost of screening when 
compared to the use of an FMT recipient’s relative as donor, who is likely to provide one donation 
only.   
 
1.3.3. E-learning tools: 
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 4 
Continuing Professional Development questions and their answers are provided for self-assessment 
in Appendix 4 of this document.  
 
2. Appendices  
Appendix 1: Glossary 
Clostridium difficile infection (CDI) - Symptomatic infection caused by the spore-forming, toxin-
secreting bacterium, Clostridium difficile.  It is the most common cause of antibiotic-associated 
diarrhoea, and symptoms include watery stools, fever, nausea, and abdominal pain. 
Refractory CDI – Failure of an episode of CDI to respond to metronidazole and oral vancomycin, 
although no uniform definition.   
Recurrent CDI – Defined in ESMID guidelines as ‘when CDI re-occurs within 8 weeks after the onset of 
a previous episode, provided the symptoms from the previous episode resolved after completion of 
initial treatment’4; however, defined more variably within the reviewed literature within this 
guideline.   
Faecal microbiota transplant – A procedure in which faecal matter (stool) is collected from a healthy 
screened donor, homogenised, strained, and introduced into the gastrointestinal tract of a patient. 
Donor – In the context of FMT, this is a healthy screened individual that provides stool for the use in 
preparation of FMT.  
Nasogastric – A means of reaching/ supplying the stomach via the nose for the purpose of treatment 
or investigation. This is usually achieved by the insertion of a tube. 
Enema – A procedure in which liquid (or gas) is infused into the rectum as means for treatment or 
investigation. 
Gut microbiota - Population of microorganisms that live in the gastrointestinal tract including bacteria, 
viruses and fungi.   
Inflammatory bowel disease – Describes a group of chronic disorders (ulcerative colitis and Crohn’s 
diseases) in which the gastrointestinal tract becomes inflamed.  The exact cause is unknown but it is 
thought to result from a combination of factors that trigger the body’s immune system to produce an 
inflammatory reaction in the gastrointestinal tract. 
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 5 
Medicines and Healthcare Products Regulatory Agency - An executive agency of the Department of 
Health in the United Kingdom which is responsible for ensuring that medicines and medical devices 
are efficacious and are acceptably safe. 
 
Appendix 2: Guideline Development 
Introduction 
The need for a guideline within this area was agreed at a HIS guideline scoping day, and a BSG Gut 
Microbiota for Health (GMfH) panel teaching/ meeting day, both in September 2015, and further 
meetings between both bodies confirmed the establishment of a working group.  Members were 
chosen to reflect the range of stakeholders, but were not limited to members of BSG or HIS.  Feedback 
from the HIS guideline scoping day (including patient representatives) was used to establish a basis 
for PICO questions, with the final structure of PICO questions agreed collectively by teleconference in 
July 2017.  No payment was made to anyone involved in this guideline. 
 
Conflict of interest 
Conflict of interest was registered from all working group members and underwent ongoing review 
up until the point of completion.  In the event of a potential conflict being identified, the working 
group agreed that the member should not contribute to the section affected.   
   
Search Strategy & Results 
i. Literature search strategy:  PICO Review Questions: 
Review Question 1:  Which patients with Clostridium difficile infection should be considered for 
faecal microbiota transplant, and how should they be followed up after treatment? 
Populations: Adults (18 years and over) with Clostridium difficile infection 
Intervention: Faecal microbiota transplant 
Comparison: Placebo 
Vancomycin 
  Metronidazole 
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  Fidaxomicin 
  Intravenous immunoglobulin 
Bezlotoxumab 
Probiotics 
Cessation of antibiotics for alternative indication 
Outcomes: Critical:  Cessation of diarrhoea and other symptoms/ relapse 
    Quality of life 
    Serious adverse events 
  Important: Negative tests for Clostridium difficile infection 
    Adverse events 
Study design: Randomised trials 
  If no randomised trials identified – prospective cohort studies and retrospective case 
  series 
 
Review Question 2:  What recipient factors influence the outcome of faecal microbiota transplant 
when treating people with Clostridium difficile infection? 
Populations: Adults (18 years and over) with Clostridium diff cile infection 
Intervention: Faecal microbiota transplant 
Comparison: Preparation of patient: 
Use of bowel purgatives vs no bowel purgatives 
For upper GI administration - use of PPI/ acid suppression prior to procedure vs no 
acid suppression 
Use of agents affecting GI motility (e.g. metoclopramide for upper GI/ loperamide for 
lower GI) vs no use  
Time before procedure that anti-CDI antibiotics are used and stopped (comparing 
time courses) 
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Comorbidities: 
Severe CDI/ toxic megacolon vs non-severe disease 
Co-existing inflammatory bowel disease (IBD) vs no IBD 
Immunosuppression vs no immunosuppression 
Chronic liver disease/ cirrhosis vs no chronic liver disease 
Outcomes: Critical:  Cessation of diarrhoea and other symptoms/ relapse 
    Quality of life 
    Serious adverse events 
  Important: Negative tests for Clostridium difficile infection 
    Adverse events 
Study design: Randomised trials 
  If no randomised trials identified – prospective cohort studies, retrospective case 
  series 
 
Review Question 3:  What donor factors influence the outcome of faecal microbiota transplant 
when treating people with Clostridium difficile infection? 
Populations: Adults (18 years and over) with Clostridium difficile infection 
Intervention: Faecal microbiota transplant 
Comparison: Related vs unrelated donor 
Donor working in healthcare setting vs donor not from healthcare setting 
BMI (comparing cut-offs used) 
Age (comparing ages) 
Length of time since donor had antibiotics (comparing cut-offs used) 
Outcomes: Critical :  Cessation of diarrhoea and other symptoms/ relapse 
Page 157 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 1 for Gut  
 
 8 
    Quality of life 
    Serious adverse events 
  Important: Negative tests for Clostridium difficile infection 
    Adverse events 
Study design: Randomised trials 
  If no randomised trials identified – prospective cohort studies and retrospective case 
  series 
 
Review Question 4:  What factors related to the preparation of the transplant influence the outcome 
of faecal microbiota transplant when treating people with Clostridium difficile infection? 
Populations: Adults (18 years and over) with Clostridium difficile infection 
Intervention: Faecal microbiota transplant 
Comparison: Time after delivery when transplant is prepared (comparing time points) 
Anaerobic preparation vs preparation in ambient air 
Manual preparation vs use of blender/ homogeniser 
Diluent used (comparing normal saline, phosphate-buffered saline, water, milk/ 
yoghurt and others) 
Amount of stool/ transplant administered (comparing amounts) 
Fresh preparation vs frozen preparation: 
-comparing glycerol vs other cryopreservative 
-comparing concentration of cryopreservative used 
-comparing length of time that frozen for before use 
Outcomes: Critical:  Cessation of diarrhoea and other symptoms/ relapse 
    Quality of life 
    Serious adverse events 
  Important: Negative tests for Clostridium difficile infection 
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 9 
    Adverse events 
Study design: Randomised trials 
  If no randomised trials identified – prospective cohort studies and retrospective case 
  series 
 
Review Question 5:  What factors related to administration of the transplant influence the outcome 
of faecal microbiota transplant when treating people with Clostridium difficile infection? 
Populations: Adults (18 years and over) with Clostridium difficile infection 
Intervention: Faecal microbiota transplant 
Comparison: Upper GI administration (nasogastric, nasoduodenal or nasojejunal tube; upper GI  
endoscopy) vs lower GI administration (enema, rectal catheter, colonoscopy) 
Encapsulated vs full transplant 
Outcomes: Critical:  Cessation of diarrhoea and other symptoms/ relapse 
    Quality of life 
    Serious adverse events 
  Important: Negative tests for Clostridium difficile infection 
    Adverse events 
Study design: Randomised trials 
If no randomised trials identified – prospective cohort studies, and retrospective case 
series 
 
Review Question 6:  What is the clinical effectiveness of faecal microbiota transplant in treating 
conditions other than Clostridium difficile infection? 
Populations: Adults  (18 years and over) with conditions of interest (e.g. inflammatory bowel 
  disease) 
Intervention: Faecal microbiota transplant 
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 10 
Comparison: Standard care for the condition of interest 
  Autologous faecal microbiota transplant 
Outcomes: Critical:  Clinical improvement 
    Improvement in laboratory/ radiological/ endoscopic tests 
    Quality of life 
    Serious adverse events 
  Important: Adverse events 
Study design: Randomised trials 
 
ii. Literature search terms: 
Review Questions 1 – 5: 
EMBASE  
1. exp Clostridium difficile infection/ or exp Clostridium difficile toxin B/ or exp Clostridium difficile 
toxin A/ 
2. clostridium difficile.ti,ab.  
3. c diff*.ti,ab.  
4. (CDAD or RCDI or CDI).ti,ab.  
5. pseudomembranous.ti,ab.  
6. exp pseudomembranous colitis/  
7. (antibiotic* adj2 (diarrhea or diarrhoea or colitis)).ti,ab.  
8. (FMT or HPI).ti,ab.  
9. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant* or infus* or transfus* or 
implant* or instil* or donat* or donor* or reconstitut* or therap* or bacteriotherapy or 
encapsulated* or capsul*)).ti,ab.  
10. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
11. transplant*.ti,ab.  
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12. exp transplantation/  
13. 8 or 9  
14. 10 and (11 or 12)  
15. 13 or 14  
16. or/1-7  
17. 15 and 16 
 
MEDLINE  
1. Clostridium difficile/  
2. clostridium difficile.ti,ab.  
3. c diff$.ti,ab.  
4. Enterocolitis, Pseudomembranous/  
5. (antibiotic$ adj2 (diarrhoea or colitis)).ti,ab.  
6. (antibiotic$ adj2 (diarrhea or colitis)).ti,ab.  
7. pseudomembranous.ti,ab.  
8. (CDAD or CDI).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier, synonyms]  
9. RCDI.ti,ab.  
10. Clostridium Infections/  
11. FMT.mp. or HPI.ti,ab. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier, synonyms]  
12. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant$ or infus$ or transfus$ 
or implant$ or instil$ or donat$ or donor or reconstitut$ or therap$ or bacteriotherapy or 
encapsulated$ or capsul$)).ti,ab.  
13. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
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 12 
14. (transplant$ or infus$ or transfus$ or implant$ or instil$ or donat$ or donor or reconstitut$ or 
therap$ or bacteriotherapy or encapsulated$ or capsul$).ti,ab.  
15. Transplantation/  
16. Transplants/  
17. 11 or 12  
18. 14 or 15 or 16  
19. 13 and 18  
20. 17 or 19  
21. or/1-10  
22. 20 and 21 
 
Limits: 
1. After 1980. 
2. Studies in English only. 
3. Human studies only.   
4. Exclude case reports. 
5. Exclude case series with less than 10 patients.   
 
Review Question 6: 
EMBASE 
1. (FMT or HPI).ti,ab.  
2. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant* or infus* or transfus* or 
implant* or instil* or donat* or donor* or reconstitut* or therap* or bacteriotherapy)).ti,ab.  
3. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
4. transplant*.ti,ab.  
5. exp transplantation/  
6. 1 or 2  
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7. 3 and (4 or 5)  
8. 6 or 7  
9. (clostridium difficile or CDAD or RCDI or CDI).ti.  
10. 8 not 9  
11. limit 10 to (clinical trial or randomized controlled trial or controlled clinical trial) 
 
MEDLINE 
1. FMT.mp. or HPI.ti,ab. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word] 
2. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant$ or infus$ or transfus$ or 
implant$ or instil$ or donat$ or donor or reconstitut$ or therap$ or bacteriotherapy)).ti,ab.  
3. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.  
4. Transplantation/  
5. Transplants/  
6. transplant$.ti,ab.  
7. Fecal Microbiota Transplantation/  
8. 4 or 5 or 6  
9. 3 and 8  
10. 1 or 2 or 7 or 9  
11. (clostridium difficile or cdiff or CDAD or RCDI or CDI or pseudomembranous).ti.  
12. 10 not 11  
13. limit 12 to (clinical trial or randomized controlled trial or controlled clinical trial) 
 
Limits: 
1. After 1980. 
2. Studies in English only. 
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3. Human studies only.   
4. Randomised trials only. 
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 15 
iii. Summary of the data extraction and literature review process (includes Q1-6): 
 
 
Appendix 3: Consultation Stakeholders: 
Individuals or organisation who were invited to and/ or attended the scoping day for these 
guidelines (as well as to provide feedback in stakeholder consultation) included: 
 HRPA (Ireland) (Dr Eadaoin Griffin attended) 
 Human Tissue Authority (Dr Robert Watson attended) 
 NHS Wales 
 NHS Scotland 
 ECDC 
 Royal College of Pathologists 
 Royal College of General Practitioners 
 Infection Prevention Society 
Records identified through database 
searching 
(n = 2658) 
Articles excluded  
(n = 20) 
Reasons:  
Duplicates – 1 
Bacteriotherapy – 4 
Not fulfilling selection 
criteria - 10 
Inadequate data - 5 
Duplicates removed 
(n = 802) 
Additional records identified through 
other sources 
(n = 0) 
Title and abstracts   
screened (n = 1856) 
Records excluded  
(n = 1778) 
Full-text articles assessed for 
eligibility  
(n = 78) 
Studies included in critical 
appraisal  
(n = 58) 
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 16 
 Public Health England 
 Royal College of Physicians 
 Royal College of Nursing 
 Royal College of Surgeons 
 ESCMID 
 MRSA Action 
 HSCNI 
 Institute of Microbiology and Infection, University of Birmingham (Prof Peter Hawkey and 
Dr Victoria McCune attended) 
 Microbiology, Royal Devon and Exeter NHS Foundation Trust (Dr Ray Sheridan, Dr Alaric 
Colville, Dr Robert Porter and Dr Melissa Baxter attended) 
 C diff support (Ms Graziella Kontkowski attended) 
 OpenBiome (Dr Majdi Osman nd Dr Carolyn Edelstein attended) 
 Dr Sally Cudmore (University College Cork) attended 
 Dr Ngozi Elumogo attended (Microbiology, Norfolk & Norwich University NHS Trust) 
 Dr Vanya Gant (University College London Hospitals) 
 Dr Simon Goldenberg attended (Guy’s and St Thomas’ NHS Foundation Trust) 
 Dr Bram Goorguis attended (Academic Medical Centre, Amsterdam) 
 Dr Geraldine Moloney attended (Microbiology, Trinity College Dublin) 
 Dr Benjamin Mullish attended (Imperial College Healthcare NHS Trust) 
 Dr Laura Prtak attended (Sheffield Teaching Hospitals NHS Trust) 
 Mr Glenn Taylor attended (Taymount Clinic) 
 Dr Mark Wilks attended (Microbiology, Barts and The London NHS Trust) 
 
Appendix 4. Continuing Professional Development material 
1) In which of the following settings would you most strongly avoid giving a patient FMT? 
a) Immunocompromised patients 
b) Decompensated liver disease 
c) Heart failure 
d) History of anaphylactic food allergy 
e) A previous failed FMT 
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Answer:  d 
 
2) Where is FMT best sourced, if available? 
a) Related healthy donor 
b) Health care professional 
c) Centralised stool bank 
d) Pooled from multiple donors  
e) Any of above 
Answer:  c 
 
3) What is the maximum recommended length of time between stool donation and stool processing? 
a) 6 hours 
b) 7 hours 
c) 8 hours 
d) 9 hours 
e) 10 hours 
Answer:  a 
 
4) For which non-CDI condition is FMT currently recommended? 
a) Irritable bowel syndrome 
b) Obesity and metabolic syndrome 
c) Parkinson’s disease 
d) Ulcerative colitis 
e) None of the above 
Answer:  e 
 
5) When considering setting up an FMT service in the UK, which organisation should be contacted to 
seek guidance in establishing the service? 
a) Medicines and Healthcare Products and Regulatory Agency 
b) Medicines and Healthcare Products Regulatory Authority 
c) Medical Drugs and Healthcare Products and Regulatory Agency 
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 18 
d) Medical Drugs and Healthcare Products Regulatory Authority 
e) None of the above 
Answer:  b 
 
3. References: 
1.  Varier RU, Biltaji E, Smith KJ, et al. Cost-Effectiveness Analysis of Fecal Microbiota 
Transpla tation for Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol. 
2015;36(4):438-444. doi:10.1017/ice.2014.80. 
2.  Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of 
competing strategies for management of recurrent Clostridium difficile infection: a decision 
analysis. Clin Infect Dis. 2014;58(11):1507-1514. doi:10.1093/cid/ciu128. 
3.  Baro E, Galperine T, Denies F, et al. Cost-Effectiveness Analysis of Five Competing Strategies 
for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in 
France. Green J, ed. PLoS One. 2017;12(1):e0170258. doi:10.1371/journal.pone.0170258. 
4.  Lapointe-Shaw L, Tran KL, Coyte PC, et al. Cost-Effectiveness Analysis of Six Strategies to Treat 
Recurrent Clostridium difficile Infection. Deshpande A, ed. PLoS One. 2016;11(2):e0149521. 
doi:10.1371/journal.pone.0149521. 
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 1 
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium 
difficile infection and other potential indications: joint British Society of Gastroenterology 
(BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Supplementary Material 2:  Additional Appendices 
 
Appendix A. Scope 
1. Guideline title 
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium 
difficile infection and other potential indications: joint British Society of Gastroenterology 
(BSG) and Healthcare Infection Society (HIS) guidelines.   
 
1.1. Short title 
The use of faecal microbiota transplant 
 
2. The remit 
i. To review the evidence (include randomised trial evidence) for the efficacy of faecal 
microbiota transplant (FMT) in the treatment of adults (≥18 years), both in Clostridium difficile 
infection (CDI) and in other clinical conditions, and use this to make recommendations about 
optimal recipient selection and management, donor assessment, material preparation and 
administration, and other key elements of FMT delivery. 
ii. To provide specific guidance about best practice for an FMT service within the context of 
the regulatory framework for the intervention as it currently exists in the UK and beyond.   
 
Whilst this is not a guideline specifically addressing the management of Clostridium difficile 
infection (CDI), the working group will include consideration of where FMT should be 
considered within the conventional treatment algorithm of patients with CDI (specifically, in 
which patients it should be considered, and at which point in their care).   
 
The working group agreed that for the purposes of this guideline, faecal microbiota transplant 
would be defined as treatment that involves the administration of manipulated whole stool.  
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 2 
There is a growing literature of the use of ‘bacteriotherapy’ originally deriving from healthy 
donor stool as a potential alternative to FMT (including commensal bacteria, spores, 
bacteriophages and/ or bacterial proteins or metabolites).  However, the working group 
considered this to still be at the research stage, and would not be considered further.   
 
2.1. Population 
2.1.1. Groups that will be covered 
Adults (≥18 years) in whom: i. FMT has been used as treatment for CDI. 
 ii. FMT has been used as treatment for a non-CDI 
indication. 
 
Given the variability in the means used to diagnose CDI within different studies, the working 
group agreed to consider the suit bility of the definition used on a study-by-study basis. 
 
2.1.2. Groups that will not be covered 
Children and young people (<18 years). 
 
2.2. Healthcare setting 
All settings in which National Health Service care is received, and/ or clinical trials are 
undertaken. 
 
2.3. Clinical management 
2.3.1. Key clinical issues that will be covered 
a) Appropriate selection of patients with CDI for FMT, and best practice in their management post-
FMT. 
b) Optimal selection of donors of faecal material, and maintenance of a donor pool.   
c) Identification of the preferred means of preparation and administration of FMT to recipients.   
d) Evaluation of the safety and efficacy of FMT in treating non-CDI indications. 
e) Best practice in the development and delivery of an FMT service.   
 
2.3.2. Clinical issues that will not be covered 
a) General management of CDI.   
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 3 
b) General management of non-CDI conditions in which FMT may have a role in therapy.  
 
2.4. Main outcomes 
Recommendations for practice 
a) Patient/ recipient selection, and peri-FMT management 
b) Donor selection 
c) Preparation and administration of FMT 
d) Efficacy and safety of FMT for non-CDI indications 
e) Provision of an FMT service 
 
2.5. Economic aspects 
Where FMT is being provided under a MHRA license according to Good Manufacturing 
Practice (GMP) standards, there are significant costs associated with initial setup and 
maintenance of the service.  These include the cost of obtaining the relevant license, 
laboratory design and equipment to enable quality assurance, storage facilities for samples, 
etc.  However, there is counterbalance to this, as the expectation of the working group is that 
the publication of this guideline may encourage provision of FMT as treatment for recurrent 
or refractory CDI.  This has consistently been shown to be cost effective in comparison with 
anti-C. difficile antimicrobial therapy31–34, so overall costs associated with treating the 
condition may actually decrease.  Furthermore, there may be changes to the practice of 
clinicians already offering the service.  For example, encouraging the use of healthy unrelated 
donors (who can provide multiple stool donations after one screening) reduces the cost of 
screening when compared to the use of an FMT recipient’s relative as donor, who is likely to 
provide one donation only.   
 
2.6. Status 
2.6.1. Scope 
This is the final scope. 
 
2.6.2. Timing 
The development of the guideline recommendation will begin in July 2017. 
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3. Related NICE guidance 
National Institute for Health and Care Excellence.  Faecal microbiota transplant for recurrent 
Clostridium difficile infection.  NICE Interventional Procedures Guidance IPG485.  London: 
NICE; 2014.  Available at: 
https://www.nice.org.uk/guidance/ipg485 [last accessed 19th December 2017]. 
 
4. Further information 
Guideline development process 
Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. 
Revised edition. Edinburgh: Healthcare Improvement Scotland; 2014. Available at: 
http://www.sign.ac.uk [last accessed December 2017]. 
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 5 
Appendix B. Declarations of interest 
B.1. Introduction 
All members of the Working Group were required to make formal declarations of interest at 
the outset, and these were updated throughout the development process.  No interests were 
declared that required any actions. 
 
B.2. Tariq Iqbal 
First meeting 19/07/17: no declarations of interest; second meeting 04/10/17: no change. 
 
Third meeting 19/10/17: consultant, advisor or speaker for: Pharmacosmos and Shield 
Therapeutics. 
 
B.3. Simon Goldenberg (co-chair) 
First meeting 19/07/17 
Advisory board and/ or consultancy and/ or speaker fees:  Astellas, MSD, Pfizer. 
 
Second meeting 04/10/17; third meeting 19/10/17: no change. 
 
No action required.  
 
B.4. Ailsa Hart 
First meeting 19/07/17 
Advisory board and/ or consultancy and/ or speaker fees:  AbbVie, Atlantic, Bristol-Myers 
Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, 
Shire and Takeda.  Global steering committee for Genentech.   
 
Second meeting 04/10/17; third meeting 19/10/17: no change. 
 
No action required.  
 
 
No declared conflict of interests for the other participants.   
Page 173 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 6 
Appendix C. Clinical evidence tables 
C.1. Reviewed case series of FMT for recurrent or refractory CDI 
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 7 
Paper 
Study and patient 
characteristics 
Donor characteristics FMT characteristics Outcomes Adverse events CRD 
Aas et al, Clinical 
Infectious 
Diseases, 2003 
Case series. 
 
Number of patients: 18. 
 
Female: male 13:5. 
 
Age (mean): 73+/-9 
(range 53-88) years. 
 
Comorbidities: x1 
patient with Crohn's 
colitis, x1 with 
leukaemia. 
  
CDI features: Recurrent 
(at least 2 x laboratory-
confirmed CDI after 
initial antibiotic 
treatment). 
 
CDI diagnosis 
confirmation: Cytotoxin 
A and B positivity. 
 
Pre-FMT antibiotics: 
Metronidazole +/- 
vancomycin (not 
defined). 
Donors were 15 family 
members, and 3 clinical 
volunteers. 
 
Working in healthcare: Yes - for 
3 donors. 
 
Donor demographics: Not 
defined. 
 
Donor screening: Questionnaire 
not explicitly stated. 
 
Travel and antibiotic exclusion 
period: No antibiotics for 6 
months prior; nil stated 
regarding travel.   
 
Screening blood tests: Hepatitis 
A, B and C, HIV-1/-2, syphilis. 
 
Screening stool tests: C.difficile, 
enteric pathogens, ova, cysts 
and parasites.  
Amount of stool per transplant / 
administered to patients: 30g stool in 
50-70ml normal saline; only 25ml of 
total administered to patient. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Homogenised in 
domestic blender, then coffee filter. 
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: all 
nasogatric (18); lower GI: nil; capsules: 
nil. 
 
Number of infusions: Single infusion for 
all patients. 
 
Bowel purgative: Not described. 
 
PPI: 20mg omeprazole on day prior to 
FMT and day of FMT. 
 
Antimotility: Not described.  
 
Prokinetics: Not described.  
 
Overall cure within 
stated follow up 
period: 83.3% 
(n=15/18). 
 
Cure with one 
infusion alone: 
83.3% (n=15/18). 
 
Total follow-up 
period: 90 days. 
Minor GI adverse 
events: Nil stated. 
 
Minor non-GI 
adverse events: Nil 
stated. 
 
Serious adverse 
events: Nil stated. 
 
Deaths: x2 - one 
related to ESRF, 
one related to 
COPD. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: No - 
89%. 
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 8 
Time before CDI treatment was stopped 
before FMT: Continued until day of FMT.  
Page 176 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 9 
Agrawal et al, 
Journal of Clinical 
Gastroenterology, 
2016 
Case series. 
 
Number of patients: 146. 
 
Female: male: 100: 46. 
 
Age(mean): 78.6 (range 
65-97) years. 
 
Comorbidities: 
Immunosupression in 15 
patients (x3 Crohn’s, x2 
UC, x1 renal transplant) 
 
CDI features: 89 with 
recurrent CDI. 
 
CDI diagnosis 
confirmation: As per 
ACG guidelines. 
 
Pre-FMT antibiotics: All 
had prior metronidazole, 
vancomycin and/ or 
fidaxomicin. 
Donors were identified by the 
patient or - if not available - 
provided by the physician. 
 
Working in healthcare: Not 
stated. 
 
Donor demographics: No 
antibiotics for last three 
months. Excluded if significant 
GI disease, metabolic 
syndrome, chronic illness, 
immunocompromise, recent 
travel, and/ or high risk lifestyle 
in last three months.  
 
Donor screening: Questionnaire 
- excluded if significant GI 
disease, metabolic syndrome, 
chronic illness, 
immunocompromise, recent 
travel, high risk lifestyle in last 
three months. 
 
Travel and antibiotic exclusion 
period:  Exclusion if travel to an 
area of high incidence of 
infectious diarrhoea, and/ or 
antibiotics within past three 
months.  
 
Screening blood tests: Hepatitis 
A, B and C, HIV-1/-2, syphilis. 
 
Screening stool tests:  C difficile, 
enteric pathogens, ova, cysts 
Amount of stool per transplant / 
administered to patients: 60-100g of 
fresh stool. 
 
Diluent used to prepare: Normal saline, 
upper GI: 75-200ml; lower GI: 250-
400ml; enema: 150-200ml.   
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Handstirred and 
blender, sifted through gauze. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): N/A. 
  
Route administered: upper GI (16); 
lower GI (130); capsules: nil. 
 
Number of infusions: 1 routinely; 2nd 
infusion given with vancomycin so data 
unable to be extracted. 
 
Bowel purgative: PEG on day prior to 
FMT. 
 
PPI:  Not stated. 
 
Antimotility: Loperamide on day of FMT. 
 
Prokinetics: Not stated. 
 
Overall cure within 
stated follow-up 
period: 83% 
(n=121/146) . 
 
Cure with one 
infusion alone: 83% 
(n=121/146) . 
 
Total follow up 
period: mean 
follow up was 12.3 
months (range 1-48 
months). 
Minor GI adverse 
events: Nil stated. 
 
Minor non-GI 
adverse events: Nil 
stated. 
 
Serious adverse 
events: x2 
microscopic colitis, 
x1 Sjögren’s, x1 
scalp follicular 
lymphoma, x1 
contact dermatitis 
and idiopathic 
Bence-Jones 
gammaglobulinaem
ia.  In addition, x1 
SCC, x1 ileus (died 
two weeks after 
ileus), x1 colonic 
perforation 
secondary to CMV 
colitis and 
subsequent death 
after 1 year.  
Patients developing 
cancers had 
underlying risk 
factors.  
 
Deaths: x10 (x4 
decompensated 
CCF, x3 
malignancies, x1 
dementia, x1 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: No. 
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 10 
and parasites, Giardia, 
Cryptosporidium, Isospora, H. 
pylori, Rotavirus. 
Time before CDI treatment was stopped 
before FMT:  Between 3 days prior to 
FMT and one day prior to FMT. 
stroke, x1 
pneumonia); 
deaths between 19 
days to 7 months 
post-FMT. 
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Alrabaa et al, 
Transplant 
Infectious 
Diseases, 2017 
Case series. 
 
Number of patients: 13. 
 
Female: male: 8:5. 
 
Age (median): 69 (range 
59-74) years. 
 
Comorbidities: Yes - x4 
OLT, x1 kidney/ liver 
transplant, x1 lung 
transplant, x1 HIV+ with 
CD4 count of 453.  x1 
immunocompromised 
patients with IBS, x1 
immunocompetent 
patient with IBS; no IBD 
patients. 
 
CDI features: Not clear if 
recurrent or refractory.  
Mean of 4 previous 
episodes of CDI prior to 
FMT. 
 
CDI diagnosis 
confirmation: PCR. 
 
Pre-FMT antibiotics: All 
patients had previously 
had oral vancomycin, x7 
prev metronidazole 
(either with or without 
vancomycin).  x5 
received fidaxomicin 
Donors were unrelated. 
 
Working in healthcare: Nox 
 
Donor demographics: As per 
OpenBiome protocolx 
 
Donor screening: Questionnaire 
- as per OpenBiome protocolx 
 
Travel and antibiotic exclusion 
period: As per OpenBiome 
protocolx 
 
Screening bloods: FBC, hepatitis 
A, B and C, LFTs, HIV, HTLV-1/-
2, syphilis. 
 
Screening stools: C.difficile 
toxin, MC&S, ova, cysts and 
parasites, H.pylori stool 
antigen. 
Amount of stool per transplant / 
administered to patients: 12.5g of stool 
in 28.5g of product. 
 
Diluent used to prepare: normal saline - 
diluted to approx 100-150ml to 
administer. 
 
Diluent used to store if frozen: Not clear. 
 
Preparation methods: As per 
OpenBiome protocol. 
 
Time from preparation to transplant 
(fresh): N/A. 
 
Time period for storage (frozen): As per 
OpenBiome protocol - not described in 
paper. 
 
Route administered: Upper GI 
(nasoduodenal): 13; lower GI: 0; 
capsules: nil. 
 
Number of infusions: One routin ly, but 
retreated if relapsed after primary 
outcome.  However - one renal 
transplant patient received 2 doses of 
FMT on consecutive days (with 
successful outcome). 
 
Bowel purgative: Bowel preparation 
used - GoLytely (PEG). 
 
PPI: 40mg pantoprazole night before 
and morning of procedure. 
Overall cure within 
stated follow up 
period: 84.6% 
(n=11/13) at eight 
weeks post-FMT. 
 
Cure with one 
infusion alone: 
100% (n=13/13) at 
5 days. 
 
Total follow up 
period: Follow up 
up to 8 weeks 
described.  
Minor GI adverse 
events: Several 
patients transient 
cramps and/ or 
diarrhoea. 
 
Minor non-GI 
adverse events: Nil 
noted. 
 
Serious adverse 
events: x1 patient 
had episode of 
CMV reactivation at 
the time of FMT - 
thought unrelated.  
X1 patient had 
episode of mild 
transplant rejection 
two months after 
FMT - thought 
unrelated. 
 
Deaths: None. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Not 
clearly described. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 12 
with or after oral 
vancomycin.   
 
Antimotility: Loperamide 4mg 1 hour 
post FMT. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: See last box. 
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 13 
Brandt et al, 
American Journal 
of 
Gastroenterology, 
2012 
Case series. 
 
Number of patients: 77. 
 
Female: male: 56: 21. 
 
Age (mean): 65+/-17 
(range 22-87) years. 
 
Comorbidities: Not 
stated. 
 
CDI features: All 
recurrent/ refractory. 
 
CDI diagnosis 
confirmation: Not clear. 
 
Pre-FMT antibiotics: 62 
patients had had prior 
metronidazole, 76 
vancomycin (25 tapered 
vancomycin), 17 
rifaximin. 
Donors were 45 spouses/ 
partners; 21 relatives; 1 
unknown person. 
 
Working in healthcare: No. 
 
Donor demographics: No 
antibiotics within past 3 
months. 
 
Donor screening: Questionnaire 
- not stated. 
 
Travel and antibiotic exclusion 
period:  Excluded if travel to 
area of high incidence of 
infectious diarrhoea, or if 
antibiotics within past three 
months.  
 
Screening blood tests: HIV-1, 
HIV-2, hepatitis A, B and C, 
Syphillis. 
 
Screening stool tests: 
Clostridium difficile toxin (if 
unavailable then EIA), MC&S, 
Giardia, Cryptosporidium, ova, 
cysts and parasites, H.pylori, 
Acid Fast stain for Cyclospora, 
Isospora. 
Amount of stool per transplant / 
administered to patients: 6 tablespoons 
of stool up to entire donation; 300-
700ml of transplant administered. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Hand blender 
used to prep. 
 
Time from preparation to transplant 
(fresh): Within 8 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI:  0; lower 
GI: all 77 colonoscopic. 
 
Number of infusions: 77 patients had 
one (patients that had second not 
included because given with concurrent 
vancomycin). 
 
Bowel purgative: All patients given prep 
but no details. 
 
PPI: Not described. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
Overall cure within 
stated follow up 
period: N/A. 
 
Cure with one 
infusion alone: 
90.9% (n=70/77). 
 
Total follow up 
period: not clear, 
but some patients 
followed-up to 3 
years. 
Minor GI adverse 
events: Not stated. 
 
Minor non-GI 
adverse events: Not 
stated. 
 
Serious adverse 
events: Nil. 
 
Deaths: x7 deaths 
(cause unknown in 
one case, x1 
metastatic 
colorectal cancer 
(present from pre-
FMT), x1 metastatic 
ovarian cancer, x1 
pneumonia (non-
enteric organism), 
x1 MI, x1 stroke, x1 
sepsis five months 
after FMT.   
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Not 
clear. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: 
Reported but not 
explained. 
 
At least 90% 
followed up: No - 
only 77%. 
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Time before CDI treatment was stopped 
before FMT: 3 days. 
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Brumbaugh et al, 
Journal of 
Pediatrics, 2017 
Case series. 
 
Number of patients: 42. 
 
Female: male: 23: 19. 
 
Age (median): 9 (range 1 
-18) years. 
 
Comorbidities: 31% had 
IBD (x4 Crohn's, x9 UC); 
29% 'medically complex', 
including oncological, 
metabolic, 
cardiopulmonary or 
neurological diagnoses. 
 
CDI features: All children 
had had at least one 
course of vancomycin. 
Previously recurrent - at 
least 2 episodes. 
 
CDI diagnosis: Diarrhoea, 
haematochezia and/ or 
crampy abdominal pain 
in combination with 
positive C. difficile PCR. 
 
Pre-FMT antibiotics: Not 
stated. 
Donor:  OpenBiome-supplied 
FMT. 
 
Working in healthcare: No.  
 
Donor demographics: Not 
stated. 
 
Donor screening: 
Questionnaire: As per 
OpenBiome protocol. 
 
Travel and antibiotic exclusion 
period: As per OpenBiome 
protocol. 
 
Screening bloods: As per 
OpenBiome protocol. 
 
Screening stools: As per 
OpenBiome protocol. 
Amount of stool per transplant / 
administered to patients: 30ml 
OpenBiome aliquot/ capsule, although 
not defined re stool quantity. 
 
Diluent used to prepare: As per 
OpenBiome protocol 
 
 
Diluent used to store if frozen: As per 
OpenBiome protocol 
 
Preparation methods: As per 
OpenBiome protocol 
 
Time from preparation to transplant 
(fresh): None given fresh 
 
Time period for storage (frozen): N/A 
 
Route administered: Upper GI: 41, 
nasogastric administration (some 
children used pre-existing gastrostomy);  
lower GI: 0; capsules: 1 (1 x 30 capsules).   
 
Number of infusions: 1 routinely 
 
Bowel purgative: Not stated 
 
PPI: Rantidine for 24hrs prior to FMT 
 
Antimotility: N/A 
 
Prokinetics: N/A 
 
Time before CDI treatment was stopped 
Overall cure within 
stated follow up 
period: 71% 
(n=30/42). 
 
Cure with one 
infusion alone: 71% 
(n=30/42) - 
remission in 94% (n 
=16/17) otherwise 
healthy children, 
54% (n =7/13) 
(54%) with IBD, 
75% (n=9/12) 
medically complex. 
Success in 71% of 
children when via 
NGT, and 67% via 
gastrostomy (non-
significant). 
 
Total follow up 
period: 5 patients 
with initial failure 
opted for 2nd and 2 
cured, so total 
success of 76% 
(n=32/42).  
Minor GI adverse 
events: 6/47 FMT 
administrations 
accompanied by 
vomiting within 
24hrs; self-
resolved. 
 
Minor non-GI 
adverse events: Nil 
reported.  
 
Serious adverse 
events: Nil 
reported. 
 
Deaths: Nil 
reported. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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before FMT: 48 hours, after minimum of 
5 days of vancomycin. 
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Chin et al, Clinical 
Gastroenterology 
& Hepatology, 
2016 
Case series. 
 
Number of patients: 35. 
 
Female: male: 16: 19. 
 
Age (mean): 43 (range 8 
-93) years. 
 
Comorbidities: IBD in all, 
8 on corticosteroids, 3 
on Immunomodulators, 
11 on biologics. 
 
CDI features: Recurrent - 
at least 2 episodes. 
 
CDI diagnosis 
confirmation: Not 
stated. 
 
Pre-FMT antibiotics: Not 
stated. 
Donors were age 18 - 50, no 
medications, BMI 18.5 – 25. 
 
Working in healthcare: Not 
stated. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
- adapted from US blood bank. 
 
Travel and antibiotic exclusion 
period: Excluded if antibiotic 
within past six months. 
 
Screening blood tests: FBC, 
U&E, LFTs, CRP, ANA, hepatitis 
A, B and C, HBV, HIV-1/-2, 
syphilis. 
 
Screening stool tests: Faecal 
occult blood, rotavirus, 
bacterial pathogens, ova, cysts 
and parasites, Acid fast stain for 
Giardia and Cryptosporidium, C 
difficile, H. pylori. 
Amount of stool per transplant / 
administered to patients: 41g of stool on 
average.  
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: Frozen in 
10% glycerol. 
 
Preparation methods: Ambient air. 
 
Time from preparation to transplant 
(fresh): N/A; given fresh. 
 
Time period for storage (frozen): Up to 
156 days. 
 
Route administered: Upper GI:  5 via 
nasogastric tube; lower GI:  3 via 
colonoscopy; capsule: 27 patients. 
 
Number of infusions: Not stated. 
 
Bowel purgative: Not routinely - just for 
colonoscopy (4 litres of PEG). 
 
PPI: 7 on PPI not as premedications. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 2 days prior to FMT. 
Overall cure within 
stated follow up 
period: N/A. 
 
Cure with one 
infusion alone: Not 
stated. 
 
Total follow up 
period: At least 2 
months (range 2 to 
6 months). 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
  
Serious adverse 
events: two 
required surgery 
(diverting 
colostomy and total 
proctectomy), two 
developed perianal 
disease with no 
prior history of it. 
 
Deaths: Ni. 
Selection/ eligibility 
reported: No. 
 
Consecutively 
recruited: No. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: No. 
Page 185 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 18 
Cohen et al, Israel 
Medical 
Association 
Journal, 2016 
Case series. 
 
Number of patients: 22. 
 
Female: male: 9: 13. 
 
Age (median): Median 
71.5 (range 16-92) years. 
 
Comorbidities: x1 IBD 
(colonoscopic group), x2 
patients on 
chemotherapy, unclear 
why.   
 
CDI features: Recurrent 
or refractory. 
 
CDI diagnosis 
confirmation: Diarrhoea 
and toxin testing. 
 
Pre-FMT antibiotics: 19 
patients given previous 
metronidazole, 9 
vancomycin (with 13 
both together). 
Donors were 13 unrelated, 9 
related. 
 
Working in healthcare: Yes - for 
unrelated. 
 
Donor demographics: No details 
- just says screening similar to 
blood donors. 
 
Donor screening: Questionnaire 
- no details. 
 
Travel and antibiotic exclusion 
period: Excluded if antibiotics 
within past six months. 
 
Screening bloods: No details. 
 
Screening stools: No details. 
Amount of stool per transplant / 
administered to patients: 60g stool 
average (35-75g), 250ml total once 
mixed with saline (100 - 300ml range). 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: Not 
stated. 
 
Preparation methods: Some fresh, some 
frozen. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): No 
details. 
 
Route administered: Upper GI: 
nasoduodenal in 10; lower GI: 
colonoscopic in 12. 
 
Number of infusions: 1 FMT. 
 
Bowel purgative: 3l of PEG if 
colonoscopic administration. 
 
PPI: PPI if upper GI administration. 
 
Antimotility: Not described. 
 
Prokinetics: Metoclopramide just prior 
to upper GI administration. 
Overall cure within 
stated follow up 
period: 72.7% 
(n=16/22) at 2 
months. 
 
Cure with one 
infusion alone: 
72.7% (n=16/22) 
(5/10 upper GI (out 
of 7 analysed), 
91.7% (n=11/12) 
for lower GI (out of 
11 analysed)). 
 
Total follow up 
period: Results 
reported at two 
months, but 
followed up to six 
months (7 months 
in the upper GI arm 
and 5 in the lower 
GI arm followed up 
to 6 months). 
Minor GI adverse 
events: x5 transient 
constipation/ 
abdominal 
discomfort. 
 
Minor non-GI 
adverse events: Not 
stated. 
 
Serious adverse 
events: See deaths. 
 
Deaths: x7 (x1 due 
to CDI, x1 chronic 
resp disease, x1 
related to dialysis, 
x2 pneumonia, x1 
sepsis at ten days 
post-FMT 
(aspiration of stool; 
had been 
gastroscopic 
administration), x1 
died at home 
?cause). 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Time before CDI treatment was stopped 
before FMT: 12-24hrs. 
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Costello et al, 
Alimentary 
Pharmacology 
and Therapeutics, 
2015 
Case series. 
 
Number of patients: 20. 
 
Female: male: not 
stated. 
 
Age(median): 69 years. 
 
Comorbidities: Not 
stated. 
 
CDI features: All 
recurrent. 
 
CDI diagnosis 
confirmation: Not 
stated. 
 
Pre-FMT antibiotics: 
Conventional therapy 
with metronidazole, 
vancomycin and/or 
fidaxomicin had failed in 
all. 
Donors were 4 healthy 
volunteers. 
 
Working in healthcare: No. 
 
Donor demographics: No 
details. 
 
Donor screening: Questionnaire 
- adapted from US blood bank. 
 
Travel and antibiotic exclusion 
period: Excluded if  travel to 
diarrhoea-endemic areas 
witihin 6 months and/ or used  
antibiotics for 3 months. 
 
Screening blood tests: HIV -1 
and -2, hepatitis A, B and C, and 
syphillis. 
 
Screening stool tests: C difficile 
toxin B PCR, routine MC&S, 
faecal Giardia antigen, faecal 
Cryptosporidium,  Acid-fast 
stain for Cyclospora, Isospora, 
ova, cysts and parasites, 
H.pylori fecal antigen. 
Amount of stool per transplant / 
administered to patients: Not stated. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: 10% 
glycerol. 
 
Preparation methods: Anaerobically 
prepared. 
 
Time from preparation to transplant 
(fresh): all frozen. 
 
Time period for storage (frozen): 16 
patients had stool stored for < 2 months. 
4 patients had stool stored > 2 months. 
 
Route administered: Upper GI: 1; lower 
GI: 19; capsule: nil.  
 
Number of infusions: 17 patients had 1, 
3 patients had 2. 
 
Bowel purgative: Not reported. 
 
PPI: Not reported. 
 
Antimotility: Not reported. 
 
Prokinetics: Not reported. 
 
Time before CDI treatment was stopped 
before FMT: Not reported. 
Overall cure within 
stated follow up 
period: 85% 
(n=17/20). 
 
Cure with one 
infusion alone: 85% 
(n=17/20). 
 
Total follow up 
period: Minimum 3 
months (but up to 
14 months). 
Minor GI adverse 
events: None. 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: None. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
Page 188 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 21 
Emanuelsson et 
al, Scandanavian 
Journal of 
Infectious 
Diseases, 2014 
Case series. 
 
Number of patients: 23. 
 
Female: male: 14: 9. 
 
Age (median): 66 years 
(range 25-99) years 
(including 8 additional 
patients treated with 
‘bacteriotherapy’). 
 
Comorbidities: 3 with 
diabetes mellitus, 1 with 
microscopic colitis.   
 
CDI features:  All 
recurrent. 
 
CDI diagnosis 
confirmation: Culture 
and/or toxin EIA. 
 
Pre-FMT antibiotics: 
Metronidazole and/or 
vancomycin used in all 
patients beforehand.   
Donors were spouses or close 
relative. 
 
Donor working in healthcare: 
No. 
 
Donor demographics: Not 
stated. 
 
Donor screening:  
Questionnaire – asked 
regarding current and previous 
GI diagnoses/ symptoms.  
  
Travel and antibiotic exclusion 
period: Definitely an antibiotic 
use restriction but not clearly 
stated. 
 
Screening blood tests: HIV-1 
and -2, hepatitis C virus, and 
hepatitis B surface antigen. 
 
Screening stool tests: 
Salmonella, Shigella, 
Campylobacter, 
enterohemolytic Escherichia 
coli, and Clostridium difficile. 
Amount of stool per transplant / 
administered to patients: 50g in 500mls. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: N/A - 
fresh. 
 
Preparation methods: Anaerobically 
prepared. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; ower 
GI: 23 (enema/ rectal catheter); 
capsules: nil. 
 
Number of infusions: 22 patients 
eceived 1 FMT, 1 patient received 2 
FMTs. 
 
Bowel purgative: Not stated. 
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was stopped 
before FMT: Not stated. 
Overall cure within 
stated follow up 
period: 65% 
(n=15/23). 
 
Cure with one 
infusion alone: 65% 
(n=15/23). 
 
Total follow up 
period: Median 
follow up of 18 
months (range 0-
201 months). 
Minor GI adverse 
events: None. 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: None. 
Selection/eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Fischer et al, 
Inflammatory 
Bowel Diseases, 
2016 
Case series 
 
Number of patients: 67 
Female: male: 39:28 
 
Age (mean/ standard 
deviation): Mean 45.42 
(+/-17.33) years. 
 
Comorbidities: x5 PSC, 
x4 liver transplant, x3 
end stage liver disease, 
concurrent IBD in all (x35 
Crohn’s, x31 UC, x1 
indeterminate colitis). 
 
CDI features:  recurrent 
or refractory. 
 
CDI diagnosis 
confirmation: Return of 
diarrhoea and positive 
CDI testing within 12 
weeks of FMT. 
 
Pre-FMT antibiotics: 
metrronidazole in 47 
patients, vancomycin in 
63, vancomycin taper in 
38 patients,, fidaxomicin 
in 7, rifaxamin in 7.  
Donors were patient-directed 
donor or unrelated healthy 
volunteers. 
 
Donors working in healthcare: 
not stated. 
 
Donor demographics: As per 
Bakken et al, Clin Gastroenterol 
Hepatol, 2011.   
 
Donor screening: Questionnaire 
- as per Bakken et al, Clin 
Gastroenterol Hepatol, 2011.   
 
 
Travel and antibiotic exclusion 
period:  Excluded as donor if 
travel within last 6 months 
where diarrheal illnesses are 
endemic or risk of travelers 
diarrhea is high, and/ or use of 
antibiotics within 3 months. 
 
Screening blood tests: HIV -1&-
2, hepatitis A, B and C, syphilis. 
 
Screening stool tests: As per 
Bakken et al, Clin Gastroenterol 
Hepatol, 2011.   
 
Amount of stool per transplant / 
administered to patients: lower GI:-25-
50ml; upper GI: 250-500ml. 
 
Diluent used to prepare:  Preservative-
free normal saline or 4% milk. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Household 
blender, homogenized and removal of 
particle matter with gauze/ urine 
strainers in a Biohazard Level 2 facility. 
 
Time from preparation to transplant 
(fresh): Certainly within 24 hours, and 
preferably within 6 hours.  
 
Time period for storage (frozen): N/A.   
 
Route administered: Upper GI: nil; lower 
GI: 67 (colonoscopy or sigmoidoscopy); 
capsule: nil.    
 
Number of infusions: 53 patients 
received one infusion, 14 received 2 
infusions. 
 
Bowel purgative: Standard bowel 
preparation, but not specified. 
 
PPI: If upper GI administration, PPI on 
the evening before and morning of the 
procedure. 
Overall cure within 
stated follow up 
period: 90% 
(n=60/67) within 3 
months. 
 
Cure with one 
infusion alone: 79% 
(n=53/67). 
 
Total follow up 
period: average 
length 10.4 (range 
3-36) months. 
Minor GI adverse 
events: x1 IBD flare, 
managed as 
outpatient.   
 
Minor non-GI 
adverse events: x4 
pneumonia. 
  
Serious adverse 
events: x1 
colectomy for 
refractory IBD,x7 
hospitalised, x2 CDI 
recurrence, x2 IBD 
exacerbation, x1 
small bowel 
obstruction, x1 
CMV colitis. 
 
Deaths: none. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: No. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: N/A.   
 
At least 90% 
followed up: N/A.   
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Antimotility: Loperamide optional for 
lower GI administration.  
 
Prokinetics: Not stated.  
 
Time before CDI treatment was stopped 
before FMT: 24-48 hrs. 
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Fischer et al, 
American Journal 
of 
Gastroenterology, 
2016 
Case series. 
 
Number of patients: 328. 
 
Female: male: 241: 87. 
 
Age (mean/ standard 
deviation): 61.4 (+/-19.3) 
years. 
 
Comorbidities: 77 
immunocompromised 
(x3 CVID, x3 selective IgA 
deficiency, x71 
immunosupressants (20 
for solid organ 
transplant, 29 for IBD, 6 
for rheumatoid arthritis, 
2 for SLE, 1 for 
pemphigoid, 1 for 
chronic obstructive 
airway disease, 1 for 
psoriasis)), x11 
chemotherapy for 
malignancy, x63 IBD (25 
UC, 33 Crohn’s), x118 
diverticulosis. 
 
CDI features: Recurrent 
disease in 87.2% and 
severe or severe-
complicated in 12.8%.   
 
CDI diagnosis 
confirmation: Postive 
stool C difficile toxin or 
Donors were 130 (40%) patient-
directed donors, and 198 
universal (60%). 
 
Donor working in healthcare: 
Not stated. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
– depended upon individual 
centre. 
 
Travel and antibiotic exclusion 
period: Depended upon 
individual centre. 
 
Screening blood tests:  
Depended upon individual 
centre. 
 
Screening stool test: Depended 
upon individual centre.  
Amount of stool per transplant / 
administered to patients: Not specified. 
 
Diluent used to prepare: Not specified. 
 
Diluent used to store if frozen: Both 
fresh and frozen, but specific details not 
given. 
 
Preparation methods: Dependent upon 
individual centre.   
 
Time from preparation to transplant 
(fresh): Dependent upon individual 
centre.  
 
Time period for storage (frozen): 
Dependent upon individual centre.  
 
Route administered: Not specified 
(‘predominantly colonoscopy’).   
 
Number of infusions: Dependent upon 
individual centre.   
 
Bowel purgative: Not specified. 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
 
Time before CDI treatment was stopped 
before FMT: Dependent upon each 
centre.   
Overall cure within 
stated follow up 
period: 1 month 
81.4% (n=267/328). 
 
Cure with one 
infusion alone: Not 
specified. 
 
Total follow up 
period: Not 
specified. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: Not 
specified. 
 
Deaths: Not 
specified. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: No. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: N/A. 
 
At least 90% 
followed up: N/A.  
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PCR. 
 
Pre-FMT antibiotics: 
vancomycin. 
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Fischer et al, Gut 
Microbes, 2017 
Case series. 
 
Number of patients: 57. 
 
Female: male: 34: 23. 
 
Age (median): Median 
72 (range 25-99) years. 
 
Comorbidities: x7 toxic 
megacolon, x12 acute 
kidney injury (x3 needing 
dialysis), x10 with 
hypovolaemic/ septic 
shock, x7 mental status 
changes, x4 on 
mechanical ventilation. 
x10 patients had 
inflammatory bowel 
disease (x5 with Crohn's 
and x5 with ulcerative 
colitis) and x10 patients 
were on 
immunosuppressive 
medications. 
 
CDI features: Severe, 
recurrent and severe-
complicated. 
 
CDI diagnosis 
confirmation: Positive 
stool C.difficle PCR. 
 
Pre-FMT antibiotics: 
Included vancomycin, 
Donors were screened patient-
selected donors for first 29 
patients, whilst next 28 from 
OpenBiome stool bank. 
 
Donors working in healthcare: 
Not specified.  
 
Donor demographics: Not 
specified. 
 
Donor screening: Questionnaire 
– for patient-selected donors, 
this was as for Bakken et al, Clin 
Gastoenterol Hepatol, 2011;  
for OpenBiome, as per 
OpenBiome protocol.   
 
Travel and antibiotic exclusion 
period: For patient-selected 
donors, this was as for Bakken 
et al, Clin Gastoenterol Hepatol, 
2011;  for OpenBiome, as per 
OpenBiome protocol.   
 
Screening blood tests: For 
patient-selected donors, this 
was as for Bakken et al, Clin 
Gastoenterol Hepatol, 2011;  
for OpenBiome, as per 
OpenBiome protocol.   
 
Screening stool tests:  Ffor 
patient-selected donors, this 
was as for Bakken et al, Clin 
Gastoenterol Hepatol, 2011;  
Amount of stool per transplant / 
administered to patients:  As per Fischer 
et al, Alim Pharm Ther, 2015 or 
OpenBiome.   
 
Diluent used to prepare: As per Fischer 
et al, Alim Pharm Ther, 2015 or 
OpenBiome.  
 
Diluent used to store if frozen: As per 
Fischer et al, Alim Pharm Ther, 2015 or 
OpenBiome . 
 
Preparation methods: As per Fischer et 
al, Alim Pharm Ther, 2015 or 
OpenBiome.   
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): As per 
OpenBiome protocols.    
 
Route administered Upper GI: nil; lower 
GI:  57 via colonoscopy or 
sigmoidoscopy. 
 
Number of infusions: 32 patients: x1, 20 
patients x2, 5 patients x3, 1 patient x4,1 
patient x5.  Pre-planned protocol for 
serial FMTs +/- vancomycin, as described 
in Fischer et al, Alim Pharm Ther, 2015.   
 
Bowel purgative: Not stated.  
 
Overall cure within 
stated follow up 
period: 91% 
(n=52/57), i.e. 
100% severe CDI 
(n=19/19), and 87% 
(n=33/38). 
 
Cure with one 
infusion alone: 
52.6% (n= 30/57). 
 
Total follow up 
period: Up to 6 
months.  
Minor GI adverse 
events: Not stated. 
 
Minor non-GI 
adverse events:  
Not stated. 
 
Serious adverse 
events: Not stated. 
 
Deaths: x7 
unrelated deaths, 
x4 CDI-related 
deaths. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: Yes. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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fidaxomicin, rectal 
vancomycin, intravenous 
metronidazole. 
for OpenBiome, as per 
OpenBiome protocol.   
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was stopped 
before FMT: Not stated. 
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Fischer et al, 
Alimentary 
Pharmacology 
and Therapeutics, 
2015 
Case series. 
 
Number of patients: 29. 
 
Female: male: 17: 12. 
 
Age (mean/ standard 
deviation): Overall, 
mean 65.2 (+/-17.9) 
years (range 25-92 
years); mean 60.8 (range 
26-87) years in severe;  
67.6 (range 60-78) years 
in severe-complicated. 
 
Comorbidities: x3 
Crohn's, x2 UC, x1 
hypogammaglobulinaem
ia, x1 ESKD, x1 ESLD, x1 
renal transplant, x1 liver 
transplant, x4 on 
immunosuppressive 
meds.  12/19 of pts 
treated in ITU at the 
time with following 
complications:  x5 
patients with toxic 
megacolon (caecal diam 
>12cm or rectosigmoid> 
6.5cm diameter); x7 AKI 
and hypovolaemic/ 
septic shock, x4 of which 
required vasopressors, 
x3 with change in mental 
status, x2 patients 
ventilated.  x22 with 
Donors were either patient 
selected-donor, or universal 
donors.  If patient-directed, 
same donor used for 
subsequent FMTs if required.  
44 FMTs in all - patient-selected 
for 16 FMTs, universal donor for 
28 FMTs. 
 
Donors working in healthcare: 
Not described.  
 
Donor demographics: Not clear. 
 
Donor screening: 
Questionnaire:  As per Bakken 
et al, Clin Gastroenterol 
Hepatol, 2011. 
 
Travel and antibiotic exclusion  
period: As per Bakken et al, Clin 
Gastroenterol Hepatol, 2011. 
 
Screening blood tests: As per 
Bakken et al, Clin Gastroenterol 
Hepatol, 2011. 
 
Screening stool tests: As per 
Bakken et al, Clin Gastroenterol 
Hepatol, 2011. 
Amount of stool per transplant / 
administered to patients: 50-200g of 
stool. 
 
Diluent used to prepare: 300ml of saline. 
 
Diluent used to store if frozen: N/A – all 
fresh. 
 
Preparation methods: No additional 
details. 
 
Time from preparation to transplant 
(fresh): Six hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: flexible sigmoidoscopy  or 
colonoscopy either proximal or distal to 
the splenic flexure at the discretion of 
the endoscopist. In practice – proximal 
to the splenic flexure in 18 FMTs, distal 
in 26.   
 
Number of infusions: As many as per 
protocol until end point.  16  x 1 FMT (7 
severe, 9 complicated), 11 x 2nd FMT (3 
severe, 8 compl), 2 x 3rd FMT (0 severe, 
2 complicated). 
 
N.B. Oral vancomycin (125 mg every 
6 hours) was resumed 24–48 hours after 
FMT for a minimum of 5 days if there 
were pseudomembranes present at 
colonoscopy. For patients who did not 
Overall cure within 
stated follow up 
period: By 3 
months, 62% 
(n=18/29) in 
remission. 
 
Cure with one 
infusion alone: 70% 
(n=7/10) in severe 
arm; 47% (n=9/19) 
in severe-
complicated arm. 
 
Total follow up 
period: Up to 3 
months. 
Minor GI adverse 
events: Not stated. 
 
Minor non-GI 
adverse events: Not  
stated. 
 
Serious adverse 
events: Nil. 
 
Deaths: x2 deaths 
by 1 month; x1 
death from sepsis 
within 24 hours of 
FMT); death 
following 
collectomy after 3x 
failed FMT in 
patient who was six 
weeks post-OLT.  
By 3 months – x2 
further deaths from 
CDI recurrence, x1 
death from cirhosis, 
x1 death from 
heart failure, x1 
death from 
respiratory failure, 
x1 death from 
aspiration. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: Yes. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 29 
pseudomembranes at 
first FMT.   
 
CDI features: 9 patients 
with first episode of CDI; 
all others with previous 
episodes. 
 
CDI diagnosis 
confirmation: Diarrhoea 
(at least 3 loose stools/ 
day) and positive toxin.   
 
Pre-FMT antibiotics: Not 
stated. 
improve by days 6–7, the vancomycin 
was stopped, and bowel prep was 
administered if no ileus was present.  
The next day (day 7–8), a repeat FMT, 
from the same donor as the first FMT if 
patient-directed, was performed by 
sigmoidoscopy or colonoscopy.  If 
pseudomembranes were present, oral 
vancomycin was resumed for an 
additional 5 days. If no 
pseudomembranes were detected, 
antibiotics were not resumed following 
the repeat FMT. 
 
Bowel purgative: Split dose 4l Golytely if 
no ileus/ obstruction. 
 
PPI: Not described.  
 
Antimotility: Not described.   
 
Prokinetics: Not described.   
 
Time before CDI treatment was stopped 
before FMT: 12-24hr prior to FMT. 
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Garborg et al, 
Scandanavian 
Journal of 
Infectious 
Diseases, 2010 
Case series. 
 
Number of patients: 40. 
 
Female: male: 21: 19. 
 
Age (mean): Mean age 
75 (range 53-94) years. 
 
Comorbidities: x1 
Wegener's, x1 AML.  
Repeated courses of 
antibiotics, not formally 
described. 
 
CDI features: Not 
described. 
 
CDI diagnosis 
confirmation: Diarrhoea 
and + C difficile toxin 
(testing for A and B). 
 
Pre-FMT antibiotics: All 
patients had had at least 
two courses of oral 
metronidazole (500mg 
three times daily) or 
vancomycin (125mg po 
four times daily). 
Donors were close relatives/ 
household members. 
 
Donors working in healthcare: 
No. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
- "Symptoms of GI disease or 
history of chronic infectious 
disease". 
 
Travel and antibiotic exclusion 
period: Not stated. 
 
Screening bloods: Hepatitis A, B 
and C, HIV. 
 
Screening stools: MC&S, 
Yersinia.  No routine paraiste 
screening ("low prevalence in 
Norway"). 
Amount of stool per transplant / 
administered to patients: 50-100g. 
 
Diluent used to prepare: 250ml sterile 
normal saline. 
 
Diluent used to store if frozen:  All fresh. 
 
Preparation methods: Stool placed on 
gauze pad and strained; flushed with 
saline; drawn up into syringes ready for 
administration. 
 
Time from preparation to transplant 
(fresh): Same day. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: OGD with 
delivery in distal duodenum; 38; lower 
GI: Colonoscopy; 2. 
 
Number of infusions: One at baseline; 
follow up if 'did not respond' although 
not specifically defined. 
 
Bowel purgative: Not mentioned, even 
for colonoscopy.   
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
Overall cure within 
stated follow up 
period: 835 
(n=33/40). 
 
Cure with one 
infusion alone: 73% 
(n=29/ 40) (28 in 
duodenum, 1 in 
colon). 
 
Total follow up 
period: Up to 80 
days. 
Minor GI adverse 
events: Not stated. 
 
Minor non-GI 
adverse events: Not 
stated. 
 
Serious adverse 
events: Not stated. 
 
Deaths: x5 deaths 
within 3 weeks - 2 
months post-FMT 
but none 
attributable to 
FMT.  x2 deaths 
attributed to 
‘frailty’, x1 
advanced 
Wegener's, x1 
AML/ antibiotics, 
one patients with 
advanced 
cardiovascular 
disease who had 
fulminant colitis, 
underwent 
colectomy, but 
died.  
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Time before CDI treatment was stopped 
before FMT: Evening prior to FMT. 
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Girotra et al, 
Digestive Diseases 
and Sciences, 
2016 
Case series. 
 
Number of patients: 29. 
 
Female: male: 6: 23. 
 
Age (mean/ standard 
deviation): 80.1 (+/-6.49) 
years (13 patients 70-79, 
14 patients 80-89, 2 
patients > 90 years). 
 
Comorbidities: x8 
patients with diabetes 
mellitus. 
  
CDI features: No specific 
details - purely 
symptoms > 6 months, 
failed at least 3 
antibiotic regimens. 
 
CDI diagnosis 
confirmation: At least 
three unformed stools in 
24 hour and positive 
stool C difficile test by 
toxin (by ELISA) or toxin 
gene B (by PCR).  All 
patients here defined 
RCDI by symptoms >6 
months and at least x3 
failed antibiotics. 
 
Pre-FMT antibiotics: Not 
indicated. 
Donors were patient-selected 
family or friends. 
 
Donors working in healthcare: 
No. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
– peptic ulcer disease/GORD, 
IBS, IBD, polyps, malignancy, 
antibiotic use/ hospitalisation 
within past 3 months. 
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotic use within the past 
three months.  
 
Screening bloods:  
HIV, HTLV-I/-II, syphilis enzyme 
immunoassay, hepatitis A 
immunoglobulin M, hepatitis B 
surface antigen, hepatitis C 
antibody, and Helicobacter 
pylori antibody.  
 
Screening stools: MC&S/ ova, 
cysts and parasites x3, 
Cryptosporidium, Microspora, C 
difficile toxin. 
Amount of stool per transplant / 
administered to patients: 450cc - 270cc 
via colonoscopy AND 180cc into jejunum 
via enteroscopy. 
 
Diluent used to prepare: Saline - whole 
stool sample (>30g) mixed with 50-70ml 
of sterile saline, made up to 5 x 90cc 
aliquots. 
 
Diluent used to store if frozen: Fresh. 
 
Preparation methods: Stool mixed with 
saline, homogenised in blender for <4 
minutes, filtered x2 with coffee filter 
paper. 
 
Time from preparation to transplant 
(fresh): Within 6 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Enteroscopy into 
jejunum AND colonoscopy in all 29 
patients. 
 
Number of infusions: 1 FMT per patient 
(combined upper and lower GI 
administration). 
 
Bowel purgative: Not described. 
 
PPI: 20mg omeprazole evening before/ 
morning of procedure. 
 
Antimotility: Not described. 
Overall cure within 
stated follow up 
period: 100% 
(n=29/29). 
 
Cure with one 
infusion alone: 
100% (n=29/29). 
 
Total follow-up 
period: Reported 
25.37 +/- 12.8 
months follow-up 
(range 8-50 
months).   
 
In addition - 
researchers report 
60% weight gain, 
40% stable weight, 
75% improved 
'failure to thrive' 
(defined as 
decrease of weight 
>10% from 
baseline, with no 
improvement 
despite medical 
treatment of CDI 
and nutritional 
treatment). 
Minor GI adverse 
events: Bloating 
10% (n=3/29). 
 
Minor non-GI 
adverse events: 
Fever 7% (n=2/29) 
(transient for one 
day). 
 
Serious adverse 
events: None. 
 
Deaths: None. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: N/A. 
 
At least 90% 
followed up: Yes. 
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Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: >12 hours. 
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Hagel et al, 
Deutsches 
Arzteblatt 
International, 
2016 
Case series. 
 
Number of patients: 133. 
 
Female: male: 86: 47. 
 
Age (median): Median 
75 (IQR 59.5 - 81.5) 
years. 
 
Comorbidities: x3 
chemotherapy, x19 
immunosuppressants, x5 
solid organ transplant, 
x1 allogeneic stem cell 
transplant, x43 GI 
comorbidities (no 
details). 
 
CDI features: Median of 
3 recurrences (IQR 1-4); 
no specific details re 
recurrent vs refractory 
confirmation. 
  
Pre-FMT antibiotics: x4 
metronidazole only, x13 
vancomycin only, x2 
fidaxomicin only, x61 
metronidazole/ 
vancomycin, x8 
vancomycin/ 
fidaxomicin, x34 
metronidazole/ 
vancomycin/ 
Donors working in healthcare: 
not stated 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
- not stated. 
 
Travel and antibiotic exclusion 
period: Not stated. 
 
Screening blood tests.: Rapid 
plasma reagin and fluorescent 
Treponemal antibody-absorbed. 
 
Screening stool tests: Not 
stated. 
 
Amount of stool per transplant / 
administered to patients: Not stated. 
 
Diluent used to prepare: Not stated. 
 
Diluent used to store if frozen: Yes, in 
some cases - no details given. 
 
Preparation methods: Not stated. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): Not 
stated. 
 
Route administered: Upper GI: 4 OGD, 
40 enteroscopy, 19 nasoenteric tube; 
lower GI: 55 'endoscopic' (no further 
details); capsule: 13.  x2 combination of 
jejunal and colonoscopic FMT.    
 
Number of infusions: 1 FMT. 
 
Bowel purgative: Yes - 117 (no d tails 
given). 
 
PPI: Yes - 31 (no details given). 
 
Antimotility: Yes - 31 (no details given). 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was stopped 
before FMT: Not stated. 
 
Overall cure within 
stated follow up 
period:  
Primary cure on 
day 30 and 90 was 
achieved in 84.2% 
(n=101/120) and 
78.3% (n=72/92). 
 
Cure with one 
infusion alone: No 
diarrhoea at 30 
days in 84.2% 
(n=101/120); no 
diarrhoea at 90 
days in 78.3% 
(n=72/92). 
 
Total follow up 
period: Median 
follow up 141 days 
(IQR 50-353 days). 
Minor GI adverse 
events: x5 nausea, 
x3 abdominal pain, 
2 belching, x2 
vomiting, x2 'food 
intolerance', x1 IBS. 
 
Minor non-GI 
adverse events: x3 
fever, x2 throat 
discomfort. 
 
Serious adverse 
events: x1 
aspiration 
pneumonia, x1 
haemorrhage 
(during endoscopy - 
no details), x1 loss 
of tooth, x1 
polyneuropathy, x1 
weight gain > 10kg 
in 12 months post-
FMT. 
 
Deaths: x7 died 
during follow up, x2 
within 90 days of 
FMT.  In x6 cases, 
definitely not 
related to CDI (in 
one patient, 
recurrence of CDI 
one week after 
FMT contributed to 
her death (but 
Selection/eligibility 
reported: Yes. 
 
Consecutively 
recruited: Not 
clear. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: Yes. 
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fidaxomicin, x11 
unknown. 
stroke described as 
primary cause of 
death). 
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Hamilton et al, 
American Journal 
of 
Gastroenterology, 
2012 
Case series. 
 
Number of patients: 43. 
 
Female: male: 31: 12. 
 
Age (mean/ standard 
deviation): Mean 59 (+/-
21) years. 
 
Comorbidities: x14 IBD 
patients.  
 
CDI features: Recurrent. 
 
CDI diagnosis 
confirmation: Toxin 
positive with at least two 
subsequent recurrences. 
 
Pre-FMT antibiotics: All 
had vancomycin, 17 
patients had addition of 
vancomycin and 2 weeks 
of rifaximin (one of these 
17 had 4 weeks of 
rifaximin); 3 patients 
took 2-4 weeks of 
nitazoxanide. 
Donors were standard donors 
for 33 FMTs, and individual 
donors for 10 FMTs. 
 
Donors working in healthcare:  
Not stated. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
- before recruitment, the 
donors were required to submit 
available medical records and 
have a separate medical history 
interview away from the 
recipient patient. The history 
included assessment of 
infectious risk, including 
identification of known risk 
factors for HIV and hepatitis, 
current communicable diseases, 
and recent travel to areas of 
the world with a higher 
prevalence of diarrheal 
illnesses. 
 
Travel and antibiotic exclusion 
period: Excluded as donors if 
recent travel to areas where 
high prevelence of diarrheal 
illness (not specified), and/ or 
antibiotic use within the past six 
months.   
 
Amount of stool per transplant / 
administered to patients: 50g. 
 
Diluent used to prepare: 250ml sterile, 
non-bacteriostatic normal saline. 
 
Diluent used to store if frozen: 10% 
glycerol. 
 
Preparation methods: Stool from 
individual donors was passed through 
stainless steel tea strainers; stool from 
universal donors was transported on ice 
to the lab, and processed within 2 hours. 
Material was weighed and homogenised 
in commercial blender under nitrogen 
gas. Slurry then passed through 2.0, 1.0, 
0.5 and 0.25mm stainless steel lab 
sieves.  The resulting material was then 
cetrifuged at 6000 x g for 15 minutes 
and resuspended to one-half the original 
volume in normal saline. 
 
Time from preparation to transplant 
(fresh): 1-2 hours. 
 
Time period for storage (frozen): 1-8 
weeks. 
 
Route administered: Upper GI: nil; lower 
GI: colonoscopy (with majority into 
terminal ileum or caecum, with a small 
proportion into other colonic areas) in 
all 43; capsules: nil. 
 
Number of infusions: 1x FMT in 37 
Overall cure within 
stated follow up 
period:  95% 
(n=41/43) within 2 
months follow-up. 
 
Cure with one 
infusion alone: 86% 
(n=37/43). 
 
Total follow up 
period: 2 months 
following FMT. 
Minor GI adverse 
events: ~1/3 of 
patients reported 
flatulance and 
excessive bowel 
movements within 
fortnight following 
procedure. 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: None. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: Yes. 
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Screening blood tests: HIV, 
hepatitis B/C, RPR, LFTs. 
 
Screening stool tests:  
Clostridium difficile toxin B PCR, 
MC&S, ova, cysts and parasites, 
Giardia, Cryptosporidium, H 
pylori antigen.   
patients, 2x FMT in 6 patients.  
 
Bowel purgative: Yes - GoLYTELY or 
Moviprep. 
 
PPI: Not described. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 2 days. 
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Hefazi et al, Mayo 
Clinic Proceedings, 
2017 
Case series. 
 
Number of patients: 23. 
 
Female: male: 13: 10. 
 
Age (median): 66 (range 
23-88) years. 
 
Comorbidities: x13 
patients had 
haematological 
malignancy (x4 diffuse 
large B cell lymphoma, 
x2 Hodgkin's lymphoma, 
x1 chronic myeloid 
leukaemia, x1 follicular 
lymphoma, x1 stage IV 
cutaneous T cell 
lymphoma, x1 B cell 
acute lymphocytic 
leukaemia, x1 hairy cell 
leukaemia, x1 chronic 
lymphocytic leukaemia, 
x1 severe aplastic 
anaemia); x1 with active 
disease at time of FMT, 
x2 with recent 
chemotherapy use, x2 
with neutropenia within 
12 weeks prior to FMT. 
x10 patients with solid 
organ malignancy (x4 
breast, x2 anal, x1 colon, 
x1 pancreatic, x1 
tonsillar, x1 non-small 
Donors:  Fresh stool from 
family/ friends in 10 patients, 
frozen stool from standard 
donors in 13 patients. 
 
Donor working in healthcare: 
Not stated. 
 
Donor demographics: Not 
stated. 
 
Donor screening: As per Patel et 
al, Mayo Clin Proc, 2013. 
 
Travel and antibiotic exclusion 
period: As per Patel et al, Mayo 
Clin Proc, 2013. 
 
Screening blood tests: As per 
Patel et al, Mayo Clin Proc, 
2013. 
 
Screening stools: As per Patel et 
al, Mayo Clin Proc, 2013. 
Amount of stool per transplant / 
administered to patients: ~50g. 
 
Diluent used to prepare: 250ml normal 
saline.  
 
Diluent used to store if frozen:  Not 
stated. 
 
Preparation methods: As per Patel et al, 
Mayo Clin Proc, 2013. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): Not 
stated. 
 
Route administered: Upper GI: nil; lower 
GI: All 23 patients received FMT via 
colonoscopy into caecum. 
 
Number of infusions: 1 FMT. 
 
Bowel purgative: Not stated. 
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was stopped 
before FMT: 24 hours.  
Overall cure within 
stated follow up 
period: 92% 
(n=11/12) 
of haematological 
malignancy 
patients (other 
patient died), and 
805 (n=8/10) solid 
malignancy 
patients. 
 
Cure with one 
infusion alone: 86% 
(n=19/22) by 
primary outcome 
criteria. 
 
Total follow up 
period: x1 CLL 
patient recurred at 
22 months post-
FMT in context of 
ibrutinib and 
coamoxiclav; 
successfully treated 
with 10 days of 
metronidazole. x1 
tonsillar cancer 
patient had CDI 
recurrence at 14 
months after 
exposure to 
cefalexin; 
successfully treated 
with 10 days of 
Minor GI adverse 
events: x3 chronic 
diarrhoea for at 
least six months 
(despite negative C 
difficile laboratory 
tests), x8 transient 
diarrhoea, x3 
abdominal cramps, 
x2 faecal urgency, 
x2 constipation, x1 
nausea. 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: x1 death 
after cardiac arrest 
of Hodgkin’s 
lymphoma patient 
at day 5 (multiple 
medical 
comorbidities 
thought likely 
cause, not FMT); x2 
deaths at > 60 days 
related to the 
underlying 
malignancy 
progressing. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 39 
cell lung. x5 with 
metastasis at time of 
FMT, x3 recent 
chemotherapy use, x1 
with recent neutropenia. 
Other comorbidities 
include x1 COPD, x1 
ESKD on haemodialysis, 
x1 graft versus host 
disease (on 
immunosuppression), x1 
granulomatosis with 
polyangiitis (Wegener’s) 
on immunosuppression, 
x1 
hypogammaglobulinaem
ia on intravenous 
immunoglobulin, x1 
inflammatory arthritis on 
corticosteroids. 
 
CDI features:  All 
recurrent. 
 
CDI diagnosis 
confirmation: Not 
explicitly defined, but 
definitions of recurrent, 
severe and complicated 
CDI as per American 
College of 
Gastroenterology. 
 
Pre-FMT antibiotics: All 
given additional 
vancomycin until 24hrs 
vancomycin then 
10 days of 
fidaxomicin.  N.B.  
In all - x10 more 
chemotherapy 
courses and x8 
more antibiotic 
courses after FMT. 
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prior to FMT. Median of 
2.5 standard treatment 
courses per patient 
(defined as at least 10 
days of metronidazole, 
vancomycin or 
fidaxomicin), x1 previous 
vancomycin taper, and 
x4 total treatment 
courses for CDI). 
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Hirsch et al, BMC 
Infectious 
Diseases, 2015 
Case series. 
 
Number of patients: 19. 
 
Female: male: 13: 6. 
 
Age (mean): 61 (range 
26-92) years. 
 
Comorbidities: x3 IBS, x2 
diabetes mellitus, x1 
diverticulitis, x1 
lymphoma, x1 acute 
myeloid leukaemia, x1 
renal cancer, x1 chronic 
renal failure.  
 
CDI features:  Refractory 
and recurrent (2 or more 
episodes). 
 
CDI diagnosis 
confirmation: Not 
stated. 
 
Pre-FMT antibiotics: 
metronidazole, 
vancomycin +/or 
fidaxomicin. 
Donors were 3 unrelated 
participants. 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: Excluded 
if BMI>25, diabetes mellitus, 
psychiatric history, IBD, or IBS. 
 
Donor screening: Questionnaire 
- standard questionnaire, with 
details as above.   
 
Travel and antibiotic exclusion 
period: Excluded if travel 
outside the USA within 30 days 
prior to donation, and/ or use 
of antibiotics within the past 6 
months.   
 
Screening blood tests: HIV, 
hepatitis A, B,C, Treponema/ 
syphilis, and HTLV-1. 
 
Screening stool tests: 
Clostridium difficile toxin B, 
Salmonella, Shigella, 
Campylobacter, E. coli, Yersinia, 
Vibrio, Aeromonas, 
Plesiomonas. 
Amount of stool per transplant / 
administered to patients: 2.3g. 
 
Diluent used to prepare: 350ml in 0.9% 
normal saline.  
 
Diluent used to store if frozen: 15% 
glycerol. 
 
Preparation methods:  Strict 
environmental contol <6 hours after 
defaecation.  All sterile, wet weight of 
stool was homogenised in 350ml 0.9% 
normal saline and aliquoted; samples 
were then centrifudged at 200 x g for 10 
mins.  Supernatent was decanted and 
centrifuged at 4600 x g for 15 minutes. 
supernatant removed and pellet re-
suspended in 0.9% normal saline with 
glycerol. The typical concentration was 
0.5g/ml. The resulting FMT slurry was 
put in 5-10ml syringes and frozen at -
80oC. 
 
Time from preparation to transplant 
(fresh): N/A. 
 
Time period for storage (frozen): 1-3 
weeks at -80oC; prior to use, syringes 
were transferred to -20oC and used 
within six weeks. 
 
Route administered: Nil upper or lower 
GI; all capsules.  Aliquots of 0.4 mL of 
FMT slurry were dispensed into Size 1 
acid-resistant hypromellose capsules, 
Overall cure within 
stated follow up 
period: 68% 
(n=13/19). 
 
Cure with one 
infusion alone: 68% 
(n=13/19) at 90 
days. 
 
Total follow up 
period: Primary 
outcome assessed 
at 90 days, whilst 
secondary outcome 
assessed at 6 weeks 
after this. 
Minor GI adverse 
events: x5 
abdominal pain 5 
(x4 self-resolved;  
x1 required opiates 
and was 
hospitalised). 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: x1 died 
from respiratory 
failure after failing 
FMT treatment. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Not 
clear. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: Yes. 
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 42 
subsequently placed within Size 0 acid-
resistant hypromellose capsules and 
then nested within Size 00 gelatin Caps. 
Capsules were administered 
immediately upon filling and capping. 
 
Number of infusions: One course was 8-
12 capsules (one only took 6). 
 
Bowel purgative: Not described. 
 
PPI: Yes - evening and morning of 
procedure. 
 
Antimotility: Not described. 
 
Prokinetics: Yes - encouraged to drink 4 
ounces of Kefir fermented milk product 
twice a day, and also given a list of 
prebiotics to consume for 3 days. 
 
Time before CDI treatment was stopped 
before FMT: On day prior to FMT. 
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Ianiro et al, 
Clinical 
Microbiology and 
Infection, 2017 
Case series. 
 
Number of patients: 64. 
 
Female:male: 39: 25. 
 
Age (mean): Mean 74 
years. 
 
Comorbidities: Not 
reported. 
 
CDI features: Recurrent 
CDI - all patients had 3 
recurrences on average 
range (range 2-6). 
 
CDI diagnosis 
confirmation: Defined 
using ESCMID guidelines. 
 
Pre-FMT antibiotics: All 
patients had had prior 
metronidazole, 
vancomycin and/ or 
fidaxomicin. 
Donors were unrelated for 36 
FMTs, and related for 28 FMTs.. 
 
Donor working in healthcare: 
No. 
 
Donor demographics: Not 
specified. 
 
Donor screening: As per 
Cammarota et al, Alim Pharm 
Ther, 2015.  
 
Travel and antibiotic exclusion 
period: As per Cammarota et al, 
Alim Pharm Ther, 2015. 
 
Screening blood tests: As per 
Cammarota et al, Alim Pharm 
Ther, 2015. 
 
Screening stool tests:  As per 
Cammarota et al, Alim Pharm 
Ther, 2015.   
Amount of stool per transplant / 
administered to patients: not reported. 
 
Diluent used to prepare: 500ml of 0.9% 
saline. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: After dilution, the 
solution was blended and supernatant 
strained and poured into sterile 
container. 
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): Not 
specified. 
 
Route administered: Upper GI: nil: lower 
GI: all 64 given FMT via colonoscopy; 
capsules: nil.   
 
Number of infusions: 44 patients had x1 
FMT, 20 patients had >1 FMT 
(undefined). 
 
Bowel purgative: 4l macrogol on last 1-2 
days of antibiotcs treatment. 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
Overall cure within 
stated follow up 
period: 975 
(n=62/64) at 8 
weeks. 
 
Cure with one 
infusion alone: 69% 
(n=44/64). 
 
Total follow up 
period: 8 weeks. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: Not 
specified. 
 
Deaths: Not 
specified.   
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Time before CDI treatment was stopped 
before FMT: FMT given on last 1 or two 
days of CDI treatment. 
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Kassam et al, 
Archives of 
Internal Medicine, 
2012 
Case series. 
 
Number of patients: 27. 
 
Female: male 13: 14. 
 
Age (mean): 69.4 (range 
26-87) years.  
 
Comorbidities: Not 
specified. 
 
CDI features: Recurrent 
and refractory. 
 
CDI diagnosis 
confirmation: (1) 
Laboratory-confirmed C 
difficile toxin using EIA 
with no other cause for 
diarrhea; (2) refractory 
CDI (defined as ongoing 
diarrhea despite 
antimicrobial treatment) 
or recurrent CDI (defined 
as symptom resolution 
for at least 2 days after 
discontinuation of 
treatment with 
recurrence of diarrhea). 
 
Pre-FMT antibiotics: All 
had at least prior 
metronidazole; 19 had 
subsequent vancomycin 
monotherapy. 8 had 
Donors were two healthy 
volunteers. 
 
Donors working in healthcare: 
Not specified. 
 
Donor demographics: Not 
specified. 
 
Donor screening: Questionnaire 
- not specified. 
 
Travel and antibiotic exclusion 
period: Excluded if used 
antibiotics within last 6 months.  
 
Screening blood tests: Hepatitis 
B surface antigen, hepatitis C 
antibody, Helicobacter pylori 
and syphilis serologic markers, 
HIV types -1 and -2, and HTLV 
types -I and -II. 
 
Screening stool tests:  Stool was 
processed for enteric bacterial 
pathogens, C difficile toxin, and 
ova and parasites.  
Amount of stool per transplant / 
administered to patients: 150g of stool. 
 
Diluent used to prepare: 300mls sterile 
water. 
 
Diluent used to store if frozen: N/A. 
 
Preparation methods: Not specified. 
 
Time from preparation to transplant 
(fresh): Not specified. 
 
Time period for storage (frozen): N/A – 
fresh. 
 
Route administered: Upper GI: nil; lower 
GI: 27 via retention enema. 
 
Number of infusions: 1 enema  in 22 
patients, 2 enemas in 5 patients.  
 
Bowel purgative: Not specified. 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
 
Time before CDI treatment was stopped 
before FMT: At least 24 hours before. 
Overall cure within 
stated follow up 
period: 81% 
(n=22/27). 
 
Cure with one 
infusion alone: 81% 
(n=22/27). 
 
Total follow up 
period: Mean 
follow-up of 427.3 
days after 
transplant.  
. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: Not 
specified. 
 
Deaths: Not 
specified. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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combination 
metronidazole and 
vancomycin therapy. 
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Kelly et al, Journal 
of Clinical 
Gastroenterology, 
2012 
Case series. 
 
Number of patients: 26. 
 
Female: male: 24:2. 
 
Age (mean): 59 years. 
 
Comorbidities:  Not 
stated. 
 
CDI features: Recurrent.  
Mean duration of 
diagnosis of CDI prior to 
FMT of 12.6 (range 4 to 
84) months. 
 
CDI diagnosis 
confirmation: Not 
stated. 
 
Pre-FMT antibiotics: All 
had previous treatment 
with metronidazole, and 
repeated tapering 
courses of vancomycin.  
19 had failed at least one 
course of rifaximin.  
Some patients had prior 
Saccharomyces boulardii 
or Lactobacillus GG.  Pre-
FMT, all had 2 weeks of 
metronidazole or 
vancomycin, 
discontinued 2-3 days 
before FMT. 
Donors were family members in 
25 cases, and friend in 1 case. 
 
Donor working in healthcare: 
No. 
 
Donor demographics: Not 
specified. 
 
Donor screening: Questionnaire 
– asked regarding known 
exposure to HIV within 12 
months, high-risk sexual 
behaviours, use of ilicit drugs, 
tattoo within 6 months, 
incarceration within 12 months, 
risk factors for Creutzfleldt-
Jakob disease, GI co-
morbidities, recent ingestion of 
allergen, systemic 
autoimmunity, chronic pain 
syndromes. 
 
Travel and antibiotic exclusion 
period: No antibiotics for 
preceeding 90 days.   
 
Screening blood tests:  blood 
for hepatitis A, B and C, HIV-1&-
2, Trepenoma pallidum. 
 
Screening stool tests:  Stool for 
culture for bacteria, stain for 
ova and parasites, C difficile 
toxin A and B. 
Amount of stool per transplant / 
administered to patients: "6:8 
tablespoons of donor stool". 
 
Diluent used to prepare:  1 litre of sterile 
water passed through gauze.  Aliquoted 
in 60ml syringes. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: As above. 
 
Time from preparation to transplant 
(fresh): 6 hours prior to transplant. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: all 26 via colonoscopy; capsules: nil.    
 
Number of infusions: not explicitly 
stated but imples single infusion for all 
patients. 
 
Bowel purgative: PEG bowel prep night 
before transplant. 
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was stopped 
Overall cure within 
stated follow up 
period: 92.3% 
(n=24/26). 
 
Cure with one 
infusion alone: 
92.3% (n=24/26). 
 
Total follow up 
period: follow up  
of mean 10.7 
months (ranged 
from 2-30 months). 
Minor GI adverse 
events: Mild 
diarrhoea post-FMT 
in x3 patients. 
 
Minor non-GI 
adverse events: No. 
 
Serious adverse 
events: No. 
 
Deaths: No. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes 
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before FMT: 2-3 days. 
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Kelly et al, 
American Journal 
of 
Gastroenterology, 
2014 
Case series. 
 
Number of patients: 80. 
 
Female: male: 42: 38. 
 
Age (mean):  N.B. 75 
adults, and 5 children.  
Mean age of adults: 53 
(range 20-88) years; 
mean age of paediatric 
patients: 10.9 (range 
6.5–16) years. 
 
Comorbidities: x36 IBD, 
x19 solid organ 
transplant, x3 HIV/AIDS, 
x7 cancer, x4 
rheumatoid arthritis, x1 
adrenal insufficiency, x6 
cirrhosis, x1 ESKD, x1 
panhypopituatarism, x1 
end-stage COPD, x1 
ESKD with allograft 
failure, x1 Sjögrens. 
 
CDI features: Both 
refractory and recurrent 
patients included as well 
as severe/ complicated 
disease. 
 
CDI diagnosis: Not 
clearly specified.  
 
Pre-FMT antibiotics: 
Donors working in healthcare: 
Not specified. 
 
Donor demographics: Not 
specified. 
 
Donor screening: 
Questionnaire: Varied by 
centre. 
 
Travel and antibiotic exclusion 
period: Varied by centre. 
 
Screening blood tests: Varied by 
centre. 
 
Screening stool tests: Varied by 
centre. 
Amount of stool per transplant / 
administered to patients: Varied by 
centre. 
 
Diluent used to prepare: Varied by 
centre. 
 
Diluent used to store if frozen: Varied by 
centre. 
 
Preparation methods: Varied by centre. 
 
Time from preparation to transplant 
(fresh): Varied by centre. 
 
Time period for storage (frozen): Varied 
by centre. 
 
Route administered: Not specified.    
 
Number of infusions: 85% (n=68/80) had 
single FMT, 15% (n=12/80) had > 1 FMT.  
 
Bowel purgative: Varied by centre. 
 
PPI: Varied by centre. 
 
Antimotility: Varied by centre. 
 
Prokinetics: Varied by centre. 
 
Time before CDI treatment was stopped 
before FMT: Varied by centre. 
Overall cure within 
stated follow up 
period: 89% 
(n=71/80) within a 
minimum of 12 
weeks. 
 
Cure with one 
infusion alone: 78% 
(n=62/80). 
 
Total follow up 
period: 12 weeks 
post-FMT. 
Minor GI adverse 
events: x3 self 
limiting diarrhoea, 
x3 bloating and 
abdominal 
discomfort, x1 
Crohn’s flare, x1 
nausea, x1 minor 
mucosal tear at 
colonoscopy. 
 
Minor non-GI 
adverse events: x1 
fever, x1 hip pain, 
x1 pertussis. 
 
Serious adverse 
events: x10 
hospitalization (x1 
for fever, 
encephalopathy 
and pancytopenia; 
x1 abdo pain post 
FMT, x3 IBD flares 
(x2 Crohn’s, x1 UC), 
x1 stroke, x1 
colectomy, x1 fall 
and sustained hip 
fracture, x1 
influenza B and 
diarrhoea, x1 
catheter infection. 
 
Deaths: x2 deaths 
(x1 pneumonia and 
x1 aspiration after 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: No. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: Yes. 
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Vancomycin 67 (84%), 
fidaxomicin 23 (29%), 
rifaximin 13 (16%), 
metronidazole 55 (69%). 
sedation for 
colonoscopic FMT).    
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Khoruts et al, 
Clinical 
Gastroenterology 
& Hepatology, 
2016 
Case series. 
 
Number of patients: 272. 
 
Female: male: 189: 83. 
 
Age (mean/  median/ 
standard deviation): 
Mean 57.2 (+/- 19.2) 
years; median 59.0 
(range 16-100) years. 
 
Comorbidities: x10 
dialysis, x22 established 
Crohn’s, x21 established 
UC, x15 lymphocytic 
colitis, x5 diagnosed with 
Crohn’s during 
colonoscopy for FMT, x1 
diagnosed UC during 
colonoscopy for FMT, 
x14 newly-diagnosed 
lymphocytic colitis. x13 
reclassified in terms of 
IBD.  x8 solid organ 
recipients, x30 patients 
without IBD were taking 
biologics (anti-TNF, 
rituximab), 
immunomodulators 
(methotrexate, purine 
analogues), and/ or 
corticosteroids. 
 
CDI features: All patients 
had at least two 
Donors working in healthcare: 
As per Hamilton et al, Am J 
Gastroenterol, 2012. 
 
Donor demographics: As per 
Hamilton et al, Am J 
Gastroenterol, 2012. 
 
Donor screening: Questionnaire 
- as per Hamilton et al, Am J 
Gastroenterol, 2012. 
 
Travel and antibiotic exclusion 
period: As per Hamilton et al, 
Am J Gastroenterol, 2012. 
 
Screening blood tests: As per 
Hamilton et al, Am J 
Gastroenterol, 2012. 
 
Screening stools: As per 
Hamilton et al, Am J 
Gastroenterol, 2012. 
Amount of stool per transplant / 
administered to patients: As per 
Hamilton et al, Am J Gastroenterol, 
2012. 
 
Diluent used to prepare: As per 
Hamilton et al, Am J Gastroenterol, 
2012. 
 
Diluent used to store if frozen: As per 
Hamilton et al, Am J Gastroenterol, 
2012. 
 
Preparation methods: As per Hamilton 
et al, Am J Gastroenterol, 2012. 
 
Time from preparation to transplant 
(fresh): As per Hamilton et al, Am J 
Gastroenterol, 2012. 
 
Time period for storage (frozen): As per 
Hamilton et al, Am J Gastroenterol, 
2012. 
 
Route administered: Upper GI: nil;  
lower GI: colonoscopy (272); capsule: 
nil.   
 
Number of infusions: One routinely, 
more than one if required - specific 
criteria not defined.  
 
Bowel purgative: Yes - all had purgative 
on day prior to procedure (as per 
Hamilton et al, Am J Gastroenterol, 
2012). 
Overall cure within 
stated follow up 
period: 74% (n= 
32/43) in IBD 
patients and 92.2% 
(n=211/229) in 
non-IBD patients. 
 
Cure with one 
infusion alone:  
74% (n= 32/43) in 
IBD patients and 
92.2% (n=211/229) 
in non IBD patients. 
 
Total follow up 
period: Up to 6 
years. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: 25.6% 
(n=11/43) of IBD 
patients diagnosed 
with FMT-related 
flare. x2 patients 
hospitalised with 
IBD flare within two 
months of FMT.  
Clearance of CDI by 
FMT generally 
associated with 
improved control of 
IBD over the long 
term. x6 patients 
struggled with IBD 
despite 
optimisation of 
immunosuppressiv
e treatment, x3 of 
whom underwent 
colectomies. 
 
Deaths: Nil. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 52 
spontaneous relapses of 
CDI following initial 
episode, defined as 
recurrence within three 
months of 
discontinuation of anti-
CDI antibiotics treatment 
in conjunction with 
diarrheal symptoms. 
 
CDI diagnosis 
confirmation: Positive 
stool testing within two 
months of FMT - not 
clearly defined.  
 
Pre-FMT antibiotics: 
x206 patients had had 
prior metronidazole, 
x270 vancomycin, x69 
fidaxomicin, x71 
rifaximin, x104 
probiotics. 
 
PPI: Not described. 
 
Antimotility: Not described.   
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 2 days.  
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Lagier et al, 
European Journal 
of Clinical 
Microbiology and 
Infectious 
Diseases, 2015 
Case series. 
 
Number of patients: 61. 
 
Female: male:  40:21. 
 
Age (mean):  84 (range 
66-101) years. 
 
Comorbidities: Not  
Specified. 
 
CDI features: Some 
patients refractory/ 
recurrent; some during 
first CDI. 
 
CDI diagnosis 
confirmation:PCR that 
detects toxin and B 
genes, and toxin C gene 
deletion that 
characterises 027. 
 
Pre-FMT antibiotics: 
Patients divided into 
'tardive transplant' (i.e. 
only after x3 antibiotic 
failures) or 'early 
transplant' (during first 
week of infection during 
first treatment, 
accompanied by 
antibiotics).  Antibiotics 
were for non-severe 
disease: metronidazole 
Donors were preferentially  
healthy family members, but 
also used healthy volunteer 
students and residents. 
 
Donor working in healthcare: 
Yes - some residents. 
 
Donor demographics: BMI<30, 
exclude active cancer, 
diarrhoea, current 
immunosuppressive drugs, 
antibiotics within past three 
months.   
 
Donor screening: 
Questionnaire: As above.   
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotic use within past three 
months. 
 
Screening blood tests: HIV, 
hepatitis A, B,C, E, active CMV, 
active EBV, Treponema 
pallidum, HTLV. 
 
Screening stool tests: MC&S, 
parasites, toxigenic C difficile.' 
Amount of stool per transplant / 
administered to patients: >30g. 
 
Diluent used to prepare: Whole stool 
mixed with 400ml normal saline, 
homogenised for 10 minutes. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: 10 minutes of 
homogenisation in blender, filtered, put 
into a syringe at room temperature. 
 
Time from preparation to transplant 
(fresh): <6 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: Via 
nasogastric tube in 61 patients; nil lower 
GI or capsules. 
 
Number of infusions: In early FMT arm - 
one FMT routine; but offered 2nd FMT if 
relapse. 
 
Bowel purgative: 4l Klean Prep/ two 
glasses of Fast Prep day before FMT. 
 
PPI: No - but used 200ml 1.4% 
bicarbonate 15 minutes before FMT. 
 
Antimotility: Not specified.  
 
Prokinetics: Not specified. 
Overall cure within 
stated follow up 
period: Global 
death rate of 19% 
(n=3/16) in early 
transplant arm (day 
20, day 37, day 
166),  
 
67% (n=2/3) died in 
arm of those 
treated by tardive 
transplant (day 28, 
day 54).   
 
None of these 
patients died with 
evidence of CDI. 
 
Cure with one 
infusion alone: 33% 
(n=1/3) treated by 
tardive FMT dead 
at day 31; 4.2% 
(n=1/16) treated by 
early FMT dead at 
day 31. 
 
Total follow up 
period: No details 
on absolute length 
of follow-up. 
Minor GI adverse 
events: x24 
diarrhoea (resolved 
day 1 after FMT), x1 
nausea. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: x1 acute 
heart failure - no 
details. 
 
Deaths: 3/16 in 
early transplant 
arm (vs 29/45 
treated by abx only 
or tardive 
transplant).  No 
sign of CDI at time 
of death (days 20, 
37, 166). 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: No - not  
stated. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 54 
orally three times a day 
for 14 days, then 
vancomycin 125mg four 
times a day for 14 days, 
then fidaxomicin 200mg 
twice a day for 10 days; 
for severe disease 
(defined as AKI, paralytic 
ileus, or peritoneal fluid), 
used vancomycin and 
metronidazole for 
primary infection, then 
fidaxomicin if relapse/ 
failure. 
Time before CDI treatment was stopped 
before FMT: Not specified. 
Page 222 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 55 
Lee et al, 
European Journal 
of Clinical 
Microbiology and 
Infectious 
Diseases, 2014 
Case series. 
 
Number of patients: 94 
 
Female: male: 53: 41. 
 
Age (mean): Mean 71.8 
(range 24-95) years. 
 
Comorbidities: x3 IBD, x3 
post-renal transplant. 
 
CDI features: Some 
patients refractory 
(defined as ongoing 
diarrhea depsite 
treatment with at least 5 
days of oral vancomycin, 
125mg four times daily), 
or recurrent (symptom 
resolution for at least 
two days after the 
discontinuation of 
treatment with 
recurrence of diarrhoea. 
 
CDI diagnosis 
confirmation: Toxin 
positive by enzyme 
immunoassay or 
polymerase chain 
reaction. 
 
Pre-FMT antibiotics: 
Average of 2.1 previous 
anti-CDI antibiotic 
Donors were volunteers. 
 
Donor working in healthcare: 
Not specified 
 
Donor demographics: Not 
specified. 
 
Donor screening: Questionnaire 
- describes use of questionnaire 
but no details given - "similar to 
the Full Length Donor History 
Questionnaire documents (US 
Food and Drug administration, 
DHQ version 1.3, May 2008" 
 
Travel and antibiotic exclusion 
period: Not specified.  
 
Screening blood testss: HIV-1/-
2, HTLV-1 and -2. Hepatitis A 
IgG/M, hepatitis B surface 
antigen, hepatitis C antibody, 
Treponema pallidum. 
 
Screening stools:  Ova, cysts 
and parasites, MC&S, C difficile 
toxin, norovirus, adenovirus, 
rotavirus. 
Amount of stool per transplant / 
administered to patients: Not specified. 
 
Diluent used to prepare: 300ml water. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Homogenisation 
of stool in water using a disposable 
spatula. 
 
Time from preparation to transplant 
(fresh): Not specified. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: retention enema in all 94 patients; nil 
capsules. 
 
Number of infusions: No fixed number - 
as many as required to achieve 
remission.  No clear definition of non-
response. 
 
Bowel purgative: Not specified. 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
 
Time before CDI treatment was stopped 
before FMT: Not specified. 
Overall cure within 
stated follow up 
period: At 6 months 
– 87% (n=81/94) in 
remission after 
FMT. 
 
Cure with one 
infusion alone: 
47.9% (n=45/94) 
with single FMT in 
remission at 6 
months. 
 
Total follow up 
period: 24 months. 
Minor GI adverse 
events: "10% 
experienced 
transient 
constipation and 
excess flatulence 
post-FMT". 
 
Minor non-GI 
adverse events: 
None described. 
 
Serious adverse 
events: None 
described. 
 
Deaths: 75% 
(n=6/8) patients 
not responding to 
FMT died (not clear 
when).  All "over 70 
years of age", with 
multiple underlying 
significant 
comorbidities and 
passed away due to 
critical illnesses; 
none had deaths 
attributable to FMT 
or directly due to 
CDI.  
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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courses (range 1-4), 
specifically: x74 
metronidazole courses 
(79.3%), x71 vancomycin 
(75%), x14 vancomycin 
taper (15.2%), x3 
probiotic 
monotreatment (0.03%), 
x16 concomitant 
metronidazole/ 
vancomycin (17.4%). 
Page 224 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 57 
MacConnachie et 
al, QJM, 2009 
Case series. 
 
Number of patients: 15. 
 
Female: male: 14: 1. 
 
Age (median): 81.5 
(range 68-95) years. 
 
Comorbidities: no 
haematological or IBD. 
 
CDI features: Relapsing 
defined as recurrence of 
loose stool following 
successful antibiotic 
treatment in a patient 
with previous toxin 
positive CDI. 
 
CDI diagnosis 
confirmation:  Not 
specified.   
 
Pre-FMT antibiotics: All 
had had previous 
metronidazole and 
vancomycin; x3 patients 
tapering vancomycin and 
intravenous 
Immunoglobulin. 
Donors were healthy related 
volunteers. 
 
Working in healthcare: Yes – in 
three cases where relatives 
could not be identified. 
 
Donor demographics: Not 
specified. 
 
Donor screening: HIV-1/-2, 
HTLV- 1 and -2, hepatitis A 
IgG/M, hepatitis B surface 
antigen, hepatitis C antibody, 
Treponema pallidum. 
 
Questionnaire: Yes, but not 
specified. 
 
Travel and antibiotic exclusion 
period: Not specified. 
 
Screening stools: Ova, cysts and 
parasites, MC&S, C difficile 
toxin. 
Amount of stool per transplant 
administered to patients: 30g. 
 
Diluent used to prepare: 0.9% normal 
saline. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Stool sample 
prepared in less than 6 hours; add 50-
70ml of normal saline, homogenise with 
handheld stool blender,gradually 
advance speed, continue for 2-4 mins 
until smooth, filter suspension in coffee 
filter paper. 
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): Not 
applicable. 
 
Route administered: Upper GI:  All 15 
patients received FMT via nasogastric 
tube; lower GI and capsules: nil. 
 
Number of infusions: 1 FMT per patient 
routinely, repeat if required. 
 
Bowel purgative: Not given. 
 
PPI: Omeprazole 20mg eve before and 
on morning. 
 
Antimotility: Not given. 
Overall cure within 
stated follow up 
period: 84% 
(n=15/18) 
“resolution”. 
 
Cure with one 
infusion alone: 
884% (n=15/18) 
“resolution”. 
 
Total follow-up 
period: 90 days. 
Minor GI adverse 
events: x1 
diarrhoea. 
 
Minor non-GI 
adverse events: Nil. 
 
Serious adverse 
events: Nil. 
 
Deaths: x2 (not felt 
related to FMT). 
 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Prokinetics: Not given. 
 
Time before CDI treatment was stopped 
before FMT: Stopped on the evening 
before FMT.  
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Mattila et al, 
Gastroenterology, 
2012 
Case series. 
 
Number of patients: 70. 
 
Female: male: 42: 28. 
 
Age (mean): Mean 73 
(range 22-90) years. 
 
Comorbidities: No IBD, 
one adenocarcinoma of 
colon diagnosed during 
colonoscopy for FMT. 
 
CDI features:  Recurrent, 
mean of 3.5 previous 
episodes of CDI pre-FMT 
(range 1-12). 
 
CDI diagnosis 
confirmation: Positive 
culture and toxin. 
 
Pre-FMT antibiotics: 
Mixture of 
metronidazole, 
vancomycin, rifaximin - 
no patient-level data. 
Donors: 61 donors were close 
relatives/ other household 
members; in 9 cases, healthy 
volunteers. 
 
Donors working in healthcare: 
Not specified. 
 
Donor demographics: Not 
specified. 
 
Donor screening: Questionnaire 
- "No antibiotics and no 
intestinal symptoms within 6 
months". 
 
Travel and antibiotic exclusion 
period: Excluded as donor if any 
antibiotic use within past six 
months; no details of travel 
restrictions.  
 
Screening blood tests: Hepatitis 
B surface antigen, Hepatitis C 
antibody, HIV-1/-2 , Treponema 
pallidum plasma reagin test; 
total blood count, C-reactive 
protein, creatinine, liver 
enzymes. 
 
Screening stool tests: C difficile 
culture/ tox A/ B; MC&S, ova 
cysts and parasites. 
Amount of stool per transplant / 
administered to patients: 20-30ml stool. 
 
Diluent used to prepare: 100-200ml 
water; 100ml of suspension 
administered to caecum. 
 
Diluent used to store if frozen: N/A – all 
fresh. 
 
Preparation methods: Not specified. 
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: colonoscopy (70); capsules: nil. 
 
Number of infusions: 1 FMT. 
 
Bowel purgative: 4l PEG (Colonsteril). 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
 
Time before CDI treatment was stopped 
before FMT: Average of 36 hours. 
Overall cure within 
stated follow up 
period: 94% 
(n=66/70) (100% 
(n=34/34) of those 
with non-027, 89% 
(n=32/36) with 027) 
within 12 weeks. 
 
Cure with one 
infusion alone: 94% 
(n=66/70) (100% 
(n=34/34) of those 
with non-027, 89% 
(n=32/36) with 027) 
within 12 weeks. 
 
Total follow up 
period: One year. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: Not 
specified. 
 
Deaths: x4 patients 
infected with 027 
did not respond to 
FMT and died 
within 3 months.  
10 other patients 
died of 'unrelated 
illnesses' during 
one year of follow-
up. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Not 
clear. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Meighani et al, 
European Journal 
of 
Gastroenterology 
and Hepatology, 
2016 
Case series. 
 
Number of patients: 201. 
 
Female: male: 125: 76. 
 
Age (mean/ standard 
deviation): Mean age 
66.6 (+/-18.3) years. 
 
Comorbidities: x37 
cancer, x30 
immunosuppressed, x26 
CKD. Immunosuppressed 
defined as 
chemotherapy within 1 
year of FMT, HIV with 
CD4 < 200, or 
prednisolone use greater 
than or equal to 20mg 
for more than 1 month.)   
 
CDI features: 61 with 
refractory, 140 with 
recurrent. 
 
CDI diagnosis 
confirmation: Positive 
toxin or polymerase 
chain reaction. 
 
Pre-FMT antibiotics: Not 
specified. 
Donors working in healthcare: 
not specified. 
 
Donor demographics: not 
specified. 
 
Donor screening:  
Questionnaire - not specified. 
 
Travel and antibiotic exclusion 
period: Not specified. 
 
Screening blood tests: Not 
specified. 
 
Screening stool tests: Not 
specified. 
Amount of stool per transplant / 
administered to patients: Not specified. 
 
Diluent used to prepare: Not specified. 
 
Diluent used to store if frozen: Not 
specified. 
 
Preparation methods: Not specified. 
 
Time from preparation to transplant 
(fresh): Not specified. 
 
Time period for storage (frozen): Not 
specified. 
 
Route administered: Upper GI: 
nasogastric tube x 76, PEG x5; lower GI: 
x45 enema, x75 colon; capsules: nil.    
 
Number of infusions: Some people 
received multiple FMT procedures - 
repeat FMTs within 90 days of previous 
FMT were still maintained as a 'single 
infection unit'. 
 
Bowel purgative: Not specified. 
 
PPI: Not specified. 
 
Antimotility: Not specified. 
 
Prokinetics: Not specified. 
 
Overall cure within 
stated follow up 
period: 88% 
(n=176/201) over 
90 days. 
 
Cure with one 
infusion alone: 
73.1% (n=147/201). 
 
 
Total follow-up 
period: Each 
patient for 90 days. 
Minor GI adverse 
events: Not 
specified. 
 
Minor non-GI 
adverse events: Not 
specified. 
 
Serious adverse 
events: Not 
described.  
 
Deaths: 18 deaths 
in cohort but no 
clear timeframe, 
and not clear if any 
related to FMT. 
Described as 
mortality rate of 
6.25% in response 
group, 28% in 
failure rate. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Time before CDI treatment was stopped 
before FMT: 24 hour - not specifically 
stated as anti-CDI treatment. 
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Meighani et al, 
Digestive Diseases 
and Sciences, 
2017 
Case series. 
 
Number of patients: 201. 
 
Female: male: 124: 77. 
 
Age (mean/ standard 
deviation): Mean 68.79 
(+/-16.78) years for x181 
non-IBD patients, mean 
46.9 (+/-19.97) for the 
x20 IBD patients. 
 
Comorbidities: 13/20 IBD 
patients were 
immunosuppressed (no 
further details); no 
further specific details 
about 
immunosuppression). 
 
CDI features: Recurrent 
CDI in 13/20 of IBD 
patients, primary 
refractory in 7/20.  1.90 
(+/- 1.02) CDI infections 
in past three months for 
IBD patients, 1.79 
(+/1.17) CDI infections in 
past three months for 
non-IBD patients. 
 
CDI diagnosis 
confirmation: GDH first, 
then toxin A and B; PCR 
Donors were typically family 
members, but small number of 
unrelated universal donors.  
Amongst IBD cohort - 6 patients 
had family members as donor, 
universal donor in other 14. 
 
Donor working in healthcare: 
Not defined. 
 
Donor demographics: Not 
defined. 
 
Donor screening: Questionnaire 
- not defined. 
 
Travel and antibiotic exclusion 
period: Not defined. 
 
Screening blood tests: Not 
defined. 
 
Screening stool tests: Not 
defined. 
Amount of stool per transplant / 
administered to patients: Not defined. 
 
Diluent used to prepare: Not defined. 
 
Diluent used to store if frozen: Not 
defined. 
 
Preparation methods: Not defined. 
 
Time from preparation to transplant 
(fresh): Not defined. 
 
Time period for storage (frozen): Not 
defined. 
 
Route administered: Upper GI: 5 
nasogastric (IBD patients only; not 
described re non-IBD patients) lower GI: 
13 colonoscopy (IBD patients only; not 
described in non-IBD patients); 2 
retention enema (IBD patients only; not 
described re non-IBD patients) (15). 
 
Number of infusions: Any relaps  
beyond 90 days was defined as 'new 
infection'.  However, not made clear if 
patients given more than one FMT.   
 
Bowel purgative: Not described. 
 
PPI: Not described. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
Overall cure within 
stated follow up 
period: As per 
primary outcome - 
difficult to give 
more specific 
information than 
already given. 
 
Cure with one 
infusion alone: 
87.3% (n=158/181) 
in non-IBD, 75% 
(15/20) in IBD; but 
17.15 (n=31/181) 
non-IBD relapse 
within 90 days/ 
13.9% (n=25/180) 
beyond 90 days, 
and 25% (n=5/20) 
IBD relapse within 
90 days/ 20% 
(n=4/20) beyond 90 
days. 3/5 failures in 
IBD arm had newly-
diagnosed IBD, 
other had severe 
active disease. 
 
Total follow up 
period: At least 90 
days. 
Minor GI adverse 
events: None. 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: None. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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 63 
used if discordance. 
 
Pre-FMT antibiotics: Not 
defined for non-IBD; for 
IBD, 15 vancomycin 
alone, 5 vancomycin and 
oral metronidazole.   
Time before CDI treatment was stopped 
before FMT: No specific deails. 
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Patel et al, Mayo 
Clinic Proceedings,  
2013 
Case series. 
 
Number of patients: 31. 
 
Female: male: 17: 14. 
 
Age (mean/ standard 
deviation): Mean 61.26 
(+/- 19.34) years. 
 
Comorbidities: x5 
diverticulosis, x5 IBS, x3 
UC, x1 Crohn's, x1 
gastroparesis, x1 
coloanal fistula, x3 prev 
sigmoid surgery for 
diverticulitis, x2 subtotal 
colectomy with 
ileosigmoid anastomosis, 
x1 left hemicolectomy 
with colostomy, x3 long 
term corticosteroids, x2 
hypogammaglobulinaem
ia, x1 OLT, x1 renal 
transplant, x1 long term 
methotrexate. 
 
CDI features: Recurrent - 
mean +/- SD number of 
confirmed relapses 
before FMT of 4 +/- 1.4 
(range 2-7) episodes. 
 
CDI diagnosis 
confirmation: At least 3x 
unformed stools/ day, at 
Donors were healthy family/ 
contacts of recipients - 14 
spouses, 9 children, 5 siblings, 3 
parents, 1 niece, 1 friend. 
 
Working in healthcare: Not 
stated. 
 
Donor demographics: No stated 
age/ BMI limits. 
 
Donor screening: Questionnaire 
- exclude if: chronic GI disease, 
active peptic ulcer disease, 
GORD requiring daily PPI, IBS, 
IBD, history of colon polyps/ 
cancer, antibiotics or 
hospitalisation in past three 
months. 
 
Travel and antibiotic exclusion 
period: No stated travel 
restrictions; excluded as donor 
if antibiotic use within past 3 
months. 
 
Screening blood tests: hepatitis 
A IgM, HBsAg, HBc IgG/M, 
hepatitis C antibody, HIV-1/-2 
antibody, HTLV-1/-2 antibody, 
RPR/ syphilis EIA. 
 
Screening stool tests: MC&S, 
ova, cysts and parasites, 
Cryptosporidium antigen, 
Amount of stool per transplant / 
administered to patients: Whole stool - 
median transplanted weight of 115g 
(range 18-397g). 
 
Diluent used to prepare: Normal saline - 
"added in 100ml increments until 
mixture suitable for instillation through 
working channel of colonoscope".  
Median volume of FMT 360 (range 180-
900) ml. 
 
Diluent used to store if frozen: N/A – 
fresh. 
 
Preparation methods: Blender/ pitcher. 
 
Time from preparation to transplant 
(fresh): Six hours; kept at room 
temperature until processing.   
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: colonoscopy (31); capsule: nil. 
 
Number of infusions: One initially. 
 
Bowel purgative: Yes - PEG day before 
FMT. 
 
PPI: Not described. 
 
Antimotility: 4mg loperamide either pre- 
or immediately after colonoscopy. 
Overall cure within 
stated follow up 
period: At 3 months 
– 91.3% (n=21/23) 
said diarrhoea no 
longer present; at 1 
year, 100% (n=6/6) 
reported 
maintained 
improvement or 
resolution. 
 
Cure with one 
infusion alone: Of 
29 with diarrhoea – 
24.1% (n=7/29) 
reported 
improvement and 
75.9% (n=22/29) 
resolution of 
diarrhoea by 
median time of 
three days. 
 
Total follow up 
period: One year. 
Minor GI adverse 
events: Not 
described. 
 
Minor non-GI 
adverse events: Not 
described. 
  
Serious adverse 
events: 
Microperforation - 
caused by biopsy of 
an area of 
presumed 
ischaemic small 
bowel injury during 
the FMT procedure; 
managed 
conservatively.   
 
Deaths: x1 death at 
three months - 
directly related to 
recently diagnosed 
metastatic 
pancreatic cancer, 
not related to FMT . 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes, 
implied that were. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes - 
at least as far as 
primary outcome. 
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 65 
least 2 x toxin positive 
episodes previously to 
participate.   
 
Pre-FMT antibiotics: All 
31 previous 
methotrexate, all 31 
previous vancomycin, 6 
previous fidaxomicin, 10 
previous rifaximin, 23 
prior probiotic. 
Microsporidia smear, C difficile 
toxin (PCR or EIA). 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: Antibiotics continued until 
4 hours before prep (i.e. stopped day 
prior to FMT). 
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Pathak et al, 
Clinical & 
Experimental 
Gastroenterology, 
2013 
Case series. 
 
Number of patients: 12. 
 
Female: male: 8: 4. 
 
Age (mean): Mean 71.9 
(range 37 – 90) years. 
 
Comorbidities: x1 UC, 1 
renal transplant, x1 left 
colon adenocarcinoma 
and diverticulitis; x1 
ruptured appendix; x2 
ventilator-dependent. 
 
CDI features: Recurrent; 
full details not given.  
Two of the patients had 
had recurrent CDI 
treated with FMT ‘many 
years ago’.   
 
CDI diagnosis 
confirmation: Not 
specifically defined. 
 
Pre-FMT antibiotics: All 
vancomycin, 8 patients 
fidaxomicin, 4 patients 
methotrexate. 
Donors were preferrably 
family/ first degree relatives; 
family used in all cases here. 
 
Working in healthcare: Not 
specifically addressed. 
 
Donor demographics: Not 
given. 
 
Donor screening: Questionnaire 
- exposure to HIV, hepatitis, 
STDs; high risk sexual 
behaviour; drug use, tattoos/ 
piercings, imprisonment, other 
high risk behaviour; known 
current communicable disease; 
GI morbidities including IBD or 
GI malignancy; antibiotic use 
within 90 days. 
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotic use within last 90 
days. 
 
Screening blood tests: HIV-1/-2, 
hepatitis A/B/C, STDs. 
 
Screening stool tests: MC&S, 
ova, cysts and parasites, C 
difficile toxin A and B. 
Amount of stool per transplant / 
administered to patients: About 6-8 
tablespoons. 
 
Diluent used to prepare: 1l of tap water. 
 
Diluent used to store if frozen: N/A - all 
fresh. 
 
Preparation methods: No specific 
details. 
 
Time from preparation to transplant 
(fresh): 6 hours. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: 
nasoduodenal tube (1; as a second 
FMT); lower GI: colonoscopy (12). 
 
Number of infusions: 1 FMT initially. 
 
Bowel purgative: PEG the night before 
FMT. 
 
PPI: Not described. 
 
Antimotility: 2 tablets diphenoxylate/ 
atropine post-FMT. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 24 hours. 
Overall cure within 
stated follow-up 
period: 91.7% 
(n=11/12). 
 
Cure with one 
infusion alone: 
91.7% (n=11/12). 
 
Total follow up 
period: 2-26 
months. 
Minor GI adverse 
events: Not stated. 
 
Minor non-GI 
adverse events: Not 
stated. 
 
Serious adverse 
events: Not stated. 
 
Deaths: x1 death. 
Patient with 
perforated 
appendix 
developed rCDI; 
didn't respond to 
six months of anti-
CDI treatment, 
went to ITU.  Donor 
was husband - no 
screening, and no 
response to 
colonoscopic FMT. 
For 2nd FMT, used 
healthy volunteer 
donor FMT via 
nasoduodenal tube 
- responded.  
Urinary tract 
infection at nursing 
home few months 
later – antibiotic 
treatment 
precipitated further 
CDI.  Further sepsis, 
returned to ITU - 
Selection/eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes, 
implied that were. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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declined treatment, 
then died, four 
months after initial 
FMT. 
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Rohlke et al, 
Journal of Clinical 
Gastroenterology, 
2010 
Case series. 
 
Number of patients: 19. 
 
Female: male: 17: 2. 
 
Age (mean): Mean age 
49 years. 
 
Comorbidities: Not 
described. 
 
CDI features: Recurrent 
CDI. 
  
CDI diagnosis 
confirmation: Positive C 
difficile toxin and 
consistently recurring 
symptoms over a span of 
six months. 
 
Pre-FMT antibiotics: Not 
given in detail - all at 
least three courses of 
conventional anti-CDI 
antibiotics, including 
pulsed and tapered 
vancomycin. 
Donors were 4 family members, 
14 partners, and 1 housemate. 
 
Donors working in healthcare: 
Excluded. 
 
Donor demographics:  
Donor screening: 
Questionnaire – included 
current or recent diarrhoeal 
illness, sexual behaviour. 
 
Travel and antibiotic exclusion 
period: Excluded if ‘recent 
antibiotic use’; not further 
defined. 
 
Screening blood tests.: HIV, 
hepatitis A, B and C, and 
Trepenoma serology. 
 
Screening stool tests: C difficile, 
bacterial culture, ova, cysts and 
parasites, Giardia, 
Cryptosporidium. 
Amount of stool per transplant / 
administered to patients: 350mls. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: N/A - 
fresh. 
 
Preparation methods: Fresh 
preparation, with manual shaking of 
stool and saline in large suction canister, 
followed by filtering. 
 
Time from preparation to transplant 
(fresh): Not stated. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: nil; lower 
GI: all given via colonoscopy. 
 
Number of infusions: One routinely, with 
one patient having a second FMT. 
 
Bowel purgative: PEG. 
 
PPI: Not described. 
 
Antimotility: Loperamide post-FMT. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 1-3 days. 
Overall cure within 
stated follow up 
period: 100% 
(n=20/20). 
 
Cure with one 
infusion alone: 95% 
(n=19/20). 
 
Total follow-up 
period: 6 months to 
5 years. 
Minor GI adverse 
events: Nil 
reported. 
 
Minor non-GI 
adverse events: Nil 
reported. 
 
Serious adverse 
events: Nil 
reported. 
 
Deaths: Nil 
reported. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes – 
variable follow-up. 
 
At least 90% 
followed up: Yes.  
Page 236 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Material 2 for Gut 
 
 69 
Rubin et al, 
Anaerobe, 2013 
Case series. 
 
Number of patients: 75. 
 
Female: male: 49: 26. 
 
Age (median): Median 
63 (range 6-94) years. 
 
Comorbidities: x10 
diabetes mellitus, x8 
malignancy, x7 
corticosteroids in prior 
three months. 
 
CDI features: Not stated. 
 
CDI diagnosis 
confirmation:Not 
described. 
 
Pre-FMT antibiotics: Oral 
metronidazole or 
vancomycin alone or in 
combination for initial 
FMT in all cases; not 
clear exact breakdown/ 
use for recurrences. 
Donors were healthy people 
from the same household as 
the patient. 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: Not 
described. 
 
Donor screening: Questionnaire 
– as per Aas et al, Clin Infect Dis, 
2003. 
Travel and antibiotic exclusion 
period: As per Aas et al, Clin 
Infect Dis, 2003. 
 
Screening blood tests: As per 
Aas et al, Clin Infect Dis, 2003. 
 
Screening stool tests: As per 
Aas et al, Clin Infect Dis, 2003. 
Amount of stool per transplant/ 
administered to patients: 30g of stool. 
 
Diluent used to prepare: Saline - As per 
Aas et al, Clin Infect Dis, 2003.  25ml of 
stool/ saline mixture per FMT. 
 
Diluent used to store if frozen: N/A - 
fresh. 
 
Preparation methods: As per Aas et al, 
Clin Infect Dis, 2003. 
 
Time from preparation to transplant 
(fresh): As per Aas et al, Clin Infect Dis, 
2003. 
 
Time period for storage (frozen): N/A – 
fresh. 
 
Route administered: Upper GI: 64 
nasogastric, 4 PEG, 7 OGD (75 
administrations to 74 patients); lower 
GI: nil; capsule: nil. 
 
Number of infusions: One routinely. 
 
Bowel purgative: Not described. 
 
PPI: Evening prior to/ morning of 
procedure - no further details. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
Overall cure within 
stated follow up 
period: 78.7% 
(n=59/75). 
 
Cure with one 
infusion alone: 
78.7% (n=59/75). 
 
Total follow up 
period: Up to 60 
days. 
Minor GI adverse 
events: Nil. 
 
Minor non-GI 
adverse events: Nil. 
 
Serious adverse 
events: Nil. 
 
Deaths: No - up to 
60 days. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Time before CDI treatment was stopped 
before FMT: Stopped on the day prior to 
procedure. 
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Satokari et al, 
Alimentary 
Pharmacology 
and Therapeutics, 
2015 
Case series. 
 
Number of patients: 49. 
 
Female: male: 34: 15. 
 
Age (mean):  
Fresh: 52 (range 22-81) 
years; frozen: 61 (range 
20-88) years. 
 
Comorbidities: Not 
described in significant 
details. 
 
CDI features: Recurrent - 
mean 4.6 (range 2-12) 
relapses in fresh; mean 
4.9 (range 1-6) relapses 
in frozen. 
 
CDI diagnosis 
confirmation:"Positive 
culture and toxin". 
 
Pre-FMT antibiotics: 
Describes using 
vancomycin with all, but 
no specific details. 
Donors were: 15 fresh FMTs 
with individual donors, 11 fresh 
FMTs with universal donors; 
and 23 frozen FMTs with 
universal donor. 
 
Donor working in healthcare: 
Not stated. 
 
Donor demographics: No clear 
age or BMI limits. 
 
Donor screening: Questionnaire 
- "No antibiotics in past six 
months and no intestinal 
symptoms". 
 
Travel and antibiotic exclusion 
period: Excluded as donors if 
had used antibiotics in past six 
months. 
 
Screening bloods: Total blood 
count, CRP, creatinine, LFTs, 
hepatitis B and C, HIV-1/-1, 
Treponema. 
 
Screening stools: C difficile 
culture and toxin A/B test, 
MC&S, ova, cysts and parasites. 
Amount of stool per transplant / 
administered to patients: Fresh - 
approximately 30g of stool. 
 
Diluent used to prepare: Fresh - 
approximately 150ml of tap water. 
 
Diluent used to store if frozen: Frozen - 
30g of stool added to 150ml N/saline 
and then glycerol  
 
Preparation methods: As described. 
 
Time from preparation to transplant 
(fresh): Fresh - less than 6 hours 
between delivery and administration; 
less than 15 minutes between making 
FMT and delivery. 
 
Time period for storage (frozen): Up to 
16 weeks; thawed over 4-5 hours at 
room temp or in 37oC water bath. 
 
Route administered: Upper GI: nil; lower 
GI: colonoscopy (49); capsules: nil. 
 
Number of infusions: One FMT routinely. 
 
Bowel purgative:  4l Colonsteril PEG/ 2l 
MoviPrep. 
 
PPI: Not described. 
 
Antimotility: Not described. 
Overall cure within 
stated follow up 
period:  
Fresh: 96% 
(n=25/26); frozen: 
96% (n=22/23). 
 
 
Total follow up 
period: 12 weeks. 
Minor GI adverse 
events: N/A. 
 
Minor non-GI 
adverse events:  
Mild transient fever 
in x2 patients with 
frozen FMT.   
 
Serious adverse 
events: N/A. 
 
Deaths: x1 fresh 
faeces patient died 
within one year of 
FMT - not related; 
x2 frozen patients 
had relapse within 
one year, both 
treated with 
further antibioitcs – 
x1 died of recurrent 
CDI, x1 died of 
arterial thrombosis. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Prokinetics: not described.  
 
Time before CDI treatment was stopped 
before FMT: Stopped at an average of 36 
hours prior to administration. 
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Yoon et al, Journal 
of Clinical 
Gastroenterology, 
2010 
Case series. 
 
Number of patients: 12. 
 
Female: male: 9: 3. 
 
Age (mean)*: Mean 66 
(range 30 - 86) years. 
 
Comorbidities: 9 with 
diverticulosis (with 2 of 
these having 
diverticulitis as index 
infection). 
 
CDI features: 1 patient 
with first CDI, 2 with 
2nd, 5 with 3rd, 1 with 
4th, 1 with 5th, 1 with 
6th, 1 with 8th. 
 
CDI diagnosis 
confirmation: Toxin 
testing for either toxin A 
or B, or assessment of 
both via EIA. 
 
Pre-FMT antibiotics: 12 
had oral metronidazole, 
3 had intravenous 
metronidazole, 12 had 
oral vancomycin, 4 x 
rifaximin, no mention of 
fidaxomicin. 
Donors were spouses/ partners 
in 8 patients; for other 4 
patients, donors were one son, 
two daughters, and one 
granddaughter. 
 
Donors working in healthcare: 
No. 
 
Donor demographics: No 
details. 
 
Donor screening: Questionnaire 
- no details. 
 
Travel and antibiotic exclusion 
period: No details given 
 
Screening bloods: Hepatitis B 
and C, HIV. 
 
Screening stools: C difficile 
toxin, enteric pathogens, ova, 
cysts and parasites - at treating 
clinician's discretion. 
Amount of stool per transplant / 
administered to patients: Stool (unclear 
how much) mixed with 1l normal saline; 
approx 250-450cc of FMT administered 
in total. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: N/A. 
 
Preparation methods: Manually shaken 
then filtered through gauze. 
 
Time from preparation to transplant 
(fresh): No details. 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI:  (N/A) 
 
Lower GI: 10-20cc of FMT administered 
every 5-10cm of withdrawal distance in 
all 12 patients. 
 
Number of infusions: Single. 
 
Bowel purgative: All colonoscopic, but 
no specific details given. 
 
PPI: Not described. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
 
Overall cure within 
stated follow up 
period: 100% 
(n=12/12).  
 
Total follow up 
period: 3 weeks to 
8 years - no details 
on relation to 
individual patients. 
Minor GI adverse 
events: Nil 
described. 
 
Minor non-GI 
adverse events: Nil 
described. 
 
Serious adverse 
events: Nil 
described. 
 
Deaths: Nil 
described. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: No. 
 
At least 90% 
followed up: Yes. 
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Time CDI treatment was stopped before 
FMT: 3 days. 
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Youngster et al, 
JAMA, 2014 
Prospective case series. 
 
Number of patients: 20. 
 
Female: male: 9: 11. 
 
Age (median): Median 
64.5 (range 11-89) years. 
 
Comorbidities: Specific 
comorbidities not 
described. 
 
CDI features: Included 
patients with both 
recurrent or refractory 
CDI. 
 
CDI diagnosis 
confirmation:Toxin and 
ELISA, PCR if toxin 
negative but ELISA is 
positive or 
indeterminate. 
 
Pre-FMT antibiotics: 
Failed vancomycin taper 
and/ or fidaxomicin.  
Donors were unrelated adult 
volunteers. 
 
Donor working in healthcare: 
Not stated. 
 
Donor demographics: Age 
range 18-50 years, BMI 18.5 - 
25.  
 
Donor screening: Questionnaire 
-  American Association of 
Blood Banks donor 
questionnaire. 
 
Travel and antibiotic exclusion 
period: Excluded as potential 
donors if used antibiotics within 
preceeding 6 months. 
 
Screening blood tests:  
Antibodies to hepatitis A, B, and 
C; HIV; and Treponema 
pallidum within 2 weeks of 
donations. 
 
Screening stool tests: " Enteric 
pathogens". 
Amount of stool per transplant / 
administered to patients: 30 capsules 
(single treatment) - total 48g of stool. 
 
Diluent used to prepare: saline in 1/10th 
volume of stool. 
 
Diluent used to store if frozen: 10% 
glycerol. 
 
Preparation methods:  Faecal matter 
solution was pipetted into size 0 
capsules (650 μL), which were closed 
and then secondarily sealed in size 00 
capsules. Capsules were stored frozen at 
−80°C until use. 
 
Time from preparation to transplant 
(fresh): N/A. 
 
Time period for storage (frozen): Mean 
113 days (30-252 days). 
 
Route administered: All courses were 30 
oral capsules. 
 
Number of treatments: 1 course (given 
as 15 capsules on 2 consecutive days). If 
failed, retreated at a mean of 7 days. 
 
Bowel purgative: Not described. 
 
PPI: Not described. 
 
Antimotility: Not described. 
Overall cure within 
stated follow up 
period: 90% 
(n=18/20). 
 
Cure with one 
infusion alone: 70% 
(n=14/20).  
 
Total follow up 
period: 8 weeks. 
Minor GI adverse 
events: Transient 
abdominal 
cramping and 
bloating in 6 
patients (30%) that 
resolved in 72 
hours. 
 
Minor non-GI 
adverse events: Not 
described. 
 
Serious adverse 
events: x1 
hospitalised with a 
documented 
relapse of severe 
CDI after taking 15 
capsules, but had 
successful 
treatment after 
receiving the 
remaining 15 
capsules. No other 
severe adverse 
events (grade 2 or 
above). 
 
Deaths: none. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: Yes. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 48 hours prior to FMT. 
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Youngster et al, 
BMC Medicine, 
2016 
Case series. 
 
Number of patients: 180. 
 
Female: male: Not 
stated. 
 
Age (median): Median 
64 (range 7–95) years.  
 
Comorbidities: Not 
described. 
 
CDI features: Three or 
more mild-to-moderate 
episodes of CDI or two 
episodes requiring 
hospitalisation. 
 
CDI diagnosis 
confirmation: Not 
specifically described. 
 
Pre-FMT antibiotics: Not 
described. 
Donors were healthy 
volunteers. 
 
Donors working in healthcare: 
Not mentioned. 
 
Donor demographics: 18-50 
years of age, on no 
medications, with a ‘normal 
body mass index’. 
 
Donor screening: Questionnaire 
- initial screening using the 
American Association of Blood 
Banks donor questionaire for 
exposure to infectious agents.  
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotic use within 6 months. 
 
Screening bloods: Blood was 
screened for antibodies to 
hepatitis A, B, and C; HIV; and 
Treponema pallidum within 2 
weeks of donations. 
 
Screening stool test: Donor 
faeces were screened for 
enteric bacterial pathogens 
including rotavirus, Listeria 
monocytogenes, Vibrio 
cholerae, Escherichia coli O157, 
ova and parasites (including 
general microscopy, acid-fast 
staining, and/or antigen testing 
Amount of stool per transplant / 
administered to patients: 30 capsules 
derived from a mean of 48g of faeces. 
 
Diluent used to prepare: Normal saline. 
 
Diluent used to store if frozen: 10% 
glycerol. 
 
Preparation methods: Homogenised 
using a commercial blender then passed 
through sieves in ambient air.   
 
Time from preparation to transplant 
(fresh): N/A. 
 
Time period for storage (frozen): Study 
of capsulised FMT.  Faecal slurry was 
double-encapsulated in hypromellose 
capsules (Capsugel, Cambridge, MA) and 
stored at –80 °C for up to 6 months 
pending use. 
 
Route administered: All received 30 
capsules as a ‘dose’.   
 
Number of infusions: 1 course of 
capsules in 147 patients, 2 courses in 26 
patients and 3 course in 4 patients. 
 
Bowel purgative: not mentioned. 
 
PPI: not mentioned. 
 
Antimotility: not mentioned. 
Overall cure within 
stated follow up 
period: 91% 
(n=164/180)  
 
Cure with one 
infusion alone: 82% 
(n=147/180) 
 
Total follow up 
period: 8 weeks for 
primary response. 
Minor GI adverse 
events: x5 
vomiting, x112 
diarrhoea, x45 
nausea/ bloating, 
x40 abdominal 
pain. 
 
Minor non-GI 
adverse events: x3 
fever, x54 fatigue, 
malaise, and 
headache, x12 
other complaints. 
 
Serious adverse 
events: Related 
serious (x1 fever, x2 
new UC, x6 
hospitalisations for 
CDI/ diarrhoea).  
 
Unrelated serious 
adverse events: x26 
hospitalisations, 
x14 deaths. 
 
Deaths: x14 
(unrelated). 
Selection/eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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for Giardia, Cryptosporidium, 
Isospora, and Microsporidia), C. 
difficile, and Helicobacter pylori 
antigen. 
 
Prokinetics: not mentioned. 
 
Time before CDI treatment was stopped 
before FMT: 24–48 hours prior. 
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Zainah et al, 
Digestive Diseases 
and Sciences, 
2014 
Case series. 
 
Number of patients: 14. 
 
Female: male: 9:5. 
 
Age (mean +/-range)*:  
73.4 (+/-11.9) years. 
 
Comorbidities: x4 
patients with cancer, x1 
OLT patient. 
 
CDI features: 8 patients 
had had prev CDI 
episodes (2-5 episodes 
prior). 
 
CDI diagnosis: Diarrhoea 
(at least 3 unformed 
stool/d for 2 consecutive 
days) + positive C difficile 
EIA and/or PCR.  All 
patients here severe by 
definition - defined here 
as age >60 years, 
albumin <2.5mg/dl, 
temp at least 38.3oC, 
WBC > 15 within 48 hour 
of CDI diagnosis; or at 
least one of the 
following: 
pseudomembranes, 
treatment in intensive 
care. 
Donors: 12 patients received 
FMT from related donor (7 
spouse, 5 children); the other 
two used unrelated donors. 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: Not 
stated. 
 
Donor screening: Questionnaire 
- not described. 
 
Travel and antibiotic exclusion 
period: No details. 
 
Screening blood tests: HIV-1/-2, 
hepatitis A IgM, hepatitis B 
serology, hepatitis C antibody, 
syphilis (RPR and FTA-ABS). 
 
Screening stools: C difficile toxin 
by PCR, stool ova, cysts and 
parasites. 
Amount of stool per transplant / 
administered to patients: 30-50g. 
 
Diluent used to prepare: Warm tap 
water. 
 
Diluent used to store if frozen: N/A. 
 
Preparation methods: Homogenised 
mixture, then filtered through gauze; 
120-180ml of suspension if through 
nasogastric tube, 300-500ml if through 
colonoscopy.   
 
Time from preparation to transplant 
(fresh): "Same day". 
 
Time period for storage (frozen): N/A. 
 
Route administered: Upper GI: 
Nasogastric administration in all but one 
patient (13 patients); lower GI: 
colonoscopic administration in one 
patient (1 patient). 
 
Number of infusions: One routinely; 
repeated if no response at 48-72hr. 
 
Bowel purgative: No details. 
 
PPI: Yes, pre nasogastric administration - 
no details given. 
 
Antimotility: Not described. 
 
Overall cure within 
stated follow up 
period: 79% 
(n=11/14) by seven 
days. 
 
Cure with one 
infusion alone: 71% 
(n=10/14). 
 
Total follow up 
period: Up to 100 
days . 
Minor GI adverse 
events: Not 
described. 
 
Minor non-GI 
adverse events: Not 
described. 
 
Serious adverse 
events: Not 
described. 
 
Deaths: x1 within 7 
days of FMT - but 
died of their 
malignancy. 
Selection/ eligibility 
reported: Yes. 
 
Consecutively 
recruited: Yes. 
 
Prospectively 
recruited: No. 
 
Loss to follow up 
explained: Yes. 
 
At least 90% 
followed up: Yes. 
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Pre-FMT antibiotics: 14 
patients prior 
vancomycin, 12 prior 
metronidazole too. 
Prokinetics: Not described. 
 
Time before CDI treatment was stopped 
before FMT: 24 hours. 
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C.2. Reviewed randomised studies of FMT for recurrent or refractory CDI 
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Paper Study and patient characteristics Donor characteristics FMT characteristics Outcomes Adverse events 
Camacho-Ortiz et 
al, PLoS ONE, 
2017 
Intervention: FMT (pooled from 
three donors). 
Number of patients: 9. 
Female: male: 3: 4 (data only 
presented for 7 patients). 
Age: Mean of 39.7 (+/- 24.8) 
years. 
 
Comparator: Vancomycin (250mg 
every 6 hours for 10-14 days). 
Number of patients: 10. 
Female: Male: 3: 6 (data only 
presented for 9 patients). 
Age (mean/median): Mean of 46.7 
(+/- 15.8) years. 
 
Comorbidities: In FMT arm – x1 
abdominal abscess, x1 Child B 
cirrhotic, x1 pulmonary TB; in 
vancomycin arm – x2 
haemodialysis patients, x1 
meningeal TB, x1 ‘abscessed 
squamous cell carcinoma’. 
 
CDI features: All first episode of 
CDI, occurring at least 48hrs after 
admission.   
 
CDI diagnosis confirmation: >3 
bowel movements during the 
previous 24 hours, Bristol scale > 
5, positive C. difficile EIA or PCR.    
 
Pre-FMT antibiotics: no antibiotics 
within FMT arm; patients in 
vancomycin arm received 250mg 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: >18 years, 
non-pregnant, BMI 20-25kg/m2 
 
Donor screening: On 
questionnaire, rejected potential 
donors who in the past three 
months had had use of PPI, use of 
antibiotics, use of 
immunosuppressives, 
hospitalisation and/ or diarrhoea.  
Also excluded if high risk sexual 
behaviour, first degree relative 
with diabetes mellitus, abdominal 
surgery, and any GI disease/ 
cancer. 
 
Travel and antibiotic exclusion 
period: Excluded if antibiotics 
within the past 3 months. 
 
Screening blood tests: Normal full 
blood count and liver enzymes 
essential for inclusion.  Also 
screened for HAV, HBV, HCV, HIV, 
CMV, EBV, Trypanosoma, 
Brucella, Treponema pallidum. 
 
Screening stool tests: Included 
parasites, enteropathogenic 
bacteria, rotavirus. 
Amount of stool per transplant: 
45ml of pooled donor stool (from 
three donors), at ~0.19g/ml.   
 
Diluent used to prepare: 0.9% 
saline. 
 
Diluent used to store if frozen: 15% 
v/v glycerol. 
 
Preparation methods: Stool from 
donors pooled, mixed, 
resuspended in saline, filtered to 
remove particles > 330m  . 
 
Time from preparation to 
transplant (fresh): N/A. 
 
Time period for storage (frozen): 
Not stated. 
 
Route administered: Upper GI: 14 
by OGD; 1 by nasojejunal tube.   
Lower GI: colonic (1; patient with 
anatomical abnormality due to 
head and neck neoplasia). Capsule: 
nil. 
 
Number of infusions:  routinely 1; 
patients not resolving after first 
FMT received 2nd FMT (as did 
patients not improving with 
vancomycin).  
 
Bowel purgative: Not stated. 
 
Treatment arm: FMT 
Overall cure rate: 71.4% 
(n=5/7) (after 2 x FMT) 
Cure with one infusion 
alone: 57.1% (n=4/7). 
 
Treatment arm: 
Vancomycin 
Overall cure rate: 88.9% 
(n=8/9) (not clear if 
failed patient received 
FMT subsequently, as is 
described in protocol). 
 
Minor GI adverse 
events: Nil stated. 
 
Minor non-GI 
adverse events: Nil 
stated. 
 
Serious adverse 
events: Nil stated. 
 
Deaths: Nil. 
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every 6hrs for 10-14 days. 
 
Total follow up period: up to one 
year. 
 
Cochrane Collaboration risk of 
bias assessment: uncertain risk of 
bias. 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was 
stopped before FMT: Nil given. 
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Cammarota et al, 
Alimentary 
Pharmacology 
and 
Therapeutics, 
2015 
Intervention: FMT. 
Number of patients: 20. 
Female: Male: 12: 8. 
Age (mean/median): Mean 71 
(range 29-89) years. 
 
Comparator: Vancomycin (125mg 
four times daily for 10 days, follow 
by a pulse regimen (125-
500mg/day every 2-3 days, for at 
least three weeks).   
Number of patients: 19. 
Female: Male: 11: 8. 
Age (mean/median): Mean 75 
(range 49-93) years. 
 
Comorbidities: No significant 
difference of Charlson 
comorbidity index between 
groups. 
 
CDI features: All recurrent.  7/20 
in FMT arm with 
pseudomembranous colitis. 
 
CDI diagnosis confirmation: 
Diarrhoea and CDT positive within 
10 weeks of previous antibiotic 
treatment. 
  
Pre-FMT antibiotics: All had had 
vancomycin or metronidazole. 
19/20 of FMT arm and 16/20 of 
vancomycin arm had had previous 
vancomycin taper. 
 
Total follow up period: 10 weeks. 
 
 
Donors working in healthcare: no. 
 
Donor demographics: Less than 
50 years of age, no antibiotics 
within past 6 months. 
 
Donor screening: Questionnaire - 
no antibiotics for last 6/12. 
Excluded if significant GI disease, 
metabolic syndrome, chronic 
illness, immunocompromise, 
recent travel, high risk lifestyle in 
last three months. 
 
Travel and antibiotic exclusion 
period: 3 month travel exclusion 
period, 6 month antibiotic 
exclusion period. 
 
Screening blood tests: Hepatitis 
A, B, and C, HIV, EBV, syphilis, 
Stongyloides, Entomoeba 
histolytica, FBC, LFTs, creatinine, 
CRP. 
 
Screening stool tests: C. difficile 
cult and toxin, enteric bacteria, 
ova, cysts and parasites, VRE, 
MRSA, Gram negative multi-drug 
resistant bacteria. 
Amount of stool per transplant / 
administered to patients: Not 
specified. 
 
Diluent used to prepare: Normal 
saline 500mls. 
 
Diluent used to store if frozen: N/A 
– fresh. 
 
Preparation methods: Blended and 
strained. 
 
Time from preparation to 
transplant (fresh): 6 hours. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered: Upper GI: nil; 
lower GI: colonic (20); capsule: nil. 
 
Number of infusions: 14 had 1 
infusion, 4 had 2 infusions, 1 had 3 
infusions and 1 had 4 infusions.  
Initial protocol was that if non-
response to first FMT, then second 
FMT after one week; however, 
after first two patients, changed to 
all patients with 
pseudomembranous colitis 
receiving repeat FMT every 3 days 
until resolution of CDI.   
  
Bowel purgative: Macrogol. 
 
PPI: No. 
 
Treatment arm: FMT 
Overall cure rate: 90% 
(n=18/20). 
Cure with one infusion 
alone: 65% (n=13/20); 
none of these were 
patients with 
pseudomembranous 
colitis.  The 7 patients 
not cured with first 
FMT all had 
pseudomembranous 
colitis; of these, 5/7 
cured with protocol of 
recurrent FMTs. 
 
Treatment arm: 
Vancomycin: 
Overall cure rate:  
Cure with one infusion 
alone: 26% (n=5/19).   
Minor GI adverse 
events: x19 
diarrhoea, x12 
bloating ( all resolved 
at 12 hours). 
 
Minor non-GI 
adverse events: 
None. 
 
Serious adverse 
events: None. 
 
Deaths: x2 from C 
difficile-related 
complications. 
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Cochrane Collaboration risk of 
bias assessment: uncertain risk of 
bias. 
Antimotility: No. 
 
Prokinetics: No. 
 
Time before CDI treatment was 
stopped before FMT: Between five 
and two days prior to FMT. 
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Allegretti et al, 
Gastroenterology 
(abstract), 
2016 
Intervention: Low dose FMT 
capsules (30 pills once). 
Number of patients: 10. 
Female: male: Not stated. 
Age (mean/median): Not stated. 
 
Comparator: High dose FMT. 
capsules (30 pills daily on two 
consecutive days). 
Number of patients: 9. 
Female: male: Not stated. 
Age (mean/median): Not stated. 
 
Comorbidities: Not stated. 
 
CDI features:Not stated. 
 
CDI diagnosis confirmation: Not 
stated. 
 
Pre-FMT antibiotics: Not stated. 
 
Total follow up period: 8 weeks. 
 
Cochrane Collaboration risk of 
bias assessment: uncertain risk of 
bias. 
Donors were unrelated donors 
from universal stool bank 
(OpenBiome). 
 
Donors working in healthcare: 
No. 
 
Donor demographics: mean age 
26, mean BMI 22.2. 
 
Donor screening: Questionnaire - 
as per OpenBiome protocol. 
 
Travel and antibiotic exclusion 
period: As per OpenBiome 
protocol. 
 
Screening bloods: As per 
OpenBiome protocol. 
 
Screening stools: As per 
OpenBiome protocol. 
Amount of stool per transplant / 
administered to patients: 30 pills a 
day for one day. 
 
Diluent used to prepare: Not 
stated. 
 
Diluent used to store if frozen: 
Stored at -80oC prior to use. 
 
Preparation methods:  Capsules 
physically stable for 30 days at 25oC 
using an emulsion-based 
production protocol. 
 
Time from preparation to 
transplant (fresh): Not stated. 
 
Time period for storage (frozen): 
Not stated. 
 
Route administered: All capsule – 
as described above. 
 
Number of infusions: 30 tablets 
(over one day). 
 
Bowel purgative: Not stated. 
 
PPI: Not stated. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was 
stopped before FMT: Not stated. 
Treatment arm: Low 
dose FMT capsules (30 
pills once). 
Overall cure rate: 70% 
(n=7/10). 
 
 
Treatment arm: High 
dose FMT capsules (30 
pills daily on two 
consecutive days). 
Overall cure rate: 77.8% 
(n=7/9). 
 
Minor GI adverse 
events: None. 
 
Minor non-GI 
adverse events: 
None.  
 
Serious adverse 
events: None. 
 
Deaths: None. 
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Hota et al, 
Clinical Infectious 
Diseases, 
2016 
Intervention: FMT. 
Number of patients: 16. 
Female: male: 11: 5. 
Age (mean/ standard deviation): 
Mean 75.7 +/- 14.5 years. 
 
Comparator: 6 week vancomycin 
taper. 
Number of patients: 12. 
Female: male: 8: 4. 
Age (mean/ standard deviation): 
Mean 69.6 +/- 14.2 years. 
 
Comorbidities: Not stated, but 
similar Charlson comorbidity index 
score between groups. 
 
CDI features: All recurrent. 
 
CDI diagnosis confirmation: 
Symptoms and toxin or PCR 
detection. 
 
Pre-FMT antibiotics: At least 1 
course of vancomycin for a 
minimum of 10 days.  The 
majority of patients in both arms 
had had prior vancomycin tapers.   
 
Total follow up period: 120 days. 
 
Cochrane Collaboration risk of 
bias assessment: uncertain risk of 
bias. 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: ≥18yrs. 
 
Donor screening: Questionnaire - 
self-screening questionnaire of 
behaviours associated with risk 
for blood-borne pathogens. 
 
Travel and antibiotic exclusion 
period: Antibiotic use for at least 
two days in the preceding three 
months. 
 
Screening blood tests: Extensive 
screening comparable with 
previous studies.  
 
Screening stool tests: Extensive 
screening comparable with 
previous studies.  
Amount of stool per transplant / 
administered to patients: 50g. 
 
Diluent used to prepare: 500mls 
normal saline. 
 
Diluent used to store if frozen: N/A 
– fresh. 
 
Preparation methods: Stomacher 
laboratory blender. 
 
Time from preparation to 
transplant (fresh): 48 hours. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered: Upper GI: nil; 
lower GI: 16; capsule: nil. 
 
Number of infusions: All had 1 
infusion. 
 
Bowel purgative: None. 
 
PPI: None. 
 
Antimotility: None. 
 
Prokinetics: None. 
 
Time before CDI treatment was 
stopped before FMT: Day prior to 
FMT.  
Treatment arm: FMT: 
Overall cure rate: 43.8% 
(n=7/16). 
Cure with one infusion 
alone: 43.8% (n=7/16). 
 
Treatment arm: 6 week 
vancomycin taper. 
Overall cure rate: 58.3% 
(n=7/12). 
 
Minor GI adverse 
events: abdominal 
pain, tenderness and 
bloating, equal in 
both groups. 
 
Minor non-GI 
adverse events: Nil. 
  
Serious adverse 
events: x1 developed 
anasarca from liver 
disease, x1 had 
perforated bowel 
from diverticulitis at 
35 days post-FMT. 
 
Deaths: None. 
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Jiang et al, 
Alimentary 
Pharmacology 
and 
Therapeutics, 
2017 
Intervention: Fresh FMT. 
Number of patients: 25. 
Female: male: 21:4. 
Age (mean): Mean 75 (range 19-
97) years.  
 
Comparator: Lyophilised FMT. 
Number of patients: 23. 
Female: Male: 13: 10. 
Age (mean): Mean 63 (range 20-
87) years. 
 
Comparator: Frozen FMT. 
Number of patients: 24 
Female: Male: 18: 6. 
Age (mean): Mean 62.5 (range 33-
88) years. 
 
CDI features: All recurrent. 
 
CDI diagnosis confirmation:Not 
explicitly stated, but includes CDI 
toxin. 
 
Pre-FMT antibiotics: Not stated. 
 
Total follow up period: 2 months. 
 
Cochrane Collaboration risk of 
bias assessment: high risk of bias. 
 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: "Normal 
BMI". 
 
Donor screening: Questionnaire -
as per van Nood et al, NEJM, 
2013. 
 
Travel and antibiotic exclusion 
period: As per van Nood et al, 
NEJM, 2013. 
 
Screening blood tests: As per van 
Nood et al, NEJM, 2013. 
 
Screening stool tests: As per van 
Nood et al, NEJM, 2013. 
Amount of stool per transplant / 
administered to patients: 50g. 
 
Diluent used to prepare: Normal 
saline. 
 
Diluent used to store if frozen: 
Implied use of glycerol for frozen 
product but not clearly stated. 
  
Preparation methods: mix stool 
with normal saline (1:10), aerobic 
conditions, use Stomacher to 
homogenise. 
 
Time from preparation to 
transplant (fresh): Within 2 hours 
of preparation. 
 
Time period for storage (frozen): 
Not specified. 
 
Route administered: All 
colonoscopic. 
 
Number of infusions: 1 
 
Bowel purgative: PEG on night 
before FMT. 
 
PPI: No. 
 
Antimotility: 4mg loperamide 3 
hours before. 
 
Prokinetics: No. 
Treatment arm: Fresh: 
Overall cure rate: 100% 
(n=25/25). 
 
Cure with one infusion 
alone: 100% (n=25/25). 
 
Treatment arm: Frozen: 
Overall cure rate: 83% 
(n=20/24). 
 
Cure with one infusion 
alone: 83% (n=20/24). 
 
Treatment arm: 
Lyophilised: 
Overall cure rate: 78% 
(n=20/23). 
Cure with one infusion 
alone: 78% (n=20/23). 
Minor GI adverse 
events: no 
differences in the 
three groups.  Mild 
transient abdominal 
pain and diarrhoea in 
86% of patients. x6 
experienced fatigue 
and x4 had a 
headache. x2 gained 
weight. 
 
Minor non-GI 
adverse events: None 
stated. 
 
Serious adverse 
events:  None. 
 
Deaths: None. 
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Time before CDI treatment was 
stopped before FMT: Not specified. 
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Kao et al, JAMA, 
2017 
Comparitor: Oral FMT capsules. 
Number of patients: 57. 
Female: male: 43: 14. 
Age (median/standard deviation): 
58.7 (+/-18.5) years. 
 
Comparitor: Colonoscopic FMT. 
Number of patients: 59. 
Female: male: 36: 13. 
Age (median/standard deviation): 
57.4 (+/-19.1) years. 
 
CDI features: All recurrent. 
 
CDI diagnosis: Recurrence of 
diarrhea (>3 unformed bowel 
movements every 24 hours) 
within 8 weeks of completing a 
prior course of treatment, with 
either a positive C difficile toxin by 
glutamate dehydrogenase and C 
difficile toxins A/B (C diff 
QuikChek Complete; Techlab) or 
by detection of glutamate 
dehydrogenase and C 
difficile cytotoxin B gene 
(Cepheid), plus resolution of 
diarrhea for the current episode. 
 
Pre-FMT antibiotics: Oral 
vancomycin (125mg twice daily) 
up to 24hrs before FMT. 
 
Total follow-up period: 12 weeks. 
 
 
 
 
Donors were unrelated 
volunteers. 
 
Working in healthcare: Not 
stated. 
 
Donor demographics: Not stated. 
Donor screening: Questionnaire:  
As per Kelly et al, 
Gastroenterology, 2015. 
 
Travel and antibiotic exclusion 
period: As per Kelly et al, 
Gastroenterology, 2015. 
 
Screening blood tests: As per 
Kelly et al, Gastroenterology, 
2015. 
 
Screening stool tests: As per Kelly 
et al, Gastroenterology, 2015. 
Amount of stool per transplant / 
administered to patients: 80-100g. 
 
Diluent used to prepare: Normal 
saline. 
 
Diluent used to store if frozen: 
100% glycerol. 
 
Preparation methods: Mix stool 
with 200ml of normal saline, and 
filtered using a Stomacher to 
homogenise 180ml of faecal slurry. 
 
Time from preparation to 
transplant (fresh): up to 2 months 
frozen, collected fresh within 12 
hours. 
 
Time period for storage (frozen): 
up to 2 months. 
 
Route administered: lower GI: 59 
(colonoscopy); capsule: 57. 
 
Number of infusions: x1 of 
colonoscopy, or x40 capsules as 
one-off. 
 
Bowel purgative: PEG on the night 
before. 
 
PPI: No. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
Treatment arm: Oral 
FMT capsules: 96.2% 
(n=51/53) absence of 
CDI at 12 weeks. 
 
Cure with one 
treatment alone: 96.2% 
(n=51/53). 
 
Treatment arm: FMT 
via colonoscopy: 96.2% 
(n=50/52). 
 
Cure with one infusion 
alone: 96.2% (n=50/52). 
 
 
Minor GI adverse 
events: Capsule 
group: x3 nausea, x2 
vomiting, x1 
abdominal pain.  
Colonoscopy group: 
x1 nausea, x1 
vomiting, x1 fever, x5 
abdominal pain. 
 
Minor non-GI 
adverse events: .1 
developed confusion 
in the colonoscopy 
group between time 
of screening and 
delivery of FMT. This 
was not 
communicated to 
team, and despite an 
uneventful FMT she 
died three days later 
from heart failure. 
 
Serious adverse 
events: None. 
 
Deaths: x1 in each 
group from 
cardiopulmonary 
disease (see above 
for colonoscopy). The 
other patient 
developed 
Staphylococcus 
epidermis 
bacteraemia 10 
weeks after capsule 
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Time before CDI treatment was 
stopped before FMT: 24 hours. 
treatment and died 
from sepsis. 
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Kelly et al, 
Annals of 
Internal 
Medicine, 
2016 
Intervention: Donor FMT. 
Number of patients: 22. 
Female: male: 18: 4. 
Age (mean/ standard deviation): 
Mean age 48 (+/-16) years. 
 
Comparator: Autologous FMT. 
Number of patients: 24. 
Female: male: 19: 5. 
Age (mean/ standard deviation): 
Mean age 55 (+/-14) years. 
 
Comorbidities: Similar median 
Charlson comorbidity scores 
between groups. 
 
CDI features: Recurrent. 
 
CDI diagnosis confirmation: ≥3 
unformed stools over 24 hours for 
2 consecutive days, and either a 
positive stool test result for C 
difficile or pseudomembranes on 
colonoscopy. 
 
Pre-FMT antibiotics:  All patients 
had had prolonged prior courses 
of vancomycin. 
  
Total follow up period: 8 week 
outcome follow up, 6 month 
safety follow-up. 
 
Cochrane Collaboration risk of 
bias assessment: low risk of bias. 
Donors working in healthcare: 
Not stated. 
 
Donor demographics: Not stated. 
 
Donor screening: Questionnaire -  
potential donors also completed 
a modified AABB full-length 
donor history questionnaire, and 
those with risk factors for 
infectious agents were excluded.  
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotics within preceeding 90 
days. 
Screening bloods: Testing for HIV-
1 and HIV-2 was performed 
within 2 weeks before donation 
for FMT. Other serologic testing 
was performed within 1 month 
before FMT and included testing 
for hepatitis A, B, and C viruses; 
also, testing for Treponema 
pallidum. 
  
Screening stool tests: polymerase 
chain reaction (PCR) testing for 
detection of C difficile toxin; 
culture for enteric pathogens 
(Escherichia coli, Salmonella, 
Shigella, Yersinia, Campylobac- 
ter, Listeria monocytogenes, 
Vibrio parahaemolyticus, and V 
cholerae); testing for fecal 
Giardia and Cryptosporidium 
antigens; acid-fast stain for 
detection of Cyclospora and 
Amount of stool per transplant / 
administered to patients: Mean 
stool dose of 64 g (standard 
deviation of 25 g; range, 20 to 
100g). 
 
Diluent used to prepare: 100g of 
stool in 500mls of normal saline. 
 
Diluent used to store if frozen: N/A. 
 
Preparation methods: Not 
reported. 
 
Time from preparation to 
transplant (fresh): 6 hours. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered: Upper GI: nil; 
lower GI: all patients in both 
groups (colonoscopy); capsule: nil. 
 
Number of infusions: 1 infusion 
only. 
 
Bowel purgative: polyethylene 
glycol (PEG). 
  
PPI: No. 
 
Antimotility: Not described. 
 
Prokinetics: No. 
 
Time before CDI treatment was 
stopped before FMT: continued 
Treatment arm: Donor 
FMT: 
Overall cure rate: 90.9% 
(n=20/22). 
Cure with one infusion 
alone:  90.9% 
(n=20/22). 
 
Treatment arm: 
Autologous FMT 
Overall cure rate: 62.5% 
(n=15/24). 
Cure with one infusion 
alone: 62.5% (n=15/24). 
Minor GI adverse 
events: Low rates of 
abdominal pain, 
bloating, nausea, 
vomiting, diarrhea, 
flatulence, anorexia, 
and constipation; 
these did not differ 
significantly between 
groups. 
  
Minor non-GI 
adverse events:  
None described.   
 
Serious adverse 
events: None 
described. 
 
Deaths: None. 
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Isospora; ova and parasite 
testing; and enzyme 
immunoassay for detection of 
Rotavirus. 
therapy until 2 to 3 days before the 
procedure. 
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Lee et al, 
JAMA, 
2016 
Intervention: Frozen FMT. 
Number of patients: 108. 
Female: male: 72: 36. 
Age (mean/ standard 
deviation): Mean age 73.0 (+/- 
16.4) years. 
 
Comparator: Fresh FMT. 
Number of patients: 111. 
Female: Male: 74: 37. 
Age (mean/ standard 
deviation): Mean age 72.5 (+/- 
16.2) years. 
 
Comorbidities: Not described.  
 
CDI features: All recurrent 
disease. 
 
CDI diagnosis confirmation: 
Toxin and PCR. 
 
Pre-FMT antibiotics: All had 
had prior metronidazole, 
vancomycin, or both in 
combination.  Almost all 
patients had had prior 
vancomycin taper. 
 
Total follow up period: 13 
weeks. 
 
Cochrane Collaboration risk of 
bias assessment: low risk of 
bias. 
Donors were unrelated 
volunteers. 
 
Donors working in healthcare: 
Not specifically described. 
 
Donor demographics: Not 
defined. 
 
Donor screening: questionnaire 
– comparable to blood donor 
screening questionnaire. 
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
travel (within the last 6 months) 
to areas of the world where 
diarrheal illnesses are endemic 
or risk of traveler's diarrhea is 
high; also excluded if antibiotics 
within the preceeding 3 
months. 
 
Screening blood tests: HIV-1 
and -2, hepatitis A IgM, HBsAg, 
anti-HBc (both IgG and IgM), 
and anti-HBs, hepatitis C 
antibody, RPR and FTA-ABS.   
 
Screening stool tests:  
Clostridium difficile toxin B by 
PCR; if unavailable, then 
evaluation for toxins A and B by 
EIA; routine bacterial culture for 
enteric pathogens; faecal 
Giardia antigen; faecal 
Cryptosporidium antigen; Acid-
fast stain for Cyclospora, 
Amount of stool per transplant / 
administered to patients: 100g of 
stool. 
 
Diluent used to prepare: 300mls of 
water. 
 
Diluent used to store if frozen: no 
solvents used for storage. 
 
Preparation methods: 100g of stool 
homogensied and mixed in 300mls 
of water. 
 
Time from preparation to 
transplant (fresh): If fresh, 
administered within 24hrs. 
 
Time period for storage (frozen): If 
frozen, kept for 30 days at -20oC. 
 
Route administered: Upper GI: nil; 
lower GI: enema FMT for all 
patients in both groups; capsule: 
nil. 
 
Number of infusions in frozen arm:  
57 patients had 1 infusion; 24 
patients had 2 infusions; rest had 
>2 infusions; in fresh arm: 56 
patients had 1 infusion; 22 patients 
had 2 infusion; rest had >2 
infusions. 
 
Bowel purgative: Not described. 
 
PPI: Nil. 
 
Treatment arm: 
Frozen: 
Overall cure rate: 
90.7% (n=98/109). 
Cure with one 
infusion alone: 52.8% 
(n=57/108). 
 
Treatment arm: 
Fresh: 
Overall cure rate: 
85.6% (n=95/111). 
Cure with one 
infusion alone: 50.5% 
(n=56/111). 
Minor GI adverse events: 
Transient diarrhoea (70%), 
abdominal cramps (10%), 
nausea (5%) in 24 hours 
post-FMT; constipation (20%) 
and flatulence (25%) in 
follow-up period. No 
difference between the two 
groups. 
 
Minor non-GI adverse 
events: None described. 
 
Serious adverse events: x12 
patients required 
hospitalization because of 
ilnesses unrelated to FMT. 
 
Deaths: x6 deaths in frozen 
and x13 deaths in fresh arm 
(all unrelated to FMT). 
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Isospora and, if antigen testing 
unavailable, Cryptosporidium; 
ova, cysts and parasites. 
 
Antimotility: Not described. 
 
Prokinetics: Not described. 
 
Time before CDI treatment was 
stopped before FMT: Discontinued 
24 - 48 hours prior to FMT.  
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van Nood et al, 
New England 
Journal of 
Medicine, 
2013 
Intervention: FMT + bowel lavage. 
Number of patients: 16. 
Female: male: 8: 8. 
Age (mean/ standard deviation): 
73 (+/- 13) years. 
 
Comparator: Vancomycin (500mg 
orally four times daily for 14 
days). 
Number of patients: 13. 
Female: male: 7: 6. 
Age (mean/ standard deviation): 
66 (+/-14) years. 
 
Comparator: Vancomycin (500mg 
orally four times daily for 14 days) 
+ bowel lavage. 
Number of patients: 13. 
Female: Male: 3: 10. 
Age (mean/ standard deviation): 
69 (+/-16) years. 
 
Comorbidities: No significant 
difference in median Charlson 
comorbidity index between 
groups. 
 
CDI features: All recurrent. 
 
CDI diagnosis confirmation: Toxin 
and PCR. 
 
Pre-FMT antibiotics: At least one 
course of adequate antibiotic 
therapy (≥10 days of vancomycin 
at a dose of ≥125mg four times a 
day or ≥10 days of metronidazole 
Donors were healthy 
volunteers. 
 
Donors working in 
healthcare: No. 
 
Donor demographics: <60 
years of age. 
 
Donor screening: 
questionnaire: 
questionnaire addressed 
risk factors for potentially 
transmissible diseases. 
 
Travel and antibiotic 
exclusion period: Excluded 
as donor if travel to tropical 
area within past 3 months, 
or antibiotic use within the 
past two months. 
  
Screening blood tests: 
Blood was screened for 
HIV; human T-cell 
lymphotropic virus types 1 
and 2; hepatitis A,B, and C; 
cytomegalovirus; Epstein-
Barr virus; Treponema 
pallidum; Strongyloides 
stercoralis; and Entamoeba 
histolytica. 
 
Screening stool tests: 
Donor feces were screened 
for parasites, including 
Blastocystis hominis and 
Dientamoeba fragilis; C  
Amount of stool per transplant / 
administered to patients: A mean 
(+/-standard deviation) of 141+/-
71g of faeces was infused.  
 
Diluent used to prepare: Faeces 
were diluted with 500mls of sterile 
saline, 0.9%. 
 
Diluent used to store if frozen: N/A. 
 
Preparation methods: The solution 
was stirred, and the supernatant 
strained and poured in a sterile 
bottle. 
 
Time from preparation to 
transplant (fresh): Mean time from 
defecation to infusion was 3.1+/-
1.9 hours. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered: Upper GI: 16 
(via nasoduodenal tube); lower GI: 
nil; capsule: nil. 
 
Number of infusions: 16 patients 
had 1 infusion; 3 who did not 
respond in this group had 2nd 
infusion. 
 
Bowel purgative:  4 litres of 
macrogol solution (Klean-Prep) on 
the last day of antibiotic treatment. 
 
PPI: Not stated. 
Treatment arm: FMT 
+ bowel lavage 
Overall cure rate: 
94% (n=15/16). 
Cure with one 
infusion alone: 81% 
(n=13/16). 
 
Treatment arm: 
Vancomycin: 
Overall cure rate: 315 
(n=4/13) patients at 
10 weeks. 
 
Treatment arm: 
Vancomycin + bowel 
lavage: 
Overall cure rate: 
23% (n=3/13) 
patients at 10 weeks. 
Minor GI adverse events: 
94% immediate diarrhoea, 
31% abdominal pain with 
cramping, 19% belching - 
resolved within 3 hours. 
During follow-up, x3 patients 
had constipation (19%). 
 
Minor non-GI adverse 
events: Nil. 
 
Serious adverse events: Nil 
described. 
 
Deaths: None. 
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at a dose of 500mg three times 
per day).  
 
Total follow up period: After first 
infusion at 10 weeks; follow-up 
was extended to 10 weeks after 
the second infusion. 
 
Cochrane Collaboration risk of 
bias assessment: low risk of bias. 
difficile, and 
enteropathogenic bacteria. 
 
Antimotility: Not stated. 
 
Prokinetics: Not stated. 
 
Time before CDI treatment was 
stopped before FMT: 24 hours. 
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Youngster et al, 
Clinical infectious 
diseases, 
2014 
Intervention: Colonoscopic FMT. 
Number of patients: 10. 
Female: male: 6:4. 
Age (mean/ standard deviation): 
Mean 50.4 (+/- 28.8) years. 
 
Intervention: Nasogastric FMT. 
Number of patients: 10. 
Female: male: 5: 5. 
Age (mean/ standard deviatoin): 
Mean 58.6(+/-19.6) years. 
 
Comorbidities: Not defined.  
 
CDI features: Relapsing or 
recurring (having at least 3 
episodes of mild-to-moderate CDI 
or at least 2 episodes of severe 
CDI resulting in hospitalization 
and associated with significant 
morbidity. 
 
CDI diagnosis confirmation: Toxin; 
initial GDH enzyme-linked 
immunosorbent assay, followed 
by PCR only if the GDH test is 
positive or indeterminate. 
 
Pre-FMT antibiotics:  Treatment 
failures of a 6- to 8-week taper 
with vancomycin (95% of patients) 
with or without an alternative 
antibiotic, including fidaxomicin 
(70% of participants). 
 
Total follow up period: 8 weeks 
follow-up for primary response. 
 
Donors were healthy 
volunteer non-pregnant 
adults. 
 
Donors working in 
healthcare: No. 
 
Donor demographics: 18-50 
years of age, on no 
medications, with a normal 
body mass index. 
 
Donor screening: 
questionnaire - initial 
screening using the 
American Associ tion of 
Blood Banks donor 
questionnaire for exposure 
to infectious agents.  
 
Travel and antibiotic 
exclusion period: Excluded 
if antibiotic use within 6 
months. 
 
Screening blood tests: 
Blood was screened for 
antibodies to hepatitis A, B, 
and C; HIV; and Treponema 
pallidum within 2 weeks of 
donations. 
 
Screening stool tests: 
Donor faeces were 
screened for enteric 
bacterial pathogens 
including rotavirus, Listeria 
monocytogenes, Vibrio 
Amount of stool per transplant / 
administered to patients: 90mls of 
thawed FMT (41g). 
 
Diluent used to prepare: Normal 
saline. 
 
Diluent used to store if frozen: 10% 
glycerol. 
 
Preparation methods: 
Homogenised using a commercial 
blender then passed through 
sieves. 
 
Time from preparation to 
transplant (fresh): N/A. 
 
Time period for storage (frozen):  
Inocula were stored frozen for up 
to 156 days, range, 29-156 days. 
 
Route administered: Upper GI 
(nasogastric) 10; lower GI 
(colonoscopy): 10; capsule: nil. 
 
Number of infusions: Colonoscopy: 
8 patients - 1 infusion, 2 patients – 
2 infusions; NG: 7 patients - 1 
infusion; 3 patients – 2 infusions. 
 
Bowel purgative: For colonic route 
- 4 liters of PEG solution. 
 
PPI: 20mg of omeprazole orally for 
48 hours prior to FMT. 
Treatment arm: 
Overall 
Overall cure rate: 
90% (n=18/20). 
Cure with one 
infusion alone: 70% 
(n=14/20). 
 
Treatment arm: 
Colonoscopy: 
Overall cure rate: 
100% (n=10/10). 
Cure with one 
infusion alone: 80% 
(n=8/10). 
 
Treatment arm: 
Nasogastric:  
Overall cure rate: 
80% (n=8/10). 
Cure with one 
infusion alone: 60% 
(n=6/10). 
Minor GI adverse events: 
Mild abdominal discomfort 
and bloating in x4 patients 
(20%). X1 child treated 
colonoscopically had a 
transient fever of 38.8oC on 
day 2 that resolved 
spontaneously. 
 
Minor non-GI adverse 
events: Nil described. 
 
Serious adverse events:  x1 
new diagnosis of malignancy, 
x1 hospitalisation for 
Fournier gangrene (unrelated 
to FMT). 
 
Deaths: x2 deaths (unrelated 
to FMT). 
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Cochrane Collaboration risk of 
bias assessment: uncertain risk of 
bias. 
cholerae, Escherichia coli 
O157, ova and parasites 
(including general 
microscopy, acid-fast 
staining, and/or antigen 
testing for Giardia, 
Cryptosporidium, Isospora, 
and Microsporidia), C 
difficile, and Helicobacter 
pylori antigen. 
 
Antimotility: single dose of oral 
loperamide prior to procedure. 
 
Prokinetics: Nil. 
 
Time before CDI treatment was 
stopped before FMT: Patients were 
required to discontinue all 
antibiotics at least 48 hours prior to 
the procedure. 
Page 267 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
100 
 
C.3. Reviewed randomised studies of FMT for non-CDI indications 
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Paper Study and patient characteristics Donor characteristics FMT characteristics Outcomes Adverse events 
Moayyedi et al, 
Gastroenterology, 
2015 
Intervention: FMT. 
Number of patients: 38. 
Female: male 20: 18. 
Age (mean +/-range)*: 42.2+/-15.0 
years. 
 
Comparator: Water enema. 
Number of patients: 37. 
Female: male: 11: 26. 
Age (mean +/-range)*: 35.8 +/- 
12.1 years. 
 
Primary outcome: Remission at 
week 7, defined as full Mayo score 
< 3 and complete healing of 
mucosa at flexible sigmoidoscopy 
(endoscopic Mayo score: 0).   
 
Secondary outcome: Clinical 
response (at least 3 point reduction 
in Mayo score), change in Mayo, 
IBD Questionnaire scores, EQ-5D 
scores.   
 
Inclusion criteria: >18 years with 
UC  - Mayo at least 4 with 
endoscopic subscore at least 1 
(included patients with severe 
disease).   
 
Exclusions - antibiotics/ probiotics 
in past 30 days, concomitant C 
difficile/ other enteric pathogens, 
disease severity requiring 
hospitalisation, pregnancy, unable 
Donors were unrelated volunteers - 
six donors used.  Plus - one patient 
in active treatment arm had spouse 
as donor (treatment failure). 
 
Working in healthcare: Not 
specifically stated. 
 
Donor demographics: 18-60 years. 
 
Donor screening: Questionnaire – 
yes. 
 
Travel and antibiotic exclusion 
period: Retesting of stool whenever 
donor travelled outside North 
America.  Excluded as donor if 
antibiotics within past 3 months.  
Screening repeated regardless every 
6 months. 
 
Screening blood tests: HIV, hepatitis 
A IgM, HBsAg, hepatitis C antibody, 
syphilis, HTLV-1/-2. 
 
Screening stool tests: MC&S, ova, 
cysts and parasites, C difficile toxin, 
VRE, MRSA. 
Amount of stool per transplant / 
administered to patients: 8.3g of 
stool per enema  
 
Diluent used to prepare: 50g of stool 
mixed with 300ml of commercial 
bottled drinking water, then 50ml of 
mixture administered as enema. 
 
Diluent used to store if frozen: No 
glycerol.  FMT administered either 
fresh, or stored at -20 degrees.  21 
received frozen, 15 received fresh, 1 
mixture of fresh and frozen. 
 
Preparation methods: Not anaerobic.  
Single donor per FMT. 
 
Time from preparation to transplant 
(fresh): Processing within 5hr of 
collection. 
 
Time period for storage (frozen): Not 
stated. 
 
Route administered and frequency:  
Upper GI: nil; lower GI: enema - 
weekly for 6 weeks.  Aimed to retain 
for at least 20 mins (38); capsule: nil. 
 
Bowel purgative: No PEG. 
 
PPI: Not described. 
 
Antimotility: Not described. 
 
FMT arm: 
Remission rates: 24% 
(n=9/38). 
Clincial response rates: 40% 
(n=15/38) had reduction in 
full Mayo score of at least 3 
points. 
Quality of Life Assessment: 
Yes - IBDQ and EQ-5D not 
significantly different 
between groups. 
 
Water enema arm: 
Remission rates: 5% 
(n=2/37) (p=0.03) 
Clincial response rates: 24% 
(n=9/37) had reduction in 
full Mayo score of at least 3 
points (p=0.16). 
FMT arm: 
Minor GI adverse events: 
Two patients developed 
patchy inflam in the 
colon and also rectal 
abscess formation - 
resolved with antibiotics. 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
x2 patients had diagnosis 
changed to Crohn's 
colitis, one was C difficile 
toxin positive at end of 
therapy. 
 
Deaths: None. 
 
 
Water enema arm: 
Minor GI adverse events: 
x1 patient developed 
patchy inflammation in 
the colon and also rectal 
abscess formation - 
resolved with antibiotics. 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
x1 patient changed 
diagnosis from UC to 
Crohn's colitis; x1 
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to give informed consent. 
 
Concomitant medications: Stable 
dose thiopurines, mesalamine, 
corticosteroids, and anti-TNF 
allowed as long as stable dose for 
at least 12 weeks (4 weeks for 
steroids). 
 
Total follow-up period: Up to 12 
months. 
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
Prokinetics: Not described. admitted with hospital 
with active severe colitis 
and required colectomy. 
 
Deaths: None. 
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Rossen et al, 
Gastroenterology, 
2015 
Intervention: Donor faeces. 
Number of patients: 23. 
Female: male: 12: 11. 
Age (median, (range)): 40 (33-56) 
years. 
 
Comparator: Autologous faeces. 
Number of patients: 25. 
Female: male: 14:11. 
Age (median, (range)): 41 (30 – 48) 
years. 
 
Primary outcome: Clinical 
remission (defined as a SCCAI score 
≤2) in combination with 1-point 
improvement on the combined 
Mayo endoscopic score of the 
sigmoid and rectum, as compared 
with baseline sigmoidoscopy, 12 
weeks after the first treatment. 
 
Secondary outcome: Endpoints at 6 
and 12 weeks were clinical 
response (defined as a reduction of 
1.5 points on the Simple Clinical 
Colitis Activity Index (SCCAI), a 
validated disease activity index tool 
in ulcerative colitis), clinical 
remission (defined as a SCCAI of 
≤2), endoscopic response, change 
in median (Inflammatory Bowel 
Disease Questionnaire [IBDQ]) 
score from baseline to shortly after 
treatment (week 6), and adverse 
events. 
 
Inclusion criteria: enteric infection, 
use of biologics within 8 weeks or 
Donors were healthy partners, 
relatives, or volunteers. 
 
Working in healthcare: Not stated 
 
Donor demographics: >18 yrs 
 
Donor screening: Questionnaire - 
Dutch Red Cross Questionnaire 
addressing risk factors for potential 
transmissible diseases used for 
screening of blood donors in The 
Netherlands. 
 
Travel and antibiotic exclusion 
period: Excluded as donor if 
antibiotics within 8 weeks. 
 
Screening blood tests:  CMV (IgG + 
IgM), EBV (IgG + IgM), hepatitis A 
(total antibody), hepatitis B (HBsAg), 
hepatitis C (hepatitis C virus 
antibody), HIV (1+2 
antibodies/antigen), HTLV (I + II 
antibodies), Entamoeba (antibodies 
against Entamoeba histolytica), 
Strongyloides (Strongyloides ELISA). 
 
Screening stools: Multiplex PCR 
containing probes against enteral 
viruses (rotavirus, norovirus, 
enterovirus parechovirus, sapovirus, 
adenovirus 40/41/52, astrovirus),  
FT + TFT II: PCR op Giardia, SSYC, 
Clostridium toxin 
Amount of stool per transplant / 
administered to patients: 120g 
 
Diluent used to prepare: Normal 
saline 
 
Diluent used to store if frozen: not 
stated 
 
Preparation methods: Not anaerobic 
 
Time from preparation to transplant 
(fresh): not stated 
 
Time period for storage (frozen): not 
stated 
 
Route administered and frequency:  
Upper GI: Nasoduodenal route. 2 
infusions three weeks apart.  Nil 
lower GI or capsule 
 
Bowel purgative: Macrogol before 
both infusions 
 
PPI: Not described 
 
Antimotility: Not described 
 
Prokinetics: Not described 
Donor faeces arm: 
Remission rates: 30% 
(n=7/23) 
Clincial response rates: 
47.8% (n=11/23) at 12 
weeks. 
Quality of Life Assessment: 
IBDQ only calculated based 
on responders vs 
nonresponders. 
 
Autologous faeces arm: 
Remission rates: 20% 
(n=5/25), (p=0.51). 
Clincial response rates: 52% 
(n=13/25) at 12 weeks. 
Minor GI adverse events: 
78.3% (n=18/23) of 
donor stool and 64% 
(n=16/25) of autologous 
stool experienced side 
effects post FMT: 
transient borborygmus, 
diarrhoea, vomiting, 
fever. 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
x4 overall (small bowel 
perforation – secondary 
to Crohn’s), CMV 
infection, abdominal 
pain, cervical carcinoma. 
 
Deaths: Nil. 
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methotrexate within 4 weeks 
 
Concomitant medications: stable 
doses of thiopurines, mesalamine, 
or corticosteroids 10 mg/day for 
the 8 weeks before inclusion. 
 
Total follow-up period: 12 weeks. 
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
Page 272 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
105 
 
Paramsothy et al, 
Lancet, 
2017 
Intervention: FMT. 
Number of patients: 41. 
Female: male 19: 22. 
Age (median, (range)): 35.6 (27.8-
48.9) years. 
 
Comparator: Placebo-isotonic 
saline with added colourant 
odourant and glycerol 
cryoprotectant (concentration 
10%). 
Number of patients: 40. 
Female: male: 15: 25. 
Age (median, (range)): 35.4 (27.7-
45.6) years. 
 
Primary outcome: Composite of 
steroid-free clinical remission and 
endoscopic remission or response 
at week 8, defined as a total Mayo 
score of 2 or less, with all Mayo 
subscores of 1 or less, and at least 
a 1 point reduction from baseline 
in the endoscopy subscore.  
 
Secondary outcome: Secondary 
outcomes were: steroid-free 
clinical remission (defined as 
combined Mayo subscores of 1 or 
less for rectal bleeding plus stool 
frequency); steroid-free clinical 
response (defined as either a 
decrease of 3 points or more on 
the Mayo score, a 50% or greater 
reduction from baseline in 
combined rectal bleeding plus stool 
frequency Mayo subscores, or 
both); steroid-free endoscopic 
Donors were between 3-7 unrelated 
donors. 
 
Working in healthcare: No. 
 
Donor demographics: Not 
described. 
 
Donor screening: Questionnaire 
asked regarding:  
· Known HIV, hepatitis B or hepatitis 
C infection 
· Known exposure to HIV or viral 
hepatitis within the previous 12 
months 
· High risk sexu l behavior (e.g. 
sexual contact with anyone with 
HIV/AIDS or viral hepatitis, men who 
have 
sex with men, sex for drugs or 
money) 
· Use of illicit drugs 
· Tattoo or body piercing within the 
preceding 6 months 
· Incarceration or history of 
incarceration 
· Known current communicable 
disease (e.g. upper respiratory tract 
infection) 
· Risk factors for variant Creutzfeldt-
Jakob disease 
· Travel within last 2 weeks to areas 
of the world where diarrhoeal 
illnesses are endemic or risk of 
traveler’s diarrhea is high 
· History of or current inflammatory 
bowel disease (IBD) 
· History of or current irritable 
Amount of stool per transplant / 
administered to patients: 37.5g of 
blended stool to isotonic saline; 
volume of each infusion was 150ml. 
 
Diluent used to prepare: isotonic 
saline with 10% glycerol 
cryoprecipitant. 
 
Diluent used to store if frozen: -80oC 
with glycerol cryoprotectant 
(concentration 10%). 
  
Preparation methods: Donors had to 
provide faeces within 4 hours of a 
bowel movement, which was 
inspected visually for suitability 
(formed stool, no blood or mucous). 
Donor stool homogenised for a given 
batch on each day in a biosafety 
cabinet in isotonic saline then 
filtered. Placebo infusions comprised 
isotonic saline; brown food 
colourant, odourant, and glycerol 
cryoprotectant (concentration 10%) 
was added to all study infusions 
(investigational and placebo). The 
volume of each infusion was 150 mL. 
Infusions were stored at −80°C until 
dispensation to patients at 
fortnightly study visits for home 
freezer storage at −20°C before daily 
administration. 
 
Time from preparation to transplant 
(fresh): Not described. 
 
Donor FMT arm: 
Remission rates: 275 
(n=11/41). 
Clincial response rates: 54% 
(n=22/41). 
Quality of Life Assessment: 
Not described. 
 
Placebo arm: 
Remission rates: 8% 
(n=3/40) (p=0.021). 
Clincial response rates: 23% 
(n=9/40)  (p=0.04). 
Quality of Life Assessment: 
Not described. 
FMT arm: 
Minor GI adverse events: 
abdominal pain x12 
(29%), colitis x10 (24%), 
flatulance x10 (24%), 
bloating x8 (20%), 
nausea x2 (5%), elevated 
ALT x2 (5%), vomiting x2 
(5%), enterocolitis x1 
(2%), diarrhoea x1 (2%), 
reflux x1 (2%), 
haemorrhoids x1 (2%), 
elective surgical 
procedure x1 (2%). 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
x2 (5%) - x1 clinical 
deterioration and 
colectomy, x1 needed 
intravenous intravenous 
steroids. 
 
Deaths: Nil. 
 
Placebo arm: 
Minor GI adverse events: 
abdominal pain x11 
(28%), colitis x9 (23%), 
flatulance x8 (20%), 
bloating x11 (28%), 
nausea x5 (13%), 
vomiting x1 (3%), 
enterocolitis x3 (8%), 
anal fissure x1 (3%), 
faecal incontinence x1 
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response (defined as a Mayo 
endoscopy subscore of 1 or less, 
with a reduction of at least 1 point 
from baseline); steroid-free 
endoscopic remission (defined as a 
Mayo endoscopy subscore of 0); 
quality of life (assessed with the 
IBDQ); and safety (assessed by 
adverse events). 
 
Inclusion criteria: 1. 18-75 years; 2. 
UC for >3 months; 3. UC of any 
extent except isolated proctitis 
<5cm; 4. currently active mild-
moderate UC as mesured by a 
Mayo score of 4-10, endoscopy 
score must be greater or equal to 1 
and a physician global assessment 
score of less than or equal to 2; 5. 
Written consent.  
 
Concomitant medications: Drugs 
permitted as long as the dose was 
stable preceding enrolment: oral 5-
aminosalicylates (stable dose for 4 
weeks); thiopurines and 
methotrexate (on medication for 
≥90 days and dose stable for 4 
weeks); and oral prednisolone 
(dose ≤20mg daily and stable for 2 
weeks). During the study, patients 
remained on the same dose of 5-
aminosalicylate, thiopurine, and 
methotrexate. For oral 
prednisolone, patients received a 
mandatory taper of up to 2·5 mg 
per week so that patients would be 
steroid-free by week 8. 
bowel syndrome (IBS), chronic 
constipation, chronic diarrhea or 
other intrinsic gastrointestinal 
illness / condition 
· History of or current 
gastrointestinal malignancy or 
known polyposis or strong family 
history of colorectal cancer 
· History of major gastrointestinal 
surgery (e.g. gastric bypass, partial 
colectomy)h 
Antimicrobials (antibiotics, 
antivirals, antifungals), probiotics or 
proton pump inhibitors (PPIs) within 
the preceding 3 months 
· Major immunosuppressive 
medications (e.g. ca cineurin 
inhibitors, biological agents, 
exogenous glucocorticoids) 
· Systemic anti-neoplastic agents 
· Household members with active GI 
infection  Systemic autoimmunity 
(e.g. multiple sclerosis, connective 
tissue disease) 
· Atopic disease (e.g. moderate - 
severe asthma, eosinophilic 
disorders of the gastrointestinal 
tract) 
· Metabolic syndrome, obesity (BMI 
>30) or moderate to severe under-
nutrition / malnutrition 
· Chronic pain syndromes (e.g. 
chronic fatigue syndrome, 
fibromyalgia) or neurologic / 
neurodevelopmental 
disorders 
· History of malignant illness or 
ongoing oncologic therapy 
Time period for storage (frozen): Not 
described. 
 
Route administered and frequency:  
Upper GI:  0; lower GI: 5 enemas per 
week following colonosopic delivery 
-5 days on, two days off for 8 weeks 
(40 enemas per patient); capsule: 0. 
 
Bowel purgative: Yes, but no details 
 
PPI: Not described 
 
Antimotility: Not described 
 
Prokinetics: Not described 
(3%), elevated ALT x2 
(5%). 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
x1 (3%) - admitted to 
hospital (no details why). 
 
Deaths: Nil. 
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Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
 
Travel and antibiotic exclusion 
period: Excluded if travel within last 
2 weeks to areas where diarrheal 
illnesses are endemic or risk of 
travelers diarrhea is high. 
 
Screening blood tests: Complete 
blood count, electrolytes, urea and 
creatinine, LFTS, ESR, CRP, HIV-1 
and -2, hepatitis A IgM, hepatitis B 
SAg, hepatitis B core antibody (IgM 
and IgG) and surface antibody, 
hepatitis c antibody, rapid plasma 
reagin and/or fluorescent 
treponemal antibody-absorbed, 
HTLV-1 and HTLV-2. 
 
Screening stools: C difficile PCR, 
faecal MC&S with routine bacterial 
culture for enteric pathiogens, 
Giardia antigen, Cryptosporidium 
antigen, faecal ova/cysts/parasites 
including Blastocystitis hominis and 
Dientamoeba fragilis, and 
Norovirus. 
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Costello et al, 
Journal of Crohn's 
and Colitis 
(abstract), 
2017 
Intervention: Donor FMT. 
Number of patients: 38. 
Female: male: Not stated. 
Age (mean/median): Not stated. 
 
Comparator: Control - autologous 
FMT in saline. 
Number of patients: 35. 
Female: male: Not stated. 
Age (mean/median): Not stated. 
 
Primary outcome: Steroid-free 
remission of UC, as defined by total 
Mayo of 2 or less with an 
endoscopic Mayo score of 1 or less 
at week 8. 
 
Secondary outcome: Clinical 
response (at least 3 point reduction 
in Mayo score), clinical remission 
(i.e. SCCAI of 2 or less), endoscopic 
remission (Mayo 1 or less), and 
safety. 
 
Inclusion criteria: UC - Mayo 3-10 
with endoscopic subscore at least 
2. 
 
Concomitant medications: Stable 
dose of immunomodulator, 5-ASA, 
biological, tapering prednisolone. 
 
Cochrane Collaboration risk of bias 
assessment: uncertain risk of bias. 
Donors were healthy volunteers. 
 
Working in healthcare: Not clear. 
 
Donor demographics: Not 
described. 
 
Donor screening: Questionnaire – 
yes but no details described. 
 
Travel and antibiotic exclusion 
period: Not described. 
 
Screening blood tests:  Yes but not 
described . 
 
Screening stool tests: Yes but not 
described. 
Amount of stool per transplant / 
administered to patients: 50g of 
stool for first FMT, 25g of stool in 
subsequent enemas. 
 
Diluent used to prepare: 65% saline. 
 
Diluent used to store if frozen: Yes - 
frozen with 10% glycerol. 
 
Preparation methods: Anaerobic 
prep, donor stool pooled from 3-4 
donors. 
 
Time from preparation to transplant 
(fresh): N/A. 
 
Time period for storage (frozen): Not 
stated. 
 
Route administered and frequency:  
Upper GI: nil; lower GI: FMT via 
colonoscopy on day 0, followed by 2 
enemas on day 7 (38); capsule: nil 
 
Bowel purgative: PEG before 
colonoscopy but not enema 
 
PPI: Not described 
 
Antimotility: Not described 
 
Prokinetics: Not described 
Donor FMT arm: 
Remission rates: 32% 
(n=12/38) in steroid-free 
remission at week 8. 
Clincial response rates: 55% 
(n=21/38). 
Quality of Life Assessment: 
Not described. 
 
Autologous FMT arm: 
Remission rates: 9%. 
(n=3/35) in steroid-free 
remission at week 8 
(p<0.01). 
Clincial response rates: 20% 
(n=7/35) (p<0.01). 
Quality of Life Assessment: 
Not described. 
Donor FMT arm: 
Minor GI adverse events: 
Nil. 
 
Minor non-GI adverse 
events: Nil. 
 
Serious adverse events:  
Worsening colitis in x2 
patients 
 
Deaths: Nil. 
 
Control - autologous FMT 
in saline arm. 
Minor GI adverse events: 
Nil. 
 
Minor non-GI adverse 
events: None. 
 
Serious adverse events: 
Worsening colitis in x2 
placebo patients. x1 
patient requiring 
colectomy, x1 
pneumonia. 
 
Deaths: Nil. 
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Johnsen et al, 
Lancet 
Gastroenterology 
and Hepatology, 
2017 
Intervention: Donor FMT. 
Number of patients: 55. 
Female: male: 36: 19. 
Age (median, (range)): 44 (33-54) 
years. 
 
Comparator: Control - autologous 
FMT . 
Number of patients: 28. 
Female: male: 19: 9. 
Age (median (range)): 45 (34-57) 
years. 
 
Primary outcome: Symptom relief 
of more than 75 points assessed by 
IBS-SSS at 3 months after FMT. 
 
Inclusion criteria: 18-75 yrs of age, 
IBS with diarrhoea or mixed IBS 
according to Rome III criteria. 
Exclusion criteria: participants with 
severe cardiac disease, pulmonary 
disease, or kidney failure, non-IBS 
type abdominal pain, 
immunodeficiency or on 
immunomodulating agents. 
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias 
Donors were two volunteers 
screened at start and at 7 months 
post donation. 
 
Working in healthcare: Not stated. 
 
Donor demographics: Not 
described. 
 
Donor screening: Questionnaire -  
new tattoos or piercings in the past 
3 months; high-risk sexual 
behaviour; former imprisonment; or 
history of any of the following 
conditions: chronic diarrhoea, 
constipation, 
inflammatory bowe  disease, IBS, 
colorectal polyps or 
cancer, immunosuppression, 
obesity, metabolic syndrome, 
atopic skin disease, or chronic 
fatigue. 
 
Travel and antibiotic exclusion 
period: Excluded if antibiotics within 
past three months. 
 
Screening blood tests: Glycated 
haemoglobin; and serology for HIV, 
Treponema pallidum, 
and hepatitis A, B, and C. 
 
Screening stool tests: Salmonella 
spp, Shigella spp, 
Campylobacter spp, Yersinia spp, 
and toxin-producing 
C difficile; faecal tests for 
Helicobacter pylori antigen, 
Amount of stool per transplant / 
administered to patients: 50 to 80g 
of stool in 50mls. 
 
Diluent used to prepare: 200ml 
isotonic saline and 50mls of 85% 
glycerol. 
 
Diluent used to store if frozen:  
glycerol, only for autologous 
transplants. 
 
Preparation methods: Aerobic, stool 
from both donors was mixed 
together. 
 
Time from preparation to transplant 
(fresh): 7 hours. 
 
Time period for storage (frozen): 2-4 
weeks. 
 
Route administered and frequency:  
upper GI:  none; lower GI: single 
infusion of FMT via colonscopy; nil 
capsule.  
Bowel purgative: Picoprep. 
 
PPI: Not described. 
 
Antimotility: Loperamide 8mg 2 
hours before. 
 
Prokinetics: Not described. 
Donor FMT arm: 
Remission rates: 66% 
(n=36/55) . 
Quality of Life Assessment: 
Not described. 
 
Autologous FMT arm: 
Remission rates: 43% 
(n=12/28) (p=0.49). 
Quality of Life Assessment: 
Not described. 
FMT arm: 
Minor GI adverse events: 
Self limiting intermittent 
abdominal pain x1, self 
limiting nausea and 
vertigo x1. 
 
Minor non-GI adverse 
events:  Nil. 
 
Serious adverse events: 
Nil. 
 
Deaths: Nil. 
 
Placebo arm: 
Minor GI adverse events: 
Self limiting intermittent 
abdominal pain x2. 
 
Minor non-GI adverse 
events:  Nil. 
 
Serious adverse events: 
Nil. 
 
Deaths: Nil. 
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viruses (norovirus, rotavirus, 
Sapovirus, adenovirus), 
and faecal calprotectin. 
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Bajaj et al, 
Hepatology, 
2017 
Intervention: Donor FMT. 
Number of patients: 10. 
Female: male: 0: 10. 
Age (mean+/-standard deviation): 
64.5 +/- 5.1 years. 
Aetiology (HCV / alcohol / 
HCV+alcohol / NAFLD / others): 
2/4/2/2/0. 
 
Comparator: Standard of care 
(lactulose/ rifaximin). 
Number of patients: 10. 
Female: male: 0: 10. 
Age (mean+/-standard deviation): 
62.9 +/- 9.8 years. 
Aetiology  (HCV / alcohol / 
HCV+alcohol / NAFLD / others): 
1/5/2/1/1. 
 
Primary outcome: Proportion of 
participants with FMT-related 
serious adverse events (SAEs) at 
day 150, a composite endpoint of 
death, hospitalisations, emergency 
room visits or transmissible 
infections, as defined by the FDA.  
 
Secondary outcomes: Changes in 
cognitive function at day 20, 
cirrhosis severity (MELD score, 
albumin), changes in liver function 
and white blood cell (WBC) count, 
development of all adverse events 
(AEs), and changes in microbiota 
composition and function in the 
FMT arm compared to standard of 
care arm.  
 
Single donor only - identified based 
on highest relative abundances of 
Lachnospiraceae and 
Ruminococcaceae (16S rRNA gene 
sequencing analysis) among a 
universal stool donor bank 
(OpenBiome). 
 
Working in healthcare: Not stated. 
 
Donor demographics: Not described 
 
Donor screening: Based on 
OpenBiome screening. 178-point 
clinical assessment for infectious 
and microbiome-mediated diseases 
and 30 stool pathogen and 
serological tests before and after 
the stool is collected. 
 
Screening blood tests:  HIV-1/-2 
status, hepatitis A/B/C, Treponema 
pallidum, 
LFT, Complete Blood Count (CBC) 
(Includes differentials and platelets), 
HTLV-I/II antibody, with Reflex to 
Confirmatory Assay.  
 
Screening stool tests: Clostridium 
difficile Toxin B and PCR, Cyclospora 
and Isospora Examination, ova, cysts 
and parasites with Giardia Antigen 
EIA, Salmonella/ Shigella/ 
Campylobacter Culture, Shiga Toxin 
EIA with Reflex to E. coli O157 
Culture and Vibrio Culture, 
Cryptosporidium Antigen EIA, 
Helicobacter pylori Antigen EIA, 
Amount of stool per transplant / 
administered to patients: 37.5g of 
stool. 
   
Diluent used to prepare: 90mls 
glycerol saline buffer in total. 
 
Diluent used to store if frozen:  
glycerol. 
 
Preparation methods: Aerobic. 
 
Time from preparation to transplant 
(fresh): N/A - frozen. 
 
Time period for storage (frozen): not 
stated. 
 
Route administered and frequency:  
Upper GI:  non; lower GI: Single 
infusion of FMT via enema. 
  
Bowel purgative: Picoprep. 
 
PPI: Not described. 
 
Antimotility: Loperamide 8mg 2 hrs 
before. 
 
Prokinetics: None. 
 
Others: Lactulose and rifaximin were 
continued for all patients throughout 
the trial. A 5-day broad-spectrum 
coverage regimen was used 
(metronidazole 500 mg orally three 
times daily, ciprofloxacin 500 mg 
orally twice-daily, and amoxicillin 
FMT arm: 
Patients with SAEs at day 
150: 20% (n =2/10) 
(p=0.02). 
 
Total SAEs at day 150: 20% 
(n =2/10) (p=0.01). 
 
Patients with altered 
mental status by day 150: 
0% (n =0/10) (p=0.03). 
 
Total HE episodes at day 
150: 0% (n =0/10) (p=0.03). 
 
Stroop OffTime+OnTime 
change (day 0 and day 20); 
positive indicates 
improvement: 29.1 +/- 27.9 
(p=0.04) (N.B. Stroop 
OffTime+OnTime is a 
validated tool for 
objectively assessing for 
hepatic encephalopathy 
using a smartphone app). 
 
PHES score change (day 0 
and day 20); negative 
indicates improvement -
3.1+/-2.1 (p=0.01). 
 
MELD score change (day 0 
and day 35): 0.1+/-2.0 
(p=0.78). 
 
Standard of care arm: 
Patients with SAEs at day 
150: 80% (n =8/10). 
FMT arm: 
Serious adverse events: 
x1 hospitalisation for 
acute kidney injury, and 
1 was due to chest pain 
(all within 5 months post 
FMT). 
 
Deaths: Nil. 
 
Standard of care arm: 
Serious adverse events: 
x11 in total.  x9 events 
linked to liver-related 
complications, of which 
x4 needed 
hospitalisation. x1 
patient developed 
pneumonia and x1 
developed 
gastroenteritis. 
 
Deaths: Nil. 
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Inclusion criteria: >/:18 yrs 
outpatients with cirrhosis and 
recurrent hepatic encephalopathy 
(HE) defined as at last two 
documented overt HE episodes 
requiring therapy. 
 
Exclusion criteria: MELD score >17, 
on oral or intravenous 
antimicrobial agents besides 
nonabsorbable 
rifaximin, allergies to pretreatment 
antibiotics, immunosuppressive 
medications, positive C. difficile 
test, pregnancy, active infection, 
those with active alcohol abuse, 
and unable to provide informed 
consent 
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias 
Stool Norovirus EIA, Stool Rotavirus 
Antigen Detection, Adenovirus 
Antigen Detection, Gastroenteritis 
EIA, Vancomycin-resistant 
Enterococcus Culture, Microsporidia 
Exam. 
500 mg orally three times daily). All 
antibiotics were discontinued at least 
12 hours before FMT. This regime 
was not used in patients randomised 
to standard of care arm. 
 
Total SAEs at day 150: 11. 
 
Patients with altered 
mental status day 150: 50% 
(n =5/10). 
 
Total HE eps day 150: 6 
Stroop OffTime+OnTime 
change (day 0 and day 20): -
43.5 +/- 95.7. 
 
PHES score change (day 0 
and day 20): 0.0 +/- 3.1. 
 
MELD score change (day 0 
and day 35):  0.2 +/- 2.7. 
 
N.B. no significant 
difference in serum 
albumin, AST, ALT, WBC or 
haemoglobin counts 
between the two groups. 
Page 280 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
113 
 
Tian et al, 
PLoS ONE, 
2017 
Intervention: Donor FMT (one for 
six days in a row). 
Number of patients: 30. 
Female: male 19: 11. 
Age (mean+/-SD): 53.1 +/- 10.2 
years. 
 
Comparator: Standard of care 
(education, behavioural strategies, 
oral laxaives; expressively told to 
avoid antibiotics).  Macrogol 
permitted if no bowel movement 
for three days, and enema 
permitted if even this failed.   
Number of patients: 30. 
Female: male 21: 9. 
Age (mean+/-SD)*: 55.4 +/- 12.1 
years. 
 
Primary outcome: At least three 
complete spontaneous bowel 
movements (CSBMs) per week 
during the 12 week follow-up.    
 
Secondary outcomes: 1) Proportion 
of patients with average increase 
of at least 1 CSBM per week; 2) 
Number of CSBMs per week; 3) 
Colonic transit time (assessed via 
abdominal x-ray/ radiopaque 
markers); 4) subjective stool 
consistency; 5) Wexner 
constipation scale.    
 
Inclusion criteria: ≥18 yrs 
outpatients with cirrhosis and 
recurrent hepatic encephalopathy 
(HE) defined as at last two 
One universal donor used 
throughout (24 year old healthy 
university student). 
 
Working in healthcare: No. 
 
Donor demographics: As above. 
 
Donor screening: Similar to FDA 
blood screening.  
 
Screening blood tests: Full blood 
count, chemistry and iron profile, 
hepatitis A, B and C, HIV-1 and-2, 
CMV, EBV, HSV, VZV, and 
Treponema pallidum.   
 
Screening stool tests: Yersinia spp, 
Salmonella spp, Shigella spp, 
Campylobacter jejuni, C difficile 
toxin, helminths, ova, parasites, and 
Helicobacter pylori.   
Amount of stool per transplant / 
administered to patients: 100g of 
stool. 
 
Diluent used to prepare: Either 
500mls normal saline, or normal 
saline amended with glycerol to final 
concentration of 10%.  
 
Diluent used to store if frozen:  
Glycerol.  
 
Preparation methods: Not stated. 
 
Time from preparation to transplant 
(fresh): 2 hours. 
 
Time period for storage (frozen): 1-4 
weeks.  
 
Route administered and frequency:  
Upper GI:  all via nasojejunal tube 
(originally placed endoscopically); 
lower GI: nil.   
 
Bowel purgative: Not described. 
 
PPI: Not described. 
 
Antimotility: Not described.  
 
Prokinetics: None. 
 
 
Donor FMT arm 
Meeting primary outcome: 
37% (n=11/30) (p=0.04). 
 
Meeting second outcomes: 
At least one more CSBM per 
week: 53% (n=16/30) 
(p=0.009). 
  
Number of CSBMs per 
week: 3.2+/-1.4. 
 
Stool consistency score:  
3.9+/-1.3. 
 
Colonic transit time (hours): 
58.5+/-9.8. 
 
Wexner constipation score: 
8.6+/-1.5. 
 
Quality of Life Assessment: 
Not described. 
 
Autologous FMT arm: 
Meeting primary outcome: 
13% (n=4/30)  
 
Meeting second outcomes: 
At least one more CSBM per 
week: 20% (n=6/30). 
 
Number of CSBMs per 
week: 2.1+/-1.2. 
 
Stool consistency score:  
2.4+/-1.1. 
 
FMT arm: 
50 in total (1 x sedation 
contraindications, x22 
endoscopy-related 
respiratory difficulty, x12 
nausea, x5 abdominal 
pain, x4 diarrhoea, x4 
flatulence, x2 transient 
fever). 
 
Placebo arm: 
x4 in total (x0 sedation 
contraindications, x0 
endoscopy-related 
respiratory difficulty, x0 
nausea, x3 abdominal 
pain, x0 diarrhoea, x1 
flatulence, x0 transient 
fever). 
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documented overt HE episodes 
requiring therapy. 
 
Exclusion criteria: At least 18 years, 
BMI of 18-25 kg/m2, and slow 
transit constipation defined as 
colonic transit time of >48hr, and 
symptoms unresponsive to dietary 
modification, enemas or 
biofeedback in the previous six 
months.  
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
Colonic transit time (hours): 
73.6+/-8.7. 
 
Wexner constipation score: 
12.7+/-2.5. 
 
Quality of Life Assessment: 
Not described. 
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Vrieze et al, 
Gastroenterology, 
2012 
Intervention: Donor FMT 
Number of patients: 9. 
Female: male 0: 9. 
Age (mean+/-SD): 47 +/- 4 years. 
 
Comparator: Autologous FMT.   
Number of patients: 9. 
Female: male 0: 9. 
Age (mean+/-SD): 53 +/- 3 years. 
 
Primary outcome:  Effect of 
lean donor gut microbiota infusion 
on insulin sensitivity 
after 6 weeks.    
 
Secondary outcomes:  Change in 
specific small- and large-gut 
microbiota as well as produced 
fecal short chain fatty acids 
 
Inclusion criteria:  Male Caucasian 
obese subjects with characteristics 
of the metabolic syndrome, 
specifically with a body 
mass index > 30 kg/m2, or waist 
circumference > 102 cm, 
and a fasting plasma glucose level > 
5.6 mmol/L.  
 
Exclusion criteria: History of 
cholecystectomy were excluded, as 
well as subjects who used any 
medication, probiotics, and/or 
antibiotics in the past 3 months. 
 
Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
Lean healthy Caucasian males (body 
mass index < 23 kg/m2. 
 
Working in healthcare: Not stated. 
 
Donor demographics: As above. 
 
Donor screening:  Questionnaires 
regarding diet and bowel habits, 
travel history, comorbidity including 
(family history of) diabetes 
mellitus, and lack of medication use. 
 
Screening blood tests:  Human 
immunodeficiency virus; human 
T-lymphotropic virus; hepatitis A, B, 
and C; cytomegalovirus; 
Epstein–Barr virus; Strongyloides; 
and amoebiasis. 
 
Screening stool tests: Presence of 
parasites (eg, Blastocystis hominis or 
Dientamoeba fragilis), Clostridium 
difficile, or other pathogenic 
bacteria (Shigella, Campylobacter, 
Yersinia, Salmonella) 
Amount of stool per transplant / 
administered to patients: Not stated. 
 
Diluent used to prepare: 500mls of 
normal saline. 
 
Diluent used to store if frozen:  N/A.  
 
Preparation methods:  Faeces was 
covered with sterile saline (500 ml 
0.9% NaCl) to reduce exposure to 
oxygen, transferred to a blender, and 
mixed for 10 minutes. The 
homogenized solution then was 
filtered twice through a clean metal 
sieve.  
 
Time from preparation to transplant 
(fresh): Same day. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered and frequency:  
Upper GI:  all via nasoduodenal tube 
(originally placed endoscopically); 
lower GI: nil.   
 
Bowel purgative: PEG solution. 
 
PPI: Not described. 
 
Antimotility: Not described.  
 
Prokinetics: None. 
 
 
Donor FMT arm: 
Median rate of glucose 
disappearance, Rd: from 
26.2 to 45.3 mol/kg/min; 
p<0.05). 
 
 
Autologous FMT arm: 
Median rate of glucose 
disappearance, Rd: from 
18.9 to 19.5 mol/kg/min). 
 
Quality of Life Assessment: 
Not described. 
 
Secondary outcomes:  No 
change in the total numbers 
of fecal bacteria (allogenic, 
from 10.8 +/- 0.2 to 11.0 +/-  
0.4 vs autologous, from 
11.6 +/- 0.6 to 11.3 +/-  0.4 
log10 bacteria/g faeces, non 
significant [NS]).  Fecal 
short-chain fatty acids 
decreased after  
allogenic gut microbiota 
infusion (median acetate 
from 49.5 to 37.6; p <0.05; 
butyrate, from 14.1 to 8.9; p 
< 0.05; and propionate, 
from 18.2 to 16.3 mmol/kg 
feces; NS). 
No adverse events 
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Kootte et al, Cell 
Metabolism, 
2017 
Intervention: Donor FMT 
Number of patients: 26. 
Female: male 0: 26. 
Age (mean): 54 years. 
 
Comparator: Autologous FMT.   
Number of patients: 12. 
Female: male 0: 12. 
Age (mean): 54 years. 
 
Primary outcome:  Change in 
intestinal microbiota composition 
upon FMT in relation to insulin 
sensitivity.    
 
Secondary outcomes: Post-prandial 
lipid, glucose excursions and 
plasma metabolites 
 
Inclusion criteria: All adult (age 21-
69 years) Caucasian males, who 
had obesity (body mass index (BMI) 
> 30 kg/m2), fulfilled the National 
Cholesterol Education Program 
(NCEP)-criteria for metabolic 
syndrome, were treatment-naive 
and who where otherwise healthy. 
 
Exclusion criteria: History of recent 
weight loss, cardiovascular event, 
cholecystectomy and the use of 
any medication known to influence 
gut microbial composition in 
the last three months (including 
proton pump inhibitors, antibiotics 
and pre-/pro-/synbiotics) or 
treatments targeting metabolic 
diseases. 
Lean healthy Caucasian males (body 
mass index < 25 kg/m2. 
 
Working in healthcare: Not stated. 
 
Donor demographics: As above. 
 
Donor screening:  Questionnaires 
regarding diet and bowel habits, 
travel history, comorbidity including 
(family history of) diabetes 
mellitus, and lack of medication use. 
 
Screening blood tests:  Human 
immunodeficiency virus; human 
T-lymphotropic virus; hepatitis A, B, 
and C; cytomegalovirus; 
Epstein–Barr virus; Strongyloides; 
lues and amoebiasis 
 
Screening stool tests: Pathogenic 
parasites (e.g., Blastocystis hominis, 
dientamoeba fragilis, giardia 
lamblia), bacteria (Shigella, 
Campylobacter, Yersinia, 
Salmonella, enteropathogenic E. coli 
and Clostridium difficile) or viruses 
(noro-, rota-, astro-, adeno 
(40/41/52)-, entero-, parecho- and 
sapovirus). 
Amount of stool per transplant / 
administered to patients: Not stated. 
 
Diluent used to prepare: 500mls 
ofnormal saline. 
 
Diluent used to store if frozen:  N/A.  
 
Preparation methods:  Faeces was 
covered with sterile saline (500 ml 
0.9% NaCl) to reduce exposure to 
oxygen, transferred to a blender, and 
mixed for 10 minutes. The 
homogenized solution then was 
filtered twice through a clean metal 
sieve.  
 
Time from preparation to transplant 
(fresh): Same day. 
 
Time period for storage (frozen): 
N/A. 
 
Route administered and frequency:  
Upper GI:  Single infusion all via 
nasoduodenal tube (originally placed 
endoscopically). A subgroup of 
patients receiving donor FMT had a 
second infusion; lower GI: nil.   
 
Bowel purgative: PEG solution. 
 
PPI: Not described. 
 
Antimotility: Not described.  
 
Prokinetics: None. 
 
Donor FMT arm: 
improved peripheral insulin 
sensitivity at week 6 (from 
25.8 to 28.8 mol/kg/min, , 
p < 0.05. This change was 
no longer significant at 
week 18 (including those 
that had a second infusion).   
 
Autologous FMT arm: 
FMT had no effect at week 
6 (from 22.5 to 20.8  
mol/kg/min, NS)  
 
Quality of Life Assessment: 
Not described. 
 
Secondary outcomes: No 
significant changes in fecal 
butyrate levels (butyrate 
from 13 to 20 mmol/g 
faeces, p = 0.096). Fecal 
acetate levels, however, 
were significantly increased 
from 62 to 85] mmol/g 
feces (p < 0.05) after 
allogenic FMT, whereas 
fecal proprionate was 
borderline signifi- cantly 
altered (from 23 to 28 
mmol/g faeces, p = 0.062). 
No adverse events 
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Cochrane Collaboration risk of bias 
assessment: low risk of bias. 
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Appendix D. Excluded clinical studies 
D.1. Clostridium difficile infection: 
D.1.1. Studies excluded at Sift 2 by working group: 
Paper: Grounds for exclusion: 
Allegretti JR, Allegretti AS, Phelps E, et al.  
Asymptomatic Clostridium difficile carriage rate post-
fecal microbiota transplant is low: a prospective 
clinical and stool assessment.  Clin Microbiol Infect 
2017; doi: 10.1016/j.cmi.2017.10.022 
Prospective case series of FMT for 
CDI, but insufficient patient data 
to fully populate data table (study 
primarily designed to evaluate C. 
difficile carriage post-FMT).   
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Appendix E. Peer review 
Healthcare Infection Society 
 Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: 
joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Closing date: 5pm on 18 January 2018 
Organisation Royal College of General Practitioners  
Title (e.g. Dr, Mr, Ms, Prof) Drs 
Name Clinical Adviser: Kevin Barrett 
Medical Director: Matthew Hoghton 
Job title or role As above 
Address and post code 30 Euston square, London, Nw1 2FB 
Telephone number 0203 188 7688 
Email address clinicaladvisers@rcgp.org.uk 
Please note: comments will only be accepted electronically on this proforma. 
 
Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are 
commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put ‘general’.  Add extra rows if 
required. 
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Section  Comments Working group response 
A This is an important consultation of an important treatment for recurrent or 
refractory CDI.  The recommendations are sensible and will help produce a 
universal service to patients across the UK.  
 
Thank you for your comment.   
B Hudson et al doi: 10.1128/CMR.00049-16Clin. Microbiol. Rev. January 2017 vol. 
30 no. 1 191-2311 January 2017 review suggests that faecal microbiotca 
transplant in the United States is used not only in refractory or recurrent 
Clostridium Difficile (CDI) but also in initial CDI and Ulcerative colitis 
 
We cannot find mention of FMT use as treatment for initial CDI 
in this review.  Updated searches have identified a small RCT 
evaluating the use of FMT as treatment for first CDI (Camacho-
Ortiz et al, 2017), and this is now evaluated by the working 
group within the guideline (Section 8.1.1.3). All published RCTs 
evaluating the use of the FMT as treatment for ulcerative colitis 
have been reviewed by the working group within the guideline 
(Section 8.6.2).     
C There is a lack of GP representation on the working group (5.6) and this is 
reflected in the consultation with a lack of a suggested referral pathway for 
community based patients 
 
We agree that the implications of this guideline for primary 
care were not well-described, and we have strengthened this 
within the guideline.  In particular, we have more strongly 
highlighted the responsibility of microbiology staff in clinical 
laboratories to liaise proactively with primary care teams 
regarding the possibility of FMT when recurrent positive stool 
samples are received from the community on a particular 
patient (Section 8.7.1).   
D There has also been a reported case of the development of obesity following 
FMT from an overweight donor but this has not been substantiated in other 
studies. The BMI restriction on donors (8.3.2) may restrict donors.  
 
The recruitment of suitable donors is relatively restrictive by 
necessity since FMT is an unlicensed and poorly-studied 
medicinal product.  There is a growing literature base 
demonstrating an association between a high or low BMI and 
perturbation of the structure and/or function of the gut 
microbiota and subclinical chronic inflammation. The 
implications of this for the safety and efficacy of FMT are not 
well-defined.  The suggested BMI range does not make it 
prohibitively difficult to find suitable donors.  As such, the 
working group believes that their existing recommendation is 
reasonable.   
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Section  Comments Working group response 
E It would be useful to have a standard UK pre and post questionnaire for patients 
to standardise recording (8.1.2.3) 
  
We agree that the introduction of standardised questionnaires 
would have clear potential advantages for clinical care and/ or 
research.  We now discuss this further in Section 10, ‘further 
research’.   
F It may useful to consider measuring the micriobiol strains of donors to monitor 
the impact of combinations of specific microbial strains to understand the 
undefined nature of faecal preparations 
We agree of the importance of this, and this is now discussed 
in more detail in Section 10, ‘further research’. 
G The lack of universal definitions of cures (8.1.2.4) is likely to hamper future 
studies 
 
We agree with this comment.  Section 10, ‘further research’ 
has been amended accordingly.  Furthermore, we expect that 
the attention generated by this guideline will highlight this 
inadequacy. 
H With the introduction of the clinical term SNOMECT across primary care in 2018 
and secondary care in 2020 it is important to record faecal microbiota transplant 
so that long term sequaelae can be measured and patients can be potentially 
contacted in the future.   
We agree that there should be specific procedure codes for 
FMT (according to route of administration), so that this can be 
accurately recorded in the patient’s medical record.  This would 
also lay the foundation for a future HRG code and tariff for the 
procedure which is not currently funded by CCGs.  Members of 
the working group are in discussion with NHS England about 
this.  
 
Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to consultations@his.org.uk 
 
 
 
Healthcare Infection Society 
 Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: 
joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.   
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Closing date: 5pm on January 2018 
Organisation NHS Highland 
Title (e.g. Dr, Mr, Ms, Prof) Dr 
Name Alex Cochrane 
Job title or role Consultant Microbiology and Infectious Diseases 
Address and post code Raigmore Hospital, Perth Road, Inverness IV2 3UJ 
Telephone number 01463 704000 
Email address Alexandra.cochrane@nhs.net 
Please note: comments will only be accepted electronically on this proforma. 
 
Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are 
commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put ‘general’.  Add extra rows if 
required. 
 
Section  Comments Working group response 
8.1.1.1 I dont think you should limit FMT for first recurrence to those with 
specific risk factors. If clinicians wish to use FMT rather than 
fidaxomicin for the first recurrence on cost effectiveness grounds 
then that is reasonable.  Suggest that you recommend FMT may be 
offered for the first or second or subsequent recurrences. 
As FMT is currently an unlicensed medicinal product with 
poorly-studied long term sequelae, the working group 
considered that it should generally be reserved for patients 
who have had more than three episodes of infection.  There 
are no studies directly comparing its effectiveness with some 
of the newer agents such as fidaxomicin or bezlotoxumab, 
hence this recommendation is made on the basis of safety.  
However, the working group felt that it may be reasonable in 
certain patient groups (with ongoing risk factors for further 
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Section  Comments Working group response 
recurrence) to offer FMT after the second episode.  Cost 
effectiveness analysis was outside the remit of the working 
group.  
8.1.1.3 (ii) I disagree that patients should have previously been treated with 
extended/pulsed vancomicin or fidaxomicin before being offered 
FMT.  You dont present any evidence to show that these antibiotic 
treatment is superior to FMT. Where FMT is the preferred treatment 
for the first recurrence it is quite likely that the patient will not have 
had a prolonged or tapered course, and this should not be a barrier 
to giving FMT which as you say is highly efficacious.  
As above, there are no studies comparing FMT to fidaxomicin 
or bezlotoxumab, and only one study comparing a 
vancomycin taper to FMT (Hota et al, 2017).  The safety 
profile of these medications is well-established from large 
randomised controlled trials, whilst randomised studies 
involving FMT have tended to be smaller, and have more 
variable patient follow-up.  As such, on the balance of safety, 
the working group agreed that antimicrobial/antitioxin 
therapy associated with reduced CDI recurrence should be 
considered prior to FMT.  Reflecting the uncertainties in this 
area within the reviewed literature, the relevant 
recommendation is ‘conditional’ rather than ‘strong’.   
8.1.1.3 (iii) You dont cite any evidence that fidaxomicin or bezlotoxumab have 
better cure rates than FMT.  My practice has been not to use 
fidaxomicin in life threatening C. difficile due to lack of evidence of 
efficacy in this setting, though I may be out of date with this. 
Pre-planned subgroup analysis of patients with severe CDI in 
a randomised trial demonstrated a significantly lower 
recurrence rate when treated with fidaxomicin (13.0%, 
n=12/92) than when treated with vancomycin (26.6%, 
n=29/209) (Louie et al, 2011); this finding was replicated in 
another randomised controlled trial, with 8.3% (n=4/48) and 
32.6% (n=14/43) experiencing a recurrence respectively 
(Cornely et al, 2012).  In a further randomised trial, 
bezlotoxumab (together with standard of care antibiotics) 
was shown to reduce recurrence of severe CDI compared to 
standard of care antibiotics alone (10.9% (n=6/55) vs 20% 
(n=13/65) respectively) (Wilcox et al, 2017).     
 
The working group noted that there are no studies comparing 
FMT to fidaxomicin or bezlotoxumab, and only one study 
comparing a vancomycin taper to FMT (Hota et al, 2017).  The 
working group agreed that in the absence of this evidence, on 
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Section  Comments Working group response 
the balance of safety and potential risks, consideration should 
be given to using antimicrobial/ antitoxin therapy associated 
with reduced CDI recurrence prior to considering the use of 
FMT.   
8.5.1.1 (iii) Is there adequate published material or experience to ensure the 
safety of loperamide?  It is usually avoided in C. difficile disease due 
To increased risk of complications. 
We agree that loperamide should not be used expressly for 
the treatment of CDI diarrhoea.  However, a number of 
studies (references within the guideline) have used a single 
dose of loperamide after lower GI FMT to retention, and no 
potential safety issues associated with this use have been 
identified.     
 
Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to consultations@his.org.uk 
 
 
 
Healthcare Infection Society 
 Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: 
joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Closing date: 5pm on January 2018 
Organisation NHS Lothian 
Title (e.g. Dr, Mr, Ms, Prof) Dr 
Name Ewan Olson 
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Job title or role Consultant Microbiologist 
Address and post code Royal Infirmary of Edinburgh 
51 Little France Crescent 
Edinburgh EH16 4SA 
 
Telephone number O131 2326048 
Email address ewan.olson@luht.scot.nhs.uk 
Please note: comments will only be accepted electronically on this proforma. 
 
Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are 
commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put ‘general’.  Add extra rows if 
required. 
 
Section  Comments Working group response 
8.3.4. Laboratory Screening of donors 
 
“Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively 
common in the community, they are of low pathogenicity, and 
screening for them was not felt to be justified.” 
 
VRE can cause life threatening infections that are difficult to treat. 
Any patient who is VRE positive requires isolation in a sideroom with 
ensuite facilities. 
 
I would suggest that donors should be screened for VRE before 
accepting stool  for donation. If there is a shortage of donor patients 
Whilst vancomycin-resistant Enterococci (VRE) carriage is 
relatively common in the community (probably related to 
food consumption) (Endtz et al, 1997), community strains of 
VRE are genetically distinct from (and generally of much lower 
pathogenicity than) those found nosocomially (Willems et al, 
2005); as such, the working group felt that routine screening 
was not justified.  However, the working group acknowledged 
that the potential infection risk from VRE (and MRSA) would 
vary regionally dependent upon local prevalence and 
pathogenicity, and as such recommended that a risk 
assessment was performed to assess whether screening for 
these organisms should be considered.   
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Section  Comments Working group response 
should be offered VRE positive donations only with informed 
consent. 
 
Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to consultations@his.org.uk 
 
 
 
 
Healthcare Infection Society 
 Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: 
joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Organisation On behalf of European Study Group for C. dificile (ESGCD), and the National Donor Feces Bank  at Leiden University 
Medical Center (drs. E. Terveer, drs. E. Boeije-Koppenol, prof. Hein Verspaget, dr. Y van Beurden, drs. R Ooijevaar, dr. 
Josbert Keller) and Department of Infectious Diseases, University of Koln (dr. Maria Vehreschild).  
Title (e.g. Dr, Mr, Ms, Prof) Prof. Dr.  
Name Ed Kuijper 
Job title or role Head of Experimental Bacteriology 
Address and post code LUMC, Albinusdreef2, 2333 ZA, Leiden 
Telephone number 31-71-5263574 
Email address e.j.kuijper@lumc.nl 
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Please note: comments will only be accepted electronically on this proforma. 
 
Closing date: 5pm on January 2018 
Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are 
commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put ‘general’.  Add extra rows if 
required. 
 
Section  Comments Working group response 
general The literature was searched until April 2017, but please use the 
recently published document of E.M Terveer et al.  entitled "How to: 
Establish and run a stool bank" and published in Clin Microbiol Infect. 
2017 Dec;23(12):924-930. This document has considerable overlap 
with the proposed guideline, but also shows some important 
unresolved issues. 
This reference has been added.  Literature searches have been 
updated, to January 2018.   
Lay summary, line 3 Capsules may also be prepared by use of non-freeze dried 
microbiota. Also, the possibility of using frozen products in general 
may be mentioned in this sentence.  
We agree that these changes are important, and these 
amendments have been accordingly.     
8.1.1.1 The authors are correct that CDI due to Type 07 responds less to FMT 
compared with CDI due to other PCR ribotypes. We register all 
infections by PCR ribotype to obtain more insights in successes and 
failures associated with strain characteristics and think that this is 
relevant for future recommendations, such as repeated FMT 
treatments for specific PCR ribotypes.  
We presume that this refers to ribotype 027, and agree that 
this is important, and further reference has been made to this 
in Section 10, further research.   
recommendation “FMT should be offered to patients with recurrent CDI who have had 
at least two recurrences, or those who have had one recurrence and 
have risk factors for further episodes, including severe CDI (strong).” 
Please elucidate how this risk assessment can be performed.  
The working party noted that these risk factors are well-
described in previous studies, and do not require further 
elucidation within the manuscript.    
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Section  Comments Working group response 
8.1.1.2 Refractory CDI is also considered as an indication for FMT. Can the 
authors please provide a recommendation on the number of FMTs 
that should be used? Are patients on Intensive Care Units with 
refractory CDI also eligible? in 8.2.1 IC admission can  be  considered 
as a contraindication,  but there are sufficient publications supporting 
to apply it for patients with severe CDI at ICU.   
In Section 8.2.1, the working group reviewed the literature on 
contraindications to receiving FMT, and noted that certain 
studies have made ‘admission to Intensive Care’ such a  
contraindication.  However, the working group have not 
themselves at any point stated that this is a contraindication to 
receiving FMT.   
 
As stated in Section 8.1.1.2, there are a relatively small number 
of cases reported in the reviewed literature of refractory CDI.  
As such, the working group are unable to give 
recommendations that patients with refractory CDI receiving 
FMT should be managed in any particular way differently to 
those with recurrent CDI.   
8.1.1.3 Antibiotic treatment of rCDI. Though the literature search was until 
April 2017, please mention the recent trials of tapered doses of 
vancomycin and fidaxomicin (PMID 29273269,  PMID: 28591789; 
PMID 29255732).  
We agree that these trials are all relevant, and have updated 
the guideline accordingly.   
 Recommendation II is less clear. How have the authors interpreted 
the literature that a tapered dosage of vancomycin before FMT 
increases the success rate of FMT? Are these studies also available 
for fidaxomicin? 
There are no studies comparing FMT to fidaxomicin or 
bezlotoxumab, and only one study comparing a vancomycin 
taper to FMT (Hota et al, 2017).  The safety profile of these 
medications is well-established from large randomised 
controlled trials, whilst randomised studies involving FMT have 
tended to be smaller, and have more variable patient follow-
up.  Furthermore, FMT remains (in the UK) an unlicensed 
medicine.  As such, on the balance of safety, the working group 
agreed that antimicrobial/ antitioxin therapy associated with 
reduced CDI recurrence should be considered prior to FMT.  
Reflecting the uncertainties in this area within the reviewed 
literature, the relevant recommendation is ‘conditional’ rather 
than ‘strong’.   
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Section  Comments Working group response 
 Recommendation iii is difficult to understand; do the authors 
recommend to treat severe and complicated CDI not with 
vancomycin, but with fidaxomicin or vanco+bezlo?  If a recurrence 
occurs, then followed by a FMT?    
The wording of this recommendation has been amended, along 
with expansion of the explanatory text of Section 8.1.1.4. 
 A recommendation for FMT treatment in severe (refractory), 
complicated CDI is missing (e.g. multiple sequential FMTs); should 
this also be accompanied with anti-CDI antibiotics? See review v. 
Beurden, Ther Advances in Gast, 2017 and Fischer, Ali Pharm Ther 
2015 
As stated in Section 8.1.1.2, there are a relatively small number 
of cases reported in the reviewed literature of refractory CDI.  
As such, the working group are unable to give 
recommendations that patients with refractory CDI receiving 
FMT should be managed in any particular way differently to 
those with recurrent CDI.   
8.1.2.1 We suggest to differentiate between "non-responding" and "late 
failure". The latter can be defined as a relapse of CDI after an initial 
response to FMT. For instance, use of antibiotics in the first month 
after FMT may provoke a new episode of CDI. This new episode 
doesn’t need a FMT and can be treated with conventional anti-CDI 
treatment, preferably microbiota sparing such as fidaxomicin.        
We agree that this distinction is useful, and have amended the 
guideline accordingly.   
8.1.2.2 Should a psychological questionnaire routinely be taken from 
recipients (before and after FMT) and from donors (regularly)? A ten-
week follow-up is too short to recognize long term side-effects of 
FMT.   
The working group did not consider that this was a priority.   
8.1.2.3 We consider swallowing disorders a contraindication for upper GI 
delivery; death of a patient due to aspiration pneumonia with upper 
GI delivery has been described (PMID: 29026601); this patient had a 
swallowing disorder following oropharyngeal radiation after surgical 
removal of a maxillary carcinoma.  
We note that this patient received a very large volume (500ml) 
of nasoduodenal FMT. This guideline recommends a much 
lower maximum volume with the specific aim of minimising this 
problem.  Nevertheless, we agree that this is an important 
consideration, and have amended Section 8.1.2.3 and Section 
8.5.2.2 accordingly.   
8.2.1 What is the advice of the committee for coeliac patients with 
recurrent CDI? 
The working group did not have any specific advice regarding 
patients with coeliac disease.   
8.2.2 FMT in immunocompromised patients:  we think that the presence 
of neutropenia (<0.5 × 109/L) can be considered as a contraindiction 
for FMT, especially if hematological patients are treated with 
The working group have recommended that FMT is offered 
‘with caution’ to immunosuppressed patients, reflecting the 
careful individualised assessment required for each patient.  
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Section  Comments Working group response 
selective gut decontamination to prevent translocation and 
infections with aerobe Gram-negatives.  Second, should donors and 
immunocompromised recipients be matched for the EBV and CMV 
status to prevent a herpesvirus infection?  
 
We agree with the comment regarding matching donors and 
immunosuppressed recipients for EBV and CMV status, and 
have updated Section 8.2.2 and Section 8.3.4 accordingly.  
8.2.3 The effect of FMT on the IBD status for IBD patients with rCDI is under 
discussion. Is it possible that FMT will result in cure of CDI but an 
exacerbation of IBD.  Should we differentiate UC from CD?  Ref 71 
suggests that IBD can worsen. The recommendation "strong" is 
debatable.  Is the IBD group not a better candidate for vancomycin 
tapering, fidaxomicin (tapering) or bezlotoxumab before FMT is 
given? 
We agree that there is evidence that FMT to treat CDI in 
patients with IBD may be associated with a flare of IBD activity 
(Qazi et al, 2017); we have updated the recommendation 
accordingly.   
8.3.2  Age and BMI of the donor. We agree with the BMI of the donor but 
have some difficulties with the age, We consider an age above 50 as 
a contraindication, based on the risks to develop colon carcinoma 
and metabolic (diabetes) diseases. Additionally, older people seems 
to have a less stable gut microbiota. 
We note from a recent paper that Bacteroides: Firmicutes ratio 
and microbial diversity were similar in donors > 60 years 
compared to younger donors, and donations from older donors 
had similar efficacy and no higher rate of adverse outcomes 
(Anand et al, 2017).  As such, the working group agreed to 
uphold their prior recommendation.   
8.3.3. Donor screening history. Donors should also undergo a long term 
follow-up to recognize microbiota related diseases, including colon 
malignancies, autoimmune diseases, metabolic diseases and 
psychiatric illnesses. 
We agree with the principle of this statement, and allude to this 
in Section 8.7.7. 
 Please consider to add to  the recommendation/evidence: Potential 
donors should be extensively screened by a questionnaire and a 
personal interview concerning risk factors for transmissible diseases 
and factors influencing the intestinal microbiota 
We agree with this suggestion, and have amended Section 
8.3.3 accordingly.   
8.3.4  Screening of the donor. Table 4. The Dutch guideline advises 
screening donors for multi-drug resistant bacteria (MDR), including 
VRE, MRSA, CPE and ESBL-producing Gram-negatives, and 
quinolone/aminoglycoside resistant Enterobacteriaceae. Most of the 
patients with rCDI have much comorbidity and are frequently 
hospitalized or encounter nosocomially acquired infections, such as 
The working group reviewed their recommendation regarding 
screening for multi-drug resistant bacteria, and Section 8.3.4 
has been updated accordingly.   
 
We agree with the principle of a ‘window period’/ quarantine 
prior to repeat donor screening in centres using frozen FMT; 
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Section  Comments Working group response 
UTI. Infections with MDR are more difficult to treat, mostly with 
intravenously administered antibiotics. If these patients become 
colonized with MDR they should be nursed with specific infection 
control precautions.  We also apply a "window period"; donors stools 
samples are stored in quarantine for 2 months and only become 
available after a negative second screening. 
 
We additionally screen for: Yersinia enterocolitica, Yersinia 
pseudotuberculosis, Plesiomonas shigelloides, shiga toxin producing 
E. coli (not only 0157 E.coli), Astrovirus, Sapovirus, Adenovirus, 
Enterovirus, Parechovirus, Hepatitis E, Entamoeba histolytica, 
Microsporidium species, Blastocystis hominis, Dientamoeba fragilis, 
and Strongyloides (if a travel history to Middle and South America, 
Africa, or Asia is present). 
 
We advise to include carriership of E. histolytica and Strongyloides to 
the mandatory screening, because of the serious infections that 
occur in immunocompromised patients.  We have detected 
unexpectedly a donor carrying E. histolyica (Terveer, CMI, 2017).  
Section 8.3.5 has been updated accordingly, and a new flow 
chart to illustrate the process (Figure 1) added.  
 
 
 
 
 
The working group agreed that recommendations should be 
made to test for Shiga toxin-producing Escherichia coli, 
hepatitis E IgM, Entamoeba histolytica serology and 
Strongyloides stercoralis IgG (Table 3).  However, the working 
group consensus was that screening with the other tests 
suggested is not justified.   
 
 
 
 
 
 
 
8.4.1 Recommendation i. Please elucidate how donors should deliver their 
stools. We favour the use of specific device systems to prevent 
contamination with environmental microorganisms.   
Recommendation ii. Processing within 6 hours is proven effective, 
consider changing ‘conditional’ to ‘strong’ recommendation 
Recommendation iii. A meta-analysis concludes that lless than 50 
gram of feces is related to a 4-fold increase in recurrence rates. The 
recommendation status should be changed to ‘strong’. 
i. We think that the text as it stands gives sufficient 
information about best practice in this area. 
ii. We agree with this suggestion, and have amended 
Section 8.4.1 accordingly. 
iii. We agree with this suggestion, and have amended 
Section 8.4.1 accordingly.  
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Section  Comments Working group response 
8.4.2 An important advantage of frozen FMT is the possibility to use a 
“window period” of, for example, two months.  When donors are 
screened after this window period, the results determine if the 
stored FMTs can be used.   
We have cross-referenced Section 8.4.2 to Section 8.3.5, 
where the concept of a window period/ quarantine is discussed 
in more detail.   
8.4.3 We think that there is not enough evidence to state that feces 
suspensions can only be used up to six months from preparation. 
There is no sufficient data that show a decreased efficacy with feces 
suspensions stored over 6 months. Additionally, multiple stool banks 
set the expiration date at 1 year after storage.    
A trend towards decrease in the viability of certain gut bacterial 
groups was noted when faecal aliquots were frozen in 10% 
glycerol for six months (Costello et al, Alimentary Pharm & 
Ther, 2015), and as such, the working group agreed that six 
months was the acceptable limit for freezing of an FMT in 
glycerol.  This rationale is now within the text.   
 Good practice point: Thawing overnight in a 4C refrigerator is also a 
good and much used alternative. 
None of the working group had sufficient experience with this 
means of thawing FMT, and as such were unable to make this 
good practice point.   
8.5.1.1. It is not clear, why the administration of a bowel lavage in upper GI 
administration, of PPI, of loperamide and of metroclopramide are 
recommended. There is no evidence to support their use, and all of 
them are drugs with known side effects. The only reason why they 
are used is that the first RCT used them. However, the RCT did not 
assess their importance, and there are many case series showing that 
FMT has a high success rate even without their use.  
All of these interventions have a clear biological or practical 
rationale for their use. Significant side effects in association 
with a single dose of these medications are generally rare, and 
their use has not been associated with adverse outcomes in 
FMT studies.  Our recommendations for their use are only 
conditional.  As such, the working group uphold their 
recommendations.  
8.5.2.1. Not all capsules necessarily contain lyophylized microbiota, frozen 
preparations have also been shown to be effective. 
We agree with this comment, and have updated the guideline 
accordingly.   
8.5.2.2  Are there studies indicating that 50 ml for upper gastrointestinal have 
comparable efficacy as 250 ml?  If not, this should be more 
pronounced mentioned, also in the research session. We use at least 
50 gram suspended in 200 ml and a slow infusion of 10cc/min.           
As described in the text, the working group considered that 
mass of stool was a more important consideration than volume 
of diluent.  They also noted that as low as 25ml of FMT has been 
demonstrated to be effective as upper GI FMT (Aas et al, Clin 
Infect Dis, 2003).  However, the working group revised their 
decision, and now recommend 100ml as the threshold volume 
for upper GI FMT administration.     
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Section  Comments Working group response 
8.5.2.4. The recommendation not to use capsules seems rather strong. It is 
unlikely that concerning transmission of infection, the risk would 
differ in any way from other ways of administration. Also, no safety 
concerns based on endoscopic complications can possibly arise. We 
would therefore not pronounce a recommendation against use.  
We agree with this statement.  Of note, whilst the Kao et al, 
2017 study (RCT of capsulised vs colonoscopic FMT) was not 
published at the time of initial searches, it has been identified 
by updated searches and has now been reviewed by the 
working group.  As such, the guideline has been updated 
accordingly.   
8.6  Consider to add that specific donor microbiota  may have better 
outcomes  (e.g. donor B in Moayyedi, gastroenterology, 2015)  
FMT for other conditions than rCDI. Why have the authors not 
included the role of FMT to eradicate MDR from the intestinal tract? 
Reference to Donor B in this paper has been added to Section 
8.6.2.2. 
 
In keeping with NICE methodology, for the consideration of 
FMT as treatment for non-CDI conditions, only RCTs could be 
considered.  The working group are aware of case studies and 
case series using FMT to attempt gut decolonisation of 
multidrug resistant microorganisms. Members of the working 
party have themselves contributed to the literature in this field. 
But no RCTs currently exist.   
8.6.3. Consider adding:  characterisation of specific CU patient population 
that would potentially benefit from FMT. “However, 
recommendations for clinical use for this indication cannot be made 
until there is clearer evidence of the most appropriate CU patient 
characteristics, methodology for its preparation, route of delivery, 
and intensity of administration of FMT”  
We agree with this comment, and have updated the guideline 
accordingly.   
8.7.2 and 8.7.4 FMT is considered as a medicinal product under supervision of MHRA 
and licensing should follow the GMP guidelines. The activities should 
be performed in a dedicated containment level 2 laboratory with 
personal protective equipment and a quality assessment system.  
Does this indicate that FMTs should be prepared under GMP 
conditions at the Pharmacy Department and not within the Medical 
Microbiology? Or is this statement too strong?   
No.  MHRA guidance does not specify where the manufacture 
should take place.  This could be pharmacy, the microbiology 
laboratory, or another place.   
 
8.7.6 Please consider to add that aliquots of donor FMT materials (and 
original feces samples) used for patients treatment should be stored, 
We agree, and we have updated Sections 6.3 and 8.7.6 
accordingly.  
Page 428 of 454
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
261 
 
Section  Comments Working group response 
enabling to use these samples when adverse effects after FMT 
developed. This should also been included in 6.3 (auditing).   
 Table 4 PCRs are more sensitive than conventional microscopy and antigen 
tests for parasites. Second, can the authors please specify the 
parasites? There is some debate on the significance of Blastocystes 
spp. and Dientamoeba spp. Why is only E. coli 157 excluded and not 
other STEC pathogens?  
Table 4 has been updated to specify Shiga toxin-producing 
Escherichia coli screening by PCR.  The working group did not 
consider that specific screening for Blastocystis spp or 
Dientamoeba spp was justified.   
Propose to add: 
Eligibility of patients for 
FMT  
At the NDFB, all requests by the treating physician are evaluated by 
at least two clinical members of our feces bank board to determine 
the eligibility of the patient. It is required that patients have a 
laboratory documented episode of recurrent CDI following at least 
one course of adequate CDI antibiotic therapy.  Recurrent CDI is 
defined as the re-appearance of diarrhoea (≥ 3 unformed stools per 
24 hours for two consecutive days; or ≥ 8 unformed stools per 48 
hours) within eight weeks after cessation of antibiotic therapy in 
combination with a positive diagnostic test for C. difficile. We strongly 
recommend a two-stage testing algorithm, as recently advised by the 
C. difficile working group/ESCMID (ESGCD).  Using this algorithm, we 
reject approximately 20% of all requests for FMT. We would like to 
add our experience that of 79 candidate patients for FMT, only 75% 
were considered as suitable candidates for FMT treatment; most 
rejected requests were patients with underlying IBD who 
concomitantly carried C. difficile. 
Thank you for this comment.  Definitions of recurrent CDI are 
outside of the remit of this working group.  Testing is discussed 
in Section 8.1.1., where we refer to current ESCMID guidance.   
Need for antimicrobial 
stewardship after FMT 
(also for 8.5.1.3)  
After FMT, we advise that an infectious disease specialist or medical 
microbiologists should be involved for antibiotic treatment (or 
prophylaxis) of the patient during the first month after FMT, since 
50% of our registered failures were patients who received antibiotics 
within one month after FMT. Interestingly, all patients responded to 
conventional anti-CDI treatment and did not need a second FMT.  It 
can be considered to use microbiota sparing fidaxomicin after FMT.    
We agree with this comment, and have updated Section 
8.5.1.3 accordingly.   
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Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to consultations@his.org.uk 
 
 
 
Healthcare Infection Society 
 Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: 
joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Closing date: 5pm on January 2018 
Organisation OpenBiome 
Title (e.g. Dr, Mr, Ms, Prof) Dr 
Name Majdi Osman 
Job title or role Clinical Program Director, OpenBiome; Visiting Assistant Professor, Harvard Medical School 
Address and post code 200 Inner Belt Road, Somerville, MA 02143 
Telephone number +1 (617) 575-2201 
Email address majdi@openbiome.org 
Please note: comments will only be accepted electronically on this proforma. 
 
Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are 
commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put ‘general’.  Add extra rows if 
required. 
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Section  Comments Working group response 
8.1.1.1. Recurrent 
Clostridium difficile 
infection 
“FMT should be offered to patients with recurrent CDI who have 
had at least two recurrences, or those who have had one recurrence 
and have risk factors for further episodes, including severe CDI 
(strong).” 
 
We agree however for full clarity we would recommend re-wording 
to: 
 
“FMT should be offered to patients with recurrent CDI who have 
had at least two recurrences, or those who have had one recurrence 
and have risk factors for further episodes, including severe and 
severe-complicated CDI (strong).” 
We agree with this statement, and have updated the 
guideline accordingly.   
8.1.1.2. Refractory 
Clostridium difficile 
infection: 
“FMT should be considered in cases of refractory CDI (conditional).” 
 
We agree. 
Thank you for this comment.  
8.1.1.3. Antimicrobial 
therapy prior to 
considering FMT for 
patients with CDI: 
i. FMT for recurrent CDI should only be considered after 
failure of antimicrobial anti-C. difficile therapy which has 
been administered for a minimum of 10 days (conditional). 
ii. Recipients of FMT as treatment for recurrent CDI should 
have previously been treated with extended/ pulsed 
vancomycin and/or fidaxomicin (conditional).  
iii. For those with severe or complicated CDI, which appears to 
be associated with reduced cure rates, consideration should 
be given to offering patients treatment with medications 
which are associated with reduced risk of recurrence (e.g. 
fidaxomicin and bezlotoxumab), before offering FMT 
(conditional). 
 
We suggest rewording point iii, that recommends fidaxomicin or 
bezlotoxumab should be offered to patients with severe or 
Pre-planned subgroup analysis of patients with severe CDI in 
a randomised trial demonstrated a significantly lower 
recurrence rate when treated with fidaxomicin (13.0%, 
n=12/92) than when treated with vancomycin (26.6%, 
n=29/209) (Louie et al, 2011); this finding was replicated in 
another randomised controlled trial, with 8.3% (n=4/48) and 
32.6% (n=14/43) experiencing a recurrence respectively 
(Cornely et al, 2012).  In a further randomised trial, 
bezlotoxumab (together with standard of care antibiotics) 
was shown to reduce recurrence of severe CDI compared to 
standard of care antibiotics alone (10.9% (n=6/55) vs 20% 
(n=13/65) respectively) (Wilcox et al, 2017).     
 
The working group noted that there are no studies comparing 
FMT to fidaxomicin or bezlotoxumab, and only one study 
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Section  Comments Working group response 
complicated CDI before FMT. There is little evidence on the role of 
bezlotoxumab and fidaxomicin in severe or severe-complicated CDI. 
Although the evidence base is similarly lacking for FMT in severe or 
severe-c mplicated disease, there is a growing body of evidence 
from trials, multiple case series and reports indicating the potential 
for FMT in this population. 
 
Bezlotuxumab: The performance of bezlotuxumab has not been 
evaluated in a severe or severe-complicated population. Results 
from MODIFY I and II suggest a modest 10% improvement in rates of 
sustained cure with bezlotoxumab. Importantly, only 15.6% were 
severe CDI. Based on the modest gains in efficacy and the few 
severe/severe-complicated patients in the MODIFY trials, we feel 
that further evidence is required before proposing bezlotuxumab be 
offered ahead of FMT in this patient population. 
 
In comparison, across similar patient populations FMT has 
demonstrated in several randomized controlled trials reduced risk of 
recurrence. Based on the available evidence we therefore feel that 
the statement that bezlotuximab is “associated with reduced risk of 
recurrence” compared to FMT is not supported by the evidence. 
 
Fidaxomicin: Similarly, there is a dearth of evidence on the role of 
fidaxomicin in the severe CDI population. We agree that it has 
demonstrated superior efficacy compared to vancomycin in the 
general CDI population. In an RCT comparing extended-pulsed 
fidaxomicin versus vancomycin for CDI, Guery et al (2017) observed 
increased recurrence in severe CDI compared to non-severe CDI with 
an odds ratio 0.57 (95% CI 0·36–0·91) p=0.019. We therefore 
recommend that fidaxomixin should be offered to patients with 
severe CDI. However, there is no evidence to suggest that the 
comparing a vancomycin taper to FMT (Hota et al, 2017).  The 
working group agreed that in the absence of this evidence, on 
the balance of safety and potential risks, consideration should 
be given to using antimicrobial/ antitoxin therapy associated 
with reduced CDI recurrence prior to considering the use of 
FMT.   
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Section  Comments Working group response 
performance of fidaxomicin would be better than FMT. We 
acknowledge that access to fidaxomicin is likely to be more timely in 
settings where FMT is not readily available. 
 
The role of FMT in severe CDI: In their recent review, Van Beurden 
et al (2017) reviewed the literature on FMT in severe CDI and found 
23 reports (12 case reports; 11 case series) about FMT as treatment 
for severe or complicated CDI. The patients described (n=200) all had 
severe or complicated CDI, did not respond to conventional CDI 
antibiotic treatment and received FMT as last resort treatment. In all 
studies, patients were treated with (sequential) FMT, whether or not 
followed by additional antibiotic treatment for CDI. FMT, with or 
without additional antibiotic CDI treatment, appears to be a 
promising curative treatment option in patients with severe and 
complicated CDI who do not respond sufficiently to conventional 
antibiotic treatment. FMT has been proposed by Fischer et al (2015) 
as an option utilizing an endoscopic response-guided approach, 
which may be particularly useful in non-surgical candidates. In an 
open-label cohort study (n = 17), FMT was delivered by colonoscopy. 
If pseudomembranes were identified, patients reinitiated oral 
vancomycin 24 hour after FMT and continued for 5 days. A repeat 
FMT by colonoscopy was given on day 7. If pseudomembranes 
persisted, vancomycin was restarted the following day for a 5 days 
course and a third FMT was offered on day 13. If pseudomembranes 
were absent during any colonoscopy, no further therapy was 
initiated. The results were promising with a combined clinical cure 
rate of 88%. 
 
In conclusion, we agree that there is a lack of evidence available to 
make a strong recommendation on the role of FMT in severe CDI. 
However, there is insufficient evidence to suggest that fidaxomicin 
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Section  Comments Working group response 
or bezlotuximab would be superior to FMT in this population. On the 
contrary, the growing pool of experience in using FMT in severe and 
severe-complicated CDI patients demonstrates that it appears to be 
generally safe and effective (quality of evidence:  3).  
 
We would therefore suggest re-wording point iii to: 
 
iii. For those with severe or complicated CDI, which appears to be 
associated with reduced cure rates, consideration should be given 
to offering patients treatment with medications which are 
associated with reduced risk of recurrence (e.g. fidaxomicin or 
bezlotuxumab), or offering FMT (conditional). 
 
Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota 
transplantation plus selected use of vancomycin for severe-
complicated Clostridium difficile infection: description of a protocol 
with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. 
doi:10.1111/apt.13290. 
 
Van Beurden YH, Nieuwdorp M, van de Berg PJEJ, Mulder CJJ, 
Goorhuis A. Current challenges in the treatment of severe 
Clostridium difficile infection: early treatment potential of fecal 
microbiota transplantation. Therapeutic Advances in 
Gastroenterology. 2017;10(4):373-381. 
doi:10.1177/1756283X17690480. 
8.1.2.1. Management of 
FMT failure: 
Further FMT should be offered after initial FMT failure (strong). 
 
We agree. 
Thank you for this comment.  
8.1.2.2. General 
approach to follow-up 
post-FMT: 
All FMT recipients should routinely receive follow-up.  Given the 
relative novelty of FMT and the potential for unexpected sequelae, 
clinicians should follow-up FMT recipients for long enough to fully 
Thank you for this comment.  In light of other comments from 
the working group and stakeholders, this follow-up period has 
been adjusted to ‘at least eight weeks in total’.   
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Section  Comments Working group response 
establish efficacy/ adverse events, and at least ten weeks in total 
(strong).   
 
We agree. 
8.1.2.3. Management of 
the FMT recipient: 
i. Immediate management after endoscopic administration 
of FMT should be as per endoscopy unit protocol (strong).   
ii. Patients shoul  be warned about short term adverse 
events, in particular the possibility of self-limiting GI 
symptoms. They should be advised that serious adverse 
events are rare (strong).  
iii. After enteral tube administration, patients may have the 
tube removed and oral water given from 30 minutes post-
administration (strong). 
 
We agree. 
Thank you for this comment.  
8.1.2.4. Definition of 
cure post-FMT for CDI: 
A decision regarding cure/remission from CDI should be recorded 
during follow-up. However, this has no uniformly-agreed definition, 
and should be decided on a case-by-case basis (strong). 
 
We agree. 
Thank you for this comment.   
8.1.2.5. Definition of 
treatment failure post-
FMT for CDI: 
Treatment failure/recurrence should be defined on a case-by-case 
basis.  Routine testing for C. difficile toxin after FMT is not 
recommended, but is appropriate to consider in the case of 
persistent CDI symptoms/suspected relapse (strong).   
When testing is to be performed, we would recommend clinicians 
follow the 2016 European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) guidelines for CDI testing, which state 
that no single commercial test can be used as a stand-alone test for 
diagnosing CDI, and recommend a 2-step approach (highly sensitive 
with reflex to highly specific test). These guidelines recommend 
performing an initial test with a high negative predicative value; 
We agree on the use of ESCMID guidelines in CDI testing, and 
refer to these clearly in Section 8.1.1.1.  However, Section 
8.1.2.5 specifically refers to diagnosing failure post-FMT for 
CDI rather than initial diagnosis of CDI, and no good uniform 
definition exists for this.  We think that the guidance given, to 
define treatment failure on a case-by-case basis, is the most 
fair summary of the current literature on this topic.   
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Section  Comments Working group response 
therefore, if negative, no further testing needs to be done. 
Specifically, they suggest glutamate dehydrogenase (GDH) EIA or 
NAAT/PCR testing. Our recommendation is GDH EIA as it is less 
expensive and has a slightly superior NPV at higher CDI prevalence 
compared with NAAT/PCR (98 vs 96 at hypothetical CDI prevalence 
of 50%), and an NPV of 100% at lower CDI prevalence. The second 
test should be a test with a high positive predictive value, such as EIA 
for toxin A/B. Obtaining CDI testing at each suspected CDI recurrence 
and working with institutional laboratories to use an appropriate 
testing algorithm is a key component to ensuring appropriate patient 
selection for FMT. 
 
As currently worded, the recommendations risk encouraging over 
testing in a context where patients may develop post-infectious IBS. 
This concept is highlighted by evidence suggesting that up to 25% of 
patients referred to an FMT center for “C difficile infection” were 
found to have an alternative diagnosis, with younger patients being 
more likely to have a non-CDI diagnosis (Jackson 2016). 
 
Jackson M, Olefson S, Machan JT, Kelly CR. A high rate of alternative 
diagnoses in patients referred for presumed clostridium difficile 
infection. J Clin Gastroenterol. 2016 Oct;50(9):742-6. 
8.2.1. General approach 
to co-morbidities and 
FMT: 
FMT should be offered with caution in patients with 
decompensated chronic liver disease and should be avoided in 
those with anaphylactic food allergy (strong). 
 
The authors may want to consider the approach recommended by 
Allegretti et al (2017). In patients with a severe food allergy, a 
potential option for FMT could be from a patient identified donor 
living with the patient (e.g. spouse) who avoids the same allergens. 
 
The working group thought it important to emphasise the 
‘good practice point’ that in patients with true anaphylaxis, 
the risks of FMT administration were likely to outweigh the 
benefits.  As such, this suggestion has not been incorporated.   
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Section  Comments Working group response 
Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 
5D framework: a clinical primer for fecal microbiota transplantation 
to treat <em>Clostridium difficile</em> infection. Gastrointest 
Endosc [Internet]. 2017 Jul 26; Available from: 
http://dx.doi.org/10.1016/j.gie.2017.05.036 
8.2.2. 
Immunosuppression 
and FMT: 
FMT should be offered with caution to immunosuppressed patients, 
in whom FMT appears efficacious without significant additional 
adverse effects (strong). 
 
We agree. 
Thank you for this comment.  
8.2.3. Other co-
morbidities and FMT: 
Recommendation:   
i. FMT should be offered to those with recurrent CDI and 
inflammatory bowel disease (strong).    
ii. FMT should be considered for appropriate patients with 
recurrent CDI regardless of other comorbidities 
(conditional). 
 
We agree. 
Thank you for this comment.  
8.3.1. General approach 
to donor selection: 
Related or unrelated donors should both be considered acceptable.  
However, where possible, FMT is best sourced from a centralised 
stool bank, from a healthy unrelated donor (conditional). 
 
We agree. 
Thank you for this comment. 
8.3.2. Age and BMI 
restrictions for 
potential donors: 
People should only be considered as potential FMT donors if they 
are ≥18 and ≤60 years old, and have a BMI of <30 kg/m2 
(conditional).   
 
We agree. 
Thank you for this comment.   
8.3.3. General approach 
to the donor screening 
assessment: 
A donor-screening history/ questionnaire is mandatory (Table 2) 
(strong). 
1. Receipt of antimicrobials within the past three months. 
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Section  Comments Working group response 
2. Known prior exposure to HIV and/ or viral hepatitis, and 
known previous or latent tuberculosis. 
3. Risk factors for blood-borne viruses - including high risk 
sexual behaviours, use of illicit drugs, any tattoo/ body 
pierci g/ needlestick injury/ blood transfusion/ 
acupuncture, all within previous six months. 
4. Receipt of a live attenuated virus within the past six 
months.   
5. Underlying gastrointesti al conditions (e.g. history of IBD, 
IBS, chronic diarrhoea, chronic constipation, coeliac 
disease, bowel resection or bariatric surgery). 
6. Family history of any significant gastrointestinal conditions 
(e.g. family history of IBD, or colorectal cancer).  
7.  History of atopy (e.g. asthma, eosinophilic disorders). 
8. Any systemic autoimmune conditions. 
9. Any metabolic conditions, including diabetes and obesity. 
10. Any neurological or psychiatric conditions, or known risk of 
prion disease.  
11. History of chronic pain syndromes, including chronic fatigue 
syndrome and fibromyalgia.  
12. History of any malignancy.   
13. Taking particular regular medications, or such medications 
within the past three months, i.e. antimicrobials, proton 
pump inhibitors, immunosuppression, chemotherapy  
14. History of receiving growth hormone, insulin from cows, or 
clotting factor concentrates. 
15. History of receiving an experimental medicine or vaccine 
within the past six months.    
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Section  Comments Working group response 
8.3.4. Laboratory 
screening of potential 
donors: 
Blood and stool screening of donors is mandatory (Tables 2 and 3) 
(strong). 
Table 3:  Recommended blood screening for stool donors: 
Pathogen screening: 
• Hepatitis A IgM 
• Hepatitis B (HBsAg and HBcAb) 
• Hepatitis C antibody 
• Hepatitis E IgM 
• HIV -1 and -2 antibodies 
• HTLV-1 and -2 antibodies 
• Treponema pallidum antibodies (TPHA, VDRL) 
• Epstein-Barr virus IgM 
• Cytomegalovirus IgM 
• Strongyloides stercoralis IgG 
• Entamoeba histolytica serology 
 
General/ metabolic screening: 
• Full blood count with differential. 
• Creatinine and electrolytes 
• Liver enzymes (including albumin, bilirubin, 
aminotransferases, gamma-glutamyltransferase and 
alkaline phosphatase). 
• C-reactive protein 
 
Table 4:  Recommended stool screening for stool donors: 
• Clostridium difficile PCR 
• Campylobacter, Salmonella, and Shigella by standard stool 
culture and/ or PCR 
• Escherichia coli 0157 H7 by culture and/or PCR 
We agree with the comment regarding matching donors and 
immunosuppressed recipients for EBV and CMV status, and 
have updated Section 8.2.2 and Section 8.3.4 accordingly. 
 
The working group did not think that screening for adenovirus 
was justified.   
 
Whilst vancomycin-resistant Enterococci (VRE) carriage is 
relatively common in the community (probably related to 
food consumption) (Endtz et al, 1997), the form of VRE in the 
community is genetically distinct from that found 
nosocomially, with much lower pathogenicity in community 
forms (Willems et al, 2005). As such, the working group 
strongly opined that routine screening was not justified.  
However, it was acknowledged that the potential infection 
risk from VRE (and MRSA) would vary regionally depending on 
local prevalence and pathogenicity, and as such a local risk 
assessment has been recommended to decide whether 
screening for these organisms should be considered.   
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Section  Comments Working group response 
• Multi-drug resistant bacteria, specifically carbapenemase-
producing Enterobacteriaceae. 
• Stool ova, cysts and parasite analysis, including for 
Microsporidia.  
• Faecal antigen for Cryptosporidium and Giardia.  
• Acid fast stain for Cyclospora and Isospora.  
• Helicobacter pylori faecal antigen. 
• Norovirus and Rotavirus PCR.  
 
We recommend: 
 
CMV and EBV: Given the high rates of carriage for both EBV and CMV 
in a healthy, adult population, excluding EBV or CMV positive donors 
would make it prohibitively difficult to identify suitable donors to 
provide access to care (Bate et al). Moreover, excluding EBV o  CMV 
positive candidates is not expected to provide a significant benefit to 
the majority of the patients that would be served by a centralized 
stool bank, who are not severely immunocompromised.  
 
Given the need to ensure a reliable supply of material for the vast 
majority of rCDI patients while protecting severely 
immunocompromised patients, until now OpenBiome has chosen 
not to test for EBV and CMV. Instead, we treat material as 
presumptively CMV and EBV positive and discourage use in severely 
immunocompromised patients who are seronegative for CMV or 
EBV.  
 
We are sensitive to the fact that this leaves clinicians with an 
additional challenge for managing these already difficult cases 
(severely immunocompromised rCDI patients). Should FMT be 
indicated then we would suggest that in the immunocompromised 
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Section  Comments Working group response 
patient at risk of CMV or EBV infection either: 1) CMV and EBV 
testing of the recipient to confirm positive serology, in which case 
FMT may be considered after extensive discussion of the risks, 
benefits, and alternatives in the informed consent process; or 2) the 
use of a directed donor with matching serology. 
 
Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in 
the United States: the national health and nutrition examination 
surveys, 1988-2004. Clin Infect Dis. 2010;50:1439–1447. 
 
Adenovirus: We recommend including adenovirus on stool in 
addition to norovirus and rotavirus. 
 
Vancomycin resistant enterococcus (VRE): VRE should be 
specifically mentioned in “Multi-drug resistant bacteria”. VRE is a 
leading cause for donor exclusion despite prospective donors having 
no known risk factors for colonization.  
 
8.3.5. Final donor 
checks prior to 
donation: 
Further final screening should take place prior to collection of a 
stool sample for processing into FMT (strong). 
 
We agree. 
Thank you for this comment.  In light of this and other 
comments, the recommendation on repeat screening has 
been strengthended.   
8.4.1. General 
principles of FMT 
preparation: 
Recommendation:  
i. Donor stool collection should follow a standard protocol 
(strong).  
ii. Donor stool should be processed within 6 hours of 
defecation (conditional). 
iii. Both aerobically and anaerobically prepared FMT 
treatments should be considered suitable when preparing 
FMT for the treatment of recurrent CDI (strong). 
Thank you for this comment.  
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Section  Comments Working group response 
iv. Sterile 0.9% saline should be considered as an appropriate 
diluent for FMT production, and cryoprotectant such as 
glycerol should be added for frozen FMT (strong). 
v. Consider ≥50g of stool for use in FMT preparation 
(conditional). 
 
Good practice points:   
i. Stool should be mix d 1:5 with diluent to make the initial 
faecal emulsion (conditional). 
ii. Homogenisation and filtration of FMT should be 
undertaken in a closed disposable system (conditional).  
 
We agree. 
8.4.2. Fresh vs frozen 
FMT: 
The use of banked frozen FMT material should be considered 
preferable to fresh preparations for CDI (strong). 
 
We agree. 
Thank you for this comment.   
8.4.3. Use of frozen 
FMT: 
Recommendation:   
FMT material stored frozen at -80oC should be regarded as having 
a maximum shelf life of six months from preparation (strong). 
 
Good practice point:  
Consider thawing frozen FMT should at ambient temperature and 
using within six hours of thawing (conditional). 
 
We agree. 
Thank you for this comment.   
8.5.1. Use of specific 
medications in the 
period around FMT 
administration:  
Recommendation:   
i. Bowel lavage should be administered prior to FMT via the 
lower GI route, and bowel lavage should be considered 
prior to FMT via the upper GI route; polyethylene glycol 
preparation is preferred (conditional). 
Thank you for this comment.   
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Section  Comments Working group response 
8.5.1.1. General 
principles of FMT 
administration: 
ii. For upper GI FMT administration, a proton pump inhibitor 
should be considered, e.g. the evening before and morning 
of delivery (conditional).   
iii. Loperamide (or other anti-motility drugs) should be 
considered following lower GI FMT delivery (conditional).   
 
Good practice point:   
i. Prokinetics (such as metoclopramide) should be considered 
prior to FMT via the upper GI route (conditional).   
ii. Best practice for prevention of further transmission of CDI 
should be applied throughout when administering FMT to 
patients with CDI (nursing with enteric precautions, 
sporicidal treatment of endoscope, etc).   
 
We agree. 
8.5.1.2. Additional 
antibiotics pre-FMT: 
Consider further antimicrobial treatment for CDI for at least 72 
hours prior to FMT (conditional).     
 
We agree. 
Thank you for this comment.  
8.5.1.3. Washout 
period between 
antibiotic use and FMT: 
To minimise any deleterious effect of antimicrobials on the FMT 
material, there should be a minimum washout period of 24 hours 
between the last dose of antibiotic and treatment with FMT 
(strong). 
 
We agree. 
Thank you for this comment.  
8.5.2.2. Upper 
gastrointestinal tract 
administration of FMT: 
Recommendation:   
i. Upper GI administration of FMT as treatment for recurrent 
or refractory CDI should be used where clinically 
appropriate (strong). 
ii. Where upper GI administration is considered most 
appropriate, FMT administration should be via nasogastric, 
Thank you for this comment.  In light of further discussion by 
the working group, the maximum volume of FMT 
recommended by upper GI administration is now 100ml.   
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nasoduodenal, or nasojejunal tube, or alternatively via 
upper GI endoscopy.  Administration via a permanent 
feeding tube is also appropriate (strong).   
 
Good practice point:  
 It is recommended that no more than 50ml of FMT is administered 
to the upper GI tract (conditional). 
 
We agree. 
8.5.2.3. Lower 
gastrointestinal tract 
administration of FMT: 
Recommendation:   
i. Colonoscopic administration of FMT as treatment for 
recurrent or refractory CDI should be used where 
appropriate (strong). 
ii. Where colonoscopic administration is employed, consider 
preferential delivery to the caecum or terminal ileum, as 
this appears to give the highest efficacy rate (conditional).  
iii. FMT via enema should be used as a lower GI option when 
colonoscopic delivery is not possible (strong).   
 
We recommend rewording point iii. Although there is limited data, 
flexible sigmoidoscopy may be the preferred route of delivery where 
colonoscopic delivery is not possible. Several experts have advised 
less invasive modalities such sigmoidoscopy in high risk patients 
(Brandt 2013; Kelly 2014). This may provide a more effective method 
for delivering material as proximally as possible and improving 
retention. We therefore recommend re-wording point iii to: 
 
FMT via enema should be used as a lower GI option when 
colonoscopic or flexible sigmoidoscopy delivery is not possible 
(strong).   
 
We agree with this suggestion, and have updated the 
guideline accordingly.   
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Brandt LJ, Aroniadis OC. An overview of fecal microbiota 
transplantation: Techniques, indications, and outcomes. 
Gastrointest Endosc. 2013 Aug;78(2):240-9. 
 
Kelly CR, Ihun ah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. 
Fecal microbiota transplant for treatment of clostridium difficile 
infection in immunocompromised patients. Am J Gastroenterol. 
2014 Jul;109(7):1065-71. 
8.5.2.4. Capsulised 
FMT: 
Capsulised FMT holds promise as a treatment option for recurrent 
CDI, but further evidence regarding its safety and efficacy is 
awaited, and it should not be considered for use at present 
(conditional).  
 
There is a growing body of evidence on encapsulated FMT and the 
delivery modality presents a potential option in circumstances where 
it may be inappropriate, contraindicated, or contrary to patient 
preferences to deliver material via traditional routes of 
administration for CDI.  
 
In terms of patient perceptions, Zipursky and colleagues report that 
more aesthetically appealing FMT formulations, such as capsules, 
would both eliminate potential barriers to treatment and reduce the 
necessity for healthcare resources and procedure time for clinicians. 
Capsules appear well tolerated. For example, the mean time of 30 
capsule administration is approximately 20 minutes (range 10-30 
minute) (Allegretti, unpublished data). 
 
Although the optimal dose is still under investigation (as with other 
FMT delivery modalities), there have been several studies that have 
shown equivalent efficacy rates. Youngster and colleagues reported 
their experience with a capsule formulation that averaged 1.6 grams 
We largely agree with this comment.  Whilst the Kao et al, 
2017 study was not published at the time of initial searches, 
it has been identified by updated searches and has now been 
reviewed by the working group.  The guideline has been 
updated accordingly.    
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of stool per capsule in which they dosed 15 capsules on 2 consecutive 
days. They reported a 70% cure rate after an initial dose in a cohort 
of 140 patients. Those that failed to achieve cure were re-treated, 
bringing the cumulative cure rate up to 90%. 
 
Similarly, Hirsch and colleagues demonstrated a clinical cure rate of 
68% in the 19 participants, using capsules containing purified, 
concentrated, and cryopreserved fecal bacteria and this increased to 
89% with retreatment.  
 
Allegretti and colleagues conducted the first dose-finding study for 
FMT capsules (0.75 grams of stool per capsule with upper GI release) 
assessing 30 capsules once (low dose) versus 30 capsules on 2 
consecutive days (high dose). Efficacy rates between the groups 
were similar on initial dose (70%) and there were no adverse events 
reported.  
 
Lastly the largest randomized control trial to date of FMT used 
encapsulated FMT with good safety and efficacy outcomes 
equivalent to colonoscopy FMT. In Kao et al’s non-inferiority 
randomized clinical trial (cited in the guidelines) that included 116 
adults with rCDI, the proportion without recurrence over 12 weeks 
was 96.2% after a single treatment in a group treated with oral 
capsules and in a group treated via colonoscopy. Given this 1+ level 
of evidence, in addition to multiple smaller studies of encapsulated 
FMT, we feel that there is a good body of evidence to support the 
short-term safety of encapsulated FMT. We agree that further 
evidence is needed on optimal dosing and formulation, however this 
applies to all delivery modalities. 
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We agree that capsule availability is very limited in the UK at present 
however this shouldn’t preclude guidelines recommending this as a 
potential FMT delivery option.  
 
We therefore recommend rewording the 8.5.2.4 to: 
 
Capsulised FMT holds promise as a treatment option for recurrent 
CDI and should be offered to patients as a potential treatment 
modality. Capsule preparations should follow a standard protocol. 
Further evidence regarding its optimal dosing and formulation is 
needed (conditional).  
 
Allegretti J*, Fischer M*, Papa E, Elliot R, Klank M, Mendolia G, et al. 
Fecal microbiota transplantation delivered via oral capsules achieves 
microbial engraftment similar to traditional delivery modalities: 
Safety, efficacy and engraftment results from a multi-center cluster 
randomized dose-finding study. Digestive Disease Week 2016.  
 
Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. 
Effectiveness of fecal- derived microbiota transfer using orally 
administered capsules for recurrent clostridium difficile infection. 
BMC Infect Dis. 2015 Apr 17;15:191,015-0930-z.  
 
Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. 
Oral, capsulized, frozen fecal microbiota transplantation for 
relapsing clostridium difficile infection. JAMA. 2014 Nov 
5;312(17):1772-8.  
 
Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. 
Patient attitudes toward the use of fecal microbiota transplantation 
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in the treatment of recurrent clostridium difficile infection. Clin 
Infect Dis. 2012 Dec;55(12):1652-8.  
8.6. What is the clinical 
effectiveness of faecal 
microbiota transplant 
in treating conditions 
other than Clostridium 
difficile infection? 
FMT is not currently recommended as treatment for inflammatory 
bowel disease.  There is insufficient evidence to recommend FMT 
for any other gastrointestinal or non-gastrointestinal disease 
(strong). 
 
We agree. 
Thank you for this comment.  
8.7. Basic requirements 
for implementing a FMT 
service 
The development of FMT centres should be encouraged (strong). 
 
We agree. 
Thank you for this comment.  
8.7.5. FMT 
manufacturing: 
Ensure traceability of supply (strong). 
 
We agree. 
Thank you for this comment.   
FMT in patients with 
IBD 
We recommend emphasizing the importance of counselling patients 
with IBD on the risk of flare or worsening IBD activity post-FMT. 
We agree with this comment, and have updated Section 
8.2.3. accordingly.   
FMT in paediatric 
populations 
A recommendation on paediatric FMT should be include. The 
evidence base is limited but safety and efficacy appears comparable 
to adult FMT. Patients and caregivers should be counselled on the 
unknown long-term risks of FMT. 
 
Recommendation: 
i. FMT should be offered to paediatric patients with recurrent CDI. 
ii. Paediatric patients and caregivers should be counselled on the 
unknown short and long-term risks of FMT. 
 
FMT in the paediatric setting is outside of the remit of this 
working group.  We have updated Section 5.4 to clarify this.   
Closing date: Please forward this electronically by 5pm on January 2018 at the very latest to consultations@his.org.uk 
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 1 
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium 
difficile infection and other potential indications: joint British Society of Gastroenterology 
(BSG) and Healthcare Infection Society (HIS) guidelines.   
 
Supplementary Material 3:  Basic requirements for implementing a FMT service: 
 
1. Basic requirements for implementing a FMT service: 
1.1. General considerations: 
Although it is possible to prepare and administer FMT on an individual patient basis in a single hospital, 
the regulatory requirements are more readily fulfilled by a specialist centre approach for the 
production of a safe FMT product. This particularly applies to record keeping and staff expertise in 
quality control and production. Recent European consensus advice suggests that FMT should be 
administered in a referral centre1, however an alternative approach which limits the need for patient 
transfer is to undertake controlled production in a large centre and transport treatment to the patient, 
a supply model which has been well established in the USA (OpenBiome)2 and has also been 
successfully replicated in the UK in a large centre in Birmingham, which has supplied FMT to nine NHS 
Trusts across three regions3.  This service design only requires that a responsible clinician is capable of 
administering the FMT safely at the satellite clinical site. It also eliminates the need for patient transfer 
between clinical sites, which in the case of severe CDI may not be practical.  
 
The working group encouraged the use of frozen FMT material supplied from a carefully controlled 
production site.  This allows donor screening more closely to meet regulatory requirements, ensuring 
that the window period between donor testing and FMT production is maintained to a minimum.  The 
costs of donor screening are substantially reduced using this supply model, as a single donor can 
provide multiple FMT donations under a single screening period.  
 
The working group also noted that given the novelty of FMT, awareness of this as a potential 
treatment option for recurrent or refractory CDI may be low amongst certain groups of clinicians.  For 
instance, clinicians working in primary care, or those whose practice is not located near to an FMT 
centre, are likely to have less knowledge about the potential suitability of FMT for patients with CDI, 
or be unaware of referral pathways.  As such, there is a responsibility for FMT centres to raise 
awareness and educate as wide a range of clinicians as possible about the potential role for FMT.  
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 2 
Furthermore, microbiology staff processing stool samples for C difficile assays from the community 
should proactively liaise with primary care teams where recurrent positive tests are received from a 
single patient to raise awareness and suggest the option of FMT.    
 
^]u]ooÇUP]ÀvZÆ]}vZ&Ddvl}}ZZu]}]}uZµ][o]loÇ}oÇv
increasing role within medicine over future years, there is also an expectation for FMT centres to not 
only educate about the potential role for FMT, but also to train relevant healthcare professionals in 
the practicalities of delivering an FMT service, to enable longer-term ongoing provision of services.  
This is likely to be most of relevance to specialty trainee and consultant physicians specialising in 
gastroenterology, infectious diseases and/ or medical microbiology, but potentially to other 
healthcare professionals too, including infection prevention and control nurses, infectious diseases 
pharmacists, etc.   
 
Recommendations:   
i. The development of FMT centres should be encouraged (GRADE of evidence: very 
low; strength of recommendation: strong). 
ii. We suggest that FMT centres should work to raise awareness about FMT as a 
treatment option amongst clinicians caring for patients with CDI, and provide 
training to relevant healthcare professionals on the practicalities of delivering an 
FMT service (GRADE of evidence: very low; strength of recommendation: weak).   
 
1.2. Legal aspects and clinical governance: 
In the United Kingdom, FMT is now considered a medicinal product based on the definitions of 
purpose and efficacy, in The Medicines Directive 2001/83 and The Human Medicines Regulations4.  As 
the competent authority for medicines regulation, the Medicines and Healthcare products Regulatory 
Agency (MHRA) has indicated that the approach to regulation will be proportionate, depending on 
factors such as supply being within or outside a legal entity and FMT production scale.  Specifically: 
x When FMT is supplied on prescription on a named patient basis, then supply under a pharmacy 
exemption may be used subject to ensuring proper governance and traceability4.   
x /(}µ]}voZvZindustrial[oÀoU(]vZby virtue of the batch sizes, the extent of 
}]vPvl}ÁZZ}v]oµ ]voµµoÇÁv oPov]][4, the route to 
Pµo]}v]À]Zv},DZv(}uoDvµ(µ[Z^]o[~D^o]vX 
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 3 
x If a supply is to a clinical trial, then an MIA (IMP) manufacturing license is required (further 
information on license applications5 and specials6 is available online). 
 
Centres establishing an FMT service should undertake steps to ensure practice meets the required 
compliance levels and seek guidance from the MHRA.  If pharmacy exemption is applied, there should 
be justifiable processes in place to ensure traceability, health and safety, governance and to prevent 
cross-contamination.  FMT is regulated as a medicine, rather than a tissue, but no products have been 
licensed following an assessment against the criteria of safety, quality and efficacy, for there is a 
possible risk that donor screening protocols will not be sufficiently considered, a step which is critical 
to the quality of the product and therefore safety of the patient7.  To mitigate this, it is advisable that 
donor screening protocols are under regularly review and risk assessment, and to ensure that 
consideration is also given to the Guide to Quality and Safety Assurance for Human Tissues and Cells 
for Patient Treatment, particularly Annex B related to donor testing8.  When formal licencing is sought, 
this is overseen by a Production Manager and Quality Control Manager if under an MS, or by a 
Qualified Person if under an MIA (IMP).  Both should follow the Good Manufacturing Practice (GMP) 
guidelines, found within The Orange Guide Rules and Guidance for Pharmaceutical Manufacturers and 
Distributors 20179, or at: https://ec.europa.eu/health/documents/eudralex/vol-4_en .  
.   
The working group noted that outside the UK, the legal and regulatory framework relating to FMT was 
highly variable between different countries.  They agreed that FMT should only be administered after 
appropriate approval from the competent body of each country.   
 
Recommendation:   
In the UK, FMT must be manufactured in accordance with MHRA guidance for human 
medicines regulation.  When FMT is supplied on a named patient basis, within a single 
organisation, a pharmacy exemption may be used, subject to ensuring proper governance 
and traceability.  All centres that are processing and distributing FMT should seek guidance 
from the MHRA and where necessary obtain appropriate licenses prior to establishing an 
FMT service.  This is a legal requirement.  In countries other than the UK, FMT should only 
be manufactured following appropriate approval from the national authority of that 
country (GRADE of evidence: very low; strength of recommendation: strong).  
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 4 
1.3. Multidisciplinary teams: 
To promote safe and high quality FMT supply, it is strongly recommended that providers adopt a 
multidisciplinary team approach.  The choice of the team required is subject to the scale of production, 
but should involve as a minimum a clinical gastroenterologist, microbiologist/infectious diseases 
clinician, state-registered experienced healthcare scientist and pharmacist.  Governance and quality 
expertise will be required, which may be provided by consultation.  If FMT production is to be under 
Z]o[o]vUZuZ}µoÆv}]voµYµo](]W}vUYµo]ÇDvPv
Production Manager, all with GMP training.  
 
Recommendation:   
We recommend that a multidisciplinary team should be formed to deliver FMT services 
(GRADE of evidence: very low; strength of recommendation: strong). 
 
1.4. Infrastructure: 
Dedicated laboratory facilities for FMT production are recommended to ensure that the process 
adheres to Health and Safety requirements, to reduce the risk of cross-contamination, and to facilitate 
standardisation of the production process.  In some studies, FMT has been prepared in a clinical 
environment10; however, this may not be advisable because of the risks of cross-contamination.  The 
manipulation of human stool should be conducted in a Containment Level 2 laboratory according to 
current Health and Safety guidance (Health and Safety at Work Act 1974, COSHH Control of Substances 
Hazardous to Health Regulations, 2002), and at least within a microbiological safety cabinet which 
provides user protection (Class I) or, ideally, user and product protection (Class II).  To meet the 
requirements of GMP, this facility should be sole use or be risk assessed for multipurpose use with 
adequate separation of different activities.  The working group recommend that the facility complies 
Á]Z Z vÁ 'DW }µ]}v (]o]Ç o](]]}v }( Zov v} ]o[X  dZ µ }( }vo
protective equipment - such as laboratory coat, gloves and face mask - is also recommended to 
prevent production contamination.  It is essential to risk assess the process and develop control 
measures to reduce microbial ingress into the facility and monitor the microbiological cleanliness of 
Z}µ]}vµ]X&Dd]}vµvZ]o[o]vZ}µovµZZproduction 
process is integrated into a Quality Management System, to safeguard production and maintain the 
minimum criteria for audit, monitoring, standard operating procedures, document control, training, 
facilities, equipment and storage.  With regard to storage, it is essential that the freezer system has 
real-time temperature monitoring which provides notification outside pre-set limits.  
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 5 
 
Recommendation:   
We recommend utilisation of suitable laboratory facilities and infrastructure for FMT 
production (GRADE of evidence: very low; strength of recommendation: strong). 
 
1.5. FMT manufacturing: 
It is strongly recommended to employ a batch numbering system to track FMT preparations from 
production to use.  It should be possible from records to identify an individual FMT aliquot, trace it to 
a specific donation, and identify all other FMT aliquots prepared from the same donation.  It must also 
be clear which FMT aliquots patients have received, which should be verifiable from the donor to the 
patient and vice-versa.  It is therefore strongly recommended that a treatment directory be 
maintained documenting all production and use of FMT, and that an unambiguous record is created 
]v Z]v[o]v]ov} } ]v](ÇZ](]&DdZvµuX  &µZ } Z]U ] ]o}
recommended that treatment directories also record clinical outcome, such as that developed in the 
USA11 and Germany12 to standardise and improve future clinical practice.  
 
Recommendation:   
We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength 
of recommendation: strong). 
 
1.6. FMT production quality control: 
Safety and clinical governance is a central responsibility for FMT centres, particularly in light of the 
absence of phase III licensing trials for FMT, which would normally be required for a novel medicinal 
product.  Reporting and investigating adverse events and reactions contributes to knowledge of the 
FMT safety profile, while also identifying previously unknown safety issues.  Governance structures 
and processes must be in place to monitor, notify and investigate all FMT-related adverse events or 
reactions locally, and FMT users are encouraged to use the MHRA Yellow Card Scheme for formal 
notification.  FMT supply should be suspended if serious adverse events or reactions occur which are 
directly attributable to FMT, and there should be a clear documented pathway to achieve this.  To 
(]o]  Zo}}l-l Æ][ ]( µ]U ] ] À]o } } }µuv]}v v ference 
samples, both product-based and donor/ patient-based.  Specifically, retention of production 
documentation should be for at least five years after the use of the batch; retention of reference FMT 
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 6 
samples (and stool samples from donors and recipients) should be for at least one year after the last 
use. Retention of excipient samples should be for at least one year after expiry of the excipient. 
 
Recommendation:   
We recommend monitoring, notification and investigation of all adverse events and 
reactions related to FMT (GRADE of evidence: very low; strength of recommendation: 
strong). 
 
1.7. Donor screening governance: 
The testing requirements for donor screening have been discussed previously; however, it is worth 
noting here the pertinent clinical governance issues which should be addressed.  Donor anonymity 
should be maintained at all times.  The laboratory undertaking testing of donor samples should be 
competent for such activity, demonstrable by accreditation with the United Kingdom Accreditation 
Service (UKAS).  The results of donor testing should remain confidential.  There should be appropriate 
standard operating procedures to ensure that the outcome of donor screening is built into a robust 
FMT batch release process.  To ensure unbiased autonomy during donor screening, it is suggested that 
a clinician independent to the FMT production team is responsible for ratifying FMT donors prior to 
donation.  Finally, the duration of donor follow-up should be considered and extend beyond the period 
of active donation to capture acute and chronic health changes.  
 
Recommendation:  
We recommend ensuring the clinical governance of donor screening (GRADE of evidence: 
very low; strength of recommendation: strong). 
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